0001628280-20-002613.txt : 20200302 0001628280-20-002613.hdr.sgml : 20200302 20200302090828 ACCESSION NUMBER: 0001628280-20-002613 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 113 CONFORMED PERIOD OF REPORT: 20191231 FILED AS OF DATE: 20200302 DATE AS OF CHANGE: 20200302 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Guardant Health, Inc. CENTRAL INDEX KEY: 0001576280 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 454139254 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38683 FILM NUMBER: 20674449 BUSINESS ADDRESS: STREET 1: 505 PENOBSCOT DR. CITY: REDWOOD CITY STATE: CA ZIP: 94063 BUSINESS PHONE: 855-698-8887 MAIL ADDRESS: STREET 1: 505 PENOBSCOT DR. CITY: REDWOOD CITY STATE: CA ZIP: 94063 10-K 1 gh-12312019x10k.htm 10-K Document
false--12-31FY20190001576280GH0883000447500072300000.00000010.000000135000000035000000085832454942614148583245494261414130000000P6Y00.00000010.000000110000000100000000000P5YP3YP3YP7Y005000000.4360.6030.5880.7510.7880.6870.7410.6870.6320.0240.0160.0220.0300.0270.0190.0250.016P6Y1MP6Y7DP6Y6M2DP5Y4DP3M29DP6MP6Y2M19DP3M15DP5Y6M 0001576280 2019-01-01 2019-12-31 0001576280 2020-02-14 0001576280 2019-06-28 0001576280 2018-12-31 0001576280 2019-12-31 0001576280 2018-01-01 2018-12-31 0001576280 gh:SeriesAConvertiblePreferredStockMember 2018-01-01 2018-12-31 0001576280 2017-01-01 2017-12-31 0001576280 gh:SeriesAConvertiblePreferredStockMember 2017-01-01 2017-12-31 0001576280 gh:SeriesDConvertiblePreferredStockMember 2017-01-01 2017-12-31 0001576280 gh:SeriesDConvertiblePreferredStockMember 2019-01-01 2019-12-31 0001576280 gh:SeriesAConvertiblePreferredStockMember 2019-01-01 2019-12-31 0001576280 gh:SeriesDConvertiblePreferredStockMember 2018-01-01 2018-12-31 0001576280 us-gaap:AccountingStandardsUpdate201409Member us-gaap:RetainedEarningsMember 2019-01-01 0001576280 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-12-31 0001576280 us-gaap:CommonStockMember 2017-01-01 2017-12-31 0001576280 us-gaap:CommonStockMember 2019-12-31 0001576280 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-12-31 0001576280 us-gaap:AccountingStandardsUpdate201609Member us-gaap:AdditionalPaidInCapitalMember 2017-01-01 0001576280 us-gaap:AccountingStandardsUpdate201409Member 2019-01-01 0001576280 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001576280 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-12-31 0001576280 us-gaap:CommonStockMember 2018-01-01 2018-12-31 0001576280 us-gaap:AdditionalPaidInCapitalMember 2017-01-01 2017-12-31 0001576280 us-gaap:RetainedEarningsMember 2019-01-01 2019-12-31 0001576280 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0001576280 gh:SeriesDConvertiblePreferredStockMember us-gaap:CommonStockMember 2018-01-01 2018-12-31 0001576280 gh:AccountingStandardsUpdate201807Member 2019-01-01 0001576280 gh:AccountingStandardsUpdate201807Member us-gaap:AdditionalPaidInCapitalMember 2019-01-01 0001576280 us-gaap:PreferredStockMember 2018-12-31 0001576280 us-gaap:AdditionalPaidInCapitalMember 2016-12-31 0001576280 gh:SeriesDConvertiblePreferredStockMember us-gaap:PreferredStockMember 2018-01-01 2018-12-31 0001576280 gh:SeriesEConvertiblePreferredStockMember us-gaap:PreferredStockMember 2017-01-01 2017-12-31 0001576280 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001576280 gh:RedeemableNoncontrollingInterestMember 2016-12-31 0001576280 us-gaap:PreferredStockMember 2016-12-31 0001576280 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001576280 us-gaap:CommonStockMember 2017-12-31 0001576280 us-gaap:RetainedEarningsMember 2017-12-31 0001576280 us-gaap:RetainedEarningsMember 2018-12-31 0001576280 us-gaap:CommonStockMember 2019-01-01 2019-12-31 0001576280 us-gaap:RetainedEarningsMember 2019-12-31 0001576280 gh:SeriesAConvertiblePreferredStockMember us-gaap:RetainedEarningsMember 2017-01-01 2017-12-31 0001576280 gh:SeriesDConvertiblePreferredStockMember us-gaap:PreferredStockMember 2017-01-01 2017-12-31 0001576280 gh:RedeemableNoncontrollingInterestMember 2019-12-31 0001576280 gh:RedeemableNoncontrollingInterestMember 2019-01-01 2019-12-31 0001576280 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-12-31 0001576280 us-gaap:CommonStockMember 2018-12-31 0001576280 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-12-31 0001576280 us-gaap:PreferredStockMember 2019-12-31 0001576280 gh:SeriesDConvertiblePreferredStockMember us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-12-31 0001576280 gh:RedeemableNoncontrollingInterestMember 2018-01-01 2018-12-31 0001576280 us-gaap:PreferredStockMember 2017-12-31 0001576280 us-gaap:RetainedEarningsMember 2016-12-31 0001576280 us-gaap:RetainedEarningsMember 2018-01-01 2018-12-31 0001576280 2017-12-31 0001576280 gh:RedeemableNoncontrollingInterestMember 2017-12-31 0001576280 us-gaap:CommonStockMember 2016-12-31 0001576280 gh:SeriesAConvertiblePreferredStockMember us-gaap:PreferredStockMember 2017-01-01 2017-12-31 0001576280 gh:SeriesEConvertiblePreferredStockMember 2017-01-01 2017-12-31 0001576280 gh:RedeemableNoncontrollingInterestMember 2018-12-31 0001576280 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001576280 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-01-01 2017-12-31 0001576280 gh:AccountingStandardsUpdate201807Member us-gaap:RetainedEarningsMember 2019-01-01 0001576280 us-gaap:AccountingStandardsUpdate201609Member 2017-01-01 0001576280 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001576280 us-gaap:RetainedEarningsMember 2017-01-01 2017-12-31 0001576280 us-gaap:AccountingStandardsUpdate201609Member us-gaap:RetainedEarningsMember 2017-01-01 0001576280 2016-12-31 0001576280 us-gaap:CommonStockMember 2017-01-01 2017-12-31 0001576280 us-gaap:CommonStockMember 2019-01-01 2019-12-31 0001576280 us-gaap:CommonStockMember 2018-01-01 2018-12-31 0001576280 us-gaap:ConvertiblePreferredStockMember 2018-01-01 2018-12-31 0001576280 us-gaap:ConvertiblePreferredStockMember 2019-01-01 2019-12-31 0001576280 us-gaap:ConvertiblePreferredStockMember 2017-01-01 2017-12-31 0001576280 2019-05-31 0001576280 us-gaap:IPOMember 2018-10-09 2018-10-09 0001576280 2018-09-19 2018-09-19 0001576280 us-gaap:IPOMember 2018-10-09 0001576280 gh:WarrantsPreferredStockMember 2018-10-09 0001576280 2019-05-01 2019-05-31 0001576280 us-gaap:ConvertiblePreferredStockMember 2018-10-09 0001576280 gh:GuardantHealthAMEAIncMember 2018-04-30 0001576280 2018-09-30 0001576280 us-gaap:OverAllotmentOptionMember 2019-05-01 2019-05-31 0001576280 2019-01-01 0001576280 us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2019-01-01 2019-12-31 0001576280 us-gaap:AccountingStandardsUpdate201409Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2019-01-01 2019-12-31 0001576280 us-gaap:AccountingStandardsUpdate201409Member 2019-12-31 0001576280 us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2019-12-31 0001576280 gh:CustomerCMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0001576280 gh:CustomerBMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-12-31 0001576280 gh:CustomerBMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0001576280 gh:CustomerBMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2017-01-01 2017-12-31 0001576280 gh:CustomerBMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0001576280 gh:CustomerAMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2017-01-01 2017-12-31 0001576280 gh:CustomerBMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-12-31 0001576280 gh:CustomerDMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0001576280 srt:MaximumMember 2019-01-01 2019-12-31 0001576280 us-gaap:OtherAssetsMember 2019-12-31 0001576280 us-gaap:CollaborativeArrangementMember 2019-12-31 0001576280 2020-01-01 2019-12-31 0001576280 us-gaap:CollaborativeArrangementMember 2018-12-31 0001576280 us-gaap:AdditionalPaidInCapitalMember 2018-10-31 0001576280 srt:MaximumMember us-gaap:MachineryAndEquipmentMember 2019-01-01 2019-12-31 0001576280 srt:MinimumMember us-gaap:MachineryAndEquipmentMember 2019-01-01 2019-12-31 0001576280 gh:ComputerEquipmentandSoftwareMember 2019-01-01 2019-12-31 0001576280 us-gaap:FurnitureAndFixturesMember 2019-01-01 2019-12-31 0001576280 srt:MinimumMember 2019-01-01 2019-12-31 0001576280 gh:SoftBankMember gh:GuardantHealthAMEAIncMember 2018-05-01 2018-05-31 0001576280 gh:SoftBankMember gh:GuardantHealthAMEAIncMember 2018-05-31 0001576280 gh:GuardantHealthAMEAIncMember 2019-01-01 2019-12-31 0001576280 gh:GuardantHealthAMEAIncMember 2019-12-31 0001576280 gh:SoftBankMember gh:GuardantHealthAMEAIncMember 2019-01-01 2019-12-31 0001576280 gh:GuardantHealthAMEAIncMember 2018-05-31 0001576280 gh:GuardantHealthAMEAIncMember 2018-05-01 2018-05-31 0001576280 us-gaap:MachineryAndEquipmentMember 2018-12-31 0001576280 us-gaap:MachineryAndEquipmentMember 2019-12-31 0001576280 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2018-12-31 0001576280 us-gaap:FurnitureAndFixturesMember 2019-12-31 0001576280 us-gaap:FurnitureAndFixturesMember 2018-12-31 0001576280 us-gaap:ConstructionInProgressMember 2018-12-31 0001576280 us-gaap:ConstructionInProgressMember 2019-12-31 0001576280 us-gaap:ComputerEquipmentMember 2018-12-31 0001576280 us-gaap:LeaseholdImprovementsMember 2018-12-31 0001576280 us-gaap:ComputerEquipmentMember 2019-12-31 0001576280 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2019-12-31 0001576280 us-gaap:LeaseholdImprovementsMember 2019-12-31 0001576280 2018-10-01 2018-12-31 0001576280 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2018-12-31 0001576280 us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0001576280 us-gaap:USTreasurySecuritiesMember 2018-12-31 0001576280 us-gaap:MoneyMarketFundsMember 2018-12-31 0001576280 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001576280 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentDebtSecuritiesMember 2019-12-31 0001576280 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001576280 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentDebtSecuritiesMember 2019-12-31 0001576280 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001576280 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001576280 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001576280 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001576280 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0001576280 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0001576280 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentDebtSecuritiesMember 2019-12-31 0001576280 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0001576280 us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001576280 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentDebtSecuritiesMember 2019-12-31 0001576280 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0001576280 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001576280 us-gaap:MoneyMarketFundsMember 2019-12-31 0001576280 us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0001576280 us-gaap:USTreasurySecuritiesMember 2019-12-31 0001576280 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001576280 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001576280 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001576280 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001576280 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001576280 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentDebtSecuritiesMember 2018-12-31 0001576280 us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001576280 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001576280 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0001576280 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentDebtSecuritiesMember 2018-12-31 0001576280 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0001576280 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0001576280 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2018-12-31 0001576280 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0001576280 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2018-12-31 0001576280 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentDebtSecuritiesMember 2018-12-31 0001576280 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001576280 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentDebtSecuritiesMember 2018-12-31 0001576280 gh:BellweatherBioInc.Member gh:CommercializationMilestonesMember 2019-04-30 0001576280 gh:BellweatherBioInc.Member 2019-04-30 0001576280 gh:BellweatherBioInc.Member 2019-12-31 0001576280 gh:BellweatherBioInc.Member gh:CovenantsNotToCompeteMember 2019-04-01 2019-04-30 0001576280 gh:BellweatherBioInc.Member 2019-04-01 2019-04-30 0001576280 gh:BellweatherBioInc.Member gh:EarnOutConsiderationMember 2019-04-30 0001576280 gh:BellweatherBioInc.Member gh:CovenantsNotToCompeteMember 2019-04-30 0001576280 gh:BellweatherBioInc.Member 2019-01-01 2019-12-31 0001576280 gh:BellweatherBioInc.Member us-gaap:NoncompeteAgreementsMember 2019-12-31 0001576280 gh:BellweatherBioInc.Member us-gaap:NoncompeteAgreementsMember 2019-01-01 2019-12-31 0001576280 gh:BellweatherBioInc.Member us-gaap:LicenseMember 2019-12-31 0001576280 gh:BellweatherBioInc.Member us-gaap:LicenseMember 2019-01-01 2019-12-31 0001576280 us-gaap:LicensingAgreementsMember 2017-01-01 2017-01-31 0001576280 us-gaap:LicensingAgreementsMember 2017-01-31 0001576280 us-gaap:LicensingAgreementsMember 2019-12-31 2019-12-31 0001576280 us-gaap:LicensingAgreementsMember 2019-12-31 0001576280 us-gaap:LicensingAgreementsMember gh:SeriesDConvertiblePreferredStockMember 2017-01-01 2017-01-31 0001576280 us-gaap:LicensingAgreementsMember 2018-10-01 2018-12-31 0001576280 us-gaap:LicensingAgreementsMember 2018-12-31 2018-12-31 0001576280 us-gaap:LicensingAgreementsMember 2018-12-31 0001576280 us-gaap:LicensingAgreementsMember 2019-01-01 2019-12-31 0001576280 us-gaap:LicensingAgreementsMember 2017-08-01 2017-08-31 0001576280 us-gaap:MeasurementInputDiscountRateMember 2017-01-31 0001576280 us-gaap:SeniorLoansMember gh:CreditAgreementMember 2015-12-31 0001576280 us-gaap:SeniorLoansMember gh:CreditAgreementMember 2015-12-31 2015-12-31 0001576280 gh:RoyaltyAgreementMember 2017-06-01 2017-06-30 0001576280 us-gaap:SeniorLoansMember gh:CreditAgreementMember 2015-01-01 2015-12-31 0001576280 gh:TierOneMember gh:RoyaltyAgreementMember 2015-12-31 2015-12-31 0001576280 gh:CreditAgreementMember 2017-06-01 2017-06-30 0001576280 2017-06-30 0001576280 gh:TierTwoMember gh:RoyaltyAgreementMember 2015-12-31 0001576280 us-gaap:SeniorLoansMember gh:RoyaltyAgreementMember 2019-12-31 0001576280 gh:TierOneMember gh:RoyaltyAgreementMember 2015-12-31 0001576280 gh:TierTwoMember gh:RoyaltyAgreementMember 2015-12-31 2015-12-31 0001576280 us-gaap:SeniorLoansMember gh:RoyaltyAgreementMember 2018-12-31 0001576280 gh:PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.Member 2017-11-01 2017-11-30 0001576280 gh:FoundationMedicineInc.vs.GuardantHealthInc.Member us-gaap:GeneralAndAdministrativeExpenseMember 2017-12-31 2017-12-31 0001576280 us-gaap:OtherIncomeMember 2018-01-01 2018-03-31 0001576280 gh:PersonalGenomeDiagnosticsInc.vs.GuardantHealthInc.Member 2018-07-01 2018-07-31 0001576280 gh:FoundationMedicineInc.vs.GuardantHealthInc.Member 2016-05-01 2016-05-31 0001576280 gh:FoundationMedicineInc.vs.GuardantHealthInc.Member 2018-07-01 2018-07-31 0001576280 2018-10-09 2018-10-09 0001576280 2018-09-01 2018-09-30 0001576280 us-gaap:PreferredStockMember 2018-10-09 2018-10-09 0001576280 us-gaap:AdditionalPaidInCapitalMember 2019-05-01 2019-05-31 0001576280 us-gaap:CommonStockMember 2018-10-09 2018-10-09 0001576280 us-gaap:CommonStockMember 2019-05-01 2019-05-31 0001576280 gh:SharesAvailableForFutureStockOptionGrantsMember 2018-12-31 0001576280 gh:SharesAvailableForFutureStockOptionGrantsMember 2019-12-31 0001576280 us-gaap:EmployeeStockMember 2018-12-31 0001576280 us-gaap:EmployeeStockMember 2019-12-31 0001576280 us-gaap:EmployeeStockOptionMember 2019-12-31 0001576280 us-gaap:EmployeeStockOptionMember 2018-12-31 0001576280 gh:SeriesAConvertiblePreferredStockMember 2013-09-30 0001576280 2012-12-31 0001576280 gh:SeriesBConvertiblePreferredStockMember 2014-10-31 0001576280 2018-10-01 2018-10-31 0001576280 gh:SeriesEConvertiblePreferredStockMember 2017-10-01 2017-10-31 0001576280 us-gaap:CommonStockMember 2017-08-01 2017-08-31 0001576280 gh:SeriesEConvertiblePreferredStockMember 2017-10-31 0001576280 2017-04-30 2017-04-30 0001576280 us-gaap:CommonStockMember 2017-07-01 2017-07-31 0001576280 gh:SoftBankMember gh:SeriesEConvertiblePreferredStockMember 2017-05-31 0001576280 gh:SoftBankMember gh:SeriesEConvertiblePreferredStockMember 2017-05-01 2017-05-31 0001576280 2017-05-01 2017-05-31 0001576280 gh:PrecisionOncologyTestingMember 2018-01-01 2018-12-31 0001576280 gh:PrecisionOncologyTestingMember 2019-01-01 2019-12-31 0001576280 us-gaap:GeneralAndAdministrativeExpenseMember 2018-01-01 2018-12-31 0001576280 us-gaap:ResearchAndDevelopmentExpenseMember 2017-01-01 2017-12-31 0001576280 gh:PrecisionOncologyTestingMember 2017-01-01 2017-12-31 0001576280 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-12-31 0001576280 us-gaap:GeneralAndAdministrativeExpenseMember 2017-01-01 2017-12-31 0001576280 us-gaap:SellingAndMarketingExpenseMember 2018-01-01 2018-12-31 0001576280 us-gaap:SellingAndMarketingExpenseMember 2019-01-01 2019-12-31 0001576280 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-12-31 0001576280 us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-12-31 0001576280 us-gaap:SellingAndMarketingExpenseMember 2017-01-01 2017-12-31 0001576280 us-gaap:EmployeeStockMember 2019-01-01 2019-12-31 0001576280 us-gaap:EmployeeStockMember 2018-01-01 2018-12-31 0001576280 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-12-31 0001576280 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0001576280 us-gaap:RestrictedStockUnitsRSUMember 2019-12-31 0001576280 us-gaap:EmployeeStockMember gh:A2018EmployeeStockPurchasePlanMember 2019-12-31 0001576280 2019-12-01 2019-12-31 0001576280 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-12-31 0001576280 us-gaap:EmployeeStockMember gh:A2018EmployeeStockPurchasePlanMember 2019-01-01 2019-12-31 0001576280 us-gaap:EmployeeStockMember gh:A2018EmployeeStockPurchasePlanMember 2018-01-01 2018-12-31 0001576280 2018-12-31 2018-12-31 0001576280 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-12-31 0001576280 us-gaap:RestrictedStockUnitsRSUMember 2018-12-31 0001576280 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2017-01-01 2017-12-31 0001576280 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2018-01-01 2018-12-31 0001576280 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0001576280 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2018-01-01 2018-12-31 0001576280 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2017-01-01 2017-12-31 0001576280 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0001576280 srt:MinimumMember us-gaap:EmployeeStockMember 2019-01-01 2019-12-31 0001576280 srt:MaximumMember us-gaap:EmployeeStockMember 2019-01-01 2019-12-31 0001576280 us-gaap:ConvertiblePreferredStockMember 2019-01-01 2019-12-31 0001576280 us-gaap:RestrictedStockUnitsRSUMember 2018-01-01 2018-12-31 0001576280 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-12-31 0001576280 us-gaap:WarrantMember us-gaap:PreferredStockMember 2019-01-01 2019-12-31 0001576280 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-12-31 0001576280 us-gaap:TreasuryStockCommonMember 2019-01-01 2019-12-31 0001576280 us-gaap:ConvertiblePreferredStockMember 2017-01-01 2017-12-31 0001576280 us-gaap:ConvertiblePreferredStockMember 2018-01-01 2018-12-31 0001576280 gh:EmployeeStockPurchasePlanObligationMember 2019-01-01 2019-12-31 0001576280 us-gaap:WarrantMember us-gaap:CommonStockMember 2018-01-01 2018-12-31 0001576280 us-gaap:RestrictedStockUnitsRSUMember 2017-01-01 2017-12-31 0001576280 us-gaap:TreasuryStockCommonMember 2017-01-01 2017-12-31 0001576280 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-12-31 0001576280 us-gaap:WarrantMember us-gaap:PreferredStockMember 2017-01-01 2017-12-31 0001576280 gh:EmployeeStockPurchasePlanObligationMember 2017-01-01 2017-12-31 0001576280 us-gaap:WarrantMember us-gaap:PreferredStockMember 2018-01-01 2018-12-31 0001576280 us-gaap:WarrantMember us-gaap:CommonStockMember 2019-01-01 2019-12-31 0001576280 us-gaap:TreasuryStockCommonMember 2018-01-01 2018-12-31 0001576280 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0001576280 gh:EmployeeStockPurchasePlanObligationMember 2018-01-01 2018-12-31 0001576280 us-gaap:WarrantMember us-gaap:CommonStockMember 2017-01-01 2017-12-31 0001576280 us-gaap:DomesticCountryMember 2019-12-31 0001576280 us-gaap:StateAndLocalJurisdictionMember 2018-12-31 0001576280 us-gaap:DomesticCountryMember 2018-12-31 0001576280 us-gaap:StateAndLocalJurisdictionMember 2019-12-31 0001576280 country:US us-gaap:AssetsMember us-gaap:GeographicConcentrationRiskMember 2018-01-01 2018-12-31 0001576280 us-gaap:AssetsMember us-gaap:GeographicConcentrationRiskMember 2019-01-01 2019-12-31 0001576280 us-gaap:NonUsMember 2018-01-01 2018-12-31 0001576280 country:US 2018-01-01 2018-12-31 0001576280 us-gaap:NonUsMember 2017-01-01 2017-12-31 0001576280 us-gaap:NonUsMember 2019-01-01 2019-12-31 0001576280 country:US 2019-01-01 2019-12-31 0001576280 country:US 2017-01-01 2017-12-31 0001576280 us-gaap:CommonStockMember us-gaap:ExecutiveOfficerMember 2018-07-01 2018-08-31 0001576280 srt:AffiliatedEntityMember 2018-01-01 2018-12-31 0001576280 srt:AffiliatedEntityMember 2019-01-01 2019-12-31 0001576280 srt:AffiliatedEntityMember 2017-01-01 2017-12-31 xbrli:pure xbrli:shares iso4217:USD iso4217:USD xbrli:shares gh:company gh:petition gh:party gh:patent iso4217:GBP
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
_____________________
FORM 10-K
_____________________
(Mark One)
☒
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2019
OR
☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                        to                        
Commission File Number: 001-38683
_____________________
GUARDANT HEALTH, INC.
(Exact Name of Registrant as Specified in its Charter)
_____________________
Delaware
 
45-4139254
(State or other jurisdiction of
incorporation or organization)
 
(I.R.S. Employer
Identification No.)
505 Penobscot Dr.
Redwood City, California 94063
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (855) 698-8887

Securities registered pursuant to Section 12(b) of the Act: 

Title of each class
 
Name of each exchange on which registered
Common Stock, par value $0.00001
 
The Nasdaq Global Select Market
 
 
 
 
Securities registered pursuant to Section 12(g) of the Act: 

None
___________________

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    Yes  ☒  No  ☐
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act.    Yes  ☐    No  ☒ 
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.     Yes  ☒    No  ☐


Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ☒    No  ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large Accelerated Filer
☒
Accelerated Filer
☐
 
 
 
 
Non-accelerated Filer
☐
Smaller reporting company
☐
 
 
 
 
Emerging growth company
☐
 
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ☐    No  ☒

The aggregate market value of the voting and non‑voting common equity held by non‑affiliates of the registrant, as of the last business day of the registrant’s most recently completed second fiscal quarter was approximately $3.4 billion (based on the closing price of the registrant’s common stock on the Nasdaq Global Select Market on June 28, 2019 of $86.33 per share).

As of February 14, 2020, the registrant had 94,382,681 shares of common stock, $0.00001 par value per share, outstanding.

DOCUMENTS INCORPORATED BY REFERENCE

Portions of the registrant’s definitive proxy statement relating to its annual meeting of stockholders to be held in 2020 (the “2020 Annual Meeting”), to be filed with the Securities and Exchange Commission (the “SEC”) within 120 days after the end of the fiscal year to which this Annual Report on Form 10-K relates, are incorporated herein by reference where indicated. Except with respect to information specifically incorporated by reference in this Annual Report on Form 10-K, such proxy statement is not deemed to be filed as part hereof.

 


GUARDANT HEALTH, INC.
FORM 10-K
For the Fiscal Year Ended December 31, 2019
TABLE OF CONTENTS
 
 
 
 
Page
Business
Risk Factors
Unresolved Staff Comments
Properties
Legal Proceedings
Mine Safety Disclosures
 
 
 
 
 
 
 
 
Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
Selected Financial Data
Management’s Discussion and Analysis of Financial Condition and Results of Operations
Quantitative and Qualitative Disclosures About Market Risk
Financial Statements and Supplementary Data
Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
Controls and Procedures
Other Information
 
 
 
 
 
 
 
 
Directors, Executive Officers and Corporate Governance
Executive Compensation
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
Certain Relationships and Related Transactions, and Director Independence
Principal Accounting Fees and Services
 
 
 
 
 
 
 
 
Exhibits, Financial Statement Schedules
Form 10-K Summary
 
Signatures
 



FORWARD-LOOKING STATEMENTS
This Annual Report on Form 10-K, including the sections titled “Business” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” contains forward-looking statements regarding future events and our future results that are based on our current expectations, estimates, forecasts and projections about our business, our results of operations, the industry in which we operate and the beliefs and assumptions of our management. Words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “would,” “could,” “should,” “intend” and “expect,” variations of these words, and similar expressions are intended to identify forward-looking statements. These forward-looking statements are only predictions and are subject to risks, uncertainties and assumptions that are difficult to predict. Therefore, actual results may differ materially and adversely from those expressed in any forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, those discussed in Part I, Item 1A,“Risk Factors,” of this Annual Report on Form 10-K and elsewhere herein, and in other reports we file with the U.S. Securities and Exchange Commission, or the SEC. While forward-looking statements are based on the reasonable expectations of our management at the time that they are made, you should not rely on them. We undertake no obligation to revise or update publicly any forward-looking statements for any reason, whether as a result of new information, future events or otherwise, except as may be required by law.
Each of the terms the “Company,” “we,” “our,” “us” and similar terms used herein refer collectively to Guardant Health, Inc., a Delaware corporation, and its consolidated subsidiaries, unless otherwise stated. 

PART I

Item 1. Business
Overview
We are a leading precision oncology company focused on helping conquer cancer globally through use of our proprietary blood-based tests, vast data sets and advanced analytics. We believe that the key to conquering cancer is unprecedented access to its molecular information throughout all stages of the disease, which we intend to enable by a routine blood draw, or liquid biopsy. Our Guardant Health Oncology Platform is designed to leverage our capabilities in technology, clinical development, regulatory and reimbursement to drive commercial adoption of our tests, improve patient clinical outcomes, lower healthcare costs and accelerate drug development. In pursuit of our goal to manage cancer across all stages of the disease, we have launched our Guardant360 and GuardantOMNI tests for advanced stage cancer. Our Guardant360 test, launched in 2014, has been used by more than 7,000 oncologists, over 50 biopharmaceutical companies and all 28 National Comprehensive Cancer Network, or NCCN, Centers in the United States, and we believe it is the world’s market leading comprehensive liquid biopsy test based on public disclosure of the number of comprehensive liquid biopsy tests sold in 2018. Our GuardantOMNI test, launched in 2017, has been used by our biopharmaceutical customers as a comprehensive genomic profiling tool to help accelerate clinical development programs in both immuno-oncology and targeted therapy. These tests fuel development of our LUNAR program, which aims to address the needs of early stage cancer patients with neoadjuvant and adjuvant treatment selection, cancer survivors with surveillance, and asymptomatic individuals eligible for cancer screening and individuals at a higher risk for developing cancer with early detection. Our LUNAR-1 assay was launched in 2018 for research use and in late 2019 for investigational use.
Precision oncology, as it is practiced today, is primarily focused on matching cancer patients to personalized treatments based on the underlying molecular profile of their tumors. There is a critical need to expand the scope of precision oncology to enable precise detection, monitoring and selection of the appropriate intervention as early in the disease state as possible. We believe a major challenge to achieving this is the limited access to cancer’s molecular information. Traditionally, tissue tests that require physical access to tumor tissue through a biopsy or surgery have been used to gain access to this information. A tissue biopsy or surgery procedure, however, is often invasive, time-consuming and costly, which limits the utility of tissue tests. Tissue tests are also not feasible for certain applications such as screening for early detection of cancer.
Our liquid biopsy tests address many of the challenges of tissue biopsies. We believe our tests can expand the scope of precision oncology to earlier stages of the disease, improve patient outcomes and lower healthcare costs. We estimate the market opportunity for our current commercial and pipeline products is over $35 billion in the United States, comprising applications for clinicians and biopharmaceutical customers to address early to late-stage disease, including:

1

Therapy selection in advanced stage cancer patients - We are pioneering the clinical comprehensive liquid biopsy market with our Guardant360 and GuardantOMNI tests. Based on SEER Cancer Registry statistics we estimate the total number of metastatic cancer patients in the United States to be approximately 700,000. Using publicly available pricing for tissue-based therapy selection tests, and assuming patients are testing an average of two times over the course of their disease, we estimate the potential market opportunity for therapy selection among these patients to be approximately $4 billion. Additionally, based on the number of targeted therapy and immuno-oncology therapy programs in the current clinical pipeline, prevalence data, and typical pricing for our tests when used by our biopharmaceutical company customers in connection with their clinical trials, we estimate that the potential market opportunity for our products in use by biopharmaceutical companies is approximately $2 billion. By combining these two, we estimate the aggregate market opportunity for therapy selection in late-stage cancer patients to be approximately $6 billion. Our Guardant360 test is a molecular diagnostic test measuring 74 cancer-related genes and our GuardantOMNI test has a broader 500-gene panel, both of which analyze circulating tumor DNA in blood. Our Guardant360 test has been used over 100,000 times by clinicians to help inform which therapy may be effective for advanced stage cancer patients with solid tumors. Our Guardant360 and GuardantOMNI tests are used by biopharmaceutical companies for a range of applications, including identifying target patient populations to accelerate translational science research, clinical trial enrollment, and drug development, and post-approval commercialization.
Neoadjuvant and adjuvant treatment selection in early stage cancer patients and surveillance in cancer survivors -We are developing tests from our LUNAR program for neoadjuvant and adjuvant treatment selection in early stage cancer patients. The American Cancer Society estimated that in 2016 there were approximately 15 million solid tumor cancer survivors. We believe this reflects a potential market opportunity of approximately $15 billion. For early stage solid tumors, neoadjuvant and adjuvant treatment may be given as a first step in care to shrink the tumor or adjuvantly as a secondary treatment after the primary treatment to reduce the risk of recurrence. However, not all early stage cancer patients may benefit from neoadjuvant and adjuvant treatment. For instance, based on data published in 2007 from a randomized study of adjuvant chemotherapy versus observation in patients with colorectal cancer, the use of adjuvant treatment showed significant benefit for a subgroup of the patients who meet certain clinical criteria, but only marginal benefit for the patients who do not meet these criteria. We are currently investigating our LUNAR-1 assay’s ability to determine if the presence of ctDNA in early stage cancer could more accurately identify patients who may benefit from neoadjuvant and adjuvant treatment. We are also developing tests from our LUNAR program for minimal residual disease and recurrence detection in cancer survivors. Our LUNAR-1 assay leverages data and learnings from our Guardant360 and GuardantOMNI tests and is designed to enable clinicians to detect minimal residual disease and to detect cancer recurrence at a stage when intervention may have a higher chance of success. We believe our LUNAR-1 assay may also help biopharmaceutical companies identify new drug development opportunities. In return, these relationships could help us establish clinical utility for our tests and create new testing opportunities related to emerging therapies.
Early detection of cancer in asymptomatic individuals eligible for cancer screening and individuals at a higher risk for developing cancer - We are developing screening tests from our LUNAR program for individuals who are eligible for colorectal cancer screening annually based on the U.S. Preventive Services Task Force, or USPTF, guidelines for colorectal cancer screening. Recent data reported at the 2019 National Colorectal Cancer Roundtable, shows that amongst this population, approximately 31% are not up to date with the recommended colorectal cancer screening. Therefore, we believe there is a significant unmet need for non-invasive modalities such as our LUNAR-2 assay that, if successfully developed, we believe could increase compliance with the USPTF guidelines. Based on an estimated 30 million individuals who are eligible for colorectal cancer screening, we believe this represents a potential market opportunity of approximately $15 billion. We are also pursuing the development of screening tests from our LUNAR program for individuals at a higher risk of developing cancer due to multiple factors, including moderate to heavy smoking, hereditary risk and pre-existing infections and/or inflammatory conditions. Based on various industry sources, we estimate there are approximately 35 million individuals that satisfy one of three criteria for being susceptible to high risk cancer. We believe this represents a potential market opportunity of approximately $18 billion. We believe that developing a blood test for early detection of cancer requires a vast amount of molecular and clinical data across all stages of the disease in order to better understand the biology and clinical relevance of tumor-specific biomarkers in blood. We further believe that we can accelerate the collection of this data pool and the development of our LUNAR-2 assay for an early detection test in a capital-efficient manner by developing and commercializing our Guardant360 test, GuardantOMNI test and LUNAR-1 assay, while we are using our development-stage LUNAR-2 assay in exploratory studies. While we believe the benefits of early detection on clinical outcomes are widely known, early cancer or precancerous detection may also benefit biopharmaceutical companies by identifying a much larger at-risk population who may benefit from early therapeutic intervention or from preventative medicines.

2

We believe that best-in-class technology is required to address these market opportunities, but is only one of many strengths required to create a market leading liquid biopsy platform. We believe our Guardant Health Oncology Platform has developed strengths across five critical layers, each of which facilitates success in the adjacent layers, and together the five layers form a barrier to entry and provide us a competitive advantage and a platform we can efficiently leverage across multiple products. These five layers include:
graphic3.jpg
Technology - Our proprietary Guardant Health Digital Sequencing Technology combines cutting edge capabilities from multiple disciplines including biochemistry, next-generation sequencing, signal processing, bioinformatics, machine learning and process engineering to enable what we believe to be the world’s market leading comprehensive liquid biopsy test with a typical turnaround time of less than seven days after we receive the sample and enable our high performing liquid biopsy tests intended for different market segments. Furthermore, our machine learning capability enables performance improvement as we incorporate additional data.
Clinical utility - We believe that success in the clinical utility layer requires both independent investments in clinical research and strategic relationships with market-leading biopharmaceutical companies. We have invested heavily in clinical studies, including more than 50 clinical outcomes studies demonstrating that overall biomarker detection rates of our non-invasive blood testing were in line with standard of care tissue testing. Our clinical research collaborations have resulted in more than 150 peer-reviewed publications. We also have relationships with over 50 biopharmaceutical customers that have provided rigorous clinical validation of our technology and early insights into test opportunities for emerging therapeutics.
Regulatory approval - We believe Guardant360 test was the first comprehensive liquid biopsy approved by the New York State Department of Health, or NYSDOH. In addition, based on our review of publicly available records, we believe our facility was the first comprehensive liquid biopsy laboratory to be certified pursuant to the Clinical Laboratory Improvement Amendments of 1988, or CLIA, accredited by the College of American Pathologists, or CAP, and NYSDOH-permitted. Our Guardant360 and GuardantOMNI tests have each been designated by the U.S. Food and Drug Administration, or the FDA, as a breakthrough device for use as a companion diagnostic in connection with certain specified therapeutic products of our biopharmaceutical customers. Among other things, designation as a breakthrough device provides for priority review by the FDA and more interactive communication with the FDA during the development process. In the fourth quarter of 2019, we submitted a premarket approval, or PMA, application to seek the FDA’s approval of our Guardant360 test to be used as a companion diagnostic, initially in connection with one therapeutic product of a biopharmaceutical customer, and to provide tumor mutation profiling for cancer patients with solid tumors. In February 2020, we submitted an additional module of the PMA application for our Guardant360 test to the FDA. We believe that FDA approval will become increasingly important for diagnostic tests to gain commercial adoption both in the United States and abroad.

3

Payer coverage and reimbursement - The analytical and clinical data that we have generated in our efforts to establish clinical utility, combined with the support we have developed with key opinion leaders, or KOLs, in the oncology space have led to positive coverage decisions by a number of commercial payers. Our Guardant360 test is currently covered by Cigna, Priority Health, multiple regional Blue Cross Blue Shield plans as well as the health plans associated with eviCore for non-small cell lung cancer, or NSCLC, which we believe gives us a competitive advantage with these payers with respect to NSCLC patients. Payment from commercial payers differs depending on whether we have entered into a contract with the payers as a “participating provider.” Payers often reimburse non-participating providers, if at all, at a lower amount than participating providers. When we are not contracted with these payers, they determine the amount they are willing to reimburse us for tests. When we contract with a payer to serve as a participating provider, reimbursements by the payer are generally made pursuant to a negotiated fee schedule and are limited to only covered indications or where prior approval has been obtained.
With respect to Medicare, in July 2018, Palmetto GBA, the Medicare Administrative Contractor, or MAC, responsible for administering Medicare’s Molecular Diagnostic Services Program, or MolDx, issued a local coverage determination, or LCD, for our Guardant360 test with respect to NSCLC patients who meet certain clinical criteria. Shortly thereafter in 2018, Noridian Healthcare Solutions, the MAC responsible for adjudicating claims in California, where our laboratory is located, and a participant in MolDx, finalized an equivalent LCD for our Guardant360 test. Pursuant to this Noridian LCD, in September 2018, we began to submit claims for reimbursement for Guardant360 clinical testing performed for NSCLC patients covered under such LCD who meet certain clinical criteria, and in October 2018, we began to receive payments for these services from Medicare. In December 2019, replacing its prior NSCLC patient LCD, Palmetto GBA finalized a new LCD for our Guardant360 test that provides limited Medicare coverage for the Guardant360 test in patients diagnosed with solid cancers of non-central nervous system origin. The new LCD covers our Guardant360 test for fee-for-service Medicare patients with advanced cancers who meet its clinical criteria for complete genomic profiling with next-generation sequencing, or NGS, of tumor tissue to optimize treatment selection decisions but have insufficient or unavailable tissue for molecular profiling. The expanded coverage decision is in line with FDA approvals of several tumor-agnostic drugs that are based on a single genomic biomarker across all cancers or that are targetable across multiple cancer types. We expect Noridian Healthcare Solutions to issue a new LCD for our Guardant360 test equivalent to the new LCD issued by Palmetto GBA, though the timing and scope of the Noridian LCD are uncertain.
We anticipate approval by the FDA, if obtained, may support further improvements in coverage and reimbursement for our Guardant360 test. We estimate total current coverage in the United States for the Guardant360 test to be more than 170 million lives, including Medicare beneficiaries and members of several commercial health plans.
Commercial adoption - Success in each of the layers above is important for commercial adoption of our tests by clinicians and biopharmaceutical companies. Additionally, for clinicians, endorsement by KOLs, utilization by academic centers and inclusion in national treatment guidelines are important, especially for adoption in the local community setting where 80% of cancer treatment occurs. Our relationships with key stakeholders across the oncology space, clinical data we believe to support use of Guardant360 test ahead of tissue based testing, as well as the inclusion of liquid biopsy as a potential alternative under certain circumstances to tissue biopsy in NCCN guidelines, have helped facilitate the use of our tests by 7,000 oncologists, who have collectively ordered our Guardant360 test over 100,000 times, and over 50 biopharmaceutical companies. We sold 49,926 tests to clinical customers in the year ended December 31, 2019, an increase from 29,238 and 25,626 in the year ended December 31, 2018 and 2017, respectively. We sold 20,643 tests to biopharmaceutical customers in the year ended December 31, 2019, an increase from 10,370 and 6,286 in the year ended December 31, 2018 and 2017, respectively.
In the United States, we market our tests to clinical customers through our targeted sales organization, which is engaged in sales efforts and promotional activities primarily to oncologists and cancer centers. Outside the United States, we market our tests to clinical customers through distributors and direct contracts with healthcare institutions. We market our tests to biopharmaceutical customers globally through our business development team, which promotes the broad utility of our tests for drug development and commercialization. Additionally, we have established a joint venture with SoftBank to accelerate commercialization of our products including in Asia, the Middle East and Africa, with our initial focus being on Japan. Our products are currently marketed in approximately 40 countries.
We generated total revenue of $214.4 million in the years ended December 31, 2019, an increase from $90.6 million and $49.8 million in the years ended December 31, 2018 and 2017, respectively. We also incurred net losses of $67.9 million, $84.3 million and $83.2 million in the years ended December 31, 2019, 2018 and 2017, respectively.


4

Summary of our product portfolio
Our product portfolio is built upon the same principle as our platform, in that success with each facilitates success for the next. Data and learnings from our Guardant360 test have benefited us in developing our GuardantOMNI test, both of which fuel development of our LUNAR program.
The table below illustrates our current products and development programs:
slide1a01.jpg

Our strategy
Our objective is to be the leading provider of precision oncology products for cancer management across all stages of the disease and drive commercial adoption of our products. To achieve this, we intend to:
•
Increase awareness of our products by:
•
building awareness of liquid biopsy and pioneering a blood-first paradigm for genotyping cancer patients;
•
educating biopharmaceutical companies, KOLs and advocacy groups;
•
advocating for inclusion of our tests in treatment guidelines; and
•
expanding access to our products globally through direct investment and by leveraging our global network of partners.
•
Expand clinical utility and increase reimbursement for our products by:
•
working with private and public payers to establish coverage and reimbursement for our tests;
•
investing in clinical evidence directly and through relationships with academia and biopharmaceutical companies to establish expanded indications for use;

5

•
demonstrating improved clinical utility and health economics from use of our tests to patients, physicians and payers; and
•
pursuing FDA approval of our tests to facilitate reimbursement and global market access.
•
Strengthen our relationships with biopharmaceutical and academia customers by:
•
demonstrating the utility of our products in connection with standard of care biopharmaceutical treatments thereby encouraging clinical adoption;
•
developing and seeking approval of our products as companion diagnostics for targeted therapies and immuno-oncology therapies; and
•
providing earlier insights into emerging clinically relevant biomarkers.
•
Leverage our Guardant Health Oncology Platform to expand our product portfolio by:
•
using our commercial engine as a force multiplier of returns on research and development investment to generate data and analytical insights to enable development of new products;
•
taking a disciplined and systematic approach to product and market development, by starting with therapy selection and then expanding sequentially towards early cancer detection;
•
utilizing our data, sample biobank and insights into biology of circulating tumor-related biomarkers in blood to develop our LUNAR program;
•
building on our regulatory and commercial infrastructure to accelerate new product launches and drive commercial efficiencies; and
•
using our strategic relationships, including our joint venture with SoftBank, to drive global commercialization of our products, with a near-term focus on Japan.
Our industry
Despite enormous investment in research and the introduction of new treatments, cancer remains a critical area of unmet medical need. According to the Centers for Disease Control and Prevention, or CDC, cancer is the second leading cause of death in the United States, exceeded only by heart disease. The American Cancer Society reported that in 2016 there were more than 15.5 million Americans with a history of cancer and that approximately 1.7 million new cancer cases would be diagnosed in 2018. Furthermore, approximately 600,000 Americans were expected to die of cancer in 2019. The International Agency for Research on Cancer predicted that the annual global burden of cancer would reach 22 million new cases and 13 million cancer deaths by 2030. The World Health Organization estimated that the total annual economic cost of cancer in 2010 was approximately $1.2 trillion.
The promise of precision oncology
Traditionally, cancer has been classified by the specific organ in which it is located and treated independently of its molecular profile. However, cancer treatment is seeing a significant shift towards precision oncology, the practice of which seeks to match patients to personalized, targeted therapies based on the specific molecular profile of their tumors. Major cancer types, including lung, breast, colorectal and melanoma, for example, have become increasingly classified and treated on the basis of molecular profile.
Discovery of new molecular biomarkers continues to result in further sub-classification of cancer patient populations, which increases complexity of diagnosing and treating the disease for clinicians. This has led to increasing clinical utility and adoption of comprehensive genomic profiling, or CGP. Unlike tests that focus on a single or limited set of biomarkers, commonly referred to as hotspot testing, CGP provides a more comprehensive view of the tumor’s molecular information. Specifically, a comprehensive genomic test must be able to identify all four classes of genetic alterations, namely single nucleotide variants, copy number variants, insertions/deletions and fusions, across multiple genes. The NCCN treatment guidelines now support multi-biomarker testing across several cancer types, which has led to increased adoption of CGP. For example, for NSCLC, NCCN treatment guidelines now include recommendations for testing across nine genes, as well as tumor mutational burden, or TMB, each associated with targeted therapies that are either FDA-approved or in late-stage development.

6

While precision oncology is improving clinical outcomes for patients across many cancer types, it is also benefiting oncology drug development. Biopharmaceutical companies are able to increase chances of a drug’s success in clinical trials by identifying and selecting patients whose cancer has the right molecular profile. This enables them to potentially require fewer patients for the trial and shorten the duration of late-stage clinical trials. According to GlobalData, approximately 66% of the solid tumor oncology clinical pipeline in 2018 was for targeted therapies and immuno-oncology therapy agents, many of which are targeting a cancer with a specific molecular profile or biomarker.
Despite improvements to clinical outcomes and oncology drug development, primarily in the advanced cancer setting, precision oncology has not significantly impacted earlier stage cancer care. For example, precision oncology has yet to fully impact neoadjuvant and adjuvant treatment management, minimal residual disease and recurrence detection in cancer survivors, or early cancer detection in screening eligible asymptomatic individuals and higher risk individuals. Many early stage cancer patients receive only non-targeted chemotherapy post-surgical resection of the tumor in the adjuvant setting and ad-hoc, symptomatic monitoring for recurrence. For early detection of cancer in screening eligible asymptomatic individuals, the current standard of care is comprised of single protein biomarker tests or radiographic imaging, which can have challenges with high false positive rates when used for screening. For example, according to the results from the national lung screening trial reported in The New England Journal of Medicine in November 2011, low-dose CT, or LDCT, imaging may identify lung nodules in heavy smokers, out of which 95% are benign. Furthermore, these tests are generally only applicable to specific cancers and incapable of broad screening for multi-cancer detection.
Limitations of tissue biopsies
We believe that precision oncology, as it is practiced currently, suffers from the major challenge of limited access to molecular information, largely resulting from a reliance on tissue biopsies. This has impeded progress on both early disease diagnosis and effective treatment selection. For a tissue biopsy to be performed, the patient typically must undergo an imaging procedure to locate the tumor, following which a biopsy of the tumor is taken using interventional procedures, such as a core needle biopsy or fine needle aspiration. As part of this procedure, the needle is placed into the tumor and cells are aspirated into a syringe. The cells are placed on a microscope slide, stained and examined by a pathologist to determine the diagnosis and classification of the disease. If genotyping is required, which could include testing with next-generation sequencing, additional slides with tumor tissue would need to be prepared for this analysis.
The tissue biopsy process holds significant challenges, including:
Adverse event risks - Tissue biopsies require use of an invasive tool to access the tumor within the body and are frequently associated with morbidity and mortality. For instance, a study published in The Journal of Oncology Practice / Clinical Lung Cancer in March 2016 reported that, according to Medicare claims data from 2009 to 2011, a lung biopsy was associated with a 19.3% complication rate. Complications included pneumothorax, respiratory failure and hemorrhage.
Delay in care - Collection of tissue biopsy often requires a medical imaging procedure to locate the cancer and coordination amongst an interventional radiologist, surgical oncologist and pathologist to interpret the imaging and collect and analyze the tissue. A traditional tissue biopsy can take several weeks to schedule and additional time to process the sample, which can be burdensome on the patient and delay the collection of critical molecular information.
Cost - According to a study published in The Journal of Oncology Practice / Clinical Lung Cancer in March 2016, the average total cost of a lung biopsy is $14,670, due largely to the required imaging, biopsy or surgical procedure to obtain the tissue, and associated morbidity.
Limited tissue availability - Tissue sampling has variable but significant failure rates due to procedural or sampling failure and may be exhausted by pathology tests for cancer diagnosis. In NSCLC, this has been documented across many institutions and happens as often as 60% of the time. In addition, tissue sampling is unavailable for a minority of patients due to medical contraindication, patient unwillingness or logistical concerns.
Limited to a small portion of a single tumor - A tissue biopsy is often limited to a small portion of a single tumor site, which may not accurately represent the entire tumor or all clinically relevant biomarkers due to tumor heterogeneity. This could lead to tissue biopsy missing mutations targetable by therapy for patients with advanced solid tumors. This limitation has been demonstrated in many tumor types, including lung, breast, gastric, renal and cholangiocarcinoma.
Inability to address applications for early stage cancer patients - For disease recurrence detection or screening for early detection of cancer, tissue tests are impractical or not feasible.

7

The potential for our liquid biopsy technology
We believe that our liquid biopsy technology can liberate molecular information across all stages of cancer and broaden the scope of precision oncology to earlier stages of the disease. Furthermore, we believe our liquid biopsy can potentially lead to dramatically greater rates of data generation and shorten cycles of learning, thereby accelerating progress in improving clinical outcomes. Relative to a tissue biopsy, a routine blood draw is:
•
minimally invasive;
•
rapidly administered;
•
cost effective; and
•
readily available.
In addition, we believe our liquid biopsy technology is:
Able to provide timely insight into tumor genomic alterations - Our liquid biopsy tests are convenient and fast. With a routine blood draw, and for example, typically seven days or less turn-around-time with our Guardant360 test, we believe our Guardant Health Oncology Platform can comprehensively genotype cancer patients and other populations to enable rapid initiation of effective treatment and potential clinical trial enrollment.
More representative of the molecular profile of the tumor in its entirety - Our test results could represent an overall summary of the entire molecular profile of the tumor or tumors and not just a subset of a single tumor that may be represented in a tissue sample. This may enable insight into potentially more targetable mutations than tissue testing.
Able to monitor response to therapy – We believe recent data suggests that changes in tumor burden can be monitored through the use of our liquid biopsy technology and successive blood draws to potentially provide quicker information as to the effectiveness of a chosen treatment than current approaches using radiographic imaging.
Able to address all stages of the disease – We believe ready access to molecular information and the ability to potentially detect cancer at early stages in blood enable our liquid biopsy technology to be used for applications, such as for minimal residual disease and recurrence detection or early cancer detection in screening eligible asymptomatic individuals and higher risk individuals.
Able to match standard-of-care tissue testing – In a recent head-to-head comparison of Guardant360 test to standard-of-care tissue testing for biomarker identification in first-line advanced NSCLC patients, our liquid biopsy technology produced biomarker detection rates in line with standard of care tissue testing.
History of liquid biopsy and challenges
The concept of a liquid biopsy is not new, and we believe that a minimally invasive tool, such as a liquid biopsy, has been an aspiration of the oncology field for many decades. Multiple modalities have been pursued to access a patient’s molecular information through blood, including ctDNA, circulating tumor cells, or CTCs, and exosomes. It has been shown that modalities using ctDNA may have distinct advantages over other known modalities. For example, ctDNA has a concentration in blood that may be over 100 times higher than CTCs, which can enable increased test sensitivity and accuracy.
However, despite this promise of higher concentration and, therefore, higher theoretical sensitivity of a ctDNA test, these fragments are still found at very low concentrations which can make their analysis challenging by conventional methods. For example, circulating cell-free fetal DNA, which is the target for a variety of non-invasive prenatal testing applications for women during pregnancy, makes up a median of 10% of the total cell-free DNA in maternal blood. By contrast, the median concentration of ctDNA genomic alterations detected by us in blood of advanced cancer patients is 0.46% and can be present at levels below 0.01% in early stage cancer patients.
Although the sensitivity and specificity of conventional next-generation sequencing is sufficient for tissue biopsy based tumor profiling, this performance is inadequate for liquid biopsies due to the low concentrations of ctDNA in blood. Moreover, comprehensive genomic profiling for precision oncology requires detection across all four classes of genomic alterations below, which can be especially challenging with ctDNA:
Single-nucleotide variants (SNVs) - variation(s) in a single nucleotide in a DNA molecule
Insertions/deletions (Indels) - short nucleotide section(s) of a DNA molecule inserted or deleted
Copy number amplifications (CNVs) - regions(s), typically spanning one or more genes of the genome that are repeated

8

Genomic rearrangements - involve gross alterations of chromosomes or large chromosomal regions and can take the form of deletions, duplications, insertions, inversions or translocations.
The market opportunity and our vision for the standard of cancer care
We believe that liquid biopsy tests can solve critical challenges of tissue-based tests, expand the scope of precision oncology across the cancer care continuum to earlier stage disease, and empower clinicians to make better decisions to improve clinical outcomes, lower healthcare costs and enable biopharmaceutical companies to advance new therapies. We believe liquid biopsy has application in the following areas, representing a market opportunity we estimate to be more than $50 billion in the United States:
Therapy selection in advanced cancers. Clinicians require genomic information in order to properly match advanced cancer patients with the appropriate treatment across multiple lines of therapy. Given the limitations of tissue biopsies, we believe a blood test that is capable of accessing the comprehensive genomic profile of the patient’s cancer represents a significant breakthrough, especially in the local community setting, where 80% of cancer patients are treated, infrastructure and expertise to access tissue may be especially limited. We also believe a comprehensive liquid biopsy test for therapy selection can benefit biopharmaceutical companies across a range of applications, including patient selection and recruitment for clinical trials and commercialization once the drug is approved, as well as identification of new molecular targets for drug development. For example, better access to molecular information can speed clinical trial enrollment and increase the probability of success of drug development in a target patient population.
We estimate this is an up to $6 billion total market opportunity in the clinical and biopharmaceutical markets. This includes a near-term clinical opportunity of $2 billion, based on an estimated 700,000 metastatic patients in the United States and an assumed average reimbursement rate of $3,000, a similar amount covered by Medicare for a comprehensive genomic profiling test. We estimate the number of metastatic patients in the United States based on the number of deaths attributable to cancer annually in the United States as reported in A Cancer Journal for Clinicians and the number of patients who are diagnosed with advanced cancer in the United States and are alive a year after diagnosis as reported in the SEER Cancer Registry. We believe this opportunity may expand by up to an additional $2 billion, as metastatic patients may require multiple tests to inform subsequent lines of therapy.
We estimate that the market opportunity with biopharmaceutical companies in the United States is over $2 billion including an opportunity of over 400,000 tests based on the industry’s current clinical pipeline of over 1,200 immuno-oncology and over 450 targeted therapy programs, involving more than 130,000 patients. These programs represent two distinct testing opportunities: (1) prospective screening to identify candidate patients for clinical trial enrollment and (2) retrospective analysis of patient samples. In addition, we estimate there is a market opportunity of $500 million in companion diagnostics development and other commercial opportunities.
The chart below represents the breakdown of the total estimated market opportunity across both the targeted therapy and immuno-oncology opportunities for the therapy selection markets:
marketopportunity.jpg


9

Neoadjuvant and adjuvant treatment in early stage cancer patients and surveillance in cancer survivors. We believe early stage cancer patients would benefit from tests that could more accurately identify patients to benefit from adjuvant treatment. A liquid biopsy test in this setting could help biopharmaceutical companies identify new opportunities in adjuvant drug development and therapies targeting earlier stage cancers. In addition, we believe cancer survivors would benefit from tests that could improve minimal residual disease and recurrence detection. Follow-up testing for surveillance in cancer survivors is often ad-hoc, leaving patients guessing as to if and when their cancer may recur. A portion of this market is currently served by prognostic and predictive molecular tests that can classify whether a patient may be at low-risk or high-risk of recurrence. We believe that a definitive diagnostic test for cancer would benefit this patient population both immediately following surgical resection of the tumor and as a monitoring tool in subsequent years. We estimate this is an approximately $15 billion market opportunity, based on an estimated 15 million solid tumor cancer survivors as of 2016, excluding survivors of blood cancers, including leukemia and Non-Hodgkin’s lymphoma, in the United States as reported by the American Cancer Society, and assuming an average price of $1,000 per test for each solid tumor cancer survivor, which is consistent with the cost to screen a patient for lung cancer as reported in the New England Journal of Medicine in November 2011.
Early detection of cancer. Earlier detection of cancer is generally correlated with better clinical outcomes and a higher cure rate for many cancer types. We believe that a test that can accurately detect cancer at its earliest stages or even pre-cancer in a largely asymptomatic population will need to overcome high technological, clinical and regulatory challenges. However, such a test can have significant benefits on mortality and perhaps eventually reduce incidence rates of cancer, if the information provided can be effectively paired with the right preventative medicine or curative intervention. We believe this represents a potential market opportunity of approximately $15 billion for non-invasive modalities such as our LUNAR-2 assay that is under development, based on an estimated 30 million individuals who are eligible for colorectal cancer screening. In addition, we estimate this is an approximately $18 billion market opportunity with respect to individuals at a higher risk of developing cancer, based on an estimated 35 million individuals at higher risk for cancer in the United States and assuming an average price of $500 per test. The estimated 35 million individuals at higher risk for cancer in the United States consist of approximately 17 million individuals at moderate to high hereditary risk of developing breast, ovarian, colorectal, endometrial or prostate cancer, based on prevalence statistics reported in Genetics in Medicine and U.S. Census Data; approximately 14.5 million people over the age of 50 who are moderate to heavy smokers, as reported by the Centers for Disease Control and Prevention; and approximately 3.5 million individuals in the United States at high risk of developing liver cancer due to Hepatitis C infection, based on the 2003-2010 data reported in Hepatology in 2015.

10

The graphic below depicts the potential opportunities of liquid biopsy across the cancer continuum of care:
slide1a03.jpg


11


The Guardant Health Oncology Platform
The Guardant Health Oncology Platform is comprised of strengths across five critical layers, each of which is tightly coupled with the others, and we believe success in each facilitates success in adjacent layers. We believe our platform and our position as a pioneer of comprehensive liquid biopsy provide us with a competitive advantage and form a barrier to entry. The following diagram depicts the five layers of our oncology platform:
guardantgraphic201910k.jpg
Technology – Guardant Health Digital Sequencing
Guardant Health Digital Sequencing combines state-of-the-art technology from multiple disciplines and is enabled by robust, high-efficiency biochemistry at the front-end, next-generation sequencing and a machine learning augmented bioinformatics pipeline. The combination of all of these technologies onto one platform has enabled our programs in liquid biopsy and what we believe is the highest performing clinical comprehensive liquid biopsy, with a turnaround time of typically less than seven days after we receive the sample. We believe our platform is able to detect all four classes of genomic alterations and microsatellite instability, or MSI, at sensitivity levels beyond comparable platforms.
Two specific enhancements we employ throughout the workflow include:
High-efficiency chemistry - Our proprietary ctDNA sample preparation biochemistry is able to convert the vast majority of extracted ctDNA molecules into a sequencing library. This enables enhanced sensitivity to detect mutations present at ultra-low variant frequency and the ability to work with limited sample volumes.
Error suppression via proprietary bioinformatics engine - Our bioinformatics pipeline reduces the sequencing error rate by 1000-fold over conventional next-generation sequencing and by 30-fold over other sequencing assays relying on molecular barcoding alone. Furthermore, the machine learning capability enables performance improvement as we incorporate data from additional blood samples.

12

Clinical utility
We believe that the measure of the clinical utility provided by a given diagnostic test or technology lies in the ability to enable the physician to match intervention with the patient to select the treatment likely to produce a more favorable outcome for the patient. We also believe that success in the clinical utility layer requires both independent, systematic investments in clinical research, and strategic relationships with market-leading biopharmaceutical companies. We aim to generate publications in independently peer-reviewed scientific journals to demonstrate clinical utility of our technology. For this reason, we have invested in directly sponsoring or participating in prospective, interventional clinical trials with leading academic cancer centers and biopharmaceutical companies, including over three dozen published clinical outcomes studies demonstrating that overall biomarker detection rates of our non-invasive blood testing were in line with tissue testing. We have built an internal clinical development team that can efficiently run clinical utility studies and continue to invest in such studies spanning many indications within the advanced cancer setting, including completed outcomes studies (27 in lung cancer, 15 in gastrointestinal cancers, 5 in breast cancer and 10 in other cancer types). We are also investing heavily in studies involving earlier stage disease.
The strength of our technology facilitates strategic relationships with academia and over 50 biopharmaceutical companies, to help them advance the development of their drug pipelines and expand the utilization of currently commercialized treatments. In return, these relationships provide rigorous clinical validation of our technology and early insights into emerging therapeutically relevant test targets.
Regulatory approval
We believe that Guardant360 test was the first comprehensive liquid biopsy approved by the NYSDOH. In addition, based on our review of publicly available records, we believe our facility was the first comprehensive liquid biopsy laboratory to become CLIA-certified, CAP-accredited and NYSDOH-permitted. Our Guardant360 and GuardantOMNI tests have each been designated by the FDA as a breakthrough device for use as a companion diagnostic in connection with certain specified therapeutic products of our biopharmaceutical customers. Among other things, designation as a breakthrough device provides for priority review by the FDA and more interactive communication with the FDA during the development process. In the fourth quarter of 2019, we submitted a PMA application to seek the FDA’s approval of our Guardant360 test to be used as a companion diagnostic, initially in connection with one therapeutic product of a biopharmaceutical customer, and to provide tumor mutation profiling for cancer patients with solid tumors. In February 2020, we submitted an additional module of the PMA application for our Guardant360 test to the FDA. Medicare’s National Coverage Determination, or NCD, for Next Generation Sequencing, or NGS, was established in 2018 and subsequently updated in 2020. The NCD provides coverage for molecular diagnostic tests such as our Guardant360 test, if, among other criteria, such tests are offered within their FDA-approved companion diagnostic labeling. We believe that this establishes a competitive advantage for tests receiving FDA approval and that FDA approval will be increasingly necessary for diagnostic tests to gain adoption, both in the United States and abroad, by clinicians, payers and biopharmaceutical companies.

Payer coverage
Coverage from public and commercial payers is primarily influenced by clinical evidence, endorsement by KOLs and treatment guidelines. The analytical and clinical data that we have generated, combined with our support from KOLs, has led to a number of positive coverage decisions from commercial payers. Guardant360 test is currently covered by Cigna, Priority Health, multiple regional Blue Cross Blue Shield plans as well as the health plans associated with eviCore for NSCLC, which we believe gives us a competitive advantage with these payers. With respect to Medicare, in July 2018, Palmetto GBA, the MAC responsible for administering MolDx, issued an LCD for our Guardant360 test with respect to NSCLC patients who meet certain clinical criteria. Subsequently in 2018, Noridian Healthcare Solutions, the MAC responsible for adjudicating claims in California, where our laboratory is located, and a participant in MolDx, finalized an equivalent LCD for our Guardant360 test, and we have been billing Medicare pursuant to this Noridian LCD. In December 2019, replacing its prior NSCLC patient LCD, Palmetto GBA finalized a new LCD for our Guardant360 test that provides limited Medicare coverage for the Guardant360 test in patients diagnosed with solid cancers of non-central nervous system origin. The new LCD covers our Guardant360 test for fee-for-service Medicare patients with advanced cancers who meet its clinical criteria for complete genomic profiling with NGS of tumor tissue to optimize treatment selection decisions but have insufficient or unavailable tissue for molecular profiling. The expanded coverage decision is in line with FDA approvals of several tumor-agnostic drugs that are based on a single genomic biomarker across all cancers or that are targetable across multiple cancer types. We expect Noridian Healthcare Solutions to issue a new LCD for our Guardant360 test equivalent to the new LCD issued by Palmetto GBA, though the timing and scope of the Noridian LCD are uncertain. We anticipate FDA approval of our Guardant360 test, if obtained, may support further improvements in coverage and reimbursement, including Medicare according to the NGS NCD.

13

Commercial adoption
Success in each of the layers above is important for commercial adoption by clinicians and biopharmaceutical companies. Additionally, for clinicians, endorsement by KOLs traction at academic centers and inclusion in national treatment guidelines is important, especially for clinical adoption in the local community setting where 80% of cancer treatment occurs. Our relationships with key stakeholders across the oncology space, as well as the recent inclusion of liquid biopsy under certain circumstances as a potential alternative to tissue biopsy in NCCN treatment guidelines has helped facilitate adoption of our tests by 7,000 oncologists, who have collectively ordered our Guardant360 test over 100,000 times, and by over 50 biopharmaceutical companies.
Our products and development programs
We have launched our Guardant360 and GuardantOMNI tests and are developing additional tests under our LUNAR program, including having launched our LUNAR-1 assay for research or investigational use. We believe our product portfolio, once completed, will address the full continuum of care and has utility in both the clinical and biopharmaceutical markets.

14

Therapy Selection
The increasing diversity of targeted therapies and associated molecular biomarkers has given rise to comprehensive genomic profiling, particularly in tumor types where multiple genomic targets can be found and treated effectively. For example, NSCLC, like other tumors, has multiple effective treatment options targeting different genomic mutations. There are nine targetable genes in NSCLC, which are comprised of alterations across all four genomic variant classes (SNVs, indels, CNVs, and fusions), as well as TMB. Five of these targets are on-label approved biomarkers for FDA-approved therapies. The NCCN treatment guidelines recently recommended testing for all of the genomic mutations or alterations across different cancer types, which demonstrates the requirement for broader genomic profiling.
Despite NCCN guidelines, data from a study of 800 NSCLC patients, published on Clinical Lung Cancer in November 2017, reported that only a minority of patients actually were tested for the guideline-recommended targetable genomic mutations, and only 8% of patients were comprehensively genotyped. A retrospective review of data extracted from electronic medical records of 1,497 patients with pathologically confirmed metastatic colon cancer, or mCC, at 23 practices across the United States, published in Journal of Clinical Oncology Precision Oncology in December 2019, showed that only 40% of such 1,497 patients were tested according to guidelines despite longstanding medical guidelines recommending biomarker testing for all patients with mCC. Such “undergenotyping” had multiple causes in the study, and primary reasons for not testing were lack of sufficient tissue, poor patient performance status or infeasibility to undergo a repeat biopsy for additional tissue.
Guardant360 Test
We believe Guardant360 test is the market leading comprehensive liquid biopsy test, based on the number of tests ordered. Guardant360 test is a 74 gene test that supports treatment selection for advanced stage cancer patients with solid tumors. The testing process requires two 10 milliliter blood samples that are sent to our laboratory in Redwood City, California, where we process and analyze the samples using proprietary, next-generation sequencing-based Guardant Health Digital Sequencing Technology. Results are typically delivered in seven days following receipt of sample and delivered by a clinical report through fax, portal or mobile device.
Since we launched our Guardant360 test in 2014, it has been ordered over 100,000 times by more than 7,000 oncologists across dozens of cancer types, by more than 50 biopharmaceutical companies and by all 28 NCCN centers. Guardant360 test is also currently being developed for use as a companion diagnostic.
Guardant360 clinical report
A typical Guardant360 clinical report contains somatic mutations detected in patient blood samples, associated treatment options and available clinical trials in the vicinity of the patient’s location. Additionally, the report depicts a proprietary visual representation that shows the evolution of somatic mutations in longitudinal blood samples.
Analytical validation
We believe there are two key performance characteristics that are critical for a liquid biopsy test. The first is sensitivity, which refers to the level of ctDNA in circulation at which the technology reliably detects variants for a given input sample amount. The second is specificity, which is the probability that a given test result is accurate. These metrics are critical for effective treatment selection based on the results of liquid biopsy testing. It can be especially challenging to maintain high specificity at detection levels below 0.25% due to the high error rates of standard next-generation sequencing protocols at these levels and the broad genomic footprint tested simultaneously in a comprehensive liquid biopsy test. In order to assess these key performance characteristics for Guardant360 test, we conducted analytical validation studies against orthogonally validated methods. The results, as published in Clinical Cancer Research, demonstrated that Guardant360 test has a detection threshold of one to two molecules across multiple alteration types, including all four classes of genomic alterations and MSI, with very high specificity which results in accurate and sensitive detection of somatic mutations in patient samples.







15

Clinical trials and publications
The goal of our clinical development with Guardant360 test is to support its use for comprehensive genomic profiling across multiple tumor types, including as a preferred alternative to tissue testing to inform first line treatment right after diagnosis and at time of disease progression. We publish peer-reviewed studies in order to influence treatment guidelines, to educate clinicians and other oncology stakeholders about the value proposition of our test and to set the stage for reimbursement with private and public payers. We have over 50 approved, completed or active clinical outcomes studies, more than 150 peer-reviewed publications and more than 400 scientific abstracts. We are proactively pursuing studies to support the use of our Guardant360 test as a preferred alternative to tissue testing to inform first line treatment right after diagnosis, with the goal to provide evidence that our Guardant360 test detects genomic alterations at a similar rate compared to standard of care tissue testing in the United States, Europe and Asia. Such a strategy is predicated on the Guardant360 test’s ability to offer accurate, reliable and fast guideline-directed comprehensive genotyping for all adult solid tumors without exposing patients to invasive biopsy procedures’ risks, delays or chance of failure.
The following summarizes the results of some of our Guardant360 test clinical studies:

Biomarker discovery rate. In the first quarter of 2019, we announced results from our Noninvasive vs. Invasive Lung Evaluation, or NILE, study after it met its primary endpoint of demonstrating that Guardant360 test detected targetable genomic biomarkers in advanced, non-squamous NSCLC at a similar rate to standard of care tissue testing. Our Guardant360 test identified guideline-recommended biomarkers in 77 of the 282 patients enrolled in the study, while tissue testing identified such biomarkers in 60 of those patients. In the study, the median time to results for Guardant360 testing was much shorter than for tissue testing, as Guardant360 test results were reported in an average of 9 days, while tissue testing results were reported in an average of 15 days, and our Guardant360 test resulted in guideline-recommended testing for three times as many patients as standard-of-care tissue testing. We believe these data support the use of our testing ahead of tissue testing for all newly diagnosed advanced NSCLC patients. Findings from an 800-patient prospective clinical trial led by the Institute of Cancer Research London for treatment selection in advanced breast cancer, which we refer to as plasmaMATCH trial, as presented at the San Antonio Breast Cancer Symposium in December 2019, showed that our Guardant360 test accurately detected biomarkers that can guide targeted treatment for late stage breast cancer patients, many with bone metastases that are often difficult to biopsy and typically yield insufficient bone tissue for biomarker analysis.

Genotyping concordance with matched tumor tissue - Results of a blinded retrospective study comprising 6,948 consecutive NSCLC samples to assess the concordance between Guardant360 test and tissue genotyping of samples received for clinical testing at our laboratory showed high positive predictive value, which is the probability that a variant detected by Guardant360 test in blood was in fact present in the corresponding tissue sample. A study published in Clinical Cancer Research in August 2019 concluded that microsatellite instability, or MSI, detection using the Guardant360 test was highly concordant with standard-of-care tissue testing, which enabled detection of MSI status concurrent with comprehensive genomic profiling and expanded access to immunotherapy for advanced cancer patients for whom current testing practices are inadequate.
Detection rate of ctDNA in patient samples - We observed a test success rate of 99.6% in a study comprising 10,593 consecutive samples to provide insights into Guardant360 test performance in real-world clinical specimens. Overall detection rates of ctDNA were consistently high (85.9%), predominantly driven by NSCLC (87.7%), colorectal (85.0%) and breast (86.8%). We believe this cohort demonstrates the need for a highly sensitive liquid biopsy as the median variant allele frequency, or VAF, found was only 0.46%.
Prospective clinical response rate - A prospective, interventional, multi-cancer clinical utility study of Guardant360 test across 193 patients with no tissue genotyping options showed an objective response rate of 87% (95% CI, 58%-98%) with disease control rate of 100% (95% CI, 75%-100%). In the NSCLC cohort, 73 patients were tested, 34 were matched with pre-specified therapy, of which 17 patients were treated with matched therapy, of which 15 patients were evaluable. Importantly, the response rate was independent of the VAF of mutations found in the blood.
Clinical relevance of actionable mutations detected at ultra-low concentrations - We analyzed the clinical response of a multi-center case series of Guardant360 test-detected targetable driver alterations in advanced NSCLC with VAFs of less than 0.2%. Twelve patients were selected who had targetable driver alterations in EGFR (n=7, VAF range 0.045%-0.14%), MET exon 14 skipping mutation (n=1, VAF = 0.06%), BRAF V600E (n=1, VAF = 0.1%), EML-ALK fusions (n=3, VAF range 0.07-0.16%). All patients responded to targeted therapy with median progression-free survival of 52 weeks. Of particular significance, 7 out of 12 patients were undergenotyped, largely due to tissue insufficiency.

16

GuardantConnect
Because metastatic cancer patients often exhaust standard of care treatment options as the disease progresses and guidelines recommend clinical trials for advanced cancer patients, clinical trial matching is an acute need in oncology. At the same time, biopharmaceutical companies need to fill clinical trials that require screening hundreds of thousands of patients. Despite these needs, clinical trial enrollment in oncology has severely lagged, with only 3-6% of cancer patients enrolling in clinical trials. GuardantConnect is our integrated software solution designed for our clinical and biopharmaceutical customers, seeking to connect patients in need tested with Guardant360 test with clinical trials.
GuardantOMNI Test
Our GuardantOMNI test is built on Guardant Health Digital Sequencing Technology and learnings from our Guardant360 test. The GuardantOMNI test, launched in 2017, has a significantly larger genomic panel footprint than the Guardant360 test and has achieved comparable analytical performance in clinical studies, including for translational science applications in collaboration with several biopharmaceutical companies, including AstraZeneca, Bristol-Myers Squibb, Merck MSD, Merck KGaA of Darmstadt, Germany and Pfizer. It covers 500 genes, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications, such as tumor mutational burden and microsatellite instability.
In order to preserve performance characteristics of our Guardant360 test across a broader gene panel, we implemented additional enhancements to the assay efficiency and bioinformatics analysis to improve the sensitivity of our GuardantOMNI test. These enhancements are critical in the context of using the GuardantOMNI test in the retrospective testing of clinical trial samples for translational science applications in collaboration with biopharmaceutical customers, as those samples are often available with only a limited volume of plasma.
Validation data indicates that the GuardantOMNI test exceeds the Guardant360 test’s sensitivity for detecting clinically actionable biomarkers. At the same time, broader panel-wide performance of small variants is roughly similar to that of Guardant360 test. The broad genomic footprint of our GuardantOMNI test enables accurate measurement of tumor mutational burden. The GuardantOMNI test received breakthrough device designation from the FDA in December 2018 and is currently being developed, including for use as a potential companion diagnostic, to identify patients who may benefit from immuno-oncology therapeutics, including patients that may more likely respond to immuno-oncology agents based on TMB.
LUNAR Program
We believe that there is a critical need to develop products to expand precision oncology to post-cancer monitoring and earlier stage settings. Such products would enable clinicians to precisely detect, monitor and select the appropriate intervention at the right times in the disease’s evolution, key to significantly improving patient clinical outcomes. In order to systematically address this need, we launched our LUNAR program to develop tests to address the needs of early stage cancer patients with neoadjuvant and adjuvant treatment selection, cancer survivors with surveillance, and asymptomatic individuals eligible for cancer screening and individuals at a higher risk for developing cancer with early detection. Our research and development results to date indicate that somatic signatures alone may be insufficient for detection of early stage cancers with high sensitivity. For this reason, we have incorporated epigenomic signatures to enhance the performance of our LUNAR assays in these settings.
Our LUNAR-1 assay is intended to address identification of those who are likely to benefit from adjuvant treatment, detection of minimal residual disease in the blood of cancer patients after surgery, and surveillance of patients who have completed curative cancer treatment to potentially detect recurrence at an earlier stage.
Our LUNAR-2 assay is being developed to address early cancer detection in screening eligible asymptomatic individuals and higher risk individuals. Early cancer detection is challenging, especially with respect to clinical specificity. There is a minimal amount of ctDNA in patients with low-disease burden. Additionally, naturally occurring genomic aberrations in blood as well as signals from non-cancer related diseases can add biological noise obfuscating detection of circulating tumor-related biomarkers. We believe we have the unique capability to overcome these challenges by leveraging our:
•
Vast data sets and deep insights: We have targeted deep sequencing data in combination with low coverage sequencing of whole genome from tens of thousands of cancer patients. This data has enabled discovery of novel epigenomic variations across multiple cancer types. We believe augmenting genomic with epigenomic signatures can enhance the clinical sensitivity and specificity of our tests significantly. Moreover, we developed a database of biological noise sources such as clonal hematopoiesis of indeterminate potential, which enables us to further enhance the sensitivity and specificity of our tests.


17

•
Extensive blood biobank: We have a biobank of tens of thousands of cancer samples that we use for discovery and, more importantly, biomarker verification and validation. For example, we are analyzing these samples with whole genome sequencing to identify and confirm tumor associated signatures. Also, we have been collecting additional samples through multiple on-going research collaborations.

Neoadjuvant and adjuvant treatment selection in early stage cancer patients
Neoadjuvant and adjuvant therapies may include chemotherapy, hormone therapy, radiation therapy, immunotherapy and targeted therapy. Neoadjuvant therapies are delivered before the main treatment to help reduce the size of a tumor or kill cancer cells that have spread. Adjuvant therapies are delivered after the primary treatment to destroy remaining cancer cells. Neoadjuvant and adjuvant therapies are often recommended when a patient with early-stage cancer undergoes surgery or radiation therapy and the oncologist believes the patient may benefit from additional systemic treatments. Neoadjuvant and adjuvant therapies benefit many, but not all, cancer patients. Our LUNAR-1 assay is intended to identify early stage cancer patients that may benefit from neoadjuvant and adjuvant treatment.
In addition, we believe there is an opportunity to evaluate clinical utility of our LUNAR-1 assay by partnering with biopharmaceutical companies to identify these patients for adjuvant trial enrollment and also monitor treatment effectiveness post-adjuvant treatment. In comparison to drug development in the metastatic setting, adjuvant drug development can cost significantly more, typically require more patients, last longer and have a lower probability of success. Identification of those most likely to benefit from adjuvant therapy is therefore an important clinical challenge. We believe that our LUNAR-1 assay could support ctDNA enrichment strategies that may reduce the cost of these development activities, lead to new therapeutic indications and potentially reduce the use of cytotoxic chemotherapy in patients unlikely to benefit. In June, 2019, results presented by us, together with the Massachusetts General Hospital Cancer Center, at the American Society of Clinical Oncology, or ASCO, annual meeting, provided evidence regarding our LUNAR-1 assay’s ability to identify early-stage colorectal cancer patients with post-operative molecular residual disease who may benefit from adjuvant therapy.
Minimal residual disease and recurrence detection in cancer survivors
Minimal residual disease is a term generally used to describe the small number of cancer cells in the body after cancer treatment. After treating cancer, remaining cancer cells can become active and start to multiply, causing a relapse of the disease. Detecting minimal residual disease may indicate that the treatment was not completely effective or that the treatment was incomplete. The number of remaining cells may be so small that they do not cause any physical signs or symptoms and often cannot even be detected through traditional methods. Testing for minimal residual disease can help the treatment team distinguish between patients who need additional or different treatment from those who do not. This knowledge can also potentially guide treatment decisions and improve patient outcomes.
A recurrence occurs when the cancer comes back after treatment. This can happen weeks, months, or even years after the primary cancer was treated. Cancer survivors in general face a risk of developing another cancer, and fear of recurrence can negatively affect quality of life.
Our LUNAR-1 assay is intended to provide cancer survivors with quantitative peace of mind through a test for minimal residual disease or recurrence and help physicians determine those patients that may still have minimal residual disease or identify a risk of relapse much earlier than conventional methods and therefore finds candidates for earlier intervention.
To further pursue this potential market opportunity, we, in collaboration with a National Clinical Trials Network group, initiated a prospective multi-center randomized controlled trial, which we refer to as the COBRA study, in approximately 1,400 patients with resected stage II colon cancer to use our LUNAR-1 assay to evaluate recurrence-free survival in patients who receive ctDNA-directed therapy as compared to the current standard-of-care active surveillance.
Early cancer detection in screening eligible asymptomatic individuals
Colorectal cancer may not cause symptoms until the cancer has spread and is difficult to treat, which makes screening for colorectal cancer in people who do not readily demonstrate symptoms appealing. It has the potential to find the cancer earlier when it may be easier to treat, and reduce disease-specific mortality. Based on the 2009-2015 cancer statistics from the Surveillance, Epidemiology, and End Results (SEER) program of the National Cancer Institute, the average five-year survival rate for all U.S. colorectal cancer patients is 64.4% and is increased to 89.9% among those diagnosed at an early stage.

18

Our LUNAR-2 assay is being developed to identify people who are likely to benefit from screening for colorectal cancer. In April 2019, at the American Association for Cancer Research, or AACR, annual meeting, we presented exploratory data around the use of our LUNAR-2 assay for potential screening applications in a cohort of 229 recently diagnosed colorectal cancer patients and aged-matched cancer-free controls. These data showed average LUNAR-2 assay sensitivity exceeding 80% with specificity of 94% for patients with stage I/II colorectal cancer in this cohort (76% in stage I and 87% in stage II). To further pursue this potential market opportunity, we initiated a prospective screening study, which we refer to as the ECLIPSE trial, to evaluate the performance of our LUNAR-2 assay in detecting colorectal cancer in average-risk adults. We expect to recruit approximately 10,000 patients and enrolled the first patient in the study in the fourth quarter of 2019.
Early cancer detection in higher risk individuals
Although cancer is the second leading cause of death in the United States, it can be cured if detected and treated at its earliest stages. For example, the introduction of the Pap smear reduced cervical cancer mortality by more than 80% from 1950 to 2005. However, despite the benefit of screening, which is recommended by the U.S. Preventive Services Task Force for cervical, breast, lung and colorectal cancers, a significant number of people do not receive screening today. For example, greater than 30% of eligible Americans are not up to date on screening for colorectal cancer.
We believe some of the major challenges lie in the limited efficacy of existing screening modalities:
Protein testing - Current screening tests using protein biomarkers for various cancers, including prostate (PSA), pancreatic (CA19-9) and ovarian (CA125), lack sensitivity and specificity.
Imaging - While radiographic imaging is sensitive, it lacks clinical specificity. For lung cancer screening, as an example, the landmark National Lung Cancer Screening Trial reported that low-dose computed tomography, or LDCT, lung cancer screening of heavy smokers significantly increased cancer diagnosis rate and decreased overall mortality. However, a recent practice survey reported that only 3.9% of the estimated 6.8 million eligible patients had received LDCT screening. An important barrier to adoption of LDCT screening has been its greater than 95% false positive rate, which results in many unnecessary biopsies or inaction on positive findings.
Our goal is to develop an accurate, affordable test with potential for high compliance for use in higher risk individuals. To support this development, we have forged several clinical research collaborations, including with institutions such as the University of San Francisco, the University of Colorado and the University of Pennsylvania, studying applications of our LUNAR-2 assay for different cancer types.

Commercialization
U.S. clinical commercial efforts
We sell our tests to clinical customers in the United States through our targeted sales organization. As of December 31, 2019, our clinician-focused sales organization in the United States is engaged in sales efforts and promotional activities primarily targeting oncologists and cancer centers. Our sales representatives typically have extensive backgrounds in laboratory testing, therapeutics and oncology. We have supplemented the team with clinical oncology specialists with extensive medical affairs experience for molecular information support in the field.  
Our clinical commercial efforts are focused on driving adoption with academic research institutions and with community oncology practices, including through leading physician networks. As we continue to grow our sales organization, we are also expanding our reach to include large community practices, community oncology networks, integrated delivery/ payer-owned systems and government medical facilities that are looking for a reliable partner for comprehensive molecular information testing. 
International clinical commercial efforts
We currently offer our tests in countries outside the United States primarily through distributor relationships or direct contracts with hospitals.
Currently, all customer samples are shipped globally to our laboratory in Redwood City, California. We are conducting studies in various jurisdictions in an effort to secure reimbursement. As these studies progress and we near commercial opportunities there, we may seek to establish an in-country laboratory and direct sales organization. Specifically, we have already demonstrated the ability to deploy our technology to partner laboratories such as cancer centers, for the development of liquid biopsy assays based on our technology platform. We believe that this capability will be important in accelerating adoption of our platform and the performance of liquid biopsy testing in certain countries.

19

Together with SoftBank, we formed a joint venture, Guardant Health AMEA, Inc., which we refer to as the Joint Venture, relating to the sale, marketing and distribution of our tests in all areas worldwide outside of North America, Central America, South America, the United Kingdom, all other member states of the European Union as of May 2017, Iceland, Norway, Switzerland and Turkey, or the JV Territory. Depending on the market opportunity in a country, the Joint Venture may create direct operations or conduct its operations through either a distribution model or a licensing model. Direct operations would entail full operations including a laboratory, sales and marketing and regulatory among other functions. Under the distribution model, our tests would be marketed and sold by the Joint Venture or third-party distributors in relevant countries within the JV Territory, and the tests would be performed by or on behalf of us or our affiliates outside of such countries on samples obtained by the Joint Venture or third-party distributors in such countries. Under the license model, the Joint Venture, or an entity designated by the Joint Venture, would be licensed to market and sell the tests in relevant countries within the JV Territory, and the Joint Venture, or an entity designated by the Joint Venture, would perform the tests on samples obtained in such countries. Following a determination by the board of directors of the Joint Venture on the appropriate model for an individual country, we will enter into an agreement with the Joint Venture with respect to the individual country that is based on either the distribution or license model. We expect to rely on the Joint Venture to accelerate commercialization of our products in Asia, the Middle East, and Africa.
Currently, we and the Joint Venture are primarily focused on expanding our commercial capabilities in Asia, with an initial focus on Japan. There are estimated to be over 400,000 deaths from solid tumor cancers annually in Japan with a significant portion relating to lung and gastric cancers. We are involved in several nationwide clinical programs that help establish clinical utility of our Guardant360 test in the Japanese population with the first patient tested in late 2018.
Biopharmaceutical commercial efforts
Our business development team is focused on enterprise selling to biopharmaceutical companies in the United States and internationally. Our strategy with each biopharmaceutical customer is to demonstrate the value proposition of the Guardant Health Oncology Platform and expand its utilization across the organization from early stage research through clinical development to commercialization. Given the broad and differentiated utility of our platform, we believe we can support our biopharmaceutical customers across many applications, including:
•
discovery of new targets and mechanisms of acquired resistance;
•
retrospective sample analysis to rapidly identify biomarkers associated with response and lack of response;
•
prospective screening and referral services to accelerate clinical trial enrollment; and
•
companion diagnostic development to support the approval and commercialization of therapeutics.
We also expect to be able to capture other commercial opportunities from our genomic data, which can be used in combination with clinical outcomes or claims data for multiple applications, including novel target identification.
Payer coverage and reimbursement
We believe our tests and services provide solutions that enhance the safety, efficacy and guide cost-effective treatment selection of cancer therapeutics, as evidenced by the adoption from key stakeholders in the healthcare ecosystem. Evidence-based analytical validity, clinical validity and clinical utility studies are key drivers of both clinical adoption and reimbursement from commercial and government payers. Peer-reviewed evidence of our products and services will continue to be a center piece of our reimbursement strategy.
We believe our products offer significant health economic value to payers in the following ways:
•reduce undergenotyping, thereby matching health plan members to targeted therapies that are both less costly and more effective than potential alternatives such as immunotherapy; and
•reduce the need for a repeat invasive biopsy, thereby avoiding the associated high costs and risks of tissue biopsy complications.
In sum, we believe our tests help payers reduce both diagnostic and treatment costs, while simultaneously and most importantly improving clinical outcomes.
We estimate total lung cancer coverage in the United States for our Guardant360 test to be a total of more than 170 million lives, including Medicare beneficiaries and members of several commercial health plans.



20

Commercial third-party payers and patient billing
Payment from third-party payers differs depending on whether we have entered into a contract with the payers as a “participating provider” or do not have a contract and are considered a “non-participating provider.” Payers will often reimburse non-participating providers at a lower amount than participating providers or not at all. Where we are not reimbursed in full or at all, we may elect to appeal the insurer’s underpayment or denial of payment or seek payment from the patient. However, insurer appeal and patient collection efforts take a substantial amount of time and resources and are often unsuccessful. Additionally, there are several national third-party commercial payers that have adopted non-coverage policies that treat both tissue and liquid comprehensive genomic profiling, or CGP, testing, including our Guardant360 test, as experimental or investigational at this time.
We have provided testing services to patients with many cancer types and indications, most of the time as a non-participating provider through 2019. We received reimbursement for tests across the spectrum of these patients, though for amounts that on average were significantly lower than for participating providers.
When we contract with a payer to serve as a participating provider, reimbursements by the payer are generally made pursuant to a negotiated fee schedule and are limited to only covered indications or where prior approval has been obtained. Becoming a participating provider can result in higher reimbursement amounts for covered uses of our test and, potentially, no reimbursement for non-covered uses identified under the payer’s policies or the contract. As a result, the potential for more favorable reimbursement associated with becoming a participating provider may be offset by a potential loss of reimbursement for non-covered uses of our tests. In addition, we have experienced situations where commercial payers proactively reduced the amounts they were willing to reimburse for our tests, and where commercial payers have determined that the amounts previously paid were too high and sought to recover those perceived excess payments by deducting such amounts from payments owed to us.
Coverage from commercial payers has been focused on NSCLC, which represented approximately 44% of our U.S. clinical testing volume in 2019 and approximately 46% of our U.S. clinical testing volume in both 2018 and 2017. To date, the benefit of increased reimbursement for covered NSCLC Guardant360 testing as a participating provider has been approximately offset by the loss of reimbursement on tests for non-covered indications previously received when we served as a non-participating provider. Therefore, the net result of receiving coverage for a particular indication, including NSCLC, may be little to no change in our average revenue per test for all our patients served by these insurance payers.
We are actively engaged to expand coverage among existing contracted providers and to achieve coverage with the remaining key commercial payers, laboratory benefit managers and evidence review organizations. This includes addressing variable coverage requirements and evidence required, and the need for enhanced guideline support. Our existing contracted payers, which include Cigna, Priority Health and multiple Blue Cross Blue Shield regional plans, have determined that the analytical validity, clinical validity and clinical utility evidence requirements for medical policy inclusion of our Guardant360 test in NSCLC have been met. In addition, as of July 1, 2019, our Guardant360 test is a covered benefit for the members of the health plans associated with eviCore, a technology assessment company, as being considered medically necessary to assist in selecting therapy for patients with advanced lung cancer.
As we broaden our coverage amongst existing providers to include additional tests, we may begin to experience increases in average revenue per test performed; however, we cannot make any assurances that we will be successful in broadening our coverage on a timely basis or at all. Similarly, as we have experienced with our existing contracted payers, we cannot assure that the addition of new contracted payers will increase our average selling price or revenue.
In addition to our existing contracted payers, various laboratory benefit managers and national expert opinion organizations who work with these plans have endorsed coverage of our Guardant360 test. The analytical validity, clinical validity and clinical utility evidence requirements for medical policy inclusion of our Guardant360 test in NSCLC have been met by multiple commercial payers and laboratory benefit managers.
Government payers
Medicare coverage is limited to items and services that are within the scope of a Medicare benefit category that are reasonable and necessary for the diagnosis or treatment of an illness or injury. National coverage determinations are made through an evidence-based process by CMS, with opportunities for public participation. Medicare’s NGS NCD (CAG-00450N) provides coverage for molecular diagnostic tests such as our Guardant360 test, if, among other criteria, such tests are offered within their FDA-approved companion diagnostic labeling.

21

In July 2018, Palmetto GBA, or Palmetto, the MAC responsible for administering MolDx, issued an LCD for the Guardant360 test for NSCLC patients with a date of service on or after August 27, 2018 who meet certain clinical criteria. Noridian Healthcare Solutions, or Noridian, the MAC responsible for adjudicating claims in California, where our laboratory is located, is a participant in MolDx. Noridian published an equivalent LCD that adopts the positive coverage decision from Palmetto in the Noridian jurisdiction, effective as of October 20, 2018. In December 2019, replacing its prior NSCLC patient LCD, Palmetto finalized a new LCD for our Guardant360 test to provide limited Medicare coverage for use of the Guardant360 test for patients diagnosed with solid cancers of non-central nervous system origin. The new LCD requires that patients are recurrent, relapsed, refractory, metastatic, or advanced cancer patients who are seeking further treatment and are potential candidates for an FDA-approved or NCCN-recommended (for Category 1 or 2A level of evidence) biomarker targeted therapy. Additionally, the patient must not have had previous Guardant360 testing and must be untreated or not responding on the patient’s current therapy. A patient who has previously been tested with the Guardant360 test and has progressed with new malignant growth since the prior test is considered to have a new primary cancer diagnosis and thus is eligible to have another test. Finally, for qualifying cancers other than NSCLC, tissue-based comprehensive genomic profiling must be infeasible for coverage. NSCLC patients would be eligible for coverage if tissue-based testing is infeasible or if previous tissue-based comprehensive genomic profiling returned no actionable results. The new LCD covers our Guardant360 test for fee-for-service Medicare patients with advanced cancers who meet its clinical criteria for complete genomic profiling with next-generation sequencing, or NGS, of tumor tissue to optimize treatment selection decisions but have insufficient or unavailable tissue for molecular profiling. The expanded Medicare coverage decision is in line with FDA approvals of several tumor-agnostic drugs that are based on a single genomic biomarker across all cancers or that are targetable across multiple cancer types. We expect Noridian Healthcare Solutions to issue a new LCD for our Guardant360 test equivalent to the new LCD issued by Palmetto, though the timing and scope of the Noridian LCD are uncertain. We anticipate approval by the FDA, if obtained, may support further improvements in coverage and reimbursement for our Guardant360 test.
Under Medicare, payment for laboratory tests like ours is generally made under the Clinical Laboratory Fee Schedule, or CLFS, with payment amounts assigned to specific procedure billing codes. In April 2014, Congress passed the Protecting Access to Medicare Act of 2014, or PAMA, which included substantial changes to the way in which clinical laboratory services are paid under Medicare. On June 23, 2016, CMS published the final rule implementing the reporting and rate-setting requirements under PAMA. Under PAMA, laboratories that receive the majority of their Medicare revenue from payments made under the CLFS were required to report to CMS, beginning in 2017 and every three years thereafter (or annually for “advanced diagnostic laboratory tests”), commercial payer payment rates and volumes for each test they perform. CMS uses this data to calculate a weighted median payment rate for each test, which is used to establish revised Medicare CLFS reimbursement rates for the test. As we have begun billing Medicare for our tests, we are subject to reporting requirements under PAMA and the Medicare rate for our tests will be calculated in the future based on our private payer rates. For tests furnished on or after January 1, 2018, Medicare payments for clinical diagnostic laboratory tests are based upon these reported commercial payer rates.
State Medicaid programs make individual coverage decisions for diagnostic tests and have taken steps to control the cost, utilization and delivery of healthcare services.
We believe that additional state and federal health care reform measures may be adopted in the future, any of which could have a material adverse effect on the clinical laboratory industry and our ability to successfully commercialize our tests. Any of these or other changes could substantially impact our revenues and increase costs. We cannot predict how future healthcare policy changes, if any, will affect our business and financial success.
Operations
We perform the Guardant360 and GuardantOMNI tests in our clinical laboratory located in Redwood City, California. Our laboratory is CAP-accredited, CLIA-certified, NYSDOH-permitted and also licensed in California, Florida, Maryland, Pennsylvania and Rhode Island.
The proprietary validated methods utilize robust semi-automated workflows designed for high throughput sample testing. This methodology allows for rapid scaling of testing volume without impacting performance metrics. These processes allow us to successfully deliver greater than 98% of results successfully. The workflows allow for rapid generation of reports delivering greater than 80% of results within seven calendar days from the day of sample receipt.
Our Guardant360 testing process includes blood collection, laboratory processing, analysis and reporting. All major processing steps utilize quality control to ensure consistent and reproducible results.



22

Guardant Health Digital Sequencing Technology
Guardant Health Digital Sequencing Technology combines state-of-the-art technology from multiple disciplines and is enabled by robust, high-efficiency biochemistry at the front-end, next-generation sequencing and a machine learning augmented bioinformatics pipeline. The technology, through machine learning, has accrued performance improvements by incorporating learnings generated from the data collected from additional samples.
Two specific enhancements achieved by Guardant Health Digital Sequencing Technology are:
•
High-efficiency chemistry: Overall efficiency of Guardant Health Digital Sequencing in recovery of ctDNA molecules from starting input amount of ctDNA to the post-sequencing analysis of reconstructed molecules indicates the vast majority of extracted ctDNA molecules are converted into a sequencing library, which exceeds most other next-generation sequencing preparations by more than 100%;
•
Error suppression via proprietary bioinformatics engine: Error suppression through Guardant Health Digital Sequencing corresponds to a typical error rate of approximately one error per 3,000,000 reconstructed molecule nucleotides of high quality. This should be compared to the simplest single-end sequencing error rate of approximately one error per 1,000 sequenced nucleotides and approximately one error per 100,000 nucleotides that could be achieved by other assays relying on molecular barcoding alone.
Supply chain
We utilize industry leading vendors for our supply chain. Most reagents and materials are sourced from a limited number of vendors and would require qualification to transition to a different vendor. To mitigate risk, we employ a multi-month, multi-lot safety stock strategy to ensure an uninterrupted supply of reagent and material to our laboratory. In the event that a latent defect is identified, the lot of material in use is expected to be timely quarantined and changed for a new vendor lot that has been previously qualified for use. The experience with our vendors during last five years has provided us confidence in their ability to produce consistent and quality instrumentation, reagents and materials.
In September 2014, we entered into a supply agreement with Illumina, Inc., or Illumina, for Illumina to provide products and services that can be used for certain research and clinical activities, including certain sequencers, equipment and other materials that we use in our laboratory operations. Subsequently, we and Illumina amended the supply agreement to, among other things, update the specific products and services to be provided, and pricing terms therefor, and to extend the initial term of the supply agreement. During the term of the supply agreement, as amended, Illumina will supply us with sequencers, reagents, and other consumables for use with the Illumina sequencers, as well as service contracts for the maintenance and repair of the sequencers.
During the term of the supply agreement, as amended, we are required to make a rolling, non-binding forecast of our expected needs for reagents and other consumables, and place purchase orders for reagents and other consumables, and Illumina may not unreasonably reject conforming purchase orders. Subject to discounts that vary depending on the volume of hardware and reagents and other consumables ordered, the price for sequencers and for service contracts is based on Illumina list prices, and the price for reagents and other consumables is based on contract prices that are fixed for a set period of time and may increase thereafter subject to limitations. The supply agreement does not require us to order minimum amounts of hardware, or to use exclusively the Illumina platform for conducting our sequencing.
The supply agreement contains negotiated use limitations, representations and warranties, indemnification, limitations of liability, and other provisions. The initial term of the supply agreement, as amended, continues until December 2021, and the supply agreement automatically renews for additional one-year terms thereafter unless either we or Illumina provide the other with notice of termination one year in advance of the date when such termination is to take effect. Either we or Illumina may terminate the supply agreement for the other’s uncured material breach, bankruptcy or insolvency-related events, or in the event a regulatory authority notifies such party that continued performance under the supply agreement would violate applicable laws or regulations.
Competition
Growing understanding of the importance of biomarkers linked with therapy selection and response is leading to more companies offering services in genomic profiling. The promise of liquid biopsy is also leading to more companies attempting to enter the space and compete with us. Our main competition is from diagnostic companies with products and services to profile genes in cancers based on either single-marker or comprehensive genomic profile testing, based on next-generation sequencing in either blood or tissue.

23

Our competitors within the liquid biopsy space include Foundation Medicine, Inc., which was acquired by Roche Holdings, Inc. in July 2018, Roche Molecular Systems, Inc., Thermo Fisher Scientific, Inc., Illumina, Inc., Personal Genome Diagnostics, Inc., Qiagen N.V. and Sysmex Inostics. In addition, GRAIL, Inc. and Natera, Inc., among others, are our competitors in early cancer detection.
Competitors within the broader genomics profiling space based on tissue include laboratory companies such as Bio-Reference Laboratories, Inc., Laboratory Corporation of America and Quest Diagnostics, Inc., as well as companies such as Foundation Medicine, Inc., Caris Life Science and Myriad Genetics, Inc. that sell molecular diagnostic tests for cancer to physicians and have or may develop tests that compete with Guardant360 and GuardantOMNI tests. In addition, we aware that certain of our customers are also developing their own tests and may decide to enter our market or otherwise stop using our tests.
In addition to developing kits, certain diagnostic companies also provide next-generation sequencing platforms that could be used for liquid biopsy testing. These include Illumina, Inc., Thermo Fisher Scientific Inc., and other companies developing next-generation sequencing platforms that are sold directly to biopharmaceutical companies, clinical laboratories and research centers. While many of the applications for these platforms are focused on research and development applications, each of these companies has launched and could continue to commercialize products focused on the clinical oncology market. These tests could include FDA-approved diagnostic kits, which can be sold to the clients who have purchased their platforms.
Furthermore, many companies are developing information technology-based tools to support the integration of next-generation sequencing testing into the clinical setting. These companies may also use their own tests or others to develop an integrated system which could limit our access to certain networks.
We believe key competitive factors affecting our success are the price and performance of our products, evidence of clinical differentiation, support by KOLs, commercial competitiveness, turnaround time and scope and quality of payer contracts. Our Guardant Health Oncology Platform has developed strengths across five layers, which we believe form a barrier to entry and a competitive advantage. However, we cannot assure that we will continue to compete effectively on each of those layers.
Intellectual property
Protection of our intellectual property is fundamental to the long-term success of our business. We seek to ensure that investments made into the development of our technology are protected by relying on a combination of patents, trademarks, copyrights, trade secrets (such as know-how), license agreements, confidentiality agreements and procedures, non-disclosure agreements, invention disclosure and assignment agreements and other contractual rights.
Our patent strategy is focused on seeking coverage for our core technology, our digital sequencing platform, and specific follow-on applications and implementations for detecting and monitoring cancer or other diseases by determining genetic variations in patient samples. In addition, we file for patent protection on our on-going research and development particularly into early stage cancer detection, including on pattern recognition based, for example, on analyzing our extensive patient blood sample database.
Our patent portfolio includes owned and licensed patents and patent applications, generally falling into three broad categories:
•
applications and patents relating to our digital sequencing platform, including claims directed to methods for sequencing cell-free DNA, identifying CNVs, SNVs, indels and fusions in cell-free DNA and techniques for enriching nucleic acid samples;
•
applications and patents relating to detecting and monitoring cancer and other diseases by determining genetic variations in biological samples; and
•
applications and patents relating to early-stage cancer detection.
Issued U.S. patents and their international counterparts currently in our patent portfolio that relate to various aspects of our technology and products are expected to expire between 2026 and 2037.
Our proprietary technology is also bolstered by our acquisition of, and procurement of licenses to, technologies developed by third parties. While we developed our digital sequencing platform internally, we believe the technologies underlying our licenses from third parties, which typically relate to improvements to next-generation sequencing technologies, are potentially valuable and of possible strategic importance to us or our competitors. Under some of these agreements, we are obligated to pay low single-digit percentage running royalties on net sales where the licensed technology is used in the product or service sold, subject to minimum annual royalties or fees in certain agreements.

24

Our customers and partners recognize us as being a leader in the liquid biopsy field. Thus, just as patent and trade secret protection is essential to protecting our technology, we believe that it is equally as important for us to protect our brand and identity. We have filed for trademark protection in our name, logo and initial products in the United States.
We intend to pursue additional intellectual property protection to the extent we believe it would advance our business objectives. Despite our efforts to protect our intellectual property rights, they may not be respected in the future or may be invalidated, circumvented or challenged. In addition, laws of various foreign countries where our products are or expected to be sold may not protect our intellectual property rights to the same extent as laws in the United States.
We also rely on trade secrets, including know-how, unpatented technology and other proprietary information, to maintain and strengthen our competitive position. We have determined that certain technologies, such as aspects of our sample preparation methods and some bioinformatic analysis techniques, are better kept as trade secrets. To mitigate the chance of trade secret misappropriation, it is our policy to enter into nondisclosure and confidentiality agreements with parties who have access to our trade secrets, such as our employees, collaborators, outside scientific collaborators, consultants, advisors and other third parties. We also enter into invention disclosure and assignment agreements with our employees and consultants that obligate them to assign to us any inventions they have developed while working for us.
Government regulations
Federal and state laboratory licensing requirements
Under CLIA, a laboratory is any facility that performs laboratory testing on specimens derived from humans for the purpose of providing information for the diagnosis, prevention or treatment of disease, or the impairment of or assessment of health. CLIA requires that a laboratory hold a certificate applicable to the type of laboratory examinations it performs and that it complies with, among other things, standards covering operations, personnel, facilities administration, quality systems and proficiency testing, which are intended to ensure, among other things, that clinical laboratory testing services are accurate, reliable and timely.
To renew our CLIA certificate, we are subject to survey and inspection every two years to assess compliance with program standards. Because we are a CAP accredited laboratory, CMS does not perform this survey and inspection and relies on our CAP survey and inspection. We also may be subject to additional unannounced inspections. Laboratories performing high complexity testing are required to meet more stringent requirements than laboratories performing less complex tests. In addition, a laboratory that is certified as “high complexity” under CLIA may develop, manufacture, validate and use proprietary tests referred to as laboratory developed tests, or LDTs. CLIA requires analytical validation including accuracy, precision, specificity, sensitivity and establishment of a reference range for any LDT used in clinical testing. The regulatory and compliance standards applicable to any testing we perform may change over time and any such changes could have a material effect on our business.
CLIA provides that a state may adopt laboratory regulations that are more stringent than those under federal law, and a number of states have implemented their own more stringent laboratory regulatory requirements. For example, state laws may require that nonresident laboratories, or out-of-state laboratories, maintain an in-state laboratory license to perform tests on samples from patients who reside in that state. As a condition of state licensure, these state laws may require that laboratory personnel meet certain qualifications, specify certain quality control procedures or facility requirements or prescribe record maintenance requirements. Because our laboratory is located in the State of California, we are required to and do maintain a California state laboratory license. We maintain a current license with NYSDOH for our laboratory. In addition, our laboratory is licensed in a few states where nonresident laboratories are required to obtain state laboratory licenses under certain circumstances, including Florida, Maryland, Pennsylvania and Rhode Island. Other states may currently have or adopt similar licensure requirements in the future, which may require us to modify, delay or stop its operations in those states.
Failure to comply with CLIA certification and state clinical laboratory licensure requirements may result in a range of enforcement actions, including certificate or license suspension, limitation, or revocation, directed plan of action, onsite monitoring, civil monetary penalties, criminal sanctions, and revocation of the laboratory’s approval to receive Medicare and Medicaid payment for its services, as well as significant adverse publicity.
CLIA and state laws and regulations, operating together, sometimes limit the ability of laboratories to offer consumer-initiated testing (also known as “direct access testing”). CLIA certified laboratories are permitted to perform testing only upon the order of an “authorized person,” defined as an individual authorized under state law to order tests or receive test results, or both. Many states do not permit persons other than licensed healthcare providers to order tests. We currently do not offer direct access testing and our CLIA tests may only be ordered by authorized healthcare providers.

25

Regulatory framework for medical devices in the United States
Pursuant to its authority under the Federal Food, Drug and Cosmetic Act, or the FDCA, the FDA has jurisdiction over medical devices, which are defined to include, among other things, in vitro diagnostic devices, or IVDs. The FDA regulates, among other things, the research, design, development, pre-clinical and clinical testing, manufacturing, safety, effectiveness, packaging, labeling, storage, recordkeeping, pre-market clearance or approval, adverse event reporting, marketing, promotion, sales, distribution and import and export of medical devices. Unless an exemption applies, each new or significantly modified medical device we seek to commercially distribute in the United States will require either a premarket notification to the FDA requesting permission for commercial distribution under Section 510(k) of the FDCA, also referred to as a 510(k) clearance, or approval from the FDA of a PMA. Both the 510(k) clearance and PMA processes can be resource intensive, expensive, and lengthy, and require payment of significant user fees.
Device classification
Under the FDCA, medical devices are classified into one of three classes-Class I, Class II or Class III-depending on the degree of risk associated with each medical device and the extent of control needed to provide reasonable assurances with respect to safety and effectiveness.
Class I includes devices with the lowest risk to the patient and are those for which safety and effectiveness can be reasonably assured by adherence to a set of FDA regulations, referred to as the General Controls for Medical Devices, which require compliance with the applicable portions of the FDA’s quality system regulation, or QSR, facility registration and product listing, reporting of adverse events and malfunctions, and appropriate, truthful and non-misleading labeling and promotional materials. Some Class I devices also require premarket clearance by the FDA through the 510(k) premarket notification process described below. Most Class I products are exempt from the premarket notification requirements.
Class II devices are those that are subject to the General Controls, as well as special controls as deemed necessary by the FDA to ensure the safety and effectiveness of the device. These special controls can include performance standards, patient registries, FDA guidance documents and post-market surveillance. Most Class II devices are subject to premarket review and clearance by the FDA. Premarket review and clearance by the FDA for Class II devices is accomplished through the 510(k) premarket notification process.
Class III devices include devices deemed by the FDA to pose the greatest risk such as life-supporting or life-sustaining devices, or implantable devices, in addition to those deemed novel and not substantially equivalent following the 510(k) process. The safety and effectiveness of Class III devices cannot be reasonably assured solely by the General Controls and special controls described above. Therefore, these devices are subject to the PMA process, which is generally more costly and time-consuming than the 510(k) process. As part of the PMA process, the applicant must submit data and information demonstrating reasonable assurance of the safety and effectiveness of the device for its intended use to the FDA’s satisfaction. Accordingly, a PMA application typically includes, but is not limited to, extensive technical information regarding device design and development, pre-clinical and clinical trial data, manufacturing information, labeling and financial disclosure information for the clinical investigators in device studies. A PMA application must also provide valid scientific evidence that demonstrates to the FDA’s satisfaction a reasonable assurance of the safety and effectiveness of the device for its intended use.
The investigational device exemption (IDE) process
In the United States, absent certain limited exceptions, human clinical trials intended to support medical device clearance or approval require an IDE application. Some types of studies deemed to present “non-significant risk” are deemed to have an approved IDE once certain requirements are addressed and institutional review board, or IRB, approval is obtained. If the device presents a “significant risk” to human health, as defined by the FDA, the sponsor must submit an IDE application to the FDA and obtain IDE approval prior to commencing the human clinical trials. The IDE application must be supported by appropriate data, such as animal and laboratory testing results, showing that it is safe to test the device in humans and that the testing protocol is scientifically sound. Generally, clinical trials for a significant risk device may begin only after the IDE application is approved by the FDA and the study protocol and informed consent are approved by appropriate IRBs at the clinical trial sites. There can be no assurance that submission of an IDE will result in the ability to commence clinical trials, and although the FDA’s approval of an IDE allows clinical testing to go forward for a specified number of subjects, it does not bind the FDA to accept the results of the trial as sufficient to prove the product’s safety and efficacy, even if the trial meets its intended success criteria.

26

Such clinical trials must be conducted in accordance with the FDA’s IDE regulations that govern investigational device labeling, prohibit promotion and specify an array of recordkeeping, reporting and monitoring responsibilities of study sponsors and study investigators. Such clinical trials must also comply with the FDA’s good clinical practice regulations for IRB approval and for informed consent and other human subject protections. Required records and reports are subject to inspection by the FDA. The results of clinical testing may be unfavorable, or, even if the intended safety and efficacy success criteria are achieved, may not be considered sufficient for the FDA to grant marketing approval or clearance of a product. The commencement or completion of any clinical trial may be delayed or halted, or be inadequate to support approval of a PMA application, for numerous reasons, including, but not limited to, the following:
•
the FDA or other regulatory authorities do not approve a clinical trial protocol or a clinical trial, or place a clinical trial on hold;
•
patients do not enroll in clinical trials at the rate expected;
•
patients do not comply with trial protocols;
•
patient follow-up is not at the rate expected;
•
patients experience adverse events;
•
patients die during a clinical trial, even though their death may not be related to the products that are part of the trial;
•
device malfunctions occur with unexpected frequency or potential adverse consequences;
•
side effects or device malfunctions of similar products already in the market that change the FDA’s view toward approval of new or similar PMAs or result in the imposition of new requirements or testing;
•
institutional review boards and third-party clinical investigators may delay or reject the trial protocol;
•
third-party clinical investigators decline to participate in a trial or do not perform a trial on the anticipated schedule or consistent with the clinical trial protocol, investigator agreement, investigational plan, good clinical practices, the IDE regulations or other FDA or IRB requirements;
•
third-party investigators are disqualified by the FDA;
•
we or third-party organizations do not perform data collection, monitoring and analysis in a timely or accurate manner or consistent with the clinical trial protocol or investigational or statistical plans, or otherwise fail to comply with the IDE regulations governing responsibilities, records and reports of sponsors of clinical investigations;
•
third-party clinical investigators have significant financial interests related to us or our study such that the FDA deems the study results unreliable, or the company or investigators fail to disclose such interests;
•
regulatory inspections of our clinical trials or manufacturing facilities, which may, among other things, require us to undertake corrective action or suspend or terminate our clinical trials;
•
changes in government regulations or administrative actions;
•
the interim or final results of the clinical trial are inconclusive or unfavorable as to safety or efficacy; or
•
the FDA concludes that our trial designs are unreliable or inadequate to demonstrate safety and efficacy.
The 510(k) clearance process
Under the 510(k) clearance process, the manufacturer must submit to the FDA a premarket notification, demonstrating that the device is “substantially equivalent” to a legally marketed predicate device. A predicate device is a legally marketed device that is not subject to a PMA, i.e., a device that was legally marketed prior to May 28, 1976 (pre-amendments device) and for which a PMA is not required, a device that has been reclassified from Class III to Class II or I, or a device that was previously found substantially equivalent through the 510(k) process. To be “substantially equivalent,” the proposed device must have the same intended use as the predicate device, and either have the same technological characteristics as the predicate device or have different technological characteristics and not raise different questions of safety or effectiveness than the predicate device. Clinical data is sometimes required to support substantial equivalence.

27

After a 510(k) premarket notification is submitted, the FDA determines whether to accept it for substantive review. If it lacks necessary information for substantive review, the FDA will refuse to accept the 510(k) notification. If it is accepted for filing, the FDA begins a substantive review. By statute, the FDA is required to complete its review of a 510(k) notification within 90 days of receiving the 510(k) notification. As a practical matter, clearance often takes longer, and clearance is never assured. Although many 510(k) premarket notifications are cleared without clinical data, the FDA may require further information, including clinical data, to make a determination regarding substantial equivalence, which may significantly prolong the review process. If the FDA agrees that the device is substantially equivalent, it will grant clearance to commercially market the device.
If the FDA determines that the device is not “substantially equivalent” to a predicate device, or if the device is automatically classified into Class III, the device sponsor must then fulfill the much more rigorous pre-marketing requirements of the PMA approval process, or seek reclassification of the device through the de novo process. The de novo classification process is an alternate pathway to classify medical devices that are automatically classified into Class III but which are low to moderate risk. A manufacturer can submit a petition for direct de novo review if the manufacturer is unable to identify an appropriate predicate device and the new device or new use of the device presents a moderate or low risk. De novo classification may also be available after receipt of a “not substantially equivalent” letter following submission of a 510(k) to FDA.
After a device receives 510(k) clearance, any modification that could significantly affect its safety or effectiveness, or that would constitute a new or major change in its intended use, will require a new 510(k) clearance or, depending on the modification, could require a PMA application. The FDA requires each manufacturer to determine whether the proposed change requires a new submission in the first instance, but the FDA can review any such decision and disagree with a manufacturer’s determination. Many minor modifications are accomplished by a letter-to-file in which the manufacture documents the change in an internal letter-to-file. The letter-to-file is in lieu of submitting a new 510(k) to obtain clearance for such change. The FDA can always review these letters to file in an inspection. If the FDA disagrees with a manufacturer’s determination regarding whether a new premarket submission is required for the modification of an existing 510(k)-cleared device, the FDA can require the manufacturer to cease marketing and/or recall the modified device until 510(k) clearance or approval of a PMA application is obtained. In addition, in these circumstances, the FDA can impose significant regulatory fines or penalties for failure to submit the requisite application(s).
In addition, over the last several years, the FDA has proposed reforms to its 510(k) clearance process, and such proposals could include increased requirements for clinical data and a longer review period, or could make it more difficult for manufacturers to utilize the 510(k) clearance process for their products. For example, in November 2018, FDA officials announced forthcoming steps that the FDA intends to take to modernize the premarket notification pathway under Section 510(k) of the FDCA. Among other things, the FDA announced that it planned to develop proposals to drive manufacturers utilizing the 510(k) pathway toward the use of newer predicates. These proposals included plans to potentially sunset certain older devices that were used as predicates under the 510(k) clearance pathway, and to potentially publish a list of devices that have been cleared on the basis of demonstrated substantial equivalence to predicate devices that are more than 10 years old. In May 2019, the FDA solicited public feedback on these proposals. The FDA requested public feedback on whether it should consider certain actions that might require new authority, such as whether to sunset certain older devices that were used as predicates under the 510(k) clearance pathway. These proposals have not yet been finalized or adopted, and the FDA may work with Congress to implement such proposals through legislation.
More recently, in September 2019, the FDA finalized guidance describing an optional “safety and performance based” premarket review pathway for manufacturers of “certain, well-understood device types” to demonstrate substantial equivalence under the 510(k) clearance pathway by showing that such device meets objective safety and performance criteria established by the FDA, thereby obviating the need for manufacturers to compare the safety and performance of their medical devices to specific predicate devices in the clearance process. The FDA intends to develop and maintain a list device types appropriate for the “safety and performance based” pathway and will continue to develop product-specific guidance documents that identify the performance criteria for each such device type, as well as the testing methods recommended in the guidance documents, where feasible.
The PMA process
Following receipt of a PMA application, the FDA conducts an administrative review to determine whether the application is sufficiently complete to permit a substantive review. If it is not, the agency will refuse to file the PMA. If it is, the FDA will accept the application for filing and begin the review. The FDA has 180 days to review a filed PMA application, although the review of an application more often occurs over a significantly longer period of time. During this review period, the FDA may request additional information or clarification of information already provided and may issue a major deficiency letter to the applicant, requesting the applicant’s response to deficiencies communicated by the FDA.

28

Before approving or denying a PMA, an FDA advisory committee may review the PMA at a public meeting and provide the FDA with the committee’s recommendation on whether the FDA should approve the submission, approve it with specific conditions, or not approve it. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.
Prior to approval of a PMA, the FDA may conduct inspections of the clinical trial data and clinical trial sites, as well as inspections of the manufacturing facility and processes. Overall, the FDA review of a PMA application generally takes between one and three years but may take significantly longer. The FDA can delay, limit or deny approval of a PMA application for many reasons, including:
•
the device may not be shown safe or effective to the FDA’s satisfaction;
•
the data from pre-clinical studies and/or clinical trials may be found unreliable or insufficient to support approval;
•
the manufacturing process or facilities may not meet applicable requirements; and
•
changes in FDA approval policies or adoption of new regulations may require additional data.
If the FDA evaluation of a PMA is favorable, the FDA will issue either an approval letter, or an approvable letter, the latter of which usually contains a number of conditions that must be met in order to secure final approval of the PMA. When and if those conditions have been fulfilled to the satisfaction of the FDA, the agency will issue a PMA approval letter authorizing commercial marketing of the device, subject to the conditions of approval and the limitations established in the approval letter. If the FDA’s evaluation of a PMA application or manufacturing facilities is not favorable, the FDA will deny approval of the PMA or issue a not approvable letter. The FDA may also determine that additional tests or clinical trials are necessary, in which case the PMA approval may be delayed for several months or years while the trials are conducted and data is submitted in an amendment to the PMA, or the PMA is withdrawn and resubmitted when the data are available. The PMA process can be expensive, uncertain and lengthy and a number of devices for which the FDA approval has been sought by other companies have never been approved for marketing.
New PMA applications or PMA supplements are required for modification to the manufacturing process, equipment or facility, quality control procedures, sterilization, packaging, expiration date, labeling, device specifications, ingredients, materials or design of a device that has been approved through the PMA process. PMA supplements often require submission of the same type of information as an initial PMA application, except that the supplement is limited to information needed to support changes from the device covered by a PMA and may or may not require as extensive technical or clinical data or the convening of an advisory panel, depending on the nature of the proposed change.
In approving a PMA application, as a condition of approval, the FDA may require some form of post-approval study or post-market surveillance, whereby the applicant conducts a follow-up study or follows certain patient groups for a number of years and makes periodic reports to the FDA on the clinical status of those patients when necessary to protect the public health or to provide additional or longer term safety and effectiveness data for the device. The FDA may also approve a PMA application with other post-approval conditions intended to ensure the safety and effectiveness of the device, such as restrictions on labeling, promotion, sale, distribution and use. New PMA applications or PMA supplements may also be required for modifications to approved diagnostic tests, including modifications to manufacturing processes, device labeling and device design, based on the findings of post-approval studies.
FDA regulation of laboratory developed tests
Although the FDA regulates medical devices, including IVDs, the FDA has historically exercised its enforcement discretion and not enforced applicable provisions of the FDCA and FDA regulations with respect to LDTs, which are a subset of IVDs that are intended for clinical use and are developed, validated and offered within a single laboratory for use only in that laboratory. We currently market our Guardant360 test as an LDT and therefore currently do not expect the FDA to enforce its medical device regulations and the applicable FDCA provisions on Guardant360 testing.

29

Legislative and administrative proposals addressing oversight of LDTs were introduced in recent years and we expect that new legislative and administrative proposals will be introduced from time to time. It is possible that legislation could be enacted into law or regulations or guidance could be issued by the FDA which may result in new or increased regulatory requirements for us to continue to offer our LDTs or to develop and introduce new tests as LDTs. For example, in 2014 the FDA issued two draft guidance documents proposing a risk-based framework with respect to applying the FDA’s oversight over LDTs. The Framework Guidance stated that the FDA intended to modify its policy of enforcement discretion with respect to LDTs in a risk-based manner consistent with the existing classification of medical devices. Thus, we believe the FDA planned to begin to enforce its medical device requirements, including premarket submission requirements, on LDTs that have historically been marketed without FDA premarket review and oversight. In November 2016, the FDA announced its intention not to finalize the 2014 draft guidance to allow for further public discussion on an appropriate oversight approach to LDTs and to give congressional authorizing committees the opportunity to develop a legislative solution. In January 2017, the FDA issued a discussion paper on possible approaches to LDT regulation.
Although the FDA halted finalization of the guidance in November 2016 to allow for further public discussion on an appropriate oversight approach to LDTs and to give congressional authorizing committees the opportunity to develop a legislative solution, the FDA could ultimately modify its current approach to LDTs in a way that would subject our products marketed as LDTs to the enforcement of regulatory requirements. Moreover, legislative measures have recently been proposed in Congress that, if ultimately enacted, could provide the FDA with additional authority to require premarket review of and regulate LDTs.
Research use only or investigational use only devices
Our GuardantOMNI test and LUNAR-1 assay are currently available for research use only, or RUO, or for investigational use only, or IUO, depending on the proposed application. An RUO device is an IVD that is in the laboratory research phase of development. RUO devices must bear prominent labeling stating: “For Research Use Only. Not for use in diagnostic procedures.” An IUO device is an IVD that in the product testing phase of development. An IUO device must bear prominent labeling stating: “For Investigational Use Only. The performance characteristics of this product have not been established.” Neither RUO or IUO devices may be used in clinical practice, and such devices cannot be advertised or promoted for clinical or diagnostic purposes. Devices that are intended for RUO or IUO and are properly labeled as RUO or IUO are exempt from compliance with the FDA requirements discussed above, including the approval or clearance and QSR requirements. A device labeled RUO or IUO but intended to be used diagnostically may be viewed by the FDA as adulterated and misbranded under the FDCA and is subject to FDA enforcement activities. The FDA may consider the totality of the circumstances surrounding distribution and use of an RUO or IUO device, including how the device is marketed, when determining its intended use.
EAP (Expedited Access Program)/Breakthrough Devices Program
The EAP was a voluntary program for certain medical devices that demonstrate the potential to address unmet medical needs for life threatening or irreversibly debilitating diseases or conditions that are subject to premarket submissions. Under the EAP, the FDA worked with device sponsors to try to reduce the time and cost from development to marketing decision without changing the FDA’s PMA standard of reasonable assurance of safety and effectiveness or any other standards of valid scientific evidence. Components of the EAP include priority review, more interactive review, senior management involvement, and assignment of a case manager.
Pursuant to the 21st Century Cures Act, the Breakthrough Devices provisions were added to the FDCA. The Breakthrough Devices Program is a voluntary program intended to expedite the review, development, assessment and review of certain medical devices that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating human diseases or conditions for which no approved or cleared treatment exists or that offer significant advantages over existing approved or cleared alternatives. For Breakthrough Devices, the FDA intends to provide interactive and timely communication with the sponsor during device development and throughout the review process. FDA also intends to assign staff to be available within a reasonable time to address questions by institutional review committees concerning the conditions and clinical testing expectations applicable to the investigational use of a Breakthrough Device. In addition, all submissions for devices designated as Breakthrough Devices will receive priority review, meaning that the review of the submission is placed at the top of the appropriate review queue and receives additional review resources, as needed. The Breakthrough Devices Program superseded the EAP and the previous priority review program for medical device submissions. The FDA has indicated that all participants previously granted EAP designation will have designation as breakthrough devices, and that no separate action will necessary for sponsors of EAP-designated devices to receive breakthrough device designation for such devices.
In January 2018, we received EAP designation from the FDA for our Guardant360 test. In December 2018, we received breakthrough device designation from the FDA for our GuardantOMNI test.

30

Companion Diagnostics
For certain of our tests, we are pursuing development as in vitro companion diagnostics for use in selecting the patients that may respond to our partners’ pharmaceutical products. Companion diagnostics are regulated by the FDA as medical devices. The FDA issued a final guidance document in July 2014 addressing agency policy in relation to in vitro companion diagnostic tests. The guidance explains that for some drugs and therapeutic biologics, the use of a companion diagnostic test is essential for the safe and effective use of the product, such as when the use of a product is limited to a specific patient subpopulation that can be identified by using the test. According to the guidance, the FDA generally requires the therapeutic product and the companion diagnostic to be developed and approved or cleared contemporaneously. In July 2016, the FDA issued a draft guidance intended to assist sponsors of the drug therapeutic and in vitro companion diagnostic device on issues related to co-development of the products, and in December 2018, FDA issued a draft guidance describing considerations for the development and labeling of in vitro companion diagnostic devices to support the indicated uses of multiple drug or biological oncology products.
Pervasive and continuing FDA regulation
After a device enters commercial distribution, numerous regulatory requirements continue to apply. These include:
•
the FDA’s QSR, which requires manufacturers, including third-party manufacturers, to follow stringent design, testing, production, control, supplier/contractor selection, complaint handling, documentation and other quality assurance procedures during all aspects of the manufacturing process;
•
labeling regulations, unique device identification requirements and FDA prohibitions against the promotion of products for uncleared, unapproved or off-label uses;
•
advertising and promotion requirements;
•
restrictions on sale, distribution or use of a device;
•
PMA annual reporting requirements;
•
PMA approval of product modifications, or the potential for new 510(k) clearances for certain modifications to 510(k)-cleared devices;
•
medical device reporting regulations, which require that manufacturers report to the FDA if their device may have caused or contributed to a death or serious injury or malfunctioned in a way that would likely cause or contribute to a death or serious injury if the malfunction were to recur;
•
medical device correction and removal reporting regulations, which require that manufacturers report to the FDA field corrections and product recalls or removals if undertaken to reduce a risk to health posed by the device or to remedy a violation of the FDCA that may present a risk to health;
•
recall requirements, including a mandatory recall if there is a reasonable probability that the device would cause serious adverse health consequences or death;
•
an order of repair, replacement or refund;
•
device tracking requirements; and
•
post-market surveillance regulations, which apply when necessary to protect the public health or to provide additional safety and effectiveness data for the device.
The FDA has broad post-market and regulatory enforcement powers. Medical device manufacturers are subject to unannounced inspections by the FDA and other state, local and foreign regulatory authorities to assess compliance with the QSR and other applicable regulations, and these inspections may include the manufacturing facilities of any suppliers. Failure to comply with applicable regulatory requirements can result in enforcement action by the FDA, which may include sanctions such as: warning letters, fines, injunctions, consent decrees and civil penalties; unanticipated expenditures, repair, replacement, refunds, recall or seizure of our products; operating restrictions, partial suspension or total shutdown of production; the FDA’s refusal of our requests for 510(k) clearance or premarket approval of new products, new intended uses or modifications to existing products; the FDA’s refusal to issue certificates to foreign governments needed to export products for sale in other countries; and withdrawing 510(k) clearance or premarket approvals that have already been granted and criminal prosecution.

31

Federal and state fraud and abuse laws
We are subject to federal fraud and abuse laws such as the federal Anti-Kickback Statute, or AKS, the federal Eliminating Kickbacks in Recovery Act, or EKRA, the federal prohibition against physician self-referral, or Stark Law, and the federal false claims law, or the False Claims Act, or FCA. We are also subject to similar state and foreign fraud and abuse laws.
The AKS prohibits knowingly and willfully offering, paying, soliciting, or receiving remuneration, directly or indirectly, overtly or covertly, in cash or in kind, in return for or to induce such person to refer an individual, or to purchase, lease, order, arrange for, or recommend purchasing, leasing or ordering, any good, facility, item or service that is reimbursable, in whole or in part, under a federal healthcare program. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. In addition, the government may assert that a claim including items or services resulting from an AKS violation constitutes a false or fraudulent claim for purposes of the False Claims Act.
The EKRA prohibits knowingly and willfully soliciting or receiving any remuneration (including any kickback, bribe or rebate) directly or indirectly, overtly or covertly, in cash or in kind, in return for referring a patient or patronage to a laboratory; or paying or offering any remuneration (including any kickback, bribe or rebate) directly or indirectly, overtly or covertly, in cash or in kind, to induce a referral of an individual to a laboratory or in exchange for an individual using the services of that laboratory. The EKRA applies to all payers including commercial payers and government payers, and EKRA violations result in significant fines and/or up to 10 years in jail, separate and apart from existing AKS regulations.
The Stark Law and similar state laws, including California’s Physician Ownership and Referral Act, generally prohibit, among other things, clinical laboratories and other entities from billing a patient or any governmental or commercial payer for any diagnostic services when the physician ordering the service, or any member of such physician’s immediate family, has a direct or indirect investment interest in or compensation arrangement with us, unless the arrangement meets an exception to the prohibition.
Other federal fraud and abuse laws to which we are subject include but are not limited to the federal civil and criminal false claims laws including the FCA, which imposes liability on any person or entity that, among other things, knowingly presents, or causes to be presented, a false or fraudulent claim for payment to the federal government, and the federal Civil Monetary Penalties Law, which prohibits, among other things, the offering or transfer of remuneration to a Medicare or state healthcare program beneficiary if the person knows or should know it is likely to influence the beneficiary’s selection of a particular provider, practitioner, or supplier of services reimbursable by Medicare or a state healthcare program, unless an exception applies. Under the FCA, private citizens can bring claims on behalf of the government through qui tam actions. We must also operate within the bounds of the fraud and abuse laws of the states in which we do business which may apply to items or services reimbursed by non-governmental third-party payers, including private insurers.
Efforts to ensure that our business arrangements with third parties comply with applicable laws and regulations will involve substantial costs. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion from government-funded healthcare programs, such as Medicare and Medicaid, disgorgement, contractual damages, reputational harm, diminished profits and future earnings, additional reporting or oversight obligations if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with the law and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. If any physicians or other healthcare providers or entities with whom we do business is found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government-funded healthcare programs.
Privacy and Security
Under the administrative simplification provisions of the Health Insurance Portability and Accountability Act of 1996, or HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, the U.S. Department of Health and Human Services, or HHS, issued regulations that establish uniform standards governing the conduct of certain electronic healthcare transactions and requirements for protecting the privacy and security of protected health information, or PHI, used or disclosed by covered entities. Covered entities and their business associates are subject to HIPAA and HITECH. Because we are a health care provider that electronically transmits health care information to payers, we are a covered entity under HIPAA. Our subcontractors that create, receive, maintain or transmit or otherwise process PHI on our behalf must also comply with HIPAA as business associates thereunder.

32

HIPAA and HITECH include the privacy and security rules, breach notification requirements and electronic transaction standards. The privacy rule covers the use and disclosure of PHI by covered entities and business associates. The privacy rule generally prohibits the use or disclosure of PHI except as permitted under the rule. The rule also sets forth individual patient rights, such as the right to access or amend certain records containing his or her PHI, or to request restrictions on the use or disclosure of his or her PHI. The security rule requires covered entities and business associates to safeguard the confidentiality, integrity, and availability of electronically transmitted or stored PHI by implementing administrative, physical and technical safeguards. Under HITECH’s breach notification rule, a covered entity must notify individuals, the Secretary of the HHS, and in some circumstances, the media of breaches of unsecured PHI.
If they are found to be in violation of HIPAA as the result of a breach of unsecured PHI, a complaint about their privacy practices or an audit by HHS, entities may be subject to significant civil and criminal fines and penalties and/or additional reporting and oversight obligations if such entities are required to enter into a resolution agreement and corrective action plan with HHS to settle allegations of HIPAA non-compliance.
In addition, we may be subject to state health information privacy, security and data breach notification laws, which may govern the collection, use, disclosure and protection of health-related and other personal information. State laws may be more stringent, broader in scope or offer greater individual rights with respect to PHI than HIPAA. California, for example, has enacted the Confidentiality of Medical Information Act, which sets forth standards in addition to HIPAA and HITECH with which all California health care providers like us must abide. In addition, the California Consumer Privacy Act, or the CCPA, was signed into law on June 28, 2018, and went into effect January 1, 2020. The CCPA contains new disclosure obligations for businesses that collect personal information about California residents and affords those individuals new rights relating to their personal information that may affect our ability to use personal information. The CCPA authorizes private lawsuits to recover statutory damages for certain data breaches. Although the CCPA exempts protected health information regulated by HIPAA and certain data regarding clinical trials, the CCPA, to the extent applicable to our business and operations, may increase our compliance costs and potential liability with respect to other personal information we maintain about California residents. The CCPA has substantial penalties for non-compliance and we continue to assess its impact on our business. Complying with these various state laws and regulations, which may differ from state to state, requires significant resources and may complicate our compliance efforts. Penalties for violation of any of these laws and regulations may include sanctions against a laboratory’s licensure, as well as civil and/or criminal penalties.
U.S. healthcare reform
In the United States, there have been a number of legislative and regulatory changes at the federal and state levels which seek to reduce healthcare costs and improve the quality of healthcare. For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act, or the ACA, became law. The ACA substantially changed the way healthcare is financed by both commercial and government payers and contains a number of provisions expected to impact our business and operations, some of which in ways we cannot currently predict, including those governing enrollment in federal and state healthcare programs, reimbursement changes and fraud and abuse.
Since its enactment, there have been efforts to repeal all or part of the ACA, and the current Presidential Administration and U.S. Congress have taken action to roll back certain provisions of the ACA. For example, the Tax Cuts and Jobs Act, among other things, removes penalties for not complying with the ACA’s individual mandate to carry health insurance. On December 14, 2018, a U.S. District Court Judge in the Northern District of Texas, or the Texas District Court Judge, ruled that the individual mandate is a critical and inseverable feature of the ACA, and therefore, because it was repealed as part of the Tax Cuts and Jobs Act, the remaining provisions of the ACA are invalid as well. On December 18, 2019, the U.S. Court of Appeals for the 5th Circuit upheld the district court’s decision that the individual mandate was unconstitutional but remanded the case back to the District Court to determine whether the remaining provisions of the Affordable Care Act are invalid as well. It is unclear how these decisions, subsequent appeals, if any, and other efforts to challenge, repeal or replace the ACA will impact the ACA.
In addition, other legislative changes have been proposed and adopted since the ACA was enacted. On August 2, 2011, the Budget Control Act of 2011 was signed into law, which, among other things, reduced Medicare payments to providers by 2% per fiscal year, effective on April 1, 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2029 unless additional Congressional action is taken.
We anticipate there will continue to be proposals by legislators at both the federal and state levels, regulators and commercial payers to reduce costs while expanding individual healthcare benefits. Certain of these changes could impose additional limitations on the prices we will be able to charge for our tests, the coverage of or the amounts of reimbursement available for our tests from payers, including commercial and government payers.

33


Employees
As of December 31, 2019, we had 622 full-time employees, with 560 in technology, research and development, sales and business development, regulatory and medical affairs, reimbursement and client services, as well as laboratory operations, and 62 in general and administrative functions. Of these full-time employees, 171 work remotely and the remainder work in our headquarters in Redwood City, California. None of our employees is represented by a labor union with respect to his or her employment with us. We consider our relationship with our employees to be good.
Corporate information
We were incorporated in Delaware in 2011 as Guardant Health, Inc.

Available information
Our website is located at https://guardanthealth.com. Our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, including their exhibits, proxy and information statements, and amendments to those reports filed or furnished pursuant to Sections 13(a), 14, and 15(d) of the Securities Exchange Act of 1934, as amended, are available through the “Investors” portion of our website free of charge as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. Information on our website is not part of this Annual Report on Form 10-K or any of our other securities filings unless specifically incorporated herein by reference. In addition, our filings with the SEC may be accessed through the SEC’s Interactive Data Electronic Applications system at http://www.sec.gov. All statements made in any of our securities filings, including all forward-looking statements or information, are made as of the date of the document in which the statement is included, and we do not assume or undertake any obligation to update any of those statements or documents unless we are required to do so by law.



34


Item 1A. Risk Factors
Our operations and financial results are subject to various risks and uncertainties including those described below. You should consider carefully the risks and uncertainties described below, in addition to other information contained in this Annual Report on Form 10-K, including our consolidated financial statements and related notes. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties that we are unaware of, or that we currently believe are not material, may also become important factors that adversely affect our business. If any of the following risks or others not specified below materialize, our business, financial condition and results of operations could be materially and adversely affected. In that case, the trading price of our common stock could decline.
Risks related to our business and strategy
We have incurred significant losses since inception, we may continue to incur losses in the future and we may not be able to generate sufficient revenue to achieve and maintain profitability.
We have incurred significant losses since our inception. For the years ended December 31, 2019, 2018 and 2017, we incurred net losses of 67.9 million, 84.3 million and 83.2 million, respectively. As of December 31, 2019, we had an accumulated deficit of 352.8 million. To date, we have financed our operations principally from the sale of stock and revenue from precision oncology testing and our development services. We have devoted substantially all of our resources to the development and commercialization of our current products and to research and development activities related to our LUNAR program, including clinical and regulatory initiatives to obtain marketing approval and sales and marketing activities. We will need to generate substantial revenue to achieve and then sustain profitability, and even if we achieve profitability, we cannot be sure that we will remain profitable for any period of time. Our failure to achieve or maintain profitability could negatively impact the value of our common stock.
We may not be able to generate sufficient revenue to achieve and maintain profitability and our current or future products may not achieve or maintain sufficient commercial market acceptance.
We are currently not profitable. Even if we succeed in increasing adoption of our existing products and services by physicians, obtaining additional coverage decisions from commercial and government payers, maintaining and creating relationships with our existing and new biopharmaceutical partners, and developing and commercializing additional products and services, we may not be able to generate sufficient revenue to achieve or maintain profitability.

We believe our commercial success is dependent upon our ability to continue to successfully market and sell our current products, including our Guardant360 and GuardantOMNI tests, and our future products, to continue to expand our current relationships and develop new relationships with clinicians and biopharmaceutical customers and to develop and commercialize new products based on our Guardant Health Oncology Platform. Our ability to achieve and maintain sufficient commercial market acceptance of our existing and future products will depend on a number of factors, including:
•
our ability to increase awareness of our tests and the benefits of liquid biopsy;
•
the rate of adoption and/or endorsement of our tests by clinicians, KOLs, advocacy groups and biopharmaceutical companies;
•
the timing and scope of any approval by the FDA for our tests;
•
our ability to obtain positive coverage decisions for our tests from additional commercial payers and to broaden the scope of indications included in such coverage decisions;
•
our ability to obtain reimbursement and expanded coverage from government payers, including Medicare;
•
the impact of our investments in product innovation and commercial growth;
•
negative publicity regarding ours or our competitors’ products resulting from defects or errors; and
•
our ability to further validate our technology through clinical research and accompanying publications.


35


We cannot assure that we will be successful in addressing each of these criteria or other criteria that might affect the market acceptance of our products. If we are unsuccessful in achieving and maintaining market acceptance of our products, our business and results of operations will suffer.
Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or any guidance we may provide.
Our quarterly and annual operating results may fluctuate significantly, which makes it difficult for us to predict our future operating results. These fluctuations may occur due to a variety of factors, many of which are outside of our control, including, but not limited to:
•
the level of demand for any of our products, which may vary significantly;
•
the timing and cost of, and level of investment in, research, development, regulatory approval and commercialization activities relating to our products, which may change from time to time;
•
the volume and customer mix of our precision oncology testing;
•
the start and completion of projects in which our development services are utilized;
•
the introduction of new products or product enhancements by us or others in our industry;
•
coverage and reimbursement policies with respect to our products and products that compete with our products;
•
expenditures that we may incur to acquire, develop or commercialize additional products and technologies;
•
changes in governmental regulations or in the status of our regulatory approvals or applications;
•
future accounting pronouncements or changes in our accounting policies;
•
developments or disruptions in the business and operations of our clinical, commercial and other partners;
•
the impact of natural disasters, political and economic instability, including wars, terrorism, and political unrest, epidemics or pandemics, including the current outbreak of novel coronavirus (2019-nCoV), boycotts, curtailment of trade and other business restrictions; and
•
general market conditions and other factors, including factors unrelated to our operating performance or the operating performance of our competitors.
Additionally, it is difficult to predict the amount we are able to collect for our tests from commercial payers. We receive reimbursement for our tests from several commercial payers for whom we are not a participating provider. Because we are not contracted with these payers, they determine the amount they are willing to reimburse us for tests. We have provided testing services to patients with many cancer types and indications, most of the time as a non-participating provider through 2019. When we have received payment as a non-participating provider, the amounts, on average, were significantly lower than for participating providers. Even when these payers have paid a claim, they may elect at any time to review previously paid claims and determine the amount they paid was too much. In these situations, the payer will typically notify us of their decision and then offset whatever amount they determine they overpaid against amounts they owe us on current claims. We have limited abilities to dispute these retroactive adjustments and we cannot predict when, or how often, a payer might engage in these reviews. A significant amount of these offsets by one or more payers in any given quarter could have a material effect on our results of operations and cause them to fall below expectations or guidance we may provide. We have sought to become a participating provider of a number of commercial payers; but that effort may not be successful and could be time-consuming and costly. Even when we have obtained positive coverage decisions for our tests from commercial payers and entered into agreements with them, such agreements typically are standard form contracts and may allow payers to terminate coverage on short notice, impose significant obligations on us and create additional regulatory and compliance risks and costs for us.
As part of our reimbursement operations, we appeal denials from payers, and if successful, we receive payments from these appeals. However, due to the inherent variability of the insurance landscape, we cannot guarantee future success of, or any payments from, appeals of reimbursement denials by payers. Historic success and payments are not indicative of future success of and payments from such appeals.

36


The cumulative effects of factors discussed above could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a period-to-period basis may not be meaningful. Investors should not rely on our past results as an indication of our future performance.
This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any guidance we may provide, or if the guidance we provide is below the expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated guidance we may provide.
New product development and commercialization involve a lengthy and complex process and we may be unable to develop or commercialize new products on a timely basis, or at all.
We launched a CLIA-validated version of our LUNAR-1 assay for research or investigational use, depending on the proposed application of the assay. Products from our LUNAR program have taken time and considerable resources to develop, and we may not be able to complete the development and commercialization of the LUNAR assay or other products from our LUNAR program for clinical use on a timely basis, or at all. There can be no assurance that our LUNAR program will produce commercial products for recurrence detection of cancer or for early detection of cancer. Before we can commercialize any new products, we will need to expend significant funds in order to:
•
conduct substantial research and development, including validation studies and clinical trials;
•
further develop and scale our laboratory processes to accommodate different products; and
•
further develop and scale our infrastructure to be able to analyze increasingly large amounts of data.
Our product development process involves a high degree of risk, and product development efforts may fail for many reasons, including:
•
failure of the product to perform as expected, including defects and errors;
•
lack of validation data; or
•
failure to demonstrate the clinical utility of the product.
Our development plan involves using data and analytical insights generated from our current products as a force multiplier of returns on research and development investment in our LUNAR program. However, if we are unable to generate additional or compatible data and insights, then we may not be able to advance our LUNAR program as quickly, or at all, or without significant additional investment.
As we develop products, we have made and will have to make significant investments in product development, marketing and selling resources, including investing heavily in clinical studies, which could adversely affect our future cash flows.
Our current revenue is primarily generated from sales of our Guardant360 and GuardantOMNI tests and we are highly dependent on them for our success.
Our ability to execute our growth strategy and become profitable is highly dependent on the continued adoption and use of our Guardant360 test and our GuardantOMNI test, which accounted for almost all of our revenue in the years ended December 31, 2018 and 2019. Continued adoption and use of our tests will depend on several factors, including the prices we charge for our tests, the scope of coverage and amount of reimbursement available from third-party payers for our tests, the availability of clinical data that supports the value of our tests and the inclusion of our tests in industry treatment guidelines. In addition, many biopharmaceutical companies have existing relationships with companies that develop molecular diagnostic tests, including our competitors, and may continue to use their tests instead of ours. Despite our business development efforts, it could be difficult, expensive and/or time-consuming for biopharmaceutical companies to switch diagnostic tests for their products, and our tests may not be widely accepted by biopharmaceutical companies, if at all, which could in turn hinder the growth of sales of our tests. If we are unable to achieve commercial success for our Guardant360 and GuardantOMNI tests, our business, results of operations and financial condition would be materially and adversely affected. We cannot assure that our tests will continue to maintain or gain market acceptance, and any failure to do so would materially harm our business and results of operations.


37


If our products, or our competitors’ liquid biopsy-based products, do not meet the expectations of patients and our customers, our operating results, reputation and business could suffer.
Our success depends on the market’s confidence that we can provide reliable, high-quality precision oncology products that will improve clinical outcomes, lower healthcare costs and enable better biopharmaceutical development. We believe that patients, clinicians and biopharmaceutical companies are likely to be particularly sensitive to product defects and errors in the use of our products, including if our products fail to detect genomic alterations with high accuracy from samples or if we fail to list or inaccurately include certain treatment options and available clinical trials in our test reports, and there can be no guarantee that our products will meet their expectations. Furthermore, if our competitors’ liquid-biopsy based products do not perform to expectations, it may result in lower confidence in liquid biopsy-based tests in general. As a result, the failure of our products or our competitors’ products to perform as expected could significantly impair our operating results and our reputation. In addition, we may be subject to legal claims arising from any defects or errors in our products.
If we are unable to support demand for our current and future products, including ensuring that we have adequate capacity to meet increased demand, or we are unable to successfully manage our anticipated growth, our business could suffer.
As our volume of test sales grows, we will need to continue to increase our workflow capacity for sample intake, customer service, billing and general process improvements, expand our internal quality assurance program and extend our platform to support comprehensive genomic analysis at a larger scale within expected turnaround times. We will need additional certified laboratory scientists and other scientific and technical personnel to process higher volumes of our precision oncology products. Portions of our process are not automated and will require additional personnel to scale. We will also need to purchase additional equipment, some of which can take several months or more to procure, setup and validate, and increase our software and computing capacity to meet increased demand. There is no assurance that any of these increases in scale, expansion of personnel, equipment, software and computing capacities or process enhancements will be successfully implemented, if at all, or that we will have adequate space in our laboratory facility or be able to secure additional facility space to accommodate such required expansion.
As we commercialize additional products, we will need to incorporate new equipment, implement new technology systems and laboratory processes, and hire new personnel with different qualifications. Failure to manage this growth or transition could result in turnaround time delays, higher product costs, declining product quality, deteriorating customer service and slower responses to competitive challenges. A failure in any one of these areas could make it difficult for us to meet market expectations for our products and could damage our reputation and the prospects for our business.
If we cannot maintain our current relationships, or enter into new relationships, with biopharmaceutical companies, our revenue prospects could be reduced.
Biopharmaceutical customers collaborate with us for analysis of whole blood or plasma samples for multiple applications primarily to support clinical trials, including patient identification, companion diagnostics and retrospective testing. In the years ended December 31, 2019, 2018 and 2017, revenue from our top five biopharmaceutical customers, including their affiliated entities, accounted for 38.0%, 36.1% and 29.7% of our total revenue, respectively, with AstraZeneca PLC, including its affiliated entities, representing 26.0%, 18.0% and 13.4% of our total revenue, respectively. The revenue attributable to our biopharmaceutical customers may also fluctuate in the future, which could have an adverse effect on our financial condition and results of operations. In addition, the termination of these relationships could result in a temporary or permanent loss of revenue. Adverse speculation about our existing or potential relationships with biopharmaceutical companies may be a catalyst for adverse speculation about us, our products and our technology, which can adversely affect our reputation and business.

38


Our future success depends in part on our ability to maintain relationships and to enter into new relationships with biopharmaceutical customers, including offering our platform to such customers for companion diagnostic development, novel target discovery and validation as well as clinical trial enrollment, and growing into other business opportunities. This can be difficult due to many factors, including the type of biomarker support required and our ability to deliver it and our biopharmaceutical customers’ satisfaction with our products or services, internal and external constraints placed on these organizations and other factors that may be beyond our control. Furthermore, our biopharmaceutical customers may decide to decrease or discontinue their use of our current products, including our Guardant360 test and our GuardantOMNI test, or our future products due to changes in their research and product development plans, failures in their clinical trials, financial constraints, or utilization of internal testing resources or tests performed by other parties, or other circumstances outside of our control. Continued usage of our tests by particular biopharmaceutical customers may also depend on whether the partner obtains positive data in its clinical trials, is able to successfully obtain regulatory approval and subsequently commercializes a therapy for which we have partnered with them to develop a companion diagnostic, or other administrative factors that are outside our control. Some of our biopharmaceutical customers have contracted with us to provide testing for large numbers of samples, which could strain our testing capacity and restrict our ability to perform tests for other customers. Furthermore, biopharmaceutical companies may decline to do business with us or decrease or discontinue their use of our tests due to their broad strategic collaboration with any of our competitors. In addition to reducing our revenue, the loss of one or more of these relationships may reduce our exposure to research and clinical trials that facilitate the collection and incorporation of new information into our platform and tests. We engage in conversations with biopharmaceutical companies regarding potential commercial opportunities on an ongoing basis. There is no assurance that any of these conversations will result in a commercial agreement, that the resulting relationship will be successful, or that clinical trials conducted as part of the engagement will produce successful outcomes. If we cannot maintain our current relationships, or enter into new relationships, with biopharmaceutical companies, our product development could be delayed and revenue and results of operations could be adversely affected.
Our payer concentration may materially adversely affect our financial condition and results of operations.
We receive a substantial portion of our revenue from a limited number of third-party commercial payers, most of which have not contracted with us to be a participating provider. If one or more of these payers were to significantly reduce, or cease to pay, the amount such payer reimburses us for tests we perform, or if such payer does not reach or maintain favorable coverage and reimbursement decisions for our tests, it could have a material adverse effect on our business, financial condition and results of operations. We have experienced situations where commercial payers proactively reduced the amounts they were willing to reimburse for our tests, and in other situations, commercial payers have determined that the amounts they previously paid were too high and have sought to recover those perceived excess payments by deducting such amounts from payments otherwise being made. If commercial payers were to decide not to include us as a participating provider, cease paying us altogether, drastically reduce the amount they were willing to pay us or attempt to recover any amounts they had already paid, it could cause significant fluctuations in our quarterly results and could harm our business and results of operations.
In September 2018, we began to submit claims for Medicare reimbursement for Guardant360 clinical testing, and in October 2018, we began to receive payments from Medicare. Approximately 38.0% of our U.S. clinical tests were for Medicare beneficiaries in each of the years 2019, 2018 and 2017. Revenue attributable to Medicare accounted for more than 10% of our total revenue in the year ended December 31, 2019. Our Medicare reimbursement currently lacks the certainty afforded by a national coverage determination by CMS. In addition, pursuant to CMS regulations, we cannot bill Medicare directly for tests provided for Medicare beneficiaries in some situations. CMS adopted an exception to its laboratory date of service regulation, and if certain conditions are met, molecular testing laboratories such as us can rely on that exception to bill Medicare directly, instead of seeking payment from the hospital. If this exception is repealed or curtailed by CMS, or its laboratory date of service regulation is otherwise changed to adversely impact our ability to bill Medicare directly, our revenue could be materially reduced.
If we fail to obtain or maintain coverage and adequate reimbursement from third-party payers, we may be unable to increase our testing volume and revenue as expected. Retrospective reimbursement adjustments, such as deductions from further payments and clawbacks, can also negatively impact our revenue and cause our financial results to fluctuate. In addition, as part of our reimbursement operations, we appeal denials from payers, and if successful, we receive payments from these appeals. However, due to the inherent variability of the insurance landscape, we cannot guarantee future success of, or any payments from, appeals of reimbursement denials by payers. Historic success and payments are not indicative of future success of and payments from such appeals.

39


If we cannot compete successfully with our competitors, we may be unable to increase or sustain our revenue or to achieve and then sustain profitability.
Growing understanding of the importance of biomarkers linked with therapy selection and response is leading to more companies offering services in genomic profiling. The promise of liquid biopsy is also leading to more companies attempting to enter the space and compete with us. Our main competition is from diagnostic companies with products and services to profile genes in cancers based on either single-marker or comprehensive genomic profile testing, based on next-generation sequencing in either blood or tissue.
Our competitors within the liquid biopsy space include Foundation Medicine, Inc., which was acquired by Roche Holdings, Inc. in July 2018, Roche Molecular Systems, Inc., Thermo Fisher Scientific Inc., Illumina, Inc., Personal Genome Diagnostics, Inc., Qiagen N.V. and Sysmex Inostics. In addition, GRAIL, Inc. and Natera Inc., among others, are developing and/or commercializing tests that are competitive with our LUNAR program for early cancer detection.
Competitors within the broader genomics profiling space based on tissue include laboratory companies such as Bio-Reference Laboratories, Inc., Laboratory Corporation of America and Quest Diagnostics, Inc., as well as companies such as Foundation Medicine, Inc., Caris Life Sciences, Inc. and Myriad Genetics, Inc., that sell molecular diagnostic tests for cancer to physicians and have or may develop tests which compete with our Guardant360 and GuardantOMNI tests. In addition, we are aware that certain of our customers are also developing their own tests and may decide to enter our market or otherwise stop using our tests.
Some of our competitors and potential competitors may have longer operating histories; larger customer bases; greater brand recognition and market penetration; substantially greater financial, technological and research and development resources and selling and marketing capabilities; and more experience dealing with third-party payers. As a result, they may be able to respond more quickly to changes in customer requirements, devote greater resources to the development, promotion and sale of their tests than we do or sell their tests at prices designed to win significant levels of market share. We may not be able to compete effectively against these organizations. Increased competition and cost-saving initiatives on the part of governmental entities and other third-party payers are likely to result in pricing pressures, which could harm our sales, profitability or ability to gain market share. In addition, competitors may be acquired by, receive investments from or enter into other commercial relationships with larger, well-established and well-financed companies. Certain of our competitors may be able to secure key inputs from vendors on more favorable terms, devote greater resources to marketing and promotional campaigns, adopt more aggressive pricing policies and devote substantially more resources to product development than we can. In addition, companies or governments that control access to genetic testing through umbrella contracts or regional preferences could promote our competitors or prevent us from performing certain services. If we are unable to compete successfully against current and future competitors, we may be unable to increase market acceptance and sales of our tests, which could prevent us from increasing our revenue or achieving profitability and could cause our stock price to decline.
Our competitors’ tests could include FDA-approved diagnostic kits, which can be sold to their clients. In addition to developing kits, certain diagnostic companies also provide next-generation sequencing platforms that could be used for liquid biopsy testing. These include Illumina, Inc., Thermo Fisher Scientific Inc. and other companies developing next-generation sequencing platforms that are sold directly to biopharmaceutical companies, clinical laboratories and research centers. While many of the applications for these platforms are focused on research and development applications, each of these companies has launched and will continue to commercialize products and services focused on the clinical oncology market.
Furthermore, many companies are developing information technology-based tools to support the integration of next-generation sequencing testing into the clinical setting. These companies may also use their own tests or others to develop an integrated system which could limit access for us to certain networks.

40


The sizes of the markets for our current and future products have not been established with precision, and may be smaller than we estimate.
Our estimates of the annual total addressable markets for our current products and products under development in our LUNAR program are based on a number of internal and third-party estimates, including, without limitation, the number of patients with late-stage, solid tumor cancer, the number of individuals who are at a higher risk for developing cancer, and the assumed prices at which we can sell tests for markets that have not been established. While we believe our assumptions and the data underlying our estimates are reasonable, these assumptions and estimates may not be correct and the conditions supporting our assumptions or estimates may change at any time, thereby reducing the predictive accuracy of these underlying factors. As a result, our estimates of the annual total addressable market for our current or future products may prove to be incorrect. If the actual number of patients who would benefit from our products, the price at which we can sell our products, or the annual total addressable market for our products is smaller than we have estimated, it may impair our sales growth and have an adverse impact on our business.
The precision oncology industry is subject to rapid change, which could make our Guardant Health Oncology Platform, our current products and any future products we may develop, obsolete.
Our industry is characterized by rapid changes, including technological and scientific breakthroughs, frequent new product introductions and enhancements and evolving industry standards, all of which could make our current and future products obsolete. Our future success will depend on our ability to keep pace with the evolving needs of our customers on a timely and cost-effective basis and to pursue new market opportunities that develop as a result of scientific and technological advances. In recent years, there have been numerous advances in technologies relating to the diagnosis and treatment of cancer. There have also been advances in methods used to analyze very large amounts of molecular information. We must continuously enhance our Guardant Health Oncology Platform and develop new products to keep pace with evolving standards of care. If we do not update our product offerings to reflect new scientific knowledge about cancer biology, information about new cancer therapies or relevant clinical trials, our products could become obsolete and sales of our current products and any new products we may develop could decline or fail to grow as expected.
We may be unable to manage our future growth effectively, which could make it difficult to execute our business strategy.
Since our inception, we have experienced rapid growth and anticipate further growth in our business operations. Our future growth could create strain on our organizational, administrative and operational infrastructure, including laboratory operations, quality control, customer service and sales organization management. We expect to continue to increase headcount and to hire more specialized personnel as we grow our business. We will need to continue to hire, train and manage additional qualified scientists, laboratory personnel, client and account services personnel, as well as sales and marketing staff, and improve and maintain our technology to properly manage our growth. If our new hires perform poorly, if we are unsuccessful in hiring, training, managing and integrating these new employees or if we are not successful in retaining our existing employees, our business may be harmed.
In addition, we may not be able to maintain the quality or expected turnaround times of our products, or satisfy customer demand as it grows, and our business may be harmed. Our ability to manage our growth properly will also require us to continue to improve our operational, financial and management controls, as well as our reporting systems and procedures. The time and resources required to implement these new systems and procedures is uncertain and could be demanding, and failure to complete this in a timely and efficient manner could adversely affect our operations.
We have limited experience in marketing and selling our products, and if we are unable to expand our sales organization to adequately address our customers’ needs, our business may be adversely affected.
We have limited experience in marketing and selling our current products, including our Guardant360 and GuardantOMNI tests, and other products we may develop. We may not be able to market, sell or distribute such tests or other products we may develop effectively enough to support our planned growth. We currently sell to clinicians in the United States through our own sales organization and to biopharmaceutical companies through our business development team.

41


Each of our target markets is large, distinctive and diverse. As a result, we believe it is necessary for our sales representatives and business development managers to have established oncology-focused expertise. Competition for such employees within the precision oncology industry is intense. We may not be able to attract and retain personnel or be able to build an efficient and effective sales organization or business development team, which could negatively impact sales and market acceptance of our products and limit our revenue growth and potential profitability.
Our expected future growth will impose significant added responsibilities on members of management, including the need to identify, recruit, maintain and integrate additional employees. Our future financial performance and our ability to commercialize our products, to increase our sales and to compete effectively will depend, in part, on our ability to manage this potential future growth effectively, without compromising quality.
Outside the United States, we established the Joint Venture with SoftBank for sales of our products throughout Asia, the Middle East and Africa. We share a measure of control of the Joint Venture, and if its sales and marketing efforts for our products in those regions are not successful, our business would be materially and adversely affected. In other territories, such as Europe, we sell our tests primarily through distributor relationships or direct contracts with hospitals. Locating, qualifying, engaging and maintaining relationships with distribution partners and hospitals with local industry experience and knowledge will be necessary to effectively market and sell our products outside the United States. We may not be successful in finding, attracting and retaining distribution partners or local hospitals, or we may not be able to enter into such arrangements on favorable terms. Sales practices utilized by any such parties that are locally acceptable may not comply with sales practices standards required under U.S. laws that apply to us, which could create additional compliance risk. If our international sales and marketing efforts are not successful, we may not achieve market acceptance for our products outside the United States, which would materially and adversely impact our business.
We rely on a limited number of suppliers or, in some cases, sole suppliers, for some of our laboratory instruments and materials and may not be able to find replacements or immediately transition to alternative suppliers.
We rely on a limited number of suppliers or, in some cases, sole suppliers, including Illumina Inc., or Illumina, for certain sequencers, reagents, blood tubes and other equipment, instruments and materials that we use in our laboratory operations. An interruption in our laboratory operations could occur if we encounter delays or difficulties in securing these laboratory equipment, instruments or materials, and if we cannot then obtain an acceptable substitute. Any such interruption could significantly and adversely affect our business, financial condition, results of operations and reputation. We rely on Illumina as the sole supplier of the sequencers and as the sole provider of maintenance and repair services for these sequencers. Any disruption in operations of Illumina or other sole or limited suppliers or termination or suspension of our relationships with them could materially and adversely impact our supply chain and laboratory operations of our precision oncology platform and thus our ability to conduct our business and generate revenue. These limited or sole suppliers could engage in diverse types of businesses, including selling products or providing services in competition with us, and there can be no assurance that we can continue to receive required equipment, instruments or materials from them.
We believe that there are only a limited number of other manufacturers that are capable of supplying and servicing the equipment and materials necessary for our laboratory operations, including sequencers and various associated reagents, and potentially replacing our current suppliers. The use of equipment or materials furnished by these replacement suppliers would require us to alter our laboratory operations. Transitioning to a new supplier would be time-consuming and expensive, may result in interruptions in our laboratory operations, could affect the performance specifications of our laboratory operations or could require that we revalidate our tests. There can be no assurance that we will be able to secure alternative equipment, reagents and other materials, bring such equipment, reagents and materials online, and revalidate our tests without experiencing interruptions in our workflow. In the case of an alternative supplier for Illumina, for example, there can be no assurance that replacement sequencers and various associated reagents will be available or will meet our quality control and performance requirements for our laboratory operations. If we should encounter delays or difficulties in securing, reconfiguring or integrating the equipment and reagents we require for our products or in revalidating our products, our business, financial condition, results of operations and reputation could be materially and adversely affected.

42


If our sole laboratory facility becomes damaged or inoperable or we are required to vacate our existing facility, our ability to perform our tests and pursue our research and development efforts may be jeopardized.
We currently derive the majority of our revenue from tests performed at a single laboratory facility located in Redwood City, California. Our facility and equipment could be harmed or rendered inoperable by natural or man-made disasters, including war, fire, earthquake, power loss, communications failure or terrorism, which may render it difficult or impossible for us to operate our Guardant Health Oncology Platform for some period of time. The inability to perform our tests or to reduce the backlog that could develop if our facility is inoperable, for even a short period of time, may result in the loss of customers or harm to our reputation, and we may be unable to regain those customers or repair our reputation. Furthermore, our facility and the equipment we use to perform our research and development work could be unavailable or costly and time-consuming to repair or replace. It would be difficult, time-consuming and expensive to rebuild our facility, to locate and qualify a new facility or enable a third party to practice our proprietary technology, particularly in light of licensure and accreditation requirements. Even if we are able to find a third party with such qualifications to perform our tests, the parties may be unable to agree on commercially reasonable terms.
We carry insurance for damage to our property and disruption of our business, but this insurance may not cover all of the risks associated with damage or disruption to our facility and business, may not provide coverage in amounts sufficient to cover our potential losses and may not continue to be available to us on acceptable terms, if at all.
The loss of any member of our senior management team or our inability to attract and retain highly skilled scientists, clinicians, sales representatives and business development managers could adversely affect our business.
Our success depends on the skills, experience and performance of key members of our senior management team, including Helmy Eltoukhy, our Chief Executive Officer, and AmirAli Talasaz, our President and Chief Operating Officer and the chairman of our board of directors. The individual and collective efforts of these employees will be important as we continue to develop our platform and additional products, and as we expand our commercial activities. The loss or incapacity of existing members of our executive management team could adversely affect our operations if we experience difficulties in hiring qualified successors. Our executive officers signed offer letters when first joining our company, but do not have employment agreements, and we cannot guarantee their retention for any period of time. We do not maintain “key person” insurance on any of our employees.
Our research and development programs and laboratory operations depend on our ability to attract and retain highly skilled scientists and technicians. We may not be able to attract or retain qualified scientists and technicians in the future due to the competition for qualified personnel among life science businesses, particularly near our headquarters in Redwood City, California. We also face competition from universities and public and private research institutions in recruiting and retaining highly qualified scientific personnel. In addition, we may have difficulties locating, recruiting or retaining qualified sales representatives and business development managers. Recruiting and retention difficulties can limit our ability to support our research and development and sales programs. All of our employees are at-will, which means that either we or the employee may terminate their employment at any time.
If we were to be sued for product liability or professional liability, we could face substantial liabilities that exceed our resources.
The marketing, sale and use of our products could lead to the filing of product liability claims were someone to allege that our products identified inaccurate or incomplete information regarding the genomic alterations of the tumor or malignancy analyzed, reported inaccurate or incomplete information concerning the available therapies for a certain type of cancer, or otherwise failed to perform as designed. We may also be subject to professional liability for errors in, a misunderstanding of, or inappropriate reliance upon, the information we provide in the ordinary course of our business activities. A product liability or professional liability claim could result in substantial damages and be costly and time-consuming for us to defend.
We maintain product and professional liability insurance, but this insurance may not fully protect us from the financial impact of defending against product liability or professional liability claims. Any product liability or professional liability claim brought against us, with or without merit, could increase our insurance rates or prevent us from securing insurance coverage in the future. Additionally, any product liability or professional liability lawsuit could damage our reputation or cause current clinical customers to terminate existing agreements with us and potential clinical customers to seek other partners, any of which could adversely impact our results of operations.

43


We are exposed to risks associated with our joint venture with SoftBank, and may not realize the advantages we expect from it.
We have a 50% ownership interest in the Joint Venture, Guardant Health AMEA, Inc., we formed with SoftBank in May 2018 to accelerate the commercialization of our products in Asia, the Middle East and Africa, with a near-term focus on Japan. However, the Joint Venture may not be successful in the timeframe we expect, or at all.
Additionally, SoftBank shares a measure of control over the operations of the Joint Venture. As a result, our investment in our joint venture involves risks that are different from the risks involved in owning facilities and operations independently. These risks include the possibility that our joint venture or SoftBank has economic or business interests or goals that are or become inconsistent with our economic or business interests or goals; is in a position to take action contrary to our instructions, requests, policies or objectives; subjects us to unexpected liabilities; takes actions that reduce our return on investment; or takes actions that harm our reputation or restrict our ability to run our business.
The joint venture agreement between us and SoftBank includes a put-call arrangement with respect to the shares of the Joint Venture held by SoftBank and its affiliates. SoftBank will have a put right to cause us to purchase all shares of the Joint Venture held by SoftBank and its affiliates, and we will have a call right to purchase all such shares in the event of (i) certain material disagreements relating to the Joint Venture or its business that may seriously affect the ability of the Joint Venture to perform its obligations under the joint venture agreement or may otherwise seriously impair the ability of the Joint Venture to conduct its business in an effective matter, other than one relating to the Joint Venture’s business plan or to factual matters that may be capable of expert determination; (ii) the effectiveness of our initial public offering, a change in control, the seventh anniversary of the formation of the Joint Venture, or each subsequent anniversary of each of the foregoing events; or (iii) a material breach of the joint venture agreement by the other party that goes unremedied within 20 business days. Unless the shares of the Joint Venture are publicly traded and listed on a nationally recognized stock exchange, the purchase price per share of the Joint Venture in these situations will be determined by a third-party valuation firm on the assumption that the sale is on an arm’s-length basis on the date of the put or call notice. The third-party valuation firm may evaluate a range of factors and employ assumptions that are subjective in nature, which may result in the fair value of Softbank’s interest in the Joint Venture being determined to be materially different from what has been recorded in our consolidated financial statements, including those included elsewhere in this Annual Report on Form 10-K. We may pay the purchase price for those shares in cash (including in the form of a promissory note), in shares of our common stock, or in a combination thereof. In the event SoftBank exercises its put right, we will choose the form of consideration. In the event we exercise our call right, SoftBank will choose the form of consideration. If we are required or choose to purchase those shares from SoftBank, we could experience significant cash outflow, our other stockholders could see their holdings diluted, and our financial condition and the price of our common stock may be adversely affected.
We may acquire businesses, form joint ventures or make investments in companies or technologies that could negatively affect our operating results, distract management’s attention from other business concerns, dilute our stockholders’ ownership, and significantly increase our debt, costs, expenses, liabilities and risks.
We have made acquisitions of businesses, technologies and assets and may pursue additional acquisitions in the future. We also may pursue strategic alliances and additional joint ventures that leverage our Guardant Health Oncology Platform and industry experience to expand our product offerings or distribution. We have limited experience with acquisitions and forming strategic partnerships. We compete for those opportunities with others including our competitors, some of which have greater financial or operational resources than we do. We may not be able to identify suitable acquisition candidates or strategic partners, we may have inadequate access to information or insufficient time to complete due diligence, and we may not be able to complete such transactions on favorable terms, if at all. If we make any acquisitions, we may not be able to integrate these acquisitions successfully into our existing business, and we could assume unknown or contingent liabilities. Difficulties in assimilating acquired businesses include redeployment or loss of key employees and their severance, combination of teams and processes in various functional areas, reorganization or closures of facilities, relocation or disposition of excess equipment, and increased litigation, regulatory and compliance risks, any of which could be expensive and time consuming and adversely affect us. Integration of an acquired business also may disrupt our ongoing operations and require management resources that we would otherwise focus on developing our existing business. In addition, any acquisition could result in the incurrence of debt, contingent liabilities or future write-offs of intangible assets or goodwill, any of which could have a material adverse effect on our financial condition, results of operations and cash flows. We may also experience losses related to investments in other companies, which could have a material negative effect on our results of operations and financial condition. We may not realize the anticipated benefits of any acquisition, technology license, strategic alliance or joint venture.


44


To finance any acquisitions, joint ventures or investments, we may choose to issue shares of our common stock as consideration, which would dilute the ownership of our stockholders. Additional funds may not be available on terms that are favorable to us, or at all. If the price of our common stock is low or volatile, we may not be able to acquire other companies or fund a joint venture project using our stock as consideration.
International expansion of our business exposes us to business, regulatory, political, operational, financial, and economic risks associated with doing business outside of the United States.
We currently have limited international operations, but our business strategy incorporates potentially significant international expansion, including through the Joint Venture with SoftBank, which we formed to accelerate the commercialization of our products in Asia, the Middle East and Africa, with a near-term focus on Japan.
We plan to maintain distributor relationships, to conduct physician and patient association outreach activities, to extend laboratory capabilities and to expand payer relationships, outside of the United States, both directly and through our joint venture. Doing business internationally involves a number of risks, including:
•
multiple, conflicting and changing laws and regulations such as privacy regulations, tax laws, export and import restrictions, economic sanctions and embargoes, employment laws, regulatory requirements and other governmental approvals, permits and licenses;
•
failure by us, our distributors, our local partners or the Joint Venture with SoftBank to obtain regulatory approvals for the use of our products in various countries;
•
additional potentially blocking or relevant third-party patent or other intellectual property rights;
•
complexities and difficulties in obtaining intellectual property protection and enforcing our intellectual property;
•
difficulties in staffing and managing foreign operations;
•
complexities associated with managing multiple payer reimbursement regimes, government payers, or patient self-pay systems;
•
logistics and regulations associated with shipping blood samples, including infrastructure conditions and transportation delays;
•
limits in our ability to penetrate international markets if we are not able to perform our tests locally;
•
financial risks, such as longer payment cycles, difficulty collecting accounts receivable, the impact of local and regional financial crises on demand and payment for our products and exposure to foreign currency exchange rate fluctuations, currency controls and cash repatriation restrictions;
•
natural disasters, political and economic instability, including wars, terrorism, and political unrest, boycotts, curtailment of trade and other business restrictions;
•
public health or similar issues, such as epidemics or pandemics, including the current outbreak of novel coronavirus (2019-nCoV), for which the World Health Organization declared a global emergency on January 30, 2020, that could cause business disruption for the Joint Venture, including the Joint Venture’s offices in Japan and Singapore, and make it more difficult to sell our tests in the affected countries or regions, many of which are in the JV Territory, and
•
regulatory and compliance risks that relate to maintaining accurate information and control over sales and distributors’ activities that may fall within the purview of the U.S. Foreign Corrupt Practices Act, or FCPA, its books and records provisions, or its anti-bribery provisions.
Any of these factors could significantly harm our future international expansion and operations and, consequently, our revenue and results of operations.

45


We could be adversely affected by violations of the FCPA and other anti-bribery laws.
International customers may currently order our Guardant360 and GuardantOMNI tests, either directly from us or through the Joint Venture with SoftBank, and we are subject to the FCPA, which prohibits companies and their intermediaries from making payments in violation of law to non-U.S. government officials for the purpose of obtaining or retaining business or securing any other improper advantage. Our reliance on independent distributors to sell our Guardant360 and GuardantOMNI tests internationally demands a high degree of vigilance in maintaining our policy against participation in corrupt activity, because these distributors could be deemed to be our agents and we could be held responsible for their actions. Other U.S. companies in the medical device and biopharmaceutical field have faced criminal penalties under the FCPA for allowing their agents to deviate from appropriate practices in doing business with these individuals. We are also subject to similar anti-bribery laws in the jurisdictions in which we operate, including the United Kingdom’s Bribery Act of 2010, which also prohibits commercial bribery and makes it a crime for companies to fail to prevent bribery. These laws are complex and far-reaching in nature, and, as a result, we cannot assure that we would not be required in the future to alter one or more of our practices to be in compliance with these laws or any changes in these laws or the interpretation thereof. Any violations of these laws, or allegations of such violations, could disrupt our operations, involve significant management distraction, cause us to incur significant costs and expenses, including legal fees, and result in a material adverse effect on our business, prospects, financial condition and results of operations. We could also suffer severe penalties, including criminal and civil penalties, disgorgement and other remedial measures.
Our employees, principal investigators, consultants and commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading.
We are exposed to the risk of fraud or other misconduct by our employees, principal investigators, consultants and commercial partners. Misconduct by these parties could include intentional failures to comply with the regulations of the FDA, CMS and non-U.S. regulators, comply with healthcare fraud and abuse laws and regulations in the United States and abroad, report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing, and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Such misconduct could also involve the improper use of information obtained in the course of clinical studies, which could result in regulatory sanctions and cause serious harm to our reputation. We currently have a code of conduct applicable to all of our employees, but it is not always possible to identify and deter employee misconduct, and our code of conduct and the other precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses, or in protecting us from governmental investigations, lawsuits or other actions stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could result in the imposition of significant civil, criminal and administrative penalties, including, without limitation, damages, monetary fines, individual imprisonment, disgorgement of profits, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs or from coverage of commercial payers, contractual damages, reputational harm, diminished profits and future earnings, additional reporting or oversight obligations if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with the law and curtailment or restructuring of our operations, which could have a significantly adverse impact on our business. Whether or not we are successful in defending against such actions, we could incur substantial costs and expenses, including legal fees, and divert the attention of management from the operation of our business.
We may need to raise additional capital to fund our existing operations, develop our platform, commercialize new products or expand our operations.
Based on our current business plan, we believe our current cash, cash equivalents and marketable securities and anticipated cash flow from operations, will be sufficient to meet our anticipated cash requirements over at least the next 12 months from the date of this Annual Report on Form 10-K. If our available cash balances and anticipated cash flow from operations are insufficient to satisfy our liquidity requirements including because of lower demand for our products, lower than currently expected rates of reimbursement from commercial third-party payers and government payers or other risks described in this Annual Report on Form 10-K, we may seek to sell equity or convertible securities, enter into a credit facility or another form of third-party funding, or seek other debt financing.

46


We may consider raising additional capital in the future to expand our business, to meet existing obligations, to pursue acquisitions or strategic investments, to take advantage of financing opportunities or for other reasons, including to:
•
increase our sales and marketing efforts to drive market adoption of our current products, including our Guardant360 and GuardantOMNI tests, and address competitive developments;
•
fund development and marketing efforts of products from our LUNAR program or any other future products we may develop;
•
expand our technologies into other types of cancer management and detection products;
•
acquire, license or invest in technologies;
•
acquire or invest in complementary businesses or assets; and
•
finance capital expenditures and general and administrative expenses.
Our present and future funding requirements will depend on many factors, including:
•
our ability to achieve revenue growth;
•
our rate of progress in establishing payer coverage and reimbursement arrangements with domestic and international commercial payers and government payers;
•
the cost of expanding our laboratory operations and product offerings, including our sales and marketing efforts;
•
our rate of progress in, and costs of our sales and marketing activities associated with, establishing adoption of and reimbursement for our current products, including our Guardant360 and GuardantOMNI tests;
•
our rate of progress in, and costs of our research and development activities associated with, products in research and early development;
•
the effect of competing technological and market developments;
•
costs related to our international expansion; and
•
the potential costs of and delays in product development as a result of any existing or new regulatory oversight applicable to our products.
The various ways we could raise additional capital carry potential risks. If we raise funds by issuing equity or convertible securities, dilution to our stockholders could result. Any preferred equity securities issued also could provide for rights, preferences or privileges senior to those of holders of our common stock. If we raise funds by issuing debt securities, those debt securities would have rights, preferences and privileges senior to those of holders of our common stock. The terms of debt securities issued or borrowings pursuant to a credit agreement could impose significant restrictions on our operations. If we raise funds through collaborations and licensing arrangements, we might be required to relinquish significant rights to our platform technologies or products or grant licenses on terms that are not favorable to us. These alternatives of raising additional capital may not be available to us on acceptable or commercially reasonable terms, if at all, or in amounts sufficient to meet our needs. The failure to obtain any required future financing may require us to reduce or curtail existing operations and could contribute to negative market perceptions about us or our securities.
We are dependent on third parties for the collection of blood samples for our tests.
We rely on third-party phlebotomy providers, including physician offices, to collect blood samples for our tests. Our current third-party phlebotomy providers may refuse to continue to collect samples for us in the future, in particular if they have agreements or arrangements with one of our competitors to collect samples for their tests, or if the phlebotomy provider is owned or controlled by a laboratory that offers tests that compete with ours. There has been a trend towards consolidation of independent phlebotomy providers. Independent phlebotomy providers, once acquired by our competitors, may terminate their relationships with us. If our patients are unable to readily access a phlebotomy provider to collect a blood sample for our tests, we may be unable to compete effectively with other laboratories that have greater access to phlebotomy providers and our business, financial condition and results of operations may be harmed.

47


In addition, if third-party phlebotomy providers fail to adequately and properly obtain and collect viable blood samples from patients and to properly package and ship the samples to us, our patients and their physicians may experience problems and delays in receiving test results, which could lead to dissatisfaction with our tests, therefore harming our reputation and adversely affecting our business, financial condition and results of operations. Similarly, our contracts with third-party phlebotomy providers to collect blood could be scrutinized under federal and state healthcare laws such as the federal Anti-Kickback Statute, or AKS, and the federal law prohibiting physician self-referral, or Stark Law, to the extent these services to us are deemed to provide a financial benefit to or relieve a financial burden for a potential referral source, or are subsequently found not to be for fair market value. If our operations are found to be in violation of any of these laws and regulations, we may be subject to administrative, civil and criminal penalties, damages, fines, individual imprisonment, exclusion from participation in federal healthcare programs or from coverage of commercial payers, refunding of payments received by us, and curtailment or cessation of our operations, any of which could harm our reputation and adversely affect our business, financial condition and results of operations.
We rely on commercial courier delivery services to transport samples to our laboratory facility in a timely and cost-efficient manner and if these delivery services are disrupted, our business will be harmed.
Our business depends on our ability to quickly and reliably deliver test results to our customers. Blood samples are typically received within days from the United States and outside the United States for analysis at our Redwood City, California facility. Disruptions in delivery services to transport samples to that facility, whether due to labor disruptions, bad weather, natural disaster, terrorist acts or threats or for other reasons could adversely affect specimen integrity and our ability to process samples in a timely manner, delay our provision of test results to our customers, and ultimately our reputation and our business. In addition, if we are unable to continue to obtain expedited delivery services to transport samples to us on commercially reasonable terms, our operating results may be adversely affected.
Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.
We have incurred net losses since our inception and we may never achieve or sustain profitability. Generally, losses incurred will carry forward until such losses expire (for losses generated prior to January 1, 2018) or are used to offset future taxable income, if any. Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, or the IRC, if a corporation undergoes an “ownership change,” generally defined as a greater than 50 percentage point change (by value) in its equity ownership by certain stockholders over a three-year period, the corporation’s ability to use its pre-change net operating loss, or NOL, carryforwards and other pre-change tax attributes (such as research tax credits) to offset its post-change income or taxes may be limited. We have not completed a study to assess whether an ownership change for purposes of Section 382 or 383 has occurred, or whether there have been multiple ownership changes since our inception. For purposes of Section 382 or 383, we may have experienced ownership changes in the past and may experience ownership changes in the future as a result of shifts in our stock ownership (some of which shifts are outside our control). As a result, if we earn net taxable income, our ability to use our pre-change NOL carryforwards to offset such taxable income will be subject to limitations. Similar provisions of state tax law may also apply to limit our use of accumulated state tax attributes. Therefore, if we attain profitability, we may be unable to use a material portion of our NOL carryforwards and other tax attributes, which could adversely affect our future cash flows. In addition, the Tax Cuts and Jobs Act of 2017 imposes a reduction to the maximum deduction allowed for NOLs generated in tax years beginning after December 31, 2017, but allow such NOLs to be carried forward indefinitely. These changes may adversely affect our future cash flow.
We depend on information technology systems, and any failure of these systems could harm our business.
We depend on information technology and telecommunications systems for significant elements of our operations, including our laboratory information management system, our computational biology system, our knowledge management system, our customer reporting and our GuardantConnect software platform. We have installed, and expect to expand, a number of enterprise software systems that affect a broad range of business processes and functional areas, including for example, systems handling human resources, financial controls and reporting, contract management, regulatory compliance and other infrastructure operations. In addition to the aforementioned business systems, we intend to extend the capabilities of both our preventative and detective security controls by augmenting the monitoring and alerting functions, the network design and the automatic countermeasure operations of our technical systems. These information technology and telecommunications systems support a variety of functions, including laboratory operations, test validation, sample tracking, quality control, customer service support, billing and reimbursement, research and development activities, scientific and medical curation and general administrative activities. In addition, our third-party provider of billing and collections services for late-stage clinical testing in the United States depends upon technology and telecommunications systems provided by its outside vendors.

48


Information technology and telecommunications systems are vulnerable to damage from a variety of sources, including telecommunications or network failures, malicious human acts and natural disasters. Moreover, despite network security and back-up measures, some of our servers are potentially vulnerable to physical or electronic break-ins, computer viruses and similar disruptive problems. For example, in the past year, we identified security incidents involving an unauthorized actor obtaining access to our email system and sending phishing messages. Despite the precautionary measures we have taken in response to such incidents and to prevent other unanticipated problems that could affect our information technology and telecommunications systems, failures or significant downtime of our information technology or telecommunications systems or those used by our third-party service providers could prevent us from performing our comprehensive genomic analysis, preparing and providing reports to pathologists and oncologists, billing payers, processing reimbursement appeals, handling patient or physician inquiries, conducting research and development activities and managing the administrative aspects of our business. Any disruption or loss of information technology or telecommunications systems on which critical aspects of our operations depend could have an adverse effect on our business and our reputation, and we may be unable to regain or repair our reputation.
Despite the security and maintenance measures we and our vendors and distributors have in place to help protect against system failures, our systems, and those of our vendors and distributors, remain vulnerable to delays, disruptions, data corruption, programming and/or human errors or other similar events, such as those due to system updates, natural disasters, malicious attacks, accidents, power disruptions, telecommunications failures, acts of terrorism or war, computer viruses, physical or electronic break-ins or similar events. Such incidents may disrupt our operations, result in losses, damage our reputation, and expose us to the risks of litigation and liability (including regulatory liability); and may have a material adverse effect on our business, results of operations and financial condition.


Risks related to our highly regulated industry
We conduct business in a heavily regulated industry, and changes in regulations or violations of regulations may, directly or indirectly, reduce our revenue, adversely affect our results of operations and financial condition, and harm our business.
The clinical laboratory testing industry is highly regulated, and there can be no assurance that the regulatory environment in which we operate will not change significantly and adversely to us in the future. Areas of the regulatory environment that may affect our ability to conduct business include, without limitation:
•
federal and state laws applicable to test ordering, documentation of tests ordered, billing practices and claims payment and/or regulatory agencies enforcing those laws and regulations;
•
federal and state health care fraud and abuse laws;
•
federal and state laboratory anti-mark-up laws;
•
coverage and reimbursement levels by Medicare, Medicaid, other governmental payers and private insurers;
•
restrictions on coverage of and reimbursement for tests;
•
federal and state laws governing laboratory testing, including CLIA, and state licensing laws;
•
federal and state laws and enforcement policies governing the development, use and distribution of diagnostic medical devices, including laboratory developed tests, or LDTs;
•
federal, state and local laws governing the handling and disposal of medical and hazardous waste;
•
federal and state Occupational Safety and Health Administration rules and regulations; and
•
the Health Insurance Portability and Accountability Act of 1996, or HIPAA, and similar state data privacy and security laws.
In particular, the laws and regulations governing the marketing of clinical laboratory tests are extremely complex, and in many instances, there are no sufficient regulatory or judicial interpretations of these laws and regulations. For example, some of our clinical laboratory tests are, or may in the future be, actively regulated by the FDA pursuant to the medical device provisions of the Federal Food, Drug and Cosmetic Act, or FDCA. The FDA defines a medical device to include

49

any instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent or other similar or related article, including a component, part or accessory, intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment or prevention of disease, in man or other animals. Our clinical laboratory tests are in vitro diagnostic products that are considered by the FDA to be medical devices. Among other things, pursuant to the FDCA and its implementing regulations, the FDA regulates the research, design, testing, manufacturing, safety, labeling, storage, recordkeeping, premarket clearance or approval, marketing and promotion and sales and distribution of medical devices in the United States to ensure that medical devices distributed domestically are safe and effective for their intended uses. In addition, the FDA regulates the import and export of medical devices. If we do not comply with these requirements or later become subject to these requirements and fail to adequately comply, our business may be harmed.
Certain of our tests are currently marketed as LDTs, and future changes in FDA enforcement discretion for LDTs could subject our operations to much more significant regulatory requirements.
The FDA has a policy of enforcement discretion with respect to LDTs whereby the FDA does not actively enforce its regulatory requirements for such tests. However, the FDA has stated its intention to modify its enforcement discretion policy with respect to LDTs. If there are changes in FDA policy, or if the FDA disagrees that we are marketing our tests as LDTs within the scope of its policy of enforcement discretion, we may become subject to extensive regulatory requirements and may be required to stop selling our existing tests or launching any other tests we may develop and to conduct additional clinical trials or take other actions prior to continuing to market our tests. This could significantly increase the costs and expenses of conducting, or otherwise harm, our business.
We currently market our Guardant360 test as an LDT and may in the future market our other tests as LDTs. While we believe that we are currently in material compliance with applicable laws and regulations as historically enforced by the FDA, we cannot assure that the FDA will agree with our determination. A determination that we have violated these laws and regulations, or a public announcement that we are being investigated for possible violations, could adversely affect our business, prospects, results of operations and financial condition.
On July 31, 2014, the FDA notified Congress of its intent to modify, in a risk-based manner, its policy of enforcement discretion with respect to LDTs. On October 3, 2014, FDA issued two draft guidances, entitled “Framework for Regulatory Oversight of Laboratory Developed Tests (LDTs),” or the Framework Guidance, and “FDA Notification and Medical Device Reporting for Laboratory Developed Tests (LDTs).” The Framework Guidance stated that the FDA intended to modify its policy of enforcement discretion with respect to LDTs in a risk-based manner consistent with the existing classification of medical devices. Thus, pursuant to the Framework Guidance, the FDA planned to begin to enforce its medical device requirements, including premarket submission requirements, on LDTs that have historically been marketed without FDA premarket review and oversight. Although the FDA halted finalization of the guidance in November 2016 to allow for further public discussion on an appropriate oversight approach to LDTs and to give congressional authorizing committees the opportunity to develop a legislative solution, the FDA could ultimately modify its current approach to LDTs in a way that would subject our products marketed as LDTs to the enforcement of regulatory requirements. If and when such changes to the regulatory framework occur, we could for the first time be subject to enforcement of regulatory requirements as a device manufacturer such as registration and listing requirements, medical device reporting requirements and the requirements of the FDA’s Quality System Regulation. Additionally, if and when the FDA begins to actively enforce its premarket submission regulations with respect to LDTs, we may be required to obtain premarket clearance or approval for our Guardant360 test and other products we plan to commercialize as LDTs. Moreover, legislative measures have recently been proposed in Congress that, if ultimately enacted, could provide the FDA with additional authority to require premarket review of and regulate LDTs.

50

There is no guarantee that the FDA will grant 510(k) clearance or a premarket approval of our products and failure to obtain necessary clearances or approvals for our products would adversely affect our ability to grow our business.
Before we begin to label and market our products for use as clinical diagnostics in the United States, including as companion diagnostics, we may be required to obtain either 510(k) clearance or a premarket approval, or PMA, from the FDA, unless an exemption applies or FDA exercises its enforcement discretion and refrains from enforcing its medical device requirements. For example, the FDA has a policy of refraining from enforcing such requirements with respect to LDTs, which the FDA considers to be a type of in vitro diagnostic test that is designed, manufactured and used within a single laboratory. Although we currently market Guardant360 test as an LDT pursuant to FDA’s policy of enforcement discretion, we could pursue clearances or approvals from the FDA for our Guardant360 and other tests, including future products we may develop. For example, in the fourth quarter of 2019, we submitted a premarket approval, or PMA, application to seek the FDA’s approval of our Guardant360 test to be used as a companion diagnostic, initially in connection with one therapeutic product of a biopharmaceutical customer, and to provide tumor mutation profiling for cancer patients with solid tumors. In February 2020, we submitted an additional module of the PMA application for our Guardant360 test to the FDA.
The process of obtaining a PMA is much more rigorous, costly, lengthy and uncertain than the 510(k) clearance process. In the PMA process, the FDA must determine that a proposed device is safe and effective for its intended use based, in part, on extensive data, including, but not limited to, technical, pre-clinical, clinical trial, manufacturing and labeling data. In the 510(k) clearance process, the FDA must determine that a proposed device is “substantially equivalent” to a device legally on the market, known as a “predicate” device, in order to clear the proposed device for marketing. To be “substantially equivalent,” the proposed device must have the same intended use as the predicate device, and either have the same technological characteristics as the predicate device or have different technological characteristics and not raise different questions of safety or effectiveness than the predicate device. Clinical data is sometimes required to support a substantial equivalence determination.
The FDA’s 510(k) clearance process usually takes from three to twelve months from submission, but may last longer. The process of obtaining a PMA generally takes from one to three years, or even longer, from the time the PMA is submitted to the FDA until an approval is obtained. Any delay or failure to obtain necessary regulatory approvals or clearances would have a material adverse effect on our business, prospects, financial condition and results of operations.
The FDA can delay, limit or deny clearance or approval of a device for many reasons, including:
•
our inability to demonstrate to the satisfaction of the FDA that our products are safe or effective for their intended uses;
•
the disagreement of the FDA with the design, conduct or implementation of our clinical trials or the analysis or interpretation of data from our pre-clinical studies or clinical trials;
•
serious and unexpected adverse effects experienced by participants in our clinical trials;
•
the data from our pre-clinical studies and clinical trials may be insufficient to support clearance or approval, where required;
•
our inability to demonstrate that the clinical and other benefits of any of our tests outweigh the risks;
•
an advisory committee, if convened by the FDA, may recommend against approval of our PMA or other application for any of our tests or may recommend that the FDA require, as a condition of approval, additional pre-clinical studies or clinical trials, limitations on approved labeling or distribution and use restrictions, or even if an advisory committee, if convened, makes a favorable recommendation, the FDA may still not approve the test;
•
the FDA may identify deficiencies in our marketing application, and in our manufacturing processes, facilities or analytical methods or those of our third-party contract manufacturers;
•
the potential for approval policies or regulations of the FDA to change significantly in a manner rendering our clinical data or regulatory filings insufficient for the clearance or approval; and
•
the FDA may audit our clinical trial data and conclude that the data is not sufficiently reliable to support a PMA application.

51

If we are unable to obtain clearance or approval for any tests for which we plan to seek clearance or approval, our business may be harmed.
Modifications to our FDA-cleared or approved products may require new 510(k) clearances or premarket approvals, or may require us to cease marketing or recall the modified products until clearances are obtained.
For any product approved pursuant to a PMA, we are required to seek supplemental approval for many types of changes to the approved product, for which we will need to determine whether a PMA supplement or other regulatory filing is needed or whether the change may be reported via the PMA Annual Report. Similarly, any modification to a 510(k)-cleared device that could significantly affect its safety or effectiveness, or that would constitute a major change in its intended use, design, or manufacture, requires new 510(k) clearance or, possibly, approval of a new PMA. The FDA requires us to make this determination in the first instance, but the FDA may review and may not agree with our determination. If the FDA disagrees with our determination and requires us to seek approvals or clearances for modifications to our previously approved or cleared products, for which we concluded that new approvals or clearances are unnecessary, we may be required to cease marketing or distribution of our products or to recall the modified product until we obtain the approval or clearance, and we may be subject to significant regulatory fines or penalties.
If third-party payers, including commercial payers and government healthcare programs, do not provide coverage of, or adequate reimbursement for, our tests, our business and results of operations will be negatively affected.
Our revenue and commercial success depend on achieving broad coverage and reimbursement for our tests from payers, including both commercial and government payers. If payers do not provide coverage of, or do not provide adequate reimbursement for, a substantial portion of our tests, we may need to seek payment from the patient, which may adversely affect demand for our tests. Coverage determinations by a payer may depend on a number of factors, including but not limited to a payer’s determination that a test is appropriate, medically necessary or cost-effective. If we are unable to provide payers with sufficient evidence of the clinical utility and validity of our test, they may not provide coverage, may provide limited coverage or may terminate coverage, which will adversely affect our revenues and our financial condition. To the extent that more competitors enter our markets, the availability of coverage and the reimbursement rate for our tests may decrease as we encounter pricing pressure from our competitors.
Each payer makes its own decision as to whether to provide coverage for our tests, whether to enter into a contract with us and how much it will reimburse for a test. Negotiating with payers could be a time-consuming and costly process, and payers often insist on their standard form contracts, which typically contain requirements that apply to ordering physicians. There is no guarantee that a payer will provide adequate coverage or reimbursement for our tests or that we can reach an agreement with the payer on reasonable terms without being subject to additional regulatory and compliance risks. In addition, the determination by a payer to cover or not cover our tests and the amount it will reimburse for them are often made on an indication-by-indication basis. In cases where there is no coverage, or we do not have a contracted rate for reimbursement as a participating provider, with the payer, the patient is typically responsible for a greater share of the cost of the test, which may result in further delay of our revenue, increase our collection costs or decrease the likelihood of collection. We maintain a financial assistance program, the Guardant Access Fee Assistance Program, under which we provide tests without charge or at a significant discount to certain patients meeting income based eligibility standards. This may result in payers requiring us to prove eligibility of such patients to pay no or reduced test fees, and if the payers disagree with such eligibility, they may recoup amounts previously paid for such tests, terminate coverage or seek to renegotiate the rate for reimbursement.
Our claims for reimbursement from payers may be denied upon submission, and we may need to take additional steps to receive payment, such as appealing the denials. Such appeals and other processes are time-consuming and expensive and may not result in payment. Payers may perform audits of historically paid claims and attempt to recoup funds years after the funds were initially distributed if the payers believe the funds were paid in error or determine that our tests were medically unnecessary. If a payer audits our claims and issues a negative audit finding, and we are not able to overturn the audit findings through appeal, the subsequent recoupment may result in a material adverse effect on our revenue. Additionally, in some cases commercial payers for whom we are not a participating provider may elect at any time to review claims previously paid and determine the amount they paid was excessive. In these situations, the payer typically notifies us of its decision and then offsets the amount it determines to be overpaid against amounts it owes us on current claims. We do not have a mechanism to dispute these retroactive adjustments, and we cannot predict when, or how often, a payer might engage in these reviews.

52

When we contract with a payer to serve as a participating provider, reimbursements by the payer are generally made pursuant to a negotiated fee schedule and are limited to only covered indications or where prior approval has been obtained. Becoming a participating provider can result in higher reimbursement amounts for covered uses of our test and, potentially, no reimbursement for non-covered uses identified under the payer’s policies or the contract. As a result, the potential for more favorable reimbursement associated with becoming a participating provider may be offset by a potential loss of reimbursement for non-covered uses of our tests.
Although we are a participating provider with some commercial payers, including Cigna, Priority Health, multiple Blue Cross Blue Shield regional plans as well as the health plans associated with eviCore, certain large, national commercial payers, including Anthem, Aetna and Humana, have issued non-coverage policies that treat both tissue and liquid CGP testing, including our Guardant360 test, as experimental or investigational. If we are not successful in obtaining coverage from such payers, including in reversing their existing non-coverage policies, or if other payers issue similar non-coverage policies, our business and results of operations could be materially and adversely affected.
Medicare’s National Coverage Determination, or NCD, for Next Generation Sequencing, or NGS, established in 2018 and subsequently updated in 2020 states that NGS tests, such as our Guardant360 test, are covered by Medicare nationally, when: (1) performed in a CLIA-certified laboratory, (2) ordered by a treating physician, (3) the patient meets certain clinical and treatment criteria, including having recurrent, relapsed, refractory, metastatic, or advanced stages III or IV cancer, (4) the test is approved or cleared by the FDA as a companion in vitro diagnostic for an FDA approved or cleared indication for use in that patient’s cancer, and (5) results are provided to the treating physician for management of the patient using a report template to specify treatment options. The NGS NCD also states that each Medicare Administrative Contractor, or MAC, may provide local coverage of other next-generation sequencing tests for cancer patients only when the test is performed by a CLIA-certified laboratory, ordered by a treating physician and the patient meets the same clinical and treatment criteria required of nationally covered next-generation sequencing tests under the NGS NCD. An NGS test is not covered by Medicare when cancer patients do not have the above-noted indications for cancer under either national or local coverage criteria. In July 2018, Palmetto GBA, the MAC responsible for administering Medicare’s Molecular Diagnostic Services Program, or MolDx, issued a local coverage determination, or LCD, for our Guardant360 test for non-small cell lung cancer, or NSCLC, patients who meet certain clinical and treatment criteria. Noridian Healthcare Solutions, the MAC responsible for adjudicating claims in California, where our laboratory is located, and a participant in MolDx, recently finalized its LCD for our Guardant360 test. Pursuant to this Noridian LCD, in September 2018, we began to submit claims to Medicare for reimbursement for Guardant360 clinical testing performed for NSCLC patients covered under the LCD who meet certain clinical criteria, and in October 2018, we began to receive payments for these services from Medicare for these clinical tests. In December 2019, replacing its prior NSCLC patient LCD, Palmetto GBA finalized a new LCD for our Guardant360 test that provides limited Medicare coverage for the Guardant360 test in patients diagnosed with solid cancers of non-central nervous system origin. We expect Noridian Healthcare Solutions to issue a new LCD for our Guardant360 test equivalent to the new LCD issued by Palmetto GBA, though the timing and scope of the Noridian LCD are uncertain. We may not be able to obtain reimbursement under the expanded Noridian LCD until it is finalized and Noridian completes certain administrative steps.
Under Medicare, payment for laboratory tests like ours is generally made under the Clinical Laboratory Fee Schedule, or CLFS, with payment amounts assigned to specific procedure billing codes. In April 2014, Congress passed the Protecting Access to Medicare Act of 2014, or PAMA, which included substantial changes to the way in which clinical laboratory services are paid under Medicare. Under PAMA, laboratories that receive the majority of their Medicare revenue from payments made under the CLFS are generally required to report to CMS, beginning in 2017 and every three years thereafter (or annually for “advanced diagnostic laboratory tests”), private payer payment rates and volumes for each test they perform. CMS uses this data to calculate a weighted median payment rate for each test, which is used to establish revised Medicare CLFS reimbursement rates for the test. Laboratories that fail to report the required payment information may be subject to substantial civil monetary penalties. As we have begun billing Medicare for our tests, we are subject to reporting requirements under PAMA and the Medicare rate for our tests will be calculated in the future based on our private payer rates. For clinical diagnostic laboratory tests furnished on or after January 1, 2018, their Medicare CLFS reimbursement rates are established upon these reported private payer rates. If we are unable to obtain and maintain favorable reimbursement rates from commercial payers for our tests, this may adversely affect the tests’ Medicare reimbursement rates. We believe that our tests do not meet the current definition of advanced diagnostic laboratory tests, and we will be required to report private payer rates for our tests every three years; but this determination may change. It is unclear what impact new Medicare pricing structures, such as those adopted under PAMA, may have on our business, financial condition, results of operations or cash flows.
The U.S. federal government continues to show significant interest in pursuing health care reform and reducing health care costs. Similarly, private payers may seek to reduce costs by reducing coverage or reimbursement for our tests.

53

Any government-adopted reform measures or changes to commercial payer coverage and policies could cause significant pricing pressure on reimbursement for health care products and services, including our tests, which could decrease demand for our tests, and adversely affect our sales, revenue and financial condition.
Some payers have implemented, or are in the process of implementing, laboratory benefit management programs, often using third-party benefit managers to manage these programs. The stated goals of these programs are to help improve the quality of outpatient laboratory services, support evidence-based guidelines for patient care and lower costs. The impact on laboratories, such as us, of active laboratory benefit management by third parties is unclear, and we expect that it would have a negative impact on our revenue in the short term. Payers may resist reimbursement for our tests in favor of less expensive tests, require pre-authorization for our tests, or impose additional pricing pressure on and substantial administrative burden for reimbursement for our tests. We expect to continue to focus substantial resources on increasing adoption of, and coverage and reimbursement for, our current tests and any future tests we may develop. We believe it may take several years to achieve broad coverage and adequate contracted reimbursement with a majority of payers for our tests. However, we cannot predict whether, under what circumstances, or at what price levels payers will cover and reimburse our tests. If we fail to establish and maintain broad adoption of, and coverage and reimbursement for, our tests, our ability to generate revenue could be harmed and our business and prospects could suffer.
Our products may in the future be subject to product recalls. A recall of our products, either voluntarily or at the direction of the FDA or another governmental authority, or the discovery of serious safety issues with our products, could have a significant adverse impact on us.
The FDA has the authority to require the recall of commercialized products that are subject to FDA regulation in the event of material deficiencies or defects in design or manufacture. The authority to require a recall must be based on an FDA finding that there is reasonable probability that the device would cause serious, adverse health consequences or death. We may also, on our own initiative, recall a product. The FDA requires that certain classifications of recalls be reported to the FDA within ten working days after the recall is initiated. If we obtain FDA approval for one of our tests, a government-mandated or voluntary recall by us or one of our distributors could occur as a result of an unacceptable risk to health, component failures, malfunctions, manufacturing errors, design or labeling defects or other deficiencies and issues. Recalls of any of our products could divert managerial and financial resources and impair our ability to produce our products in a cost-effective and timely manner in order to meet our customers’ demands, which would have an adverse effect on our reputation, results of operations and financial condition. We may be subject to liability claims, may be required to bear costs or may take other actions that may have a negative impact on our future sales and our ability to generate profits. Companies are required to maintain certain records of recalls, even if they are not reportable to the FDA. We may initiate voluntary recalls involving our products in the future that we determine do not require notification of the FDA. If the FDA disagrees with our determinations, the FDA could require us to report those actions and take enforcement action for failing to report the recalls when they were conducted. A future recall announcement could harm our reputation with customers and negatively affect our sales and financial condition.
If we initiate a correction or removal for one of our tests, issue a safety alert or undertake a field action or recall to reduce a risk to health imposed by the test, this could lead to increased scrutiny by the FDA and our customers regarding the quality and safety of our tests and to negative publicity, including FDA alerts, press releases or administrative or judicial actions. Furthermore, circulation of any such negative publicity could harm our reputation, be used by competitors against us in competitive situations and cause customers to delay purchase decisions or cancel orders.

54

Clinical development involves a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results.
Our ongoing research and development and clinical trial activities are subject to extensive regulation and review by numerous governmental authorities both in the United States and abroad. We are currently conducting pre-and post-market clinical studies of some of our tests. In the future we may conduct clinical trials to support approvals of new products. The commencement of clinical trials may be delayed due to insufficient patient enrollment, which is a function of many factors, including the size of the patient population, the nature of the protocol, the proximity of patients to clinical sites and the trial eligibility criteria. Clinical studies may need to be conducted in compliance with FDA regulations or the FDA may take enforcement action. The data collected from these clinical studies may ultimately be used to support marketing authorization for these products. Even if our clinical trials are completed as planned, we cannot be certain that their results will support our marketing claims or that the FDA or foreign authorities will agree with our conclusions regarding them. Success in pre-clinical studies and early clinical trials does not ensure that later clinical trials will be successful, and we cannot be sure that the later trials will replicate the results of prior trials and studies. The clinical trial process may fail to demonstrate that our tests are safe and effective for the proposed indicated uses, which could cause us to abandon or delay development of our tests. Any delay or termination of our clinical trials will delay the filing of our marketing applications. Many of the factors that may cause or lead to a delay in the commencement or completion of clinical trials may also ultimately lead to delay or denial of regulatory clearance or approval, and any such event may render us unable to commercialize our tests and generate revenue.
We may find it necessary to engage contract research organizations to perform data collection and analysis and other aspects of our clinical trials, which might increase the cost and complexity of our trials. We may also depend on clinical investigators, medical institutions and contract research organizations to perform the trials, and would control only certain aspects of their activities. Nevertheless, we would be responsible for ensuring that each of our trials is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards, and our reliance on these third parties would not relieve us of our regulatory responsibilities. We and our third-party contractors are required to comply with good clinical practices, or GCPs, which are regulations and guidelines enforced by the FDA, and comparable regulations enforced by foreign regulatory authorities for products in clinical development. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any third-party contractor fails to comply with applicable GCPs, the clinical data generated in clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before clearing or approving our marketing applications. A failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory clearance or approval process. In addition, if these parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, or if the quality, completeness or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or for other reasons, our clinical trials may have to be extended, delayed or terminated.
Many of these factors would be beyond our control. We may not be able to undertake additional trials, repeat trials or enter into new arrangements with third parties without undue delays or considerable expenditures. If there are delays in testing or clearances or approvals as a result of the failure to perform by third parties, our research and development costs would increase, and we may not be able to obtain regulatory clearance or approval for our tests. In addition, we may not be able to establish or maintain relationships with these parties on favorable terms, if at all. Each of these outcomes would harm our ability to market our tests, generate revenue or to achieve sustained profitability.
Our “research use only” and “investigational use only” products could become subject to more onerous regulation by the FDA or other regulatory agencies in the future, which could increase our costs and delay our commercialization efforts, thereby materially and adversely affecting our business and results of operations.
In the United States, our GuardantOMNI test and our LUNAR-1 assay are currently available for research use only, or RUO, or for investigational use only, or IUO, depending on the proposed application. We make our RUO and IUO products available to a variety of parties, including biopharmaceutical companies and research institutes. Because RUO and IUO products are not intended for use in clinical practice and cannot be advertised or promoted for clinical or diagnostic claims, they are exempt from many regulatory requirements otherwise applicable to medical devices. In particular, while the FDA regulations require that RUO products be labeled “For Research Use Only. Not for use in diagnostic procedures,” and that IUO products be labeled “For Investigational Use Only. The performance characteristics of this product have not been established,” such products are not subject to the FDA’s pre- and post-market controls for medical devices.

55

A significant change in the laws governing RUO or IUO products or how they are enforced may require us to change our business model in order to maintain compliance. For instance, in November 2013 the FDA issued a guidance document entitled “Distribution of In Vitro Diagnostic Products Labeled for Research Use Only or Investigational Use Only,” or the RUO/IUO Guidance, which highlights the FDA’s interpretation that distribution of RUO or IUO products with any labeling, advertising or promotion that suggests that clinical laboratories can validate the test through their own procedures and subsequently offer it for clinical diagnostic use as an LDT is in conflict with the RUO or IUO status. The RUO/IUO Guidance further articulates the FDA’s position that any assistance offered in performing clinical validation or verification, or similar specialized technical support, to clinical laboratories, is in conflict with RUO or IUO status. If we engage in any activities that the FDA deems to be in conflict with the RUO or IUO status held by any of our products so labeled, we may be subject to immediate, severe and broad FDA enforcement action that would adversely affect our ability to continue operations. Accordingly, if the FDA finds that we are distributing our RUO or IUO products in a manner that is inconsistent with its RUO/IUO Guidance, we may be forced to stop distribution of our RUO/IUO tests until we are in compliance, which would reduce our revenue, increase our costs and adversely affect our business, prospects, results of operations and financial condition. In the event that the FDA requires, or we apply for, marketing authorization of our RUO or IUO products in the future, there can be no assurance that the FDA will grant any clearance or approval requested by us in a timely manner, or at all.
Even if we receive regulatory approval of our current products, including our Guardant360 and GuardantOMNI tests, or any of our other products, we will continue to be subject to extensive regulatory oversight.
Medical devices are subject to extensive regulation by the FDA in the United States and by regulatory agencies in other territories where we do business. If any of our products are approved by the FDA or other regulatory agencies, we will be required to timely file various reports. If these reports are not filed timely, regulators may impose sanctions and sales of our products may suffer, and we may be subject to product liability or regulatory enforcement actions, all of which could harm our business. In addition, as a condition of approving a PMA application, the FDA may also require some form of post-approval study or post-market surveillance, whereby the applicant conducts a follow-up study or follows certain patient groups for a number of years and makes periodic reports to the FDA on the clinical status of those patients when necessary to protect the public health or to provide additional safety and effectiveness data for the device. The product labeling must be updated and submitted in a PMA supplement as results, including any adverse event data from the post-approval study, become available. Failure to conduct or timely complete post-approval studies in compliance with applicable regulations, update the product labeling, or comply with other post-approval requirements could result in withdrawal of approval of the PMA, which would harm our business and revenue.
The FDA and the Federal Trade Commission, or FTC, also regulate the advertising and promotion of medical devices to ensure that their promotional claims made are consistent with the applicable marketing authorizations, that there are adequate and reasonable data to substantiate the claims, and that the promotional labeling and advertising is neither false nor misleading in any respect. If the FDA or FTC determines that any of our promotional claims are false, misleading, not substantiated or not permissible, we may be subject to enforcement actions and we may be required to revise our promotional claims and make other corrections or restitutions.
The FDA, state and foreign authorities have broad enforcement powers. Our failure to comply with applicable regulatory requirements could result in enforcement action by the FDA, state or foreign regulatory agencies, which may include any of the following sanctions:
•
adverse publicity, warning letters, untitled letters, fines, injunctions, consent decrees and civil penalties;
•
repair, replacement, refunds, recalls, termination of distribution, administrative detention or seizures of our products;
•
operating restrictions, partial suspension or total shutdown of production;
•
customer notifications or repair, replacement or refunds;
•
refusing our requests for clearances or approvals of new products, new intended uses or modifications to existing products;
•
withdrawals of current clearances or approvals, resulting in prohibitions on sales of our products;
•
refusal to issue certificates needed to export products for sale in other countries; and

56

•
criminal prosecution.
Any of these sanctions could also result in higher than anticipated costs or lower than anticipated sales of our products and have a material adverse effect on our reputation, business, results of operations and financial condition.
In addition, the FDA may change its clearance and approval policies, adopt additional regulations or revise existing regulations, or take other actions which may prevent or delay approval or clearance of our current or future products under development. For example, in November 2018, FDA officials announced forthcoming steps that the FDA intends to take to modernize the premarket notification pathway under Section 510(k) of the FDCA.
Among other things, the FDA announced that it planned to develop proposals to drive manufacturers utilizing the 510(k) pathway toward the use of newer predicates. These proposals included plans to potentially sunset certain older devices that were used as predicates under the 510(k) clearance pathway, and to potentially publish a list of devices that have been cleared on the basis of demonstrated substantial equivalence to predicate devices that are more than 10 years old. In May 2019, the FDA solicited public feedback on these proposals. The FDA requested public feedback on whether it should consider certain actions that might require new authority, such as whether to sunset certain older devices that were used as predicates under the 510(k) clearance pathway. These proposals have not yet been finalized or adopted, and the FDA may work with Congress to implement such proposals through legislation. Accordingly, it is unclear the extent to which any proposals, if adopted, could impose additional regulatory requirements on us that could delay our ability to obtain new 510(k) clearances, increase the costs of compliance, or restrict our ability to maintain our current clearances, or otherwise create competition that may negatively affect our business.
More recently, in September 2019, the FDA finalized guidance describing an optional “safety and performance based” premarket review pathway for manufacturers of “certain, well-understood device types” to demonstrate substantial equivalence under the 510(k) clearance pathway by showing that such device meets objective safety and performance criteria established by the FDA, thereby obviating the need for manufacturers to compare the safety and performance of their medical devices to specific predicate devices in the clearance process. The FDA intends to develop and maintain a list device types appropriate for the “safety and performance based” pathway and will continue to develop product-specific guidance documents that identify the performance criteria for each such device type, as well as the testing methods recommended in the guidance documents, where feasible. The FDA may establish performance criteria for classes of devices for which we or our competitors seek or currently have received clearance, and it is unclear the extent to which such performance standards, if established, could impact our ability to obtain new 510(k) clearances or otherwise create competition that may negatively affect our business.
In addition, FDA regulations and guidance are often revised or reinterpreted by the FDA in ways that may significantly affect our business and our products. Any new statutes, regulations or revisions or reinterpretations of existing regulations may impose additional costs or lengthen review times of our current or future products or make it more difficult to obtain clearance or approval for, manufacture, market or distribute our products. We cannot determine what effect changes in regulations, statutes, legal interpretation or policies, when and if promulgated, enacted or adopted may have on our business in the future. Such changes could, among other things, require: additional testing prior to obtaining clearance or approval; changes to manufacturing methods; recall, replacement or discontinuance of our products; or additional record keeping.
The FDA’s and other regulatory authorities’ policies may change and additional government regulations may be promulgated that could prevent, limit or delay regulatory clearance or approval of our product candidates.
We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. For example, certain policies of the Trump administration may impact our business and industry. In particular, the Trump administration has taken several executive actions, including the issuance of a number of executive orders, that could impose significant burdens on, or otherwise materially delay, the FDA’s ability to engage in regulatory and oversight activities such as implementing statutes through rulemaking, issuance of guidance and review and approval of marketing applications. It is difficult to predict how these executive actions, will be implemented, and the extent to which they will affect the FDA’s ability to exercise its regulatory authority. If these executive actions impose constraints on the FDA’s ability to engage in regulatory and oversight activities, including approving our applications, in the normal course, our business may be negatively impacted.

57

Failure to comply with federal, state and foreign laboratory licensing requirements and the applicable requirements of the FDA or any other regulatory authority, could cause us to lose the ability to perform our tests, experience disruptions to our business, or become subject to administrative or judicial sanctions.
We are subject to the Clinical Laboratory Improvement Amendments, or CLIA, a federal law that regulates clinical laboratories that perform testing on specimens derived from humans for the purpose of providing information for the diagnosis, prevention or treatment of disease. CLIA regulations establish specific standards with respect to personnel qualifications, facility administration, proficiency testing, quality control, quality assurance and inspections. Any testing subject to CLIA regulation must be performed in a CLIA certified laboratory. CLIA certification is also required in order for us to be eligible to bill state and federal healthcare programs, as well as commercial payers, for our tests. We have a current CLIA certificate to perform our tests at our laboratory in Redwood City, California. To maintain this certificate, we are subject to survey and inspection every two years. Moreover, CLIA inspectors may make random inspections of our laboratory from time to time.
We are also required to maintain a California clinical laboratory license to perform testing in California. California laboratory laws establish standards for day-to-day operation of our clinical laboratory in Redwood City, California, including the training and skills required of personnel and quality control. In addition, some other states require our California laboratory to be licensed in the state in order to test specimens from those states. In addition to California, our laboratory is licensed in Florida, Maryland, Pennsylvania, Rhode Island and New York. Although we have obtained licenses from states where we believe we are required to be licensed, it is possible that other states we are not aware of currently require out-of-state laboratories to obtain licensure in order to test specimens from the state, and that other states may adopt similar requirements in the future.
We may also be subject to regulations in foreign jurisdictions as we seek to expand international utilization of our tests or as such jurisdictions adopt new licensure requirements, which may require review of our tests in order to offer them or may have other limitations such as restrictions on the transport of specimens necessary for us to perform our tests that may limit our ability to make our tests available outside of the United States. Complying with licensure requirements in new jurisdictions may be expensive, time-consuming and subject us to significant and unanticipated delays.
Failure to comply with applicable clinical laboratory licensure requirements may result in a range of enforcement actions, including suspension, limitation or revocation of our CLIA certificate and/or state licenses, imposition of a directed plan of action, on-site monitoring, civil monetary penalties, criminal sanctions, inability to receive reimbursement from Medicare, Medicaid and commercial payers, as well as significant adverse publicity. Any sanction imposed under CLIA, its implementing regulations, or state or foreign laws or regulations governing clinical laboratory licensure or our failure to renew our CLIA certificate, a state or foreign license or accreditation, could have a material adverse effect on our business, financial condition and results of operations. Even if we were able to bring our laboratory back into compliance, we could incur significant expenses and potentially lose revenue in doing so.
In order to test specimens from New York, LDTs must be approved by the New York State Department of Health, or NYSDOH, on a product-by-product basis before they are offered, and our Guardant360 test has been approved by NYSDOH. We will need to seek NYSDOH approval of any future LDTs we develop and want to offer for clinical testing to New York residents, and there can be no assurance that we will be able to obtain such approval. As a result, we are subject to periodic inspection by the NYSDOH and are required to demonstrate ongoing compliance with NYSDOH regulations and standards. To the extent NYSDOH identified any non-compliance and we are unable to implement satisfactory corrective actions to remedy such non-compliance, the State of New York could withdraw approval for our tests.
The College of American Pathologists, or CAP, maintains a clinical laboratory accreditation program. While not required to operate a CLIA-certified laboratory, many private insurers require CAP accreditation as a condition to contracting with clinical laboratories to cover their tests. In addition, some countries outside the United States require CAP accreditation as a condition to permitting clinical laboratories to test samples taken from their citizens. In 2014, we obtained CAP accreditation for our Redwood City, California laboratory, and in order to maintain such accreditation, we are subject to survey for compliance with CAP standards every two years. Failure to maintain CAP accreditation could have a material adverse effect on the sales of our tests and the results of our operations.



58

We are subject to numerous federal and state healthcare statutes and regulations; complying with such laws pertaining to our business is an expensive and time-consuming process, and any failure to comply could result in substantial penalties and a material adverse effect to our business and results of operations.
Our operations are subject to other extensive federal, state, local and foreign laws and regulations, all of which are subject to change. These laws and regulations may include, among others:
•
the AKS, which prohibits knowingly and willfully offering, paying, soliciting or receiving remuneration, directly or indirectly, overtly or covertly, in cash or in kind (e.g. provision of free or discounted goods, services or items), in return for or to induce such person to refer an individual, or to purchase, lease, order, arrange for or recommend purchasing, leasing or ordering, any good, facility, item or service that is reimbursable, in whole or in part, under a federal healthcare program. The term ‘‘remuneration’’ has been broadly interpreted to include anything of value, such as phlebotomy kits. Although there are a number of statutory exceptions and regulatory safe harbors protecting certain common activities from prosecution or other regulatory sanctions, the exceptions and safe harbors are drawn narrowly, and practices that involve remuneration that are alleged to be intended to induce referrals, purchases or recommendations of covered items or services may be subject to scrutiny if they do not qualify for an exception or safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the AKS. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all its facts and circumstances. Several courts have held that if any one purpose of an arrangement involving remuneration is to induce referrals of federal healthcare covered business, the AKS has been violated. Moreover, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Violations are subject to significant civil monetary penalties, plus up to three times the remuneration involved. Violations of the AKS may also result in criminal penalties, including additional fines and imprisonment of up to ten years, and exclusion from Medicare, Medicaid or other governmental healthcare programs;
•
the EKRA, which prohibits knowingly and willfully soliciting or receiving any remuneration (including any kickback, bribe or rebate) directly or indirectly, overtly or covertly, in cash or in kind, in return for referring a patient or patronage to a laboratory; or paying or offering any remuneration (including any kickback, bribe or rebate) directly or indirectly, overtly or covertly, in cash or in kind, to induce a referral of an individual to a laboratory or in exchange for an individual using the services of that laboratory. The EKRA applies to all payers including commercial payers and government payers. Violations of EKRA are subject to significant fines and/or up to 10 years in jail, separate and apart from existing AKS regulations and penalties;
•
the Stark Law, which prohibits a physician from making a referral for certain designated health services covered by the Medicare or Medicaid program, including laboratory and pathology services, if the physician or an immediate family member of the physician has a financial relationship with the entity providing the designated health services and prohibits that entity from billing, presenting or causing to be presented a claim for the designated health services furnished pursuant to the prohibited referral, unless an exception applies. Sanctions for violating the Stark Law include denial of payment, significant civil monetary penalties (on a per claim basis and additional penalties for a circumvention scheme), and exclusion from the federal health care programs;
•
the federal Civil Monetary Penalties Law, which prohibits, among other things, the offering or transfer of remuneration to a Medicare or state healthcare program beneficiary if the person knows or should know it is likely to influence the beneficiary’s selection of a particular provider, practitioner or supplier of services reimbursable by Medicare or a state healthcare program, unless an exception applies. Violations can result in significant civil monetary penalties for each wrongful act;
•
federal and state “Anti-Markup” rules, which, among other things, typically prohibit a physician or supplier billing for clinical or diagnostic tests (with certain exceptions) from marking up the price of a purchased test performed by another physician or supplier that does not “share a practice” with the billing physician or supplier;

59

•
the federal Physician Payments Sunshine Act, which requires certain manufacturers of drugs, biologicals, and kits, medical devices or supplies that require premarket approval by or notification to the FDA, and for which payment is available under Medicare, Medicaid or the Children’s Health Insurance Program to report annually to CMS, information related to (i) payments and other transfers of value to physicians, certain other health care professionals beginning in 2022, and teaching hospitals, and (ii) ownership and investment interests in such manufacturers held by physicians and their immediate family members. Failure to submit required information may result in significant civil monetary penalties for any payments, transfers of value or ownership or investment interests that are not timely, accurately, and completely reported in an annual submission, and may result in liability under other federal laws or regulations;
•
the federal government may bring a lawsuit under the False Claims Act, or the FCA, against any party whom it believes has knowingly or recklessly presented, or caused to be presented, a false or fraudulent request for payment from the federal government, or who has made a false statement or used a false record to get a claim for payment approved. The federal government and a number of courts have taken the position that claims presented in violation of certain other statutes, including the AKS or the Stark Law, can also be considered a violation of the FCA based on the theory that a provider impliedly certifies compliance with all applicable laws, regulations, and other rules when submitting claims for reimbursement. An FCA violation may provide the basis for the imposition of administrative penalties as well as exclusion from participation in governmental healthcare programs, including Medicare and Medicaid. A number of states including California have enacted laws that are similar to the federal FCA. Private individuals can bring FCA “qui tam” actions, on behalf of the government and such individuals, commonly known as “whistleblowers,” may share in amounts paid by the entity to the government in fines or settlement. When an entity is determined to have violated the FCA, the government may impose civil fines and penalties for each false claim, plus treble damages, and exclude the entity from participation in federal healthcare programs;
•
the HIPAA fraud and abuse provisions, which created federal criminal statutes that prohibit, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private insurers, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;
•
federal and state laws related to, among other things, unlawful schemes to defraud, excessive fees for services, unlawful trade practices, insurance fraud, kickbacks, patient inducement and statutory or common law fraud restrict the provision of products, services or items for free or at reduced charge to government or non-government healthcare program beneficiaries. These laws and regulations relating to the provision of items or services for free are complex and are subject to interpretation by the courts and by government agencies;
•
other federal and state fraud and abuse laws, such as state anti-kickback, self-referrals, false claims and anti-markup laws, any of which may extend to services reimbursable by any payer, including private insurers;
•
state laws that prohibit other specified practices, such as billing physicians for tests that they order; providing tests at no or discounted cost to induce adoption; waiving co-insurance, co-payments, deductibles or other amounts owed by patients; billing a state healthcare program at a price that is higher than what is charged to other payers; or employing, exercising control over or splitting fees with licensed medical professionals; and
•
similar foreign laws and regulations in the countries in which we operate or may operate in the future.
As a clinical laboratory, our business practices may face additional scrutiny from various government agencies such as the Department of Justice, the U.S. Department of Health and Human Services Office of Inspector General, or OIG, and CMS. Certain arrangements between clinical laboratories and referring physicians have been identified in fraud alerts issued by the OIG as implicating the AKS. The OIG has stated that it is particularly concerned about these types of arrangements because the choice of laboratory and the decision to order laboratory tests typically are made or strongly influenced by the physician, with little or no patient input. Moreover, the provision of payments or other items of value by a clinical laboratory to a referral source could be prohibited under the Stark Law unless the arrangement meets all criteria of an exception. The government has been active in enforcement of these laws against clinical laboratories.

60

Numerous states have enacted laws prohibiting business corporations, such as us, from practicing medicine and from employing or engaging physicians and other medical professionals (generally referred to as the prohibition against the corporate practice of medicine), which could include physician laboratory directors. These laws are designed to prevent interference in the medical decision-making process by anyone who is not a licensed medical professional. For example, California’s Medical Board has indicated that determining the appropriate diagnostic tests for a particular condition and taking responsibility for the ultimate overall care of a patient, including making treatment options available to the patient, would constitute the unlicensed practice of medicine if performed by an unlicensed person. Violation of these laws may result in sanctions and civil or criminal penalties. It is possible that governmental authorities may conclude that our business practices, including our consulting and advisory board arrangements with physicians and other healthcare providers, some of whom receive stock or stock options as compensation for services provided, do not comply with current or future corporate practice of medicine statutes, regulations, agency guidance or case law.
The growth and international expansion of our business may increase the potential of violating applicable laws and regulations. The risk is further increased by the fact that many such laws and regulations have not been fully interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of interpretations. Efforts to ensure that our internal operations and business arrangements with third parties comply with applicable laws and regulations will involve substantial costs. Any action brought against us for violation of these or other laws or regulations, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management’s attention from the operation of our business. Any of the foregoing consequences could seriously harm our business and our financial results. To the extent our business operations are found to be in violation of any of these laws or regulations, we may be subject to significant civil, criminal and administrative penalties, including, without limitation, damages, monetary fines, individual imprisonment, disgorgement of profits, possible exclusion from participation in Medicare, Medicaid and other healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, additional reporting or oversight obligations if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with the law and curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and pursue our strategy. If any of the healthcare providers or other parties with whom we interact or may interact in the future, are found not to be in compliance with applicable laws and regulations, they may be subject to criminal, civil or administrative sanctions, including exclusions from participation in various healthcare programs, which could also negatively affect our business or revenue.
If the validity of an informed consent from patients regarding our test was challenged, we could be forced to stop offering our products or using our resources, our business and results of operations would be negatively affected.
We offer our tests to physicians and to biopharmaceutical companies in connection with clinical trials. We have implemented measures to ensure that data and biological samples that we receive have been collected from subjects who have provided appropriate informed consent. We also act as a sponsor of clinical trials in connection with the development of our tests, which are frequently conducted in collaboration with different parties. We seek to receive approval from an ethical review board, or institutional review board, or IRB, for projects that meet the definition of “human subjects research,” which includes review and approval of processes for subject informed consent and authorization for use of personal information or waivers thereof. We and our biopharmaceutical partners could conduct clinical trials in a number of different countries. When we are acting as a vendor in connection with a clinical trial sponsored by our biopharmaceutical partners, we rely upon them to comply with the requirements to obtain the subject’s informed consent and to comply with applicable laws and regulations. The collection of data and samples in many different countries results in complex legal questions regarding the adequacy of informed consent and the status of genetic material under a large number of different legal systems. Those informed consents could be challenged and prove invalid, unlawful, or otherwise inadequate for our purposes. Any such findings against us, or our biopharmaceutical partners, could force us to stop accessing or using data and samples or servicing or conducting clinical trials, which would hinder our product offerings or development. We could also become involved in legal actions, which could consume our management and financial resources.

We may be subject to fines, penalties, licensure requirements, or legal liability, if it is determined that through our test reports we are practicing medicine without a license.


61

Our test reports delivered to physicians provide information regarding FDA-approved therapies and clinical trials that oncologists may use in making treatment decisions for their patients. We make members of our organization available to discuss the information provided in the reports. Certain state laws prohibit the practice of medicine without a license. Our customer service representatives and medical affairs team provide support to our customers, including assistance in interpreting the test report results. A governmental authority or other parties could allege that the identification of available therapies and clinical trials in our reports and the related customer service we provide constitute the practice of medicine. A state may seek to have us discontinue the inclusion of certain aspects of our test reports or the related services we provide, or subject us to fines, penalties, or licensure requirements. Any determination that we are practicing medicine without a license may result in significant liability to us, and our business and reputation would be harmed.

Our billing and claim processing are complex and time-consuming, and any delay in submitting claims or failure to comply with applicable billing requirements could hinder collection and have an adverse effect on our revenue.
Billing for our tests is complex, time-consuming and expensive. Depending on the billing arrangement and applicable law, we bill various payers, such as Medicare, Medicaid, health plans, insurance companies and patients, all of which may have different billing requirements. Several factors make the billing process complex, including:
•
differences between the list prices for our tests and the reimbursement rates of payers;
•
compliance with complex federal and state regulations related to billing government healthcare programs, including Medicare and Medicaid, to the extent our tests are covered by such programs;
•
differences in coverage among payers and the effect of patient co-payments or co-insurance;
•
differences in information, pre-authorization and other billing requirements among payers;
•
changes to codes and coding instructions governing our tests;
•
incorrect or missing billing information; and
•
the resources required to manage the billing and claim appeals process.
These billing complexities and the related uncertainty in obtaining payment for our tests could negatively affect our revenue and cash flow, our ability to achieve profitability and the consistency and comparability of our results of operations. In addition, if claims for our tests are not submitted to payers on a timely basis, or if we fail to comply with applicable billing requirements, it could have an adverse effect on our revenue and our business.
In addition, the coding procedure used by third-party payers to identify various procedures, including our test, during the billing process is complex, does not adapt well to our tests and may not enable coverage and adequate reimbursement rates. Third-party payers usually require us to identify the test for which we are seeking reimbursement using a Current Procedural Terminology, or the CPT code. CPT coding plays a significant role in how our Guardant360 test is reimbursed both from commercial and governmental payers. The CPT code set is maintained by the American Medical Association, or AMA. In cases where there is not a specific CPT code to describe a test, such as Guardant360 test, the test may be billed under an unlisted molecular pathology procedure code or through the use of a combination of single gene CPT codes, depending on the payer. The Protecting Access to Medicare Act, or PAMA authorized the adoption of new, temporary billing codes and unique test identifiers for FDA-cleared or approved tests as well as advanced diagnostic laboratory tests. The AMA has created a new section of CPT codes, Proprietary Laboratory Analyses codes, to facilitate implementation of this section of PAMA. In addition, CMS maintains the Healthcare Common Procedure Coding System, or HCPCS, and may assign unique level II HCPCS code to tests that are not already described by a unique CPT code. If our Guardant360 test receives approval from the FDA, we may be required to obtain a new code to report the Guardant360 test on claims submitted to U.S. payers. New CPT codes are issued annually and new HCPCS codes are issued as frequently as quarterly. Payers’ acceptance of the new code could be delayed, and transition to the new code could result in a decrease in reimbursement for our tests, both of which could potentially reduce revenue from commercial and government payers. Changes to the codes used to report the Guardant360 test to payers may result in significant changes in its reimbursement, which could negatively impact our revenue.
Because the current coding for reporting our products does not describe a specific test, the claim must be examined to determine what test was provided, whether the test was appropriate and medically necessary, and whether payment should be rendered, which may require a letter of medical necessity from the ordering physician. This process can result in a delay in processing the claim, a lower reimbursement amount or denial of the claim. Because billing third-party

62

payers for our tests is an unpredictable, challenging, time-consuming and costly process, we may face long collection cycles and the risk that we may never collect at all, either of which could adversely affect our business, results of operations and financial condition, and we may have to increase collection efforts and incur additional costs.
Changes in healthcare laws, regulations and policies could increase our costs, decrease our sales and revenues and negatively impact reimbursement for our tests.
In March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act, or the ACA, became law. This law substantially changed the way health care is financed by both commercial payers and government payers, and significantly impacted our industry. The ACA contains a number of provisions expected to impact existing state and federal health care programs or result in the development of new programs, including those governing enrollments in state and federal health care programs, reimbursement changes and fraud and abuse. Our business and operations could be affected by the ACA, including in ways we cannot currently predict.
Since its enactment, there have been efforts to repeal all or part of the ACA, and the current Presidential Administration and the U.S. Congress have taken action to roll back certain provisions of the ACA. For example, the Tax Cuts and Jobs Act, among other things, removes penalties for not complying with the ACA’s individual mandate to carry health insurance. On December 14, 2018, a U.S. District Court Judge in the Northern District of Texas, or the Texas District Court Judge, ruled that the individual mandate is a critical and inseverable feature of the ACA, and therefore, because it was repealed as part of the Tax Cuts and Jobs Act, the remaining provisions of the ACA are invalid as well. On December 18, 2019, the U.S. Court of Appeals for the 5th Circuit upheld the district court’s decision that the individual mandate was unconstitutional but remanded the case back to the District Court to determine whether the remaining provisions of the Affordable Care Act are invalid as well. It is unclear how these decisions, subsequent appeals, if any, and other efforts to challenge, repeal or replace the ACA will impact the ACA or our business.
In addition, other legislative changes have been proposed and adopted since the ACA was enacted. On August 2, 2011, the Budget Control Act of 2011 was signed into law, which, among other things, reduced Medicare payments to providers by 2% per fiscal year, effective on April 1, 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2029 unless additional Congressional action is taken.
We anticipate there will continue to be proposals by legislators at both the federal and state levels, regulators and commercial and government payers to reduce healthcare costs while expanding individual healthcare benefits. Certain of these changes could impose additional limitations on the prices we will be able to charge for our tests, the coverage of or the amounts of reimbursement available for our tests from commercial and government payers.
Our collection, use and disclosure of personally identifiable information, including patient and employee information, is subject to privacy and security regulations, and our failure to comply with those regulations or to adequately secure the information in our possession could result in significant liability or reputational harm.
The privacy and security of personally identifiable information stored, maintained, received or transmitted, including electronically, is a major issue in the United States and abroad. We collect, process, maintain, retain, evaluate, utilize and distribute large amounts of personal health and financial information and other confidential and sensitive data about our customers and others in the ordinary course of our business. While we strive to comply with all applicable privacy and security laws and regulations, as well as our own posted privacy policies, legal standards for privacy, including but not limited to ‘‘unfairness’’ and ‘‘deception,’’ as enforced by the FTC and state attorneys general, continue to evolve and any failure or perceived failure to comply may result in proceedings or actions against us by government entities or others, or could cause us to lose customers and payer coverage, which could have a material adverse effect on our business and results of operations. Recently, there has been an increase in public awareness of privacy issues in the wake of revelations about the various privacy-related government investigations and enforcement actions and civil lawsuits against healthcare companies. Concerns about and claims challenging our practices with regard to the collection, use, retention, disclosure or security of personally identifiable information or other privacy-related matters, even if unfounded and even if we are in compliance with applicable laws, could damage our reputation and harm our business.
Numerous federal, state and foreign laws and regulations govern collection, dissemination, use and confidentiality of personally identifiable information and protected health information, including HIPAA, state privacy and confidentiality laws (including state laws requiring disclosure of breaches); federal and state consumer protection and employment laws; and European and other foreign data protection laws. And new privacy legislation may create additional rights for consumers and impose additional requirements on businesses. As these laws and regulations increase in complexity and number, they may change frequently, sometimes conflict and increase our compliance efforts, costs and risks.

63

HIPAA, as amended by HITECH, establishes a set of national privacy and security standards for the protection of protected health information, or PHI, by health plans, certain healthcare providers and others that submit certain covered transactions electronically, or ‘‘covered entities,’’ and their ‘‘business associates,’’ which are persons or entities that perform certain services for, or on behalf of, a covered entity that involve creating, receiving, maintaining or transmitting PHI. We are a covered entity under HIPAA and therefore must comply with its requirements to protect the privacy and security of health information and must provide individuals with certain rights with respect to their health information. If we engage a business associate to help us carry out healthcare activities and functions, we must have a written business associate contract or other arrangement with the business associate that establishes specifically what the business associate has been engaged to do and requires the business associate to comply with the same requirements.
On December 12, 2018, HHS issued a request for information, or RFI, seeking input from the public on how the HIPAA regulations, and the Privacy Rule in particular, could be modified to amend existing, or impose additional, obligations relating to the processing of PHI. We will monitor this process and assess the impact of changes to the Privacy Rule or other HIPAA regulations to our business.
Penalties for violations of these laws vary. For instance, a single breach incident can result in findings of violations of multiple HIPAA provisions. Penalties for failure to comply with a requirement of HIPAA and HITECH vary significantly, and include civil monetary penalties for each provision of HIPAA that is violated and, in certain circumstances, criminal penalties, including imprisonment and/or additional fines. A person who knowingly obtains or discloses individually identifiable health information in violation of HIPAA may face additional fines and up to one-year imprisonment. The criminal penalties increase if the wrongful conduct involves false pretenses or the intent to sell, transfer, or use identifiable health information for commercial advantage, personal gain, or malicious harm. In addition, responding to government investigations regarding alleged violations of these and other laws and regulations, even if ultimately concluded with no findings of violations or no penalties imposed, can consume company resources and impact our business and, if public, harm our reputation.
Further, various states, such as California and Massachusetts, have implemented similar privacy laws and regulations, such as the California Confidentiality of Medical Information Act, that impose restrictive requirements regulating the use and disclosure of health information and other personally identifiable information, and the California Consumer Privacy Act, which came into effect on January 1, 2020, and creates new data privacy rights for users,. These laws and regulations are not necessarily preempted by HIPAA, particularly if a state affords greater protection to individuals than HIPAA. Where state laws are more protective, we may have to comply with the stricter provisions. In addition to fines and penalties imposed upon violators, some of these state laws also afford private rights of action to individuals who believe their personal information has been misused. The interplay of federal and state laws may be subject to varying interpretations by courts and government agencies, creating complex compliance issues for us and our clients, and potentially exposing us to additional expense, adverse publicity and liability. Further, as regulatory focus on privacy issues continues to increase and laws and regulations concerning the protection of personal information expand and become more complex, these potential risks to our business could intensify. Changes in laws or regulations associated with the enhanced protection of certain types of sensitive data, such as PHI, or personally identifiable information along with increased demands for enhanced data security infrastructure, could greatly increase our costs of providing our services, decrease demand for our services, reduce our revenue and/or subject us to additional risks.
In addition, the interpretation and application of consumer, health-related, and data protection laws, especially with respect to genetic samples and data, in the United States, the European Union, or the EU, and elsewhere are often uncertain, contradictory, and in flux. We and our joint ventures operate or may operate in a number of countries outside of the United States whose laws may in some cases be more stringent than the requirements in the United States. For example, EU member countries have specific requirements relating to cross-border transfers of personal data to certain jurisdictions, including to the United States where our laboratory resides. In addition, some countries have stricter consumer notice and/or consent requirements relating to personal data collection, use or sharing, more stringent requirements relating to organizations’ privacy programs and provide stronger individual rights. Moreover, international privacy and data security regulations may become more complex and have greater consequences. For instance, the General Data Protection Regulation, or GDPR, went into effect in May 2018 and imposes stringent data protection requirements for controllers and processors of personal data of persons within the EU. The GDPR applies to any company established in the EU as well as to those outside the EU if they collect and use personal data in connection with the offering of goods or services to individuals in the EU or the monitoring of their behavior. The GDPR enhances data protection obligations for processors and controllers of personal data, including, for example, higher standards for obtaining consent from individuals to process their personal data, more robust disclosures to individuals and a strengthened individual data rights regime, shortened timelines for data breach notifications, limitations on retention of information, increased requirements pertaining to health data, other special categories of personal data and pseudonymised (i.e., key-coded) data and additional obligations when we contract third-party processors in connection

64

with the processing of the personal data. The GDPR provides that EU member states may make their own further laws and regulations limiting the processing of personal data, including genetic, biometric or health data, which could limit our ability to use and share personal data or could cause our costs could increase, and harm our business and financial condition. Failure to comply with the requirements of GDPR and the applicable national data protection laws of the EU Member States may result in fines of up to €20,000,000 or up to 4% of the total worldwide annual turnover of the preceding financial year, whichever is higher, and other administrative penalties. Failure to comply with the GDPR and other applicable privacy or data security-related laws, rules or regulations could result in material penalties imposed by regulators, affect our compliance with client contracts and have an adverse effect on our business, financial condition and results of operations.
European data protection law also imposes strict rules on the transfer of personal data out of the EU to the United States. These obligations may be interpreted and applied in a manner that is inconsistent from one jurisdiction to another and may conflict with other requirements or our practices. In addition, these rules are constantly under scrutiny. For example, both the EU-U.S. Privacy Shield Framework and EU Standard Contractual Clauses are the subject of legal challenges in European courts and may face additional challenges in the future, and the absence of successor safeguards for continued data transfer could require us to create duplicative, and potentially expensive, information technology infrastructure and business operations in Europe or limit our ability to collect and use personal information collected in Europe. In addition, the EU Commission has proposed a new ePrivacy Regulation that would address various matters, including provisions specifically aimed at the use of cookies to identify an individual’s online behavior, and any such ePrivacy Regulation may provide for new compliance obligations and significant penalties. Any of these changes to EU data protection law or its interpretation could disrupt and harm our business. We rely on a mixture of safeguards to transfer personal data from our EU business to the U.S., and could be impacted by changes in law as a result of a future review of these transfer mechanisms by European regulators or current challenges to these mechanisms in the European courts.
In addition, the United Kingdom leaving the EU could also lead to further legislative and regulatory changes. It remains unclear how the United Kingdom data protection laws or regulations will develop in the medium to longer term and how data transfer to the United Kingdom from the EU will be regulated, especially following the United Kingdom's departure from the EU on January 31, 2020 without a deal. However, the United Kingdom has transposed the GDPR into domestic law with the Data Protection Act 2018, which remains in force following the United Kingdom's departure from the EU.
Because of the breadth of these laws and the narrowness of their exceptions and safe harbors, it is possible that our current practices are challenged under one or more of such laws. The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform. Federal, state and foreign enforcement bodies have increased their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry.
Cyber-based attacks, security breaches, loss of data and other disruptions in relation to our information systems and computer networks could compromise sensitive information related to our business, prevent us from accessing it and expose us to liability, which could adversely affect our business and reputation.
Cyber-attacks, security breaches, computer viruses, malware and other incidents could cause misappropriation, loss or other unauthorized disclosure of confidential data, materials or information, including those concerning our customers and employees. Increasingly complex methods have been used in cyber-attacks, including ransomware, phishing, structured query language injections and distributed denial-of-service attacks. A cyber-attack can also be in the form of unauthorized access or a blocking of authorized access. We can provide no assurance that we or our vendors will be able to detect, prevent or contain the effects of such attacks or other information security risks or threats in the future. The costs of attempting to protect against the foregoing risks and the costs of responding to a cyber-attack are significant. Large scale data breaches at other entities increase the challenge we and our vendors face in maintaining the security of our information technology systems and of our customers’ sensitive information. Following a cyber-attack, our and/or our vendors’ remediation efforts may not be successful, and a cyber-attack could result in interruptions, delays or cessation of service, and loss of existing or potential customers. In addition, breaches of our and/or our vendors’ security measures and the unauthorized dissemination of sensitive personal information or proprietary information or confidential information about us, our customers or other third-parties, could expose our customers' private information and our customers to the risk of financial or medical identity theft, or expose us or other third parties to a risk of loss or misuse of this information, and result in investigations, regulatory enforcement actions, material fines and penalties, loss of customers, litigation or other actions which could have a material adverse effect on our business, prospects, reputation, results of operations and financial condition. In addition, if we fail to adhere to our privacy policy and other published statements or applicable laws concerning our processing, use, transmission and disclosure of protected

65

information, or if our statements or practices are found to be deceptive or misrepresentative, we could face regulatory actions, fines and other liability.

In the ordinary course of our business, we collect and store sensitive data, including PHI, personally identifiable information, credit card and other financial information, intellectual property and proprietary business information owned or controlled by us or other parties such as customers and payers. We manage and maintain our applications and data utilizing a combination of on-site systems and cloud-based data centers. We utilize external security and infrastructure vendors to manage parts of our data centers. We also communicate sensitive data, including patient data, through phone, Internet, facsimile, multiple third-party vendors and their subcontractors or integrations with third-party electronic medical records. These applications and data encompass a wide variety of information critical to our business, including research and development information, patient data, commercial information and business and financial information. We face a number of risks related to protecting this critical information, including loss of access, inappropriate use or disclosure, unauthorized access, inappropriate modification and our being unable to adequately monitor, audit or modify our controls over such critical information. This risk extends to the third-party vendors and subcontractors we use to manage this sensitive data or otherwise process it on our behalf.
The secure processing, storage, maintenance and transmission of this critical information are vital to our operations and business strategy, and we devote significant resources to protecting such information. Although we take reasonable measures to protect sensitive data from unauthorized access, use, modification or disclosure, no security measures can be perfect and our information technology infrastructure could be vulnerable to hackers, phishing scams, malware, viruses, security flaws, employee errors, and other malfeasance or inadvertent disruptions. Any breach or interruption of our security measures or information technology infrastructure could compromise our networks, and the information stored there could be accessed by unauthorized parties, publicly disclosed, lost or stolen. Any such access, breach, or other loss of information could result in legal claims or proceedings, and liability under federal, state or foreign laws that protect the privacy of personal information, such as HIPAA or HITECH, and regulatory penalties. Notice of breaches is required to be made to affected individuals, the Secretary of the Department of Health and Human Services or other state, federal or foreign regulators, and for extensive breaches, notice may need to be made to the media or State Attorneys General. Such a notice could harm our reputation and our ability to compete. Although we have implemented security measures and an enterprise security program to prevent unauthorized access to patient data, such data is currently accessible through multiple channels, and there is no guarantee we can protect all data from breach. Unauthorized access, loss or dissemination could disrupt our operations (including our ability to perform our analysis, provide test results, bill payers or patients, process claims and appeals, provide customer assistance, conduct research and development, develop intellectual property, collect, process and prepare financial information, provide information about our tests and continue other patient and physician education and outreach efforts, and manage our business) and damage our reputation, any of which could adversely affect our business and financial condition. We continue to prioritize security and the development of practices and controls to protect our systems. As cyber threats evolve, we may be required to expend significant additional resources to continue to modify or enhance our protective measures or to investigate and remediate any information security vulnerabilities, and these efforts may not be successful.
For example, in July 2018, we experienced security incidents involving an unauthorized actor obtaining access to our email system and sending phishing messages. We promptly engaged an independent cybersecurity firm to support our investigation, assess our systems and bolster security thereof. These incidents resulted in the unauthorized access of certain information relating to an aggregate of approximately 1,700 individuals. For approximately 1,100 of these individuals, the information accessed included PHI and primarily consisted of patients’ names, contact information, birth dates, medical diagnosis codes and, in a very limited number of cases, Social Security numbers. For the remaining individuals, information accessed did not include PHI and primarily consisted of Social Security numbers and certain other personal financial information, and credit card information in one of the incidents. We have provided timely notices to the U.S. Department of Health and Human Services, or the HHS, certain state regulators and certain credit agencies, as applicable, as well as to the individuals affected. We have offered credit monitoring and identity protection services to those who have been affected by this cyber-attack. While the cyber-attack did not have a material impact on our business, cash flows, financial condition and results of operations, we have incurred and may continue to incur internal and external costs, including those relating to mitigation of the incidents, and may be subject to penalties, such as those described above. We have implemented and continue to implement additional security measures as appropriate to help prevent future unauthorized access to our systems and the data we maintain, but we cannot guarantee that future incidents can be avoided. In addition, because the cybersecurity firm’s investigation only analyzed our email accounts dating back to February 2018 (the time period for which security logs were available in our email software), we cannot assure that no similar incidents took place before that time.

66

In connection with a former employee’s complaints alleging non-compliance with applicable provisions of HIPAA, we received requests for information from the HHS Office for Civil Rights, or OCR, in August 2019. After we responded to these requests, we were informed by the OCR that it has closed this matter without further action.
We have contingency plans and insurance coverage for certain potential claims, liabilities, and costs relating to security incidents that may arise from our business or operations; however, the coverage may not be sufficient to cover all claims, liabilities, and costs arising from the incidents, including fines and penalties. It could be difficult to predict the ultimate resolution of any such incidents or to estimate the amounts or ranges of potential loss, if any, that could result therefrom. If we cannot successfully resolve a security incident or contain any potential loss, it could materially impact our ability to operate our business as well as our results of operations and financial position.

Risks related to our intellectual property
If we are unable to obtain and maintain sufficient intellectual property protection for our technology, or if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize our products may be impaired.
We rely on patent protection as well as trademark, copyright, trade secret and other intellectual property rights protection and contractual restrictions to protect our proprietary technologies, all of which provide limited protection and may not adequately protect our rights or permit us to gain or keep any competitive advantage. If we fail to protect our intellectual property, third parties may be able to compete more effectively against us. In addition, we have incurred and may continue to incur substantial litigation costs in our attempts to recover or restrict use of our intellectual property.
To the extent our intellectual property offers inadequate protection, or is found to be invalid or unenforceable, we would be exposed to a greater risk of direct competition. If our intellectual property does not provide adequate coverage of our competitors’ products, our competitive position could be adversely affected, as could our business. Both the patent application process and the process of managing patent disputes can be time-consuming and expensive.
As is the case with other biotechnology companies, our success depends in large part on our ability to obtain and maintain protection of the intellectual property we own solely and may own jointly with others or we have licensed and may continue to license from others, particularly patents, in the United States and other countries with respect to our products and technologies. We apply for patents covering our products and technologies and uses thereof, as we deem appropriate. However, obtaining and enforcing biotechnology patents is costly, time-consuming and complex, and we may fail to apply for patents on important products, services and technologies in a timely fashion or at all, or we may fail to apply for patents in potentially relevant jurisdictions. We may not be able to file and prosecute all necessary or desirable patent applications, or maintain, enforce and license any patents that may issue from such patent applications, at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. We may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the rights to patents licensed to third parties. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business.
We own or license numerous U.S. patents and pending U.S. patent applications, with international counterparts in certain countries. It is possible that our or our licensors’ pending patent applications will not result in issued patents in a timely fashion or at all, and even if patents are granted, they may not provide a basis for intellectual property protection of commercially viable products or services, may not provide us with any competitive advantages, or may be challenged and invalidated by third parties. It is possible that others will design around our current or future patented technologies. Some of such patent rights are being challenged, including at the United States Patent and Trademark Office, or USPTO, in post-grant proceedings, at the European Patent Office, or EPO, in opposition proceedings, and some of such patent rights may be challenged in the future. We may not be successful in defending any such challenges made against our owned or licensed patents or patent applications. Any successful third-party challenge to such patent rights could result in their unenforceability or invalidity and increased competition to our business. We have challenged and may choose to challenge the patents or patent applications of third parties. The outcome of patent litigation or other proceeding can be uncertain, and any attempt by us to enforce our patent rights against others or to challenge the patent rights of others may not be successful, or, if successful, may take substantial time and result in substantial cost, and may divert our efforts and attention from other aspects of our business.

67

The patent positions of life sciences companies can be highly uncertain and involve complex legal and factual questions for which important legal principles remain unresolved. No consistent policy regarding the breadth of claims allowed in such companies’ patents has emerged to date in the United States or elsewhere. Courts frequently render opinions in the biotechnology field that may affect the patentability of certain inventions or discoveries, including opinions that may affect the patentability of methods for analyzing or comparing DNA sequences.
In particular, the patent positions of companies engaged in the development and commercialization of genomic diagnostic tests, like our current products, including our Guardant360 and GuardantOMNI tests, and our future products, are particularly uncertain. Various courts, including the U.S. Supreme Court, have rendered decisions that affect the scope of patentability of certain inventions or discoveries relating to certain diagnostic tests and related methods. These decisions state, among other things, that a patent claim that recites an abstract idea, natural phenomenon or law of nature (for example, the relationship between particular genetic variants and cancer) are not themselves patentable. Precisely what constitutes a law of nature is uncertain, and it is possible that certain aspects of genetic diagnostics tests would be considered natural laws. Accordingly, the evolving legal and administrative standards around the world, including in the United States may adversely affect our ability to obtain patents and may facilitate third-party challenges to any owned or licensed patents. The laws of some foreign jurisdictions do not protect intellectual property rights to the same extent as the laws of the United States, and we may encounter difficulties in protecting and defending such rights in foreign jurisdictions. The legal systems of many foreign jurisdictions do not favor the enforcement of patent rights and other intellectual property protection, particularly those relating to biotechnology, which could make it difficult for us to stop the infringement of our patent rights and other intellectual property rights thereunder. Proceedings to enforce our patent rights and other intellectual property protection in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business.
Changes in patent law in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products.
Changes in either the patent laws or in interpretations of patent laws in the United States or other countries or regions may diminish the value of our intellectual property. We cannot predict the breadth of claims that may be allowed or enforced in our patents or in third-party patents. We may not develop additional proprietary products, methods and technologies that are patentable.
Assuming that other requirements for patentability are met, prior to March 16, 2013, in the United States, the first to invent the claimed invention was entitled to the patent, while outside the United States, the first to file a patent application was entitled to the patent. On or after March 16, 2013, under the Leahy-Smith America Invents Act, or the America Invents Act, enacted in September 16, 2011, the United States transitioned to a first inventor to file system in which, assuming that other requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. A third party that files a patent application in the USPTO on or after March 16, 2013, but before us could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by such third party. This will require us to be cognizant of the time from invention to filing of a patent application. Since patent applications in the United States and most other countries are confidential for a period of time after filing or until issuance, we cannot be certain that we or our licensors were the first to either (i) file any patent application related to our product candidates or (ii) invent any of the inventions claimed in our or our licensor’s patents or patent applications.
The America Invents Act also includes a number of significant changes that affect the way patent applications will be prosecuted and also affect patent litigation. These include allowing third-party submission of prior art to the USPTO during patent prosecution or post-grant proceedings, including post-grant review, inter partes review and derivation proceedings, to attack the validity of a patent. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence might not be sufficient to invalidate the claim if presented in a district court action. Accordingly, third parties have used and may continue to use the USPTO proceedings to invalidate our patent claims that would not have been invalidated if first challenged by the third party in a district court action. Therefore, the America Invents Act and its implementation could increase the uncertainties and costs surrounding our or our licensors' prosecution of patent applications and enforcement or defense of issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects.

68

Issued patents covering our products could be found invalid or unenforceable if challenged.
The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability. Some of our owned or licensed patent rights have been, are being or may be challenged at a future point in time in opposition, derivation, re-examination, inter partes review, post-grant review or interference. Any successful third-party challenge to our patent rights in this or any other proceeding could result in the unenforceability or invalidity of such patent rights, which may lead to increased competition to our business, which could harm our business. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize our current or future products.
We may not be aware of all third-party intellectual property rights potentially relating to our product candidates. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until approximately 18 months after filing or, in some cases, not until such patent applications issue as patents. We might not have been the first to make the inventions covered by each of our pending patent applications and we might not have been the first to file patent applications for these inventions. To determine the priority of these inventions, we have participated and may continue to participate in interference proceedings, derivation proceedings or other post-grant proceedings declared by the USPTO that could result in substantial cost to us. The outcome of such proceedings is uncertain. No assurance can be given that other patent applications will not have priority over our patent applications. In addition, changes to the patent laws of the United States allow for various post-grant opposition proceedings that have not been extensively tested, and their outcome is therefore uncertain. Our licensors may also license patent rights to others, and we may not be aware of such licenses before they are granted or such licenses may be subject to disputes or uncertainties that affect patent rights licensed by us or could limit our ability to enforce such patent rights. If third parties bring actions against our owned or licensed patent rights, we could experience significant costs and management distraction.
In patent litigation in the United States or abroad, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the patent office or made a misleading statement during prosecution. Similar claims may also be raised before patent offices in the United States or abroad, even outside the context of litigation, through mechanisms including re-examination, post-grant review and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). Such proceedings could result in revocation or amendment to our patent rights in such a way that they no longer cover our products. The outcome of patent litigation or patent office proceedings following assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our products. Such a loss of patent protection could have a material adverse impact on our business.
We and some of our licensors have initiated, are currently involved in, and may in the future initiate or become involved in legal proceedings against a third party to enforce a patent covering one of our products. For example, we filed separate patent infringement suits against Foundation Medicine, Inc. (“Foundation Medicine”) and Personal Genome Diagnostics, Inc. (“Personal Genome Diagnostics”), alleging that each infringed patent related to our digital sequencing technology.
Defendants in such proceedings could counterclaim that the patents covering our product are invalid or unenforceable and could institute legal proceedings to challenge such patents both in court and before patent offices. For example, Foundation Medicine and Personal Genome Diagnostics have each asserted counterclaims of patent invalidity, unenforceability under the doctrine of inequitable conduct, and non-infringement. Personal Genome Diagnostics has also alleged antitrust violations related to the enforcement of our patent rights. In addition, Personal Genome Diagnostics and Foundation Medicine have each filed petition for post-grant review with the Patent Trial and Appeal Board at the USPTO, challenging the patentability of certain patents asserted by us. If Foundation Medicine or Personal Genome Diagnostics were to prevail on their assertions of invalidity and/or unenforceability, we would lose at least part of the patent protection on our products. Such a loss of patent protection could have a material adverse impact on our business. A counterclaim, even if not successful, could be time-consuming and expensive to defend, damage our reputation in the marketplace and the prospects for our business, and divert our management’s attention.

69

We rely on licenses from third parties, and if we lose these licenses then we may be subjected to future litigation.
We are, and we may acquire companies that are, party to various royalty-bearing license agreements that grant us rights to use certain intellectual property, including patents and patent applications, typically in certain specified fields of use. We may need to obtain additional licenses from others to advance our research, development and commercialization activities. Our license agreements impose, and we expect that future license agreements will impose, various development, diligence, commercialization and other obligations on us, including obligations to making payments to our licensors upon achievement of milestones.
In spite of our efforts, our licensors have asserted and may in the future assert that we have materially breached our obligations under such license agreements and could therefore seek or threaten to terminate the license agreements. If these licenses are terminated, or if the underlying patent rights fail to provide the intended exclusivity, our ability to develop and commercialize products and technology covered by these license agreements would be limited or lost, and our competitors or other third parties might have the freedom to develop, produce, seek regulatory approval of, or to market, products identical or similar to ours and we may be required to cease our development and commercialization activities. Our actual or potential licensors could take action with respect to our licensed intellectual property that may decrease the value of such licensed intellectual property. Any of the foregoing could have a material adverse effect on our competitive position, business, financial condition, results of operations and prospects. Moreover, disputes could arise with respect to any aspect of our license agreements, including:
•
the scope of rights granted under the license agreement and other interpretation-related issues;
•
the extent to which our products or product candidates, technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;
•
the licensing of patent and other rights controlled by our licensors or developed under our collaborative development relationships to others;
•
our diligence obligations under the license agreement and what activities satisfy those diligence obligations;
•
the inventorship and ownership of inventions and know-how licensed to us or resulting from the joint creation or use of intellectual property by our licensors, us and/or our partners;
•
the validity, enforceability or priority of licensed patent rights; and
•
the amount of royalties and other payments we are obligated to pay under the license agreement.
If we do not prevail in such disputes, we may lose any of such license agreements, the license agreements may not be meaningful for our business and operations, and we may be subject to unnecessary or additional payment obligations.
In addition, the agreements under which we currently license intellectual property or technology from third parties are complex, and certain provisions in such agreements could be susceptible to multiple interpretations. The resolution of any such contract interpretation disagreement could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects. Moreover, if disputes over licensed intellectual property impair our ability to enforce licensed intellectual property against third parties or use it to defend ourselves in litigation, the value of such licensed intellectual property may be diminished.

70

If we fail to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates, which could have a material adverse effect on our business, financial condition, results of operations and prospects. If any of these license agreements is terminated, if the licensor fails to abide by the terms of the license agreement, if the licensor fails to prevent infringement by third parties, or if the licensed patent or other rights are found to be invalid or unenforceable, our may be unable to achieve our business goals and our results of operations and financial condition could be adversely affected. Absent the license agreements, we could infringe patents subject to those agreements, and if the license agreements are terminated, we may be subject to litigation by the licensor. Litigation could result in substantial costs and be a distraction to management. If we do not prevail, we may be required to pay damages, including treble damages, attorneys’ fees, costs and expenses, royalties or, be enjoined from selling our products or services, including our Guardant360 and GuardantOMNI tests, which could adversely affect our ability to offer products or services, our ability to continue operations and our financial condition.
If we cannot license and maintain rights to use third-party technology on reasonable terms, we may not be able to successfully commercialize our products. Our licensed or acquired technology may lose value or utility or over time.
From time to time, we may identify third-party technology we may need, including to develop or commercialize new products or services. We may also need to negotiate licenses to patents or patent applications before or after introducing a commercial product, and we may not be able to obtain necessary licenses to such patents or patent applications. If we are unable to enter into the necessary licenses on acceptable terms or at all, if any necessary licenses are subsequently terminated, if the licensors fail to abide by the terms of the licenses or fail to prevent infringement by third parties, or if the licensed patents or other rights are found to be invalid or unenforceable, our business may suffer. In addition, any technology licensed or acquired by us may lose value or utility, including as a result of a change of in the industry, in our business objectives, others' technology, our dispute with the licensor, and other circumstances outside our control. In return for the use of a third party’s technology, we may agree to pay the licensor royalties based on sales of our products or services. Royalties are a component of cost of products or services and affect the margins on our products or services. If we are unable to negotiate reasonable royalties or if we have to pay royalties on technology that becomes less useful for us or ceases to provide value to us, our profit margin will be reduced and we may suffer losses.
We may not be able to protect or enforce our intellectual property rights adequately throughout the world.
Filing, prosecuting and defending patents on our products and services in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some territories outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries and regions do not protect intellectual property rights to the same extent as the laws of the United States, and we may encounter difficulties in protecting and defending such rights in foreign jurisdictions. Consequently, we may not be able to prevent third parties from practicing our inventions in all jurisdictions, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our inventions in jurisdictions where we have not obtained patent protection to develop their own products and may also export infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our products. Our patents or other intellectual property rights existing outside the United States may not be effective or sufficient to prevent them from competing. Similarly, intellectual property rights may be exhausted in certain situations, and others could import our products sold abroad and compete with us domestically.
Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of many other countries and regions do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biotechnology, which could make it difficult for us to stop the infringement of our patents in such jurisdictions. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded to us, if any, may not be commercially meaningful. Accordingly, our efforts to enforce intellectual property rights around the world may be inadequate to obtain a significant commercial advantage.

71

If we are unable to protect the confidentiality of our trade secrets, the value of our technology could be materially adversely affected and our business could be harmed.
In addition to pursuing patents on our technology, we take steps to protect our intellectual property and proprietary technology by entering into agreements, including confidentiality agreements, non-disclosure agreements and intellectual property assignment agreements, with our employees, consultants, academic institutions, corporate partners and, when needed, our advisers. However, we cannot be certain that such agreements have been entered into with all relevant parties, and we cannot be certain that our trade secrets and other proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. For example, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Such agreements may not be enforceable or may not provide meaningful protection for our trade secrets or other proprietary information in the event of unauthorized use or disclosure or other breaches of the agreements, and we may not be able to prevent such unauthorized use or disclosure. If we are required to assert our rights against such party, it could result in significant cost and distraction.
Monitoring unauthorized use or disclosure is difficult, and we do not know whether the steps we have taken to prevent such use or disclosure are, or will be, adequate. If we were to enforce a claim that a third party had illegally obtained and was using our trade secrets, it would be expensive and time-consuming, and the outcome would be unpredictable. In addition, courts outside the United States may be less willing to protect trade secrets.
We also seek to preserve the integrity and confidentiality of our proprietary information by maintaining physical security of our premises and physical and electronic security of our information technology systems, but it is possible that these security measures could be breached. If any of our confidential proprietary information were to be lawfully obtained or independently developed by a competitor, absent patent protection, we would have no right to prevent such competitor from using that technology or information to compete with us, which could harm our competitive position.
We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties or that our employees have wrongfully used or disclosed trade secrets of their former employers.
We have employed or engaged and expect to employ or engage individuals who were previously employed at or associated with universities or other companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and independent contractors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers or other third parties, or to claims that we have improperly used or obtained such trade secrets. Litigation may be necessary to defend against these claims. If we lose, in addition to paying monetary damages, we may be deprived of valuable intellectual property and face increased competition. A loss of key research personnel or work product could hamper or prevent our ability to commercialize potential products, which could harm our business. Even if we are successful in defending against these claims, litigation could result in damage to our reputation and substantial costs and be a distraction to management and affected individuals.
We may not be able to protect and enforce our trademarks and we could infringe others’ trademarks.
We have not yet registered trademarks in all of our potential markets, although we have registered Guardant Health, Guardant360 and GuardantOMNI in the United States. If we apply to register additional trademarks in the United States and other countries, our applications may not be allowed for registration in a timely fashion or at all, and our registered trademarks may not be maintained or enforced. In addition, opposition or cancellation proceedings may be filed against our trademark applications and registrations, and our trademarks may not survive such proceedings. If we do not timely register and enforce marks used in connection with our products or services, we may encounter difficulty in enforcing them against third parties, and if these marks are registered by others, we could infringe such trademarks.

72

We may be subject to claims challenging the inventorship or ownership of our owned or licensed intellectual property.
We or our licensors may be subject to claims that former employees, collaborators or other third parties have an interest in or right to our owned or licensed patents, trade secrets or other intellectual property. For example, we or our licensors may have inventorship disputes arise from conflicting obligations of employees, consultants or others who are involved in developing such intellectual property. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership of our owned or licensed patents, trade secrets or other intellectual property. If we or our licensors fail in defending against any such claims, we may lose exclusive ownership of, or right to use, valuable intellectual property. Even if we are successful in defending against such claims, litigation could result in damage to our reputation and substantial costs and be a distraction to management and other employees. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.
We are and may continue to be involved in litigation and other legal proceedings related to intellectual property, which could be time-intensive and costly and may adversely affect our business, operating results or financial condition.
We have been, are currently in, and may also in the future be, involved with litigation or USPTO actions with various third parties. We expect that the number of such claims may increase as the number of our products or services grows, and the level of competition in our industry segments increases. Any infringement claim, regardless of its validity, could harm our business by, among other things, resulting in time-consuming and costly litigation, diverting management’s time and attention from the development of our business, or requiring the payment of monetary damages (including treble damages, attorneys’ fees, costs and expenses if we are found to have willfully infringed) and ongoing royalties.
Litigation may be necessary for us to enforce our intellectual property and proprietary rights or to determine the scope, coverage and validity of the intellectual property and proprietary rights of others. We are currently engaged in lawsuits against Foundation Medicine, Inc. and Personal Genome Diagnostics, Inc. for infringement over some of our patents and in proceedings before the USPTO in relation to certain such patents. The outcome of such lawsuits, as well as any other litigation or proceeding, is inherently uncertain and might not be favorable to us. Further, we could encounter delays in product introductions, or interruptions in sale of products or services, as we develop alternative products or services. In addition, if we resort to legal proceedings to enforce our intellectual property rights (as we have against Foundation Medicine, Inc. and Personal Genome Diagnostics, Inc.) or to determine the validity, scope and coverage of the intellectual property or other proprietary rights of others, the proceedings could be burdensome and expensive, even if we were to prevail. If we do not prevail in such legal proceedings, we may be required to pay damages, and we may lose significant intellectual property protection for our products or services, such that competitors could copy our products or services. Any litigation that may be necessary in the future could result in substantial costs and diversion of resources and could have a material adverse effect on our business, operating results or financial condition.
As we move into new markets and applications for our products or services, incumbent participants in such markets may assert their patents and other intellectual property or proprietary rights against us as a means of slowing our entry into such markets or as a means to extract substantial license and royalty payments from us. As our business matures and our public profile grows, we may also be subject to an increased number of allegations of patent infringement, whether by our competitors or other patent owners, both in the United States and throughout the world wherever we seek to commercialize our products and services. Our competitors and others may have significantly larger and more mature patent portfolios than we have. In addition, while we can assert our own patents or other rights during litigation, our own patents may provide little or no deterrence or protection against patent holding companies or other patent owners who have no relevant product or service revenue. Therefore, our commercial success may depend in part on our non-infringement of the patents or other rights of third parties and on our success in defending ourselves in litigation.

73

However, our research, development and commercialization activities are currently and may in the future be subject to claims that we infringe or otherwise violate patents or other intellectual property rights owned or controlled by third parties. There is a substantial amount of litigation and other patent challenges, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology industry, including patent infringement lawsuits, interferences, oppositions and inter partes review proceedings before the USPTO, and corresponding proceedings before foreign patent offices. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing products. As the precision oncology industry expands and more patents are issued, the risk increases that our products or services may be subject to claims of infringement of the patent rights of third parties. Numerous significant intellectual property issues have been litigated, are being litigated and will likely continue to be litigated, between existing and new participants in our existing and targeted markets, and our competitors have asserted and may in the future assert that our products or services infringe their intellectual property rights as part of a business strategy to impede our successful entry into or growth in those markets, and we may enforce our owned or licensed intellectual property rights against our competitors and other parties. For example, we have been or are currently involved in legal proceedings against Foundation Medicine and Personal Genome Diagnostics related to our patent rights both in court and before the USPTO.
Third parties have asserted and may in the future assert that we are employing their proprietary technology or trade secrets without authorization. For instance, Foundation Medicine, Inc. filed a lawsuit for patent infringement against us in May 2016, which we settled in July 2018. We are also aware of issued U.S. patents and patent applications with claims related to our products and services, and there may be other related third-party patents or patent applications of which we are not aware. By interacting with us, our licensors may learn more about our business or technology and could assert additional patent rights against us, such as patent rights that are not currently licensed to us or patent rights that may be obtained by any such licensors in the future, which may occur if such patent rights are not available for licensing or if they are not offered on acceptable or commercially reasonable terms. Because patent applications can take many years to issue and are not publicly available until a certain period of time passes from filing, there may be currently pending patent applications which may later result in issued patents that our current or future products and services may infringe. In addition, similar to what other companies in our industry have experienced, we expect our competitors and others may develop or obtain patents with our products or services in mind and claim that making, having made, using, selling, offering to sell or importing our products or services infringes these patents.
We could incur substantial costs and divert the attention of our management and technical personnel in defending against any of these claims. Parties making claims against us may be able to sustain the costs of complex patent litigation more effectively than we can, for example, because they have substantially greater resources.
Parties making claims against us may be able to obtain injunctive or other relief, which could block our ability to develop, commercialize and sell certain products or services, and could result in the award of substantial damages against us, including treble damages, attorney’s fees, costs and expenses if we are found to have willfully infringed. In the event of a successful claim of infringement against us, we may be required to pay damages and ongoing royalties, and obtain one or more licenses from third parties, or be prohibited from selling certain products or services. We may not be able to obtain these licenses on acceptable or commercially reasonable terms, if at all, or these licenses may be non-exclusive, which could result in our competitors gaining access to the same intellectual property. In addition, we could encounter delays in product or service introductions while we attempt to develop alternative products or services to avoid infringing third-party patents or proprietary rights. Defense of any lawsuit or failure to obtain any of these licenses could prevent us from commercializing products or services, and the prohibition of sale of any of our products or services could materially affect our business and our ability to gain market acceptance for our products or services.
Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, during the course of this kind of litigation, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock.
In addition, our agreements with some of our customers, suppliers or other entities with whom we do business require us to defend or indemnify these parties to the extent they become involved in infringement claims, including the types of claims described above. We could also voluntarily agree to defend or indemnify third parties in instances where we are not obligated to do so if we determine it would be important to our business relationships. If we are required or agree to defend or indemnify third parties in connection with any infringement claims, we could incur significant costs and expenses that could adversely affect our business, operating results or financial condition.

74

Obtaining and maintaining our patent protection depends on compliance with various required procedures, document submissions, fee payments and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.
Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to be paid to the USPTO and various governmental patent agencies outside of the United States at several stages over the lifetime of the patents and/or applications. We have systems in place to remind us to pay these fees, and we rely on our outside counsel to pay these fees due to non-U.S. patent agencies. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar requirements during the patent application process. We employ reputable law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which non-compliance can result in abandonment or forfeiture of the patent or patent application and thus loss of patent rights in the relevant jurisdiction. Such an event would allow our competitors to enter the unprotected market and have a material adverse effect on our business.
Patent terms may be inadequate to protect our competitive position for an adequate amount of time.
Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our products or services are obtained, once the patent life has expired, we may be open to competition. Given the amount of time required for the development, testing and regulatory review of our new products or services, patents protecting them might expire before or shortly after they are commercialized. As a result, our owned and licensed patent portfolio may not provide us with a sufficient exclusivity period to exclude others from commercializing products or services similar or identical to ours.
Risks related to our common stock
An active trading market for our common stock may not be maintained.
We can provide no assurance that we will be able to maintain an active trading market for our common stock on the Nasdaq Global Select Market, or Nasdaq, or any other exchange in the future. If an active market for our common stock is not maintained, or if we fail to satisfy the continued listing standards of Nasdaq for any reason and our common stock is delisted, it may be difficult for our stockholders to sell shares without depressing the market price for the shares or at all. An inactive trading market may also impair our ability to both raise capital by selling shares of common stock and acquire other complementary products, technologies or businesses by using our shares of common stock as consideration.
The price of our common stock has fluctuated substantially and may do so in the future, and you may not be able to resell shares of our common stock at or above the price at which you purchased them.
The market price of our common stock has been volatile and may fluctuate substantially in the future due to many factors, including:
•
volume and customer mix for our precision oncology testing;
•
the introduction of new products or product enhancements by us or others in our industry;
•
disputes or other developments with respect to our or others’ intellectual property rights;
•
our ability to develop, obtain regulatory clearance or approval for, and market new and enhanced products on a timely basis;
•
product liability claims or other litigation;
•
quarterly or annual variations in our results of operations or those of others in our industry;
•
media exposure of our products or of those of others in our industry;
•
changes in governmental regulations or in the status of our regulatory approvals or applications;

75

•
changes in earnings estimates or recommendations by securities analysts; and
•
general market conditions and other factors, including factors unrelated to our operating performance or the operating performance of our competitors.
In recent years, the stock markets generally have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of those companies. Broad market and industry factors may significantly affect the market price of our common stock, regardless of our actual operating performance. In addition, in the past, class action litigation has often been instituted against companies whose securities have experienced periods of volatility in market price. Securities litigation brought against us following volatility in our stock price, regardless of the merit or ultimate results of such litigation, could result in substantial costs, which would hurt our financial condition and operating results and divert management’s attention and resources from our business.
Securities analysts may not publish favorable research or reports about our business or may publish no information at all, which could cause our stock price or trading volume to decline.
The trading market for our common stock is influenced to some extent by the research and reports that industry or financial analysts publish about us and our business. We do not control these analysts. The analysts who publish information about our common stock may have had relatively little experience with us or our industry, which could affect their ability to accurately forecast our results and could make it more likely that we fail to meet their estimates. In the event we obtain securities or industry analyst coverage, if any of the analysts who cover us provide inaccurate or unfavorable research or issue an adverse opinion regarding our stock price, our stock price could decline. If one or more of these analysts cease coverage of us or fail to publish reports covering us regularly, we could lose visibility in the market, which in turn could cause our stock price or trading volume to decline.
If our estimates or judgments relating to our critical accounting policies are based on assumptions that change or prove to be incorrect, our operating results could fall below our publicly announced guidance or the expectations of securities analysts and investors, resulting in a decline in the market price of our common stock.
The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America, or GAAP, requires management to make estimates and assumptions that affect the amounts reported in our financial statements and accompanying notes. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets, liabilities, equity, revenue and expenses that are not readily apparent from other sources. In connection with adopting and implementing a new revenue recognition standard, FASB ASC Topic 606, Revenue from Contracts with Customers, management has made and will continue to make judgments and assumptions based on our interpretation of the new standard. The new revenue recognition standard is principle-based and interpretation of those principles may vary from company to company based on their unique circumstances. We also adopted a new lease accounting standard, FASB ASC Topic 842, Leases, which involved significant judgment and assumptions, including the estimation of incremental borrowing rate used to discount our lease liabilities and the assessment of risks associated with the specific economic environment of our leased assets. It is possible that interpretation, industry practice and guidance may evolve as we work toward implementing these new accounting standards. If our assumptions change or if actual circumstances differ from our assumptions, our operating results may be adversely affected and could fall below our publicly announced guidance or the expectations of analysts and investors, resulting in a decline in the market price of our common stock.
A significant portion of our total outstanding shares may be sold into the market in the near future. This could cause the market price of our common stock to drop significantly, even if our business is doing well.
Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales, or the perception in the market that the holders of a large number of shares intend to sell their shares, could result in a decrease in the market price of our common stock. Moreover, holders of approximately 2.6 million shares of our common stock will have rights, subject to some conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. We also registered shares of our common stock that have been issued or that we may issue under our current equity compensation plans, which shares can be freely sold in the public market, subject to volume limitations applicable to affiliates.

76

Our executive officers, directors and principal stockholders have significant voting power and may take actions that may not be in the best interests of our other stockholders.
As of December 31, 2019, our executive officers and directors as well as entities affiliated with them collectively controlled approximately 37% of our outstanding common stock. As a result, these stockholders, if they act together, may be able to effectively control or exert significant influence over the management and affairs of our company and most matters requiring stockholder approval, including the election of directors and approval of significant corporate transactions. This concentration of ownership may have the effect of delaying or preventing a change of control and might adversely affect the market price of our common stock. This concentration of ownership may not be in the best interests of our other stockholders.
We expect to incur significant additional costs as a result of being a public company, which may adversely affect our business, financial condition and results of operations.
We expect to incur costs associated with corporate governance requirements that are applicable to us as a public company, including rules and regulations of the SEC, under the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, and the Securities Exchange Act of 1934, as amended, or the Exchange Act, as well as the rules of Nasdaq. These rules and regulations, including those applicable to a large accelerated filer such as us, significantly increase our accounting, legal and financial compliance costs and make some activities more time-consuming. These rules and regulations also make it more expensive for us to maintain directors’ and officers’ liability insurance. Accordingly, increases in costs incurred as a result of being a publicly traded company may adversely affect our business, financial condition and results of operations.
If we experience material weaknesses in the future or otherwise fail to maintain an effective system of internal controls in the future, we may not be able to accurately report our financial condition or results of operations which may adversely affect investor confidence in us and, as a result, the value of our common stock.
As a result of becoming a public company, we are required, under Section 404 of the Sarbanes-Oxley Act, to furnish annual reports by management on, among other things, the effectiveness of our internal control over financial reporting. This assessment needs to include disclosure of any material weaknesses identified by our management in our internal control over financial reporting. A material weakness is a deficiency or combination of deficiencies in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of a company’s annual and interim financial statements will not be detected or prevented on a timely basis.
If we identify one or more material weaknesses in our internal control over financial reporting, we will be unable to assert that our internal controls are effective. The effectiveness of our controls and procedures may be limited by a variety of factors, including:
•
faulty human judgment and simple errors, omissions or mistakes;
•
fraudulent action of an individual or collusion of two or more people;
•
inappropriate management override of procedures; and
•
the possibility that any enhancements to controls and procedures may still not be adequate to assure timely and accurate financial control.
Pursuant to the Sarbanes-Oxley Act and the rules and regulations promulgated by the SEC, we are required to furnish in this Annual Report on Form 10-K a report by our management regarding the effectiveness of our internal control over financial reporting. The report includes, among other things, an assessment of the effectiveness of our internal control over financial reporting as of the end of our fiscal year, including a statement as to whether or not our internal control over financial reporting is effective. This assessment must include disclosure of any material weaknesses in our internal control over financial reporting identified by management. While we believe our internal control over financial reporting is currently effective, the effectiveness of our internal controls in future periods is subject to the risk that our controls may become inadequate because of changes in conditions. Establishing, testing and maintaining an effective system of internal control over financial reporting requires significant resources and time commitments on the part of our management and our finance staff, may require additional staffing and infrastructure investments and would increase our costs of doing business.

77

In addition, under the federal securities laws, our auditors are required to express an opinion on the effectiveness of our internal controls. If we are unable to confirm that our internal control over financial reporting is effective, or if our independent registered public accounting firm is unable to express an opinion on the effectiveness of our internal controls, we could lose investor confidence in the accuracy and completeness of our financial reports, which could cause the price of our common stock to decline.
Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.
We are subject to the periodic reporting requirements of the Exchange Act. We designed our disclosure controls and procedures to provide reasonable assurance that information we must disclose in reports we file or submit under the Exchange Act is accumulated, communicated to management, recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met.
These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.
Provisions in our corporate charter documents and under Delaware law could make a change in control of us more difficult and may prevent attempts by our stockholders to replace or remove our current management.
Provisions in our amended and restated certificate of incorporation and our amended and restated bylaws may discourage, delay or prevent a merger, acquisition or other change in control of us that stockholders may consider favorable, including transactions in which our stockholders might otherwise receive a premium for their shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, these provisions may make it more difficult for our stockholders to replace current members of our board of directors or add new members thereto. Because our board of directors is responsible for appointing the members of our management team, these provisions could in turn affect any attempts by our stockholders to change our management team. Among others, these provisions include that:
•
our board of directors has the exclusive right to expand its size and to elect directors to fill a vacancy created by the expansion of the board or the resignation, death or removal of a director, which prevents stockholders from being able to fill vacancies on our board of directors;
•
our board of directors is divided into three classes, Class I, Class II and Class III, with each class serving staggered three-year terms, which may delay the ability of stockholders to change the membership of a majority of our board of directors;
•
our stockholders may not act by written consent, which forces stockholder action to be taken at an annual or special meeting of our stockholders;
•
a special meeting of stockholders may be called only by our board of directors, its chairman, our chief executive officer or our president, which may delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors;
•
our amended and restated certificate of incorporation prohibits cumulative voting in the election of directors, which limits the ability of minority stockholders to elect their director candidates;
•
our board of directors may alter our bylaws without obtaining stockholder approval;
•
approval of the holders of at least two-thirds of the shares entitled to vote at an election of directors is required to adopt, amend or repeal our bylaws or repeal the provisions of our amended and restated certificate of incorporation regarding the election and removal of directors;
•
stockholders must provide advance notice and additional disclosures in order to nominate candidates for election to the board of directors or to propose matters that can be acted upon at a stockholders’ meeting, which may discourage or deter a potential acquiror from conducting a solicitation of proxies to elect the acquiror’s own slate of directors or otherwise attempting to obtain control of our company; and

78

•
our board of directors is authorized to issue shares of preferred stock and to determine the terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquiror.
Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner. Furthermore, our amended and restated certificate of incorporation specifies that, unless we consent in writing to the selection of an alternative forum, to the fullest extent permitted by law, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for most legal actions involving actions brought against us by stockholders; provided that, the exclusive forum provision will not apply to suits brought to enforce any liability or duty created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction; and provided further that, if and only if the Court of Chancery of the State of Delaware dismisses any such action for lack of subject matter jurisdiction, such action may be brought in another state or federal court sitting in the State of Delaware. We believe these provisions may benefit us by providing increased consistency in the application of Delaware law by Delaware courts, particularly experienced in resolving corporate disputes, efficient administration of cases on a more expedited schedule relative to other forums and protection against the burdens of multi-forum litigation. However, these provisions may have the effect of discouraging lawsuits brought against us and our directors and officers by our stockholders. The enforceability of similar choice of forum provisions in other companies’ certificates of incorporation has been challenged in legal proceedings, and it is possible that, in connection with any applicable action brought against us, a court could find the choice of forum provisions contained in our amended and restated certificate of incorporation to be inapplicable or unenforceable in such action.
Our amended and restated certificate of incorporation also provides that the federal district courts of the United States of America will be the exclusive forum for the resolution of any complaint asserting a cause of action against us or any of our directors, officers, employees or agents and arising under the Securities Act. However, a Delaware court recently held that such an exclusive forum provision relating to federal courts was unenforceable under Delaware law, and unless and until the Delaware court decision is reversed on appeal or otherwise abrogated, we do not intend to enforce such a provision in the event of a complaint asserting a cause of action arising under the Securities Act against us or any of our directors, officers, employees or agents.
Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain.
We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. In addition, future debt or other agreements we may enter into may preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future.

79

Item 1B. Unresolved Staff Comments
None.
Item 2. Properties
Our headquarters is located in Redwood City, California, where we lease approximately 163,000 square feet of space in several buildings. These leases currently have expiration dates ranging from 2025 to 2027. Our CLIA-certified laboratory is located in these facilities, where testing for both clinical and biopharmaceutical customers is performed. We also maintain leased office spaces in Spring City, Texas and Seattle, Washington. While we believe our existing facilities are adequate to meet our current requirements, we expect to expand our facilities as our operations grow over time. We believe we will be able to obtain such additional space on acceptable and commercially reasonable terms.
Item 3. Legal Proceedings
We may from time to time be involved in various legal proceedings and other matters arising in the normal course of business. For example, we have received, and may in the future continue to, receive letters, claims or complaints from others alleging false advertising, patent infringement, violation of employment practices and trademark infringement. We have also instituted, and may in the future institute additional, legal proceedings to enforce our rights and seek remedies, such as monetary damages, injunctive relief and declaratory relief. We cannot predict the results of any such disputes, and despite the potential outcomes, the existence thereof may have an adverse material impact on us because of diversion of management time and attention as well as the financial costs related to resolving such disputes.
The information under the caption “Commitments and Contingencies - Legal Proceedings” in Note 10 to the consolidated financial statements included elsewhere in this Annual Report on Form 10-K, concerning certain legal proceedings in which we are involved, is hereby incorporated by reference. The resolution of any such legal proceeding is subject to inherent uncertainty and could have a material adverse effect on our financial condition, cash flows or results of operations.
Item 4. Mine Safety Disclosures.
Not applicable.
PART II
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
Market information for common stock
Our common stock is traded on the Nasdaq Global Select Market, or Nasdaq, under the symbol “GH.”
Holders of record
As of February 14, 2020, there were 65 holders of record of our common stock. Because many of our shares of common stock are held by brokers and other institutions on behalf of stockholders, we are unable to estimate the total number of stockholders represented by these record holders.
Dividend policy
We have never declared or paid any dividends on our common stock. We currently intend to retain all available funds and any future earnings for the operation and expansion of our business. Accordingly, we do not anticipate declaring or paying dividends in the foreseeable future. The payment of any future dividends will be at the discretion of our board of directors and will depend on our results of operations, capital requirements, financial condition, prospects, contractual arrangements, including any limitations on payment of dividends, and other factors that the board may deem relevant.
Unregistered sales of equity securities
None.

80

Purchases of equity securities by the issuer and affiliated purchasers
None.
Securities authorized for issuance under equity compensation plans
The information required by this item with respect to our equity compensation plans is incorporated by reference to our definitive proxy statement relating to our 2020 Annual Meeting of Stockholders to be filed with the SEC within 120 days after the end of the fiscal year to which this Annual Report on Form 10-K relates (the “2020 Proxy Statement”).

Stock performance graph
The graph below shows a comparison, from October 4, 2018 (the date our common stock commenced trading on the Nasdaq) through December 31, 2019, of the cumulative total return to stockholders of our common stock relative to the Nasdaq Composite Index (“NBI”) and the Nasdaq Biotechnology Index (“IXIC”). The graph assumes that $100 was invested in each of our common stock, the Nasdaq Composite and the Nasdaq Biotechnology at their respective closing prices on October 4, 2018 and assumes reinvestment of gross dividends. The stock price performance shown in the graph represents past performance and should not be considered an indication of future stock price performance.
stockchart.jpg
This graph is not “soliciting material,” is not deemed “filed” with the SEC and is not to be incorporated by reference into any of our filings under the Securities Act or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing.

Item 6. Selected Financial Data
The following selected consolidated financial data should be read in conjunction with Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and the audited consolidated financial statements and related notes included in Part II, Item 8, “Financial Statements and Supplementary Data,” of this Annual Report on Form 10-K, including factors that may affect the comparability of such selected information. The consolidated statements of operations data for the years ended December 31, 2019, 2018 and 2017, respectively, and the consolidated balance sheet data as of December 31, 2019 and 2018, respectively, are derived from our audited consolidated financial statements and

81

related notes included elsewhere in this Annual Report on Form 10-K. The consolidated statements of operations data for the year ended December 31, 2016 and the consolidated balance sheet data as of December 31, 2017 and 2016, respectively, are derived from our audited consolidated financial statements that is not included in this Annual Report on Form 10-K. The selected consolidated financial data in this section are not intended to replace our consolidated financial statements and the related notes, and are qualified in their entirety by the consolidated financial statements and related notes included elsewhere in this Annual Report on Form 10-K. Our historical results are not necessarily indicative of our results in any future period.
 
 
Year Ended December 31,
(in thousands, except per share data)
 
2019
 
2018
 
2017
 
2016
 
 
 
 
 
 
 
 
 
Statements of Operations Data:
 
 
 
 
 
 
 
 
Revenue:
 
 
 
 
 
 
 
 
Precision oncology testing (1)
 
$
180,462

 
$
78,407

 
$
42,088

 
$
24,496

Development services (1)
 
33,913

 
12,232

 
7,754

 
753

Total revenue
 
214,375

 
90,639

 
49,842

 
25,249

Costs and operating expenses:
 
 
 
 
 
 
 
 
Cost of precision oncology testing
 
62,255

 
39,846

 
28,883

 
22,065

Cost of development services
 
8,465

 
3,364

 
2,735

 
59

Research and development expense
 
86,292

 
50,714

 
25,562

 
10,859

Sales and marketing expense
 
78,335

 
53,465

 
32,497

 
26,192

General and administrative expense
 
61,399

 
36,192

 
36,777

 
9,921

Total costs and operating expenses
 
296,746

 
183,581

 
126,454

 
69,096

Loss from operations
 
(82,371
)
 
(92,942
)
 
(76,612
)
 
(43,847
)
Interest income
 
13,741

 
5,266

 
2,234

 
733

Interest expense
 
(1,181
)
 
(1,251
)
 
(2,702
)
 
(3,018
)
Loss on debt extinguishment
 
—

 
—

 
(5,075
)
 
—

Other income (expense), net
 
88

 
4,702

 
(1,059
)
 
(1
)
Loss before provision for income taxes
 
(69,723
)
 
(84,225
)
 
(83,214
)
 
(46,133
)
Provision for (Benefit from) income taxes
 
(1,872
)
 
38

 
7

 
6

Net loss
 
(67,851
)
 
(84,263
)
 
(83,221
)
 
(46,139
)
Adjustment of redeemable noncontrolling interest
 
(7,800
)
 
(800
)
 
—

 
—

Net loss attributable to Guardant Health, Inc.
 
$
(75,651
)
 
$
(85,063
)
 
$
(83,221
)
 
$
(46,139
)
Deemed dividend related to repurchase of Series A convertible preferred stock
 
—

 
—

 
(4,716
)
 
—

Deemed dividend related to change in conversion rate of Series D convertible preferred stock
 
—

 
—

 
(1,058
)
 
—

Net loss attributable to Guardant Health, Inc. common stockholders
 
$
(75,651
)
 
$
(85,063
)
 
$
(88,995
)
 
$
(46,139
)
Net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted
 
$
(0.84
)
 
$
(2.80
)
 
$
(7.07
)
 
$
(3.53
)
Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted
 
90,597

 
30,403

 
12,582

 
13,053



82

 
 
As of December 31,
 
 
(in thousands)
 
2019
 
2018
 
2017
 
2016
 
 
 
 
 
 
 
 
 
Balance Sheet Data:
 
 
 
 
 
 
 
 
Cash, cash equivalents and marketable securities
 
$
791,585

 
$
496,524

 
$
294,574

 
$
95,256

Working capital (1),(2),(3)
 
524,624

 
422,047

 
223,308

 
88,813

Total assets (1),(3)
 
962,535

 
587,403

 
342,938

 
116,565

Total liabilities (3)
 
114,542

 
62,451

 
34,332

 
36,869

Redeemable noncontrolling interest
 
49,600

 
41,800

 
—

 
—

Total stockholders’ equity (1)
 
798,393

 
483,152

 
308,606

 
79,696

(1) Fiscal years 2018, 2017 and 2016 results do not reflect the impact of the adoption of the new revenue accounting standard in fiscal year 2019.
(2) We define working capital as current assets less current liabilities. See our audited financial statements and related notes included elsewhere in this Annual Report on Form 10-K for further details regarding our current assets and current liabilities.
(3) Fiscal years 2018, 2017 and 2016 do not reflect the impact of adoption of the new leasing standard in fiscal year 2019.
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations
You should read the following discussion and analysis of financial condition and results of operations together with the consolidated financial statements and related notes included elsewhere in this Annual Report on Form 10-K. This discussion and other parts of this Annual Report on Form 10-K contain forward-looking statements that involve risk and uncertainties, such as statements of our plans, objectives, expectations and intentions. Our actual results could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in Part I, Item 1A“Risk Factors,” of this Annual Report on Form 10-K.
The following generally compares our results of operations for the years ended December 31, 2019 and 2018. A detailed discussion comparing our results of operations for the years ended December 31, 2018 and 2017 can be found in Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” of our Annual Report on Form 10-K for the year ended December 31, 2018.
Overview
We are a leading precision oncology company focused on helping conquer cancer globally through use of our proprietary blood tests, vast data sets and advanced analytics. We believe that the key to conquering cancer is unprecedented access to its molecular information throughout all stages of the disease, which we intend to enable by a routine blood draw, or liquid biopsy. Our Guardant Health Oncology Platform is designed to leverage our capabilities in technology, clinical development, regulatory and reimbursement to drive commercial adoption, accelerate drug development, improve patient clinical outcomes and lower healthcare costs. In pursuit of our goal to manage cancer across all stages of the disease, we launched our Guardant360 and GuardantOMNI liquid biopsy-based tests for advanced stage cancer. Our Guardant360 test, launched in 2014, has been used by more than 7,000 oncologists, over 50 biopharmaceutical companies and all 28 National Comprehensive Cancer Network, or NCCN, Centers. Our GuardantOMNI test, launched in 2017, has been used by our biopharmaceutical customers as a comprehensive genomic profiling tool to help accelerate clinical development programs in both immuno-oncology and targeted therapy. These tests fuel development of our LUNAR program, which aims to address the needs of early stage cancer patients with neoadjuvant and adjuvant treatment selection, cancer survivors with surveillance, asymptomatic individuals eligible for cancer screening and individuals at a higher risk for developing cancer with early detection. Our LUNAR-1 assay was launched in 2018 for research use and in late 2019 for investigational use.

Since our inception, we have devoted substantially all of our resources to research and development activities related to our Guardant360 and GuardantOMNI tests and our LUNAR program, including clinical and regulatory initiatives to obtain approval by the U.S. Food and Drug Administration, or the FDA, as well as sales and marketing activities. We have over 50 approved, completed or active clinical outcomes studies, more than 150 peer-reviewed publications and more than 400 scientific abstracts. We are pioneering the clinical comprehensive liquid biopsy market with our Guardant360 and GuardantOMNI tests, both of which analyze circulating tumor DNA in blood. Our Guardant360 test is a molecular diagnostic test measuring 74 cancer-related genes and has been used by clinicians to help inform which therapy may be effective for advanced stage cancer patients with solid tumors and by biopharmaceutical companies

83

for a range of applications, including identifying target patient populations to accelerate translational science research, clinical trial enrollment, and drug development, and post-approval commercialization. Our GuardantOMNI test has a broader 500-gene panel, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications, such as tumor mutational burden and microsatellite instability, and has achieved comparable analytical performance in clinical studies, including for translational science applications in collaboration with several biopharmaceutical companies, including AstraZeneca, Bristol-Myers Squibb, Merck MSD, Merck KGaA of Darmstadt, Germany and Pfizer.

Our Guardant360 and GuardantOMNI tests have each been designated by the FDA as a breakthrough device for use as a companion diagnostic in connection with certain specified therapeutic products of our biopharmaceutical customers. Among other things, designation as a breakthrough device provides for priority review by the FDA and more interactive communication with the FDA during the development process. Our Guardant360 and GuardantOMNI tests are both being developed as companion diagnostics under collaborations with biopharmaceutical companies, including AstraZeneca and Amgen.

We perform our Guardant360, GuardantOMNI and other tests in our clinical laboratory located in Redwood City, California. Our laboratory is certified pursuant to the Clinical Laboratory Improvement Amendments of 1988, or CLIA, accredited by the College of American Pathologists, or CAP, permitted by the New York State Department of Health, or NYSDOH, and licensed in California and four other states.
The analytical and clinical data that we have generated in our efforts to establish clinical utility, combined with the support we have developed with key opinion leaders, or KOLs, in the oncology space have led to positive coverage decisions by a number of commercial payers. Our Guardant360 test is currently covered by Cigna, Priority Health, multiple Blue Cross Blue Shield plans as well as the health plans associated with eviCore, which have adopted policies that specifically cover Guardant360 test for non-small cell lung cancer, or NSCLC, which we believe gives us a competitive advantage with these payers.
In July 2018, Palmetto GBA, the Medicare Administrative Contractor, or MAC, responsible for administering Medicare’s Molecular Diagnostic Services Program, or MolDx, issued a local coverage determination, or LCD, for our Guardant360 test for NSCLC patients who meet certain clinical criteria. We worked with Palmetto GBA to obtain this positive coverage decision through the submission of a detailed dossier of analytical and clinical data to substantiate that the test meets Medicare’s medical necessity requirements. Subsequently in 2018, Noridian Healthcare Solutions, the MAC responsible for adjudicating claims in California, where our laboratory is located, and a participant in MolDx, also finalized its LCD for Guardant360 test. Pursuant to this Noridian LCD, in September 2018, we began to submit claims for reimbursement for Guardant360 clinical testing performed for NSCLC patients covered under the LCD who meet certain clinical criteria, and in October 2018, we began to receive payments for these services from Medicare.
We estimate that approximately 75% of Medicare patients tested for NSCLC are covered by the LCDs for NSCLC patients. For the years ended December 31, 2019 and 2018, respectively, approximately 44% and 46% of our U.S. clinical tests were for patients tested for NSCLC.

In December 2019, replacing its prior NSCLC patient LCD, Palmetto GBA finalized a new LCD for our Guardant360 test that provides limited Medicare coverage for the Guardant360 test in patients diagnosed with solid cancers of non-central nervous system origin. The new LCD requires that patients are recurrent, relapsed, refractory, metastatic, or advanced cancer patients who are seeking further treatment and are potential candidates for an FDA-approved or NCCN-recommended (for Category 1 or 2A level of evidence) biomarker targeted therapy. Additionally, the patient must not have had a previous Guardant360 testing and must be untreated or not responding on the patient’s current therapy. A patient who has previously been tested with the Guardant360 test and has progressed with new malignant growth since the patient’s prior test is considered to have a new primary cancer diagnosis and thus is eligible to have another test. Finally, for qualifying cancers other than NSCLC, tissue-based comprehensive genomic profiling must be infeasible for coverage. NSCLC patients would be eligible for coverage if tissue-based testing is infeasible or if previous tissue-based comprehensive genomic profiling returned no actionable results. The new LCD covers our Guardant360 test for fee-for-service Medicare patients with advanced cancers who meet its clinical criteria for complete genomic profiling with next-generation sequencing, or NGS, of tumor tissue to optimize treatment selection decisions but have insufficient or unavailable tissue for molecular profiling. The expanded Medicare coverage decision is in line with FDA approvals of several tumor-agnostic drugs that are based on a single genomic biomarker across all cancers or that are targetable across multiple cancer types. We expect Noridian Healthcare Solutions to issue a new LCD for our Guardant360 test equivalent to the new LCD issued by Palmetto GBA, though the timing and scope of the Noridian LCD are uncertain. Based on historic physician ordering patterns, we believe the new Noridian LCD, if issued, would significantly expand

84

coverage for use of the Guardant360 test for Medicare patients. We also anticipate approval by the FDA, if obtained, may support further improvements in coverage and reimbursement for our Guardant360 test.
In the United States, we market our tests to clinical customers through our sales organization, which is engaged in sales efforts and promotional activities primarily targeting oncologists and cancer centers. Outside the United States, we market our tests to clinical customers through distributors and direct contracts with healthcare institutions. We also market our tests to biopharmaceutical customers globally through our business development team, which promotes the broad utility of our tests throughout drug development and commercialization. Additionally, we have established a joint venture with SoftBank to accelerate commercialization of our products including in Asia, the Middle East and Africa, with our initial focus being on Japan. Our products are currently marketed in approximately 40 countries.

We generated total revenue of $214.4 million, $90.6 million and $49.8 million for the years ended December 31, 2019, 2018 and 2017, respectively. We also incurred net losses of $67.9 million, $84.3 million and $83.2 million in the years ended December 31, 2019, 2018 and 2017, respectively. We have funded our operations to date principally from the sale of our stock and revenue from our precision oncology testing and development services. In 2017, we raised $320.4 million through the sale of our Series E convertible preferred stock. In October 2018, we completed our initial public offering, or the IPO, selling 14,375,000 shares of our common stock and raising $249.5 million net of underwriting discounts and commissions and other expenses payable by us. In May 2019, we completed an underwritten public offering of a total of 5,175,000 shares of our common stock, through which we received net proceeds of approximately $349.7 million after deducting underwriting discounts and commissions and offering expenses payable by us. As of December 31, 2019, we had cash, cash equivalents and marketable securities of $791.6 million.

Factors affecting our performance
We believe there are several important factors that have impacted and that we expect will impact our operating performance and results of operations, including:

•
Testing volume, pricing and customer mix. Our revenue and costs are affected by the volume of testing and mix of customers from period to period. We evaluate both the volume of tests that we perform for patients on behalf of clinicians and the number of tests we perform for biopharmaceutical companies. Our performance depends on our ability to retain and broaden adoption with existing customers, as well as attract new customers. We believe that the test volume we receive from clinicians and biopharmaceutical companies are indicators of growth in each of these customer verticals. Customer mix for our tests has the potential to significantly affect our results of operations, as the average selling price for biopharmaceutical sample testing is currently higher than our average selling price for clinical tests because we are not a contracted provider for, or our tests are not covered by clinical patients’ insurance for, the majority of the tests that we perform for patients on behalf of clinicians. Approximately 38% of our U.S. clinical tests for the years ended December 31, 2019 and 2018 were for Medicare beneficiaries. Prior to the third quarter of 2018, Medicare did not cover our tests and we did not submit claims for reimbursement. In September 2018, we began to submit claims to Medicare for reimbursement for Guardant360 clinical tests for NSCLC patients covered under MolDx who meet certain clinical criteria, and in October 2018, we began to receive payments from Medicare for these clinical tests. In December 2019, Palmetto GBA expanded its LCD for our Guardant360 test to provide limited Medicare coverage for use of Guardant360 for qualifying patients diagnosed with solid tumor cancers of non-central nervous system origin. Noridian Healthcare Solutions, or Noridian, is the MAC responsible for adjudicating claims in California where our laboratory is located. Noridian is a participant in MolDx and recently issued a draft LCD for the Guardant360 test modeled on the expanded Palmetto LCD. We may not be able to obtain reimbursement under the expanded Noridian LCD until it is finalized and Noridian completes certain administrative steps.

•
Regulatory approval. Our Guardant360 test was the first comprehensive liquid biopsy test approved by NYSDOH. In addition, we believe our facility was the first comprehensive liquid biopsy laboratory to be CLIA-certified, CAP-accredited and NYSDOH-permitted. In the fourth quarter of 2019, we submitted a premarket approval, or PMA, application to seek the FDA’s approval of our Guardant360 test to be used as a companion diagnostic, initially in connection with one therapeutic product of a biopharmaceutical customer, and to provide tumor mutation profiling for cancer patients with solid tumors. In February 2020, we submitted an additional module of the PMA application for our Guardant360 test to the FDA. Medicare’s National Coverage Determination for Next Generation Sequencing established in 2018 and subsequently updated in 2020 provides coverage for molecular diagnostic tests such as our Guardant360 test, if, among other criteria, such tests are offered within their FDA-approved companion diagnostic labeling. We believe that this establishes a competitive advantage for tests receiving FDA approval and that FDA approval will be increasingly necessary for diagnostic tests to gain adoption, both in the United States and abroad. We believe FDA approval, if obtained, will help increase adoption of our tests and

85

facilitate favorable reimbursement decisions by Medicare and commercial payers. We also intend to pursue regulatory approvals in specific markets outside of the United States, including in Europe, Japan and China. Any negative regulatory decisions or changes in regulatory requirements affecting our business could adversely impact our operations and financial results.

•
Payer coverage and reimbursement. Our revenue depends on achieving broad coverage and reimbursement for our tests from third-party payers, including both commercial and government payers. Payment from commercial payers can vary depending on whether we have entered into a contract with the payers as a “participating provider” or do not have a contract and are considered a “non-participating provider.” Payers often reimburse non-participating providers, if at all, at a lower amount than participating providers. We have received a substantial portion of our revenue from a limited number of commercial payers, most of which have not contracted with us to be a participating provider. We have received reimbursement for tests of patients with a variety of cancers, though for amounts that on average are significantly lower than for participating providers. We have experienced situations where commercial payers proactively reduced the amounts they were willing to reimburse for our tests, and in other situations, commercial payers have determined that the amounts they previously paid were too high and have sought to recover those perceived excess payments by deducting such amounts from payments otherwise being made. When we contract with a payer to serve as a participating provider, reimbursements by the payer are generally made pursuant to a negotiated fee schedule and are limited to only covered indications or where prior approval has been obtained. Becoming a participating provider can result in higher reimbursement amounts for covered uses of our test and, potentially, no reimbursement for non-covered uses identified under the payer’s policies or the contract. As a result, the potential for more favorable reimbursement associated with becoming a participating provider may be offset by a potential loss of reimbursement for non-covered uses of our tests. Current Procedural Terminology, or CPT, coding plays a significant role in how our Guardant360 test is reimbursed both from commercial and governmental payers. Changes to the codes used to report the Guardant360 test to payers may result in significant changes in its reimbursement. If our Guardant360 test receives approval from the FDA, we may be required to obtain a new code to report the Guardant360 test on claims submitted to U.S. payers. If a coding change were to occur, payments for certain uses of the Guardant360 test could be reduced or eliminated by such payers. Cigna, Priority Health, multiple Blue Cross Blue Shield plans as well as the health plans associated with eviCore adopted policies that cover our Guardant360 test for the majority of NSCLC patients we test. If their policies were to change in the future to cover additional cancer indications, we anticipate that our total reimbursement would increase. In September 2018, we began to submit claims for reimbursement with respect to Guardant360 clinical testing performed for NSCLC patients covered under the LCD who meet certain clinical criteria, and in October 2018, we began to receive payments from Medicare. We estimate total coverage in the United States for the Guardant360 test to be more than 170 million lives, including Medicare beneficiaries and members of several commercial health plans. If we fail to obtain or maintain coverage and adequate reimbursement from third-party payers, we may be unable to increase our testing volume and revenue as expected. Retrospective reimbursement adjustments, such as deductions from further payments and clawbacks, can also negatively impact our revenue and cause our financial results to fluctuate. Due to the inherent variability of the insurance landscape, historic success of, and payments from, appeals of reimbursement denials by payers are not indicative of future success of and payments from such appeals.

•
Biopharmaceutical customers. Our revenue also depends on our ability to attract new, and to maintain and expand relationships with existing, biopharmaceutical customers, and we expect to increase our sales and marketing expense in furtherance of this goal. As we continue to develop these relationships, we expect to support a growing number of clinical trials both in the United States and internationally. If our relationships expand with biopharmaceutical customers, we believe we may continue to have opportunities to offer our platform to such customers for companion diagnostic development, novel target discovery and validation as well as clinical trial enrollment, and to grow into other business opportunities. For example, we believe that our genomic data, in combination with clinical outcomes or claims data, has revenue-generating potential, supporting novel drug development and companion diagnostic development.


86

•
Research and development. A significant aspect of our business is our investment in research and development, including the development of new products, such as those being developed as part of our LUNAR program. In particular, we have invested heavily in clinical studies, including more than 50 clinical outcomes studies, the largest-ever liquid-to-tissue concordance study, and a prospective interventional clinical utility study demonstrating clinical overall response rates in line with tissue biopsy approaches. Our clinical research has resulted in over 150 peer-reviewed publications. With respect to our LUNAR program, we initiated a prospective screening study, which we refer to as the ECLIPSE trial, to recruit approximately 10,000 patients and evaluate the performance of our LUNAR-2 assay in detecting colorectal cancer in average-risk adults, and in collaboration with a National Clinical Trials Network group, initiated a prospective multi-center randomized controlled trial, which we refer to as the COBRA study, in approximately 1,400 patients with resected stage II colon cancer to use our LUNAR-1 assay to evaluate recurrence-free survival in patients who receive ctDNA-directed therapy as compared to the current standard-of-care active surveillance. Furthermore, we are collaborating with investigators from multiple academic cancer centers, including MD Anderson Cancer Center, the University of Colorado, Memorial Sloan Kettering Cancer Center, Massachusetts General Cancer Center, Wake Forest Cancer Center and the University of California San Francisco, as well as several international institutions. We believe these studies are critical to gaining physician adoption and driving favorable coverage decisions by payers, and expect our investments in clinical studies to increase. We expect to increase our research and development expense with the goal of fueling further innovation.

•
International expansion. A component of our long-term growth strategy is to expand our commercial footprint internationally, and we expect to increase our sales and marketing expense to execute on this strategy. We currently offer our tests in countries outside the United States primarily through distributor relationships or direct contracts with hospitals. In May 2018, we formed and capitalized a joint venture, Guardant Health AMEA, Inc., which we refer to as the Joint Venture, with SoftBank, relating to the sale, marketing and distribution of our tests generally outside the Americas and Europe. We expect to rely on the Joint Venture to accelerate commercialization of our products in Asia, the Middle East and Africa, with our initial focus being on Japan. The recent outbreak of novel coronavirus may disrupt operations for the Joint Venture and make it more difficult to sell our tests in the affected countries or regions, many of which are in the JV Territory. While the impact of this outbreak on the Joint Venture’s business is still uncertain and depends on many factors, including how long the outbreak goes uncontained, the Joint Venture’s revenue and results of operations could be adversely affected.

While each of these areas presents significant opportunities for us, they also pose significant risks and challenges that we must address. See Part I, Item 1A, “Risk Factors” of this Annual Report on Form 10-K for more information.

Components of results of operations
Revenue
We derive our revenue from two sources: (i) precision oncology testing and (ii) development services.
Effective January 1, 2019, we adopted a new revenue recognition standard FASB ASC Topic 606, Revenue from Contracts with Customers, or ASC 606, which primarily impacted our recognition of revenue related to patient claims paid by third-party commercial and governmental payors. We adopted ASC 606 using the modified retrospective method, which means that the cumulative effect of applying ASC 606 has been recognized to beginning accumulated deficit at January 1, 2019, the date of adoption of ASC 606, and prior comparative periods were not recast to reflect ASC 606. As a result, revenue for the year ended December 31, 2018 is presented in accordance with FASB ASC Topic 605, Revenue Recognition, or ASC 605, whereas revenue for the year ended December 31, 2019 is presented under ASC 606. ASC 606 provides a five-step model for recognizing revenue that includes identifying the contract with a customer, identifying the performance obligations in the contract, determining the transaction price, allocating the transaction price to the performance obligations, and recognizing revenue when, or as, an entity satisfies a performance obligation.

Precision oncology testing. Precision oncology testing revenue is generated from sales of our Guardant 360 and GuardantOMNI tests to clinical and biopharmaceutical customers. In the United States, through December 31, 2019, we generally performed tests as an out-of-network service provider without contracts with health insurance companies. We submit claims for payment for tests performed for patients covered by U.S. private payers. Prior to the third quarter of 2018, Medicare did not cover our tests and we did not submit claims for reimbursement for these tests. In September 2018, we began to submit claims to Medicare for reimbursement for Guardant360 clinical testing performed for NSCLC patients covered under Medicare’s Molecular Diagnostic Services Program who meet certain clinical criteria. Tests for

87

patients covered by Medicare represented approximately 38% of our U.S. clinical tests in both 2019 and 2018. Due to the historical general lack of contracts with U.S. private payers and variability in payments received for claims submitted to them, as well as the limited claims experience to date with Medicare, from our inception through the end of 2018 revenue had not been recognized by us at the time the service was performed as the price of the transaction was not fixed or determinable and collectability was not reasonably assured. As we provide precision oncology testing to biopharmaceutical customers under contracts for which all recognition criteria are met, we have recognized revenue on an accrual basis for those services.

Development services. Development services revenue represents services, other than precision oncology testing, that we provide to biopharmaceutical companies and large medical institutions. It includes companion diagnostic development and regulatory approval services, clinical trial referrals and liquid biopsy testing development and support. We collaborate with biopharmaceutical companies in the development and clinical trials of new drugs. As part of these collaborations, we provide services related to regulatory filings with the FDA to support companion diagnostic device submissions for our liquid biopsy panels. Under these arrangements, we generate revenue from progression of our collaboration efforts, as well as from provision of on-going support. Development services revenue can vary over time as different projects start and complete.

Costs and operating expenses
Cost of precision oncology testing. Cost of precision oncology testing generally consists of cost of materials, direct labor, including bonus, benefit and stock-based compensation; equipment and infrastructure expenses associated with processing liquid biopsy test samples, including sample accessioning, library preparation, sequencing, quality control analyses and shipping charges to transport blood samples; freight; curation of test results for physicians; and license fees due to third parties. Infrastructure expenses include depreciation of laboratory equipment, rent costs, amortization of leasehold improvements and information technology costs. Costs associated with performing our tests are recorded as the tests are performed regardless of whether revenue was recognized with respect to the tests. Royalties for licensed technology are calculated as a percentage of revenues generated using the associated technology and recorded as expense at the time the related revenue is recognized. One-time royalty payments related to signing of license agreements or other milestones, such as issuance of new patents, are amortized to expense over the expected useful life of the patents. While we do not believe the technologies underlying these licenses are necessary to permit us to provide our tests, we do believe these technologies are potentially valuable and of possible strategic importance to us or our competitors. Cost of precision oncology testing revenue included royalty expense of $4.4 million and $1.4 million for the years ended December 31, 2019 and 2018, respectively.
We expect the cost of precision oncology testing to generally increase in line with the increase in the number of tests we perform, but the cost per test to decrease modestly over time due to the efficiencies we may gain as test volume increases, and from automation and other cost reductions.
Cost of development services. Cost of development services includes costs incurred for the performance of development services requested by our customers. For development of new products, costs incurred before technological feasibility has been achieved are reported as research and development expenses, while costs incurred thereafter are reported as cost of revenue. Cost of development services will vary depending on the nature, timing and scope of customer projects.
Research and development expense. Research and development expenses consist of costs incurred to develop technology and include salaries and benefits, reagents and supplies used in research and development laboratory work, infrastructure expenses, including allocated facility occupancy and information technology costs, contract services, other outside costs and costs to develop our technology capabilities. Research and development expenses also include costs related to activities performed under contracts with biopharmaceutical companies before technological feasibility has been achieved. Research and development costs are expensed as incurred. Payments made prior to the receipt of goods or services to be used in research and development are deferred and recognized as expense in the period in which the related goods are received or services are rendered. Costs to develop our technology capabilities are recorded as research and development unless they meet the criteria to be capitalized as internal-use software costs. We expect that our research and development expenses will continue to increase in absolute dollars as we continue to innovate and develop additional products, expand our genomic and medical data management resources and conduct our ongoing and new clinical trials, with a particular focus on our LUNAR program.
Sales and marketing expense. Our sales and marketing expenses are expensed as incurred and include costs associated with our sales organization, including our direct sales force and sales management, client services, marketing and reimbursement, medical affairs, as well as business development personnel who are focused on our biopharmaceutical customers. These expenses consist primarily of salaries, commissions, bonuses, employee benefits, travel expenses

88

and stock-based compensation, as well as marketing and educational activities and allocated overhead expenses. We expect our sales and marketing expenses to increase in absolute dollars as we expand our sales force, increase our presence within and outside of the United States, and increase our marketing activities to drive further awareness and adoption of our Guardant360 and GuardantOMNI tests.
General and administrative expense. Our general and administrative expenses include costs for our executive, accounting and finance, legal and human resources functions. These expenses consist principally of salaries, bonuses, employee benefits, travel expenses and stock-based compensation, as well as professional services fees such as consulting, audit, tax and legal fees, and general corporate costs and allocated overhead expenses. We expect that our general and administrative expenses will continue to increase in absolute dollars, primarily due to increased headcount and costs associated with operating as a public company, including expenses related to legal, accounting, regulatory, maintaining compliance with exchange listing and requirements of the SEC, director and officer insurance premiums and investor relations. These expenses, though expected to increase in absolute dollars, are expected to decrease modestly as a percentage of revenue in the long term, though they may fluctuate as a percentage of revenue from period to period due to the timing and extent of these expenses.
Interest income
Interest income consists of interest earned on our cash, cash equivalents and marketable securities.
Interest expense
Interest expense consists primarily of interest from finance leases or capital leases and royalty obligations.
Other income (expense), net
In the first quarter of 2018, we settled a commercial legal dispute. In connection with the settlement, we received a payment of $4.25 million, which was recognized as one-time other income (expense), net for the year ended December 31, 2018.
Other income (expense), net also consists of foreign currency exchange gains and losses. We expect our foreign currency gains and losses to continue to fluctuate in the future due to changes in foreign currency exchange rates.
Provision for (Benefit from) income tax
Income taxes are recorded using an asset and liability approach. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. Tax benefits are recognized when it is more likely than not that a tax position will be sustained during an audit. Deferred tax assets are reduced by a valuation allowance if current evidence indicates that it is considered more likely than not that these benefits will not be realized.
Our tax positions are subject to income tax audits. We recognize the tax benefit of an uncertain tax position only if it is more likely than not that the position is sustainable upon examination by the taxing authority, based on the technical merits. The tax benefit recognized is measured as the largest amount of benefit which is more likely than not to be realized upon settlement with the taxing authority. We recognize interest accrued and penalties related to unrecognized tax benefits in its tax provision. We evaluate uncertain tax positions on a regular basis. The evaluations are based on a number of factors, including changes in facts and circumstances, changes in tax law, correspondence with tax authorities during the course of the audit, and effective settlement of audit issues. The provision for (benefit from) income taxes includes the effects of any accruals that we believe are appropriate, as well as the related net interest and penalties.


89

Results of operations
The following table sets forth the significant components of our results of operations for the periods presented.
 
Year Ended December 31,
 
2019
 
2018
 
 
 
 
 
 
 
(in thousands)
Revenue:
 
 
 
 
Precision oncology testing (1)
$
180,462

 
$
78,407

 
Development services (1)
33,913

 
12,232

 
Total revenue
214,375

 
90,639

 
Costs and operating expenses:
 
 
 
 
Cost of precision oncology testing(2)
62,255

 
39,846

 
Cost of development services
8,465

 
3,364

 
Research and development expense(2)
86,292

 
50,714

 
Sales and marketing expense(2)
78,335

 
53,465

 
General and administrative expense(2)(3)
61,399

 
36,192

 
Total costs and operating expenses
296,746

 
183,581

 
Loss from operations
(82,371
)
 
(92,942
)
 
Interest income
13,741

 
5,266

 
Interest expense
(1,181
)
 
(1,251
)
 
Other income (expense), net
88

 
4,702

 
Loss before provision for income taxes
(69,723
)
 
(84,225
)
 
Provision for (benefit from) income taxes
(1,872
)
 
38

 
Net loss
$
(67,851
)
 
$
(84,263
)
 
(1)
Fiscal year 2018 results do not reflect the impact of the adoption of the new revenue accounting standard in fiscal year 2019.
(2)
Amounts include stock-based compensation expense as follows:
 
Year Ended December 31,
 
2019
 
2018
 
 
 
 
 
 
 
(in thousands)
Cost of precision oncology testing
$
863

 
$
512

 
Research and development expense
5,907

 
1,684

 
Sales and marketing expense
4,716

 
1,727

 
General and administrative expense(3)
5,468

 
2,928

 
Total stock-based compensation expense
$
16,954

 
$
6,851

 
(3)
Amounts include $157,000 of compensation expenses associated with repurchase of common stock for the year ended December 31, 2018.


90

Comparison of the Years Ended December 31, 2019 and 2018
Revenue
 
Year Ended December 31,
 
Change
 
2019
 
2018
 
$
 
%
 
 
 
 
 
 
 
 
 
(in thousands)
 
 
Precision oncology testing
$
180,462

 
$
78,407

 
$
102,055

 
130
%
Development services
33,913

 
12,232

 
21,681

 
177
%
Total revenue
$
214,375

 
$
90,639

 
$
123,736

 
137
%
Total revenue was $214.4 million for the year ended December 31, 2019 compared to $90.6 million for the year ended December 31, 2018, an increase of $123.7 million, or 137%.
Precision oncology testing revenue increased to $180.5 million for the year ended December 31, 2019 from $78.4 million for the year ended December 31, 2018, an increase of $102.1 million, or 130%.
Precision oncology revenue from tests for clinical customers was $101.0 million for the year ended December 31, 2019, up 131.1% from $43.7 million for the year ended December 31, 2018. This increase in clinical testing revenue was driven primarily by increases in test volume plus higher average revenue per test. Precision oncology revenue for the year ended December 31, 2019 included $6.8 million of payments received during that year from successful appeals of payers’ denials of reimbursement for samples processed in 2018. Given the age of the samples associated with these successful appeals, we do not believe this appeals revenue is indicative of results in the ordinary course of our operations. Precision oncology tests for clinical customers increased to 49,926 for the year ended December 31, 2019 from 29,238 for the year ended December 31, 2018 (excluding 354 tests in 2018 from a customer that in March 2018 began processing tests in-house). We believe this volume increase is due to a number of factors including increases in our commercial programs, additional clinical data including from the NILE study, and new drugs which continue to expand the need for comprehensive genomic profiling. Average revenue per test increased due to reimbursement for testing of most Medicare lung cancer patients starting in the fourth quarter of 2018, increases in commercial payer payments that we believe were beneficially affected by the Protecting Access to Medicare Act of 2014 (“PAMA”), and the $6.8 million from appeals of samples tested in 2018.
Precision oncology revenue from tests for biopharmaceutical customers was $79.5 million for the year ended December 31, 2019, up 129.1% from $34.7 million for the year ended December 31, 2018. Precision oncology tests for biopharmaceutical customers increased to 20,643 for the year ended December 31, 2019 from 10,370 for the year ended December 31, 2018 due to an increase in the number of biopharmaceutical customers and their contracted projects. The average selling price of precision oncology tests for biopharmaceutical customers was $3,850 for the year ended December 31, 2019, up from $3,347 the year ended December 31, 2018, due to a greater number of such tests being GuardantOMNI test, which has a higher selling price than the Guardant360 test. The change to accounting for revenue under ASC 606 increased precision oncology revenue from tests for pharmaceutical customers by $1.0 million since revenue under ASC 605 for precision oncology revenue from tests for pharmaceutical customers for the year ended December 31, 2019 would have been approximately $78.5 million.

Development services revenue increased to $33.9 million for the year ended December 31, 2019 from $12.2 million for the year ended December 31, 2018, an increase of $21.7 million, or 177%. This increase in development services revenue was due to revenue received from new projects in 2019 and was mainly received from biopharmaceutical customers related to companion diagnostic development and regulatory approval services.

Costs and operating expenses
Cost of precision oncology testing
 
Year Ended December 31,
 
Change
 
2019
 
2018
 
$
 
%
 
 
 
 
 
 
 
 
 
(in thousands)
 
 
Cost of precision oncology testing
$
62,255

 
$
39,846

 
$
22,409

 
56
%

91


Cost of precision oncology testing revenue was $62.3 million for the year ended December 31, 2019 compared to $39.8 million for the year ended December 31, 2018, an increase of $22.4 million, or 56%. This increase in cost of precision oncology testing was primarily due to a $11.2 million increase in material costs, a $5.2 million increase in labor and manufacturing overhead costs, and a $2.9 million increase in royalties and $3.2 million increase in other costs including costs related to freight, curation of test results for physicians.
Cost of development services
 
Year Ended December 31,
 
Change
 
2019
 
2018
 
$
 
%
 
 
 
 
 
 
 
 
 
(in thousands)
 
 
Cost of development services
$
8,465

 
$
3,364

 
$
5,101

 
152
%
Cost of development services was $8.5 million for the year ended December 31, 2019 compared to $3.4 million for the year ended December 31, 2018, an increase of $5.1 million, or 152%. This increase in cost of development services was primarily due to an increase in labor costs related to companion diagnostic development and regulatory approval service contracts.
Research and development expense
 
Year Ended December 31,
 
Change
 
2019
 
2018
 
$
 
%
 
 
 
 
 
 
 
 
 
(in thousands)
 
 
Research and development
$
86,292

 
$
50,714

 
$
35,578

 
70
%
Research and development expenses were $86.3 million for the year ended December 31, 2019 compared to $50.7 million for the year ended December 31, 2018, an increase of $35.6 million, or 70%. This increase in research and development expense was primarily due to an increase of $14.9 million in personnel-related costs, an increase of $4.2 million in noncash stock-based compensation for employees in our research and development group, an increase of $2.2 million related to allocated facilities and information technology infrastructure costs, and a $0.9 million increase in office administrative costs as we increased our headcount to support continued investment in our technology. The increase is also attributable to an increase of $7.9 million in material costs relating to the development of our LUNAR programs and the continuous improvement in our Guardant360 and GuardantOMNI liquid biopsy panels, and an increase of $4.9 million in development consulting fees.
Sales and marketing expense
 
Year Ended December 31,
 
Change
 
2019
 
2018
 
$
 
%
 
 
 
 
 
 
 
 
 
(in thousands)
 
 
Sales and marketing
$
78,335

 
$
53,465

 
$
24,870

 
47
%
Selling and marketing expenses were $78.3 million for the year ended December 31, 2019 compared to $53.5 million for the year ended December 31, 2018, an increase of $24.9 million, or 47%. This increase was primarily due to an increase of $15.6 million in personnel-related costs and an increase of $3.0 million in noncash stock-based compensation associated with the expansion of our commercial organization, an increase of $2.9 million related to office administrative costs, an increase of $2.3 million in travel expenses, an increase of $0.5 million related to allocated facilities and information technology infrastructure costs, and an increase of $0.6 million in professional service expenses related to marketing activities.

92

General and administrative expense
 
Year Ended December 31,
 
Change
 
2019
 
2018
 
$
 
%
 
 
 
 
 
 
 
 
 
(in thousands)
 
 
General and administrative
$
61,399

 
$
36,192

 
$
25,207

 
70
%

General and administrative expenses were $61.4 million for the year ended December 31, 2019 compared to $36.2 million for the year ended December 31, 2018, an increase of $25.2 million, or 70%. This increase was primarily due to an increase of $15.6 million in personnel-related costs including an increase of $2.5 million in noncash stock-based compensation expense and an increase of $1.2 million in administration expenses as we increased our headcount, and an increase of $11.9 million in professional service expenses related to outside legal, accounting, consulting and IT services. This increase was offset by a $3.0 million reduction in legal costs due to settlements of a patent lawsuits and commercial legal disputes that were finalized and incurred in 2018.
Interest income
 
Year Ended December 31,
 
Change
 
2019
 
2018
 
$
 
%
 
 
 
 
 
 
 
 
 
(in thousands)
 
 
Interest income
$
13,741

 
$
5,266

 
$
8,475

 
161
%
Interest income was $13.7 million for the year ended December 31, 2019 compared to $5.3 million for the year ended December 31, 2018, an increase of $8.5 million, or 161%. The increase was primarily due to a higher cash, cash equivalents and marketable securities average balance year over year due to the timing of receipt of cash proceeds from our initial public offering and the follow-on offering that was completed in May 2019.
Interest expense
 
Year Ended December 31,
 
Change
 
2019
 
2018
 
$
 
%
 
 
 
 
 
 
 
 
 
(in thousands)
 
 
Interest expense
$
1,181

 
$
1,251

 
$
(70
)
 
(6
)%
Interest expense was $1.2 million for the year ended December 31, 2019 compared to $1.3 million for the year ended December 31, 2018, a decrease of $0.1 million, or 6%. This decrease was primarily due to reduced outstanding balance of an obligation related to a royalty in connection with a patent license agreement entered into in January 2017.
Other income (expense), net
 
Year Ended December 31,
 
Change
 
2019
 
2018
 
$
 
%
 
 
 
 
 
 
 
 
 
(in thousands)
 
 
Other income (expense), net
$
88

 
$
4,702

 
$
(4,614
)
 
*
*    Not meaningful
Other income (expense), net included a gain of $4.3 million for settlement of a commercial legal dispute for the year ended December 31, 2018. There was no similar charge or gain for the year ended December 31, 2019.
Other income (expense), net also included foreign currency exchange gains of $0.4 million for the year ended December 31, 2018. Foreign currency exchange gains/losses for the year ended December 31, 2019 was immaterial.

93

Provision for (benefit from) income taxes
 
Year Ended December 31,
 
Change
 
2019
 
2018
 
$
 
%
 
 
 
 
 
 
 
 
 
(in thousands)
 
 
Provision for (benefit from) income taxes
$
(1,872
)
 
$
38

 
$
(1,910
)
 
(5,026
)%

Benefit from income taxes of $1.9 million for the year ended December 31, 2019 compared to an expense of $38,000 for the year ended December 31, 2018 was primarily due to the release of valuation allowance of $1.6 million associated with nondeductible intangible assets recorded as part of the Bellwether Bio acquisition.  Additionally, there was a benefit of $0.4 million associated with the utilization of tax losses from continuing operations against other comprehensive income gains.


94

Quarterly results of operations
The following tables set forth our unaudited quarterly consolidated statements of operations data for each of the eight quarters in the 24-month period ended December 31, 2019.  The information for each of these quarters has been prepared in accordance with generally accepted accounting principles in the United States of America and on the same basis as our audited consolidated financial statements included elsewhere in this Annual Report on Form 10-K. In the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of our results of operations. This data should be read in conjunction with our audited financial statements and related notes included elsewhere in this Annual Report on Form 10-K. These quarterly operating results are not necessarily indicative of our operating results for the full year or any future period.
 
 
Three Months Ended
 
 
December 31, 2019
 
September 30, 2019
 
June 30,
2019
 
March 31, 2019
 
December 31, 2018
 
September 30, 2018
 
June 30,
2018
 
March 31, 2018
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(unaudited)
 
 
(in thousands)
Revenue:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Precision oncology testing (1)
 
$
57,414

 
$
52,147

 
$
42,064

 
$
28,837

 
$
28,096

 
$
18,298

 
$
17,822

 
$
14,191

Development services (1)
 
5,483

 
8,701

 
11,911

 
7,818

 
4,777

 
3,394

 
1,560

 
2,501

Total revenue
 
62,897

 
60,848

 
53,975

 
36,655

 
32,873

 
21,692

 
19,382

 
16,692

Costs and operating expenses:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cost of precision oncology testing
 
20,004

 
16,578

 
14,650

 
11,023

 
12,624

 
9,671

 
9,506

 
8,045

Cost of development services
 
1,834

 
1,936

 
2,183

 
2,512

 
1,323

 
380

 
453

 
1,208

Research and development expense
 
25,875

 
24,569

 
19,532

 
16,316

 
16,652

 
14,253

 
11,554

 
8,255

Sales and marketing expense
 
22,287

 
18,802

 
19,439

 
17,807

 
17,114

 
13,464

 
11,575

 
11,312

General and administrative expense
 
18,859

 
16,440

 
13,439

 
12,661

 
12,547

 
8,129

 
8,997

 
6,519

Total costs and operating expenses
 
88,859

 
78,325

 
69,243

 
60,319

 
60,260

 
45,897

 
42,085

 
35,339

Loss from operations
 
(25,962
)
 
(17,477
)
 
(15,268
)
 
(23,664
)
 
(27,387
)
 
(24,205
)
 
(22,703
)
 
(18,647
)
Interest income
 
3,871

 
4,286

 
3,099

 
2,485

 
2,334

 
958

 
989

 
985

Interest expense
 
(321
)
 
(280
)
 
(287
)
 
(293
)
 
(299
)
 
(304
)
 
(317
)
 
(331
)
Other income (expense), net
 
(187
)
 
179

 
(51
)
 
147

 
115

 
43

 
395

 
4,149

Loss before provision for income taxes
 
(22,599
)
 
(13,292
)
 
(12,507
)
 
(21,325
)
 
(25,237
)
 
(23,508
)
 
(21,636
)
 
(13,844
)
Provision for(benefit from) income taxes
 
(489
)
 
(202
)
 
(1,207
)
 
26

 
35

 
—

 
3

 
—

Net loss
 
(22,110
)
 
(13,090
)
 
(11,300
)
 
(21,351
)
 
(25,272
)
 
(23,508
)
 
(21,639
)
 
(13,844
)
Adjustment of redeemable noncontrolling interest
 
(3,100
)
 
300

 
(300
)
 
(4,700
)
 
150

 
(950
)
 
—

 
—

Net loss attributable to Guardant Health, Inc.
 
$
(25,210
)
 
$
(12,790
)
 
$
(11,600
)
 
$
(26,051
)
 
$
(25,122
)
 
$
(24,458
)
 
$
(21,639
)
 
$
(13,844
)
Net loss attributable to Guardant Health, Inc. common stockholders
 
$
(25,210
)
 
$
(12,790
)
 
$
(11,600
)
 
$
(26,051
)
 
$
(25,122
)
 
$
(24,458
)
 
$
(21,639
)
 
$
(13,844
)
Net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted
 
$
(0.27
)
 
$
(0.14
)
 
$
(0.13
)
 
$
(0.30
)
 
$
(0.30
)
 
$
(1.94
)
 
$
(1.75
)
 
$
(1.16
)
Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted
 
93,997

 
93,303

 
89,036

 
85,935

 
84,123

 
12,582

 
12,388

 
11,920

(1) Quarterly periods in 2018 do not reflect the adoption of the new revenue accounting standards in 2019.

95

Liquidity and capital resources
We have incurred losses and negative cash flows from operations since our inception, and as of December 31, 2019, we had an accumulated deficit of $352.8 million. We expect to incur additional operating losses in the near future and our operating expenses will increase as we continue to invest in clinical trials and develop new product offerings from our research programs, including our LUNAR program, expand our sales organization, and increase our marketing efforts to drive market adoption of our Guardant360 and GuardantOMNI tests. As demand for our Guardant360 and GuardantOMNI tests are expected to continue to increase from physicians and biopharmaceutical companies, we anticipate that our capital expenditure requirements will also increase in order to build additional capacity.
We have funded our operations to date principally from the sale of stock and revenue from precision oncology testing and development services. As of December 31, 2019, we had cash and cash equivalents of $143.2 million and marketable securities of $648.4 million. Cash in excess of immediate requirements is invested in accordance with our investment policy, primarily with a view to liquidity and capital preservation. Currently, our funds are held in marketable securities consisting of United States treasury securities and corporate bonds.
Based on our current business plan, we believe our current cash, cash equivalents and marketable securities and anticipated cash flow from operations will be sufficient to meet our anticipated cash requirements over at least the next 12 months from the date of this Annual Report on Form 10-K. We may consider raising additional capital to expand our business, to pursue strategic investments, to take advantage of financing opportunities or for other reasons. As revenue from precision oncology testing and development service is expected to grow, we expect our accounts receivable and inventory balances to increase. Any increase in accounts receivable and inventory may not be completely offset by increases in accounts payable and accrued expenses, which could result in greater working capital requirements.
If our available cash, cash equivalents and marketable securities and anticipated cash flow from operations are insufficient to satisfy our liquidity requirements including because of lower demand for our products as a result of lower than currently expected rates of reimbursement from our customers or other risks described in this Annual Report on Form 10-K, we may seek to sell additional common or preferred equity or convertible debt securities, enter into a credit facility or another form of third-party funding or seek other debt financing. The sale of equity and convertible debt securities may result in dilution to our stockholders and, in the case of preferred equity securities or convertible debt, those securities could provide for rights, preferences or privileges senior to those of our common stock. The terms of debt securities issued or borrowings pursuant to a credit agreement could impose significant restrictions on our operations. If we raise funds through collaborations and licensing arrangements, we might be required to relinquish significant rights to our platform technologies or products or grant licenses on terms that are not favorable to us. Additional capital may not be available to us on reasonable terms, or at all.
Cash flows
The following table summarizes our cash flows for the periods presented:
 
Year Ended December 31,
 
2019
 
2018
 
 
 
 
 
 
 
(in thousands)
Cash used in operating activities
$
(47,134
)
 
$
(72,185
)
 
Cash used in investing activities
(317,570
)
 
(153,028
)
 
Cash provided by financing activities
367,304

 
293,161

 
Operating activities
Cash used in operating activities during the year ended December 31, 2019 was $47.1 million, which resulted from a net loss of $67.9 million and net change in our operating assets and liabilities of $6.1 million, partially offset by non-cash charges of $26.8 million. Non-cash charges primarily consisted of $11.4 million of depreciation and amortization and $17.0 million of stock-based compensation, partially offset by $2.3 million of amortization of discount on investment. The net change in our operating assets and liabilities was primarily the result of a $7.4 million increase in accounts receivable driven by higher sales to biopharmaceutical customers and adoption of ASC 606, a $6.2 million increase in prepaid expenses and other current assets, a $6.0 million increase in inventory to support testing volumes, a $2.9 million increase in other assets for security deposits relating to new leases entered into in 2019 and a $3.9 million decrease in deferred revenue partially offset by a $9.2 million increase in accrued expenses and other current liabilities,

96

a $5.6 million increase in accrued compensation due to increased personnel, a $4.3 million increase in accounts payable and a $1.0 million increase in operating lease liabilities as a result of the adoption of ASC 842.
Cash used in operating activities during the year ended December 31, 2018 was $72.2 million, which resulted from a net loss of $84.3 million and net change in our operating assets and liabilities of $1.1 million, partially offset by non-cash charges of $13.2 million. Non-cash charges primarily consisted of $7.1 million of depreciation and amortization and $6.9 million of stock-based compensation, partially offset by $0.4 million of amortization of discount on investment. The net change in our operating assets and liabilities was primarily the result of a $22.9 million increase in accounts receivable driven by higher sales to biopharmaceutical customers, a $3.7 million increase in prepaid expenses and other current assets and a $1.8 million increase in inventory due to higher testing volumes, partially offset by a $13.0 million increase in deferred revenue, an $8.1 million increase in accrued compensation due to increased personnel, a $5.0 million increase in accounts payable and a $1.3 million increase in deferred rent.

Investing activities
Cash used in investing activities during the year ended December 31, 2019 was $317.6 million, which resulted primarily from purchases of marketable securities of $614.3 million, purchases of property and equipment of $18.7 million purchase of business of $7.3 million and purchase of intangible assets of $2.5 million, partially offset by our proceeds from the maturities of marketable securities of $325.3 million.
Cash used in investing activities during the year ended December 31, 2018 was $153.0 million, which resulted primarily from purchases of marketable securities of $287.5 million and purchases of property and equipment of $20.2 million, partially offset by our proceeds from the maturities of marketable securities of $154.6 million.

Financing activities
Cash provided by financing activities during the year ended December 31, 2019 was $367.3 million which was primarily due to proceeds of $350.4 million from the follow-on offering completed in May 2019, and receipt of proceeds of $18.0 million from issuance of common stock upon exercise of stock options and issuance of shares under our ESPP.
Cash provided by financing activities during the year ended December 31, 2018 was $293.2 million, which was primarily due to proceeds from the IPO of $254.0 million, net of underwriting discounts and commissions, and net proceeds from sale of equity interests in noncontrolling interests of $41.0 million.

Contractual obligations and commitments
Our contractual commitments will have an impact on our future liquidity. The following table summarizes our contractually committed future obligations as of December 31, 2019:
 
Payments due by period
 
Total

 
Less than
 1 year

 
1-3 years

 
3-5 years

 
More than 5 years

 
 
 
 
 
 
 
 
 
 
 
(in thousands)
Operating lease obligations (1) (2)
$
65,425

 
$
8,408

 
$
18,630

 
$
19,473

 
$
18,914

Royalty obligation (3)
11,775

 
1,402

 
3,084

 
3,364

 
3,925

Total
$
77,200

 
$
9,810

 
$
21,714

 
$
22,837

 
$
22,839

(1)
We lease our office and laboratory space in Redwood City, California, and office space in Spring City, Texas and Seattle, Washington under operating leases that expire between January 2021 - November 2027. We also have operating leases for manufacturing and office equipment through March 2023.
(2)
Includes payments relating to a facility agreement entered into as of December 31, 2019 for a lease commencing in 2020 net of sublease income of $0.1 million.
(3)
We have patent license agreements with four parties. Under these agreements, we have made one-time and milestone license fee payments that we have capitalized and are amortizing to expense ratably over the useful life of the applicable underlying patent rights. Under some of these agreements, we are obligated to pay low single-digit percentage running royalties on net sales where the patent right(s) are used in the product or service sold, subject to minimum annual royalties or fees in certain agreements.



97


Off-balance sheet arrangements
As of December 31, 2019, we have not had any off-balance sheet arrangements as defined in the rules and regulations of the SEC.
Critical accounting policies and estimates
We have prepared our financial statements in accordance with accounting principles generally accepted in the United States of America (“GAAP”). Our preparation of these financial statements requires us to make estimates, assumptions and judgments that affect the reported amounts of assets, liabilities, expenses and related disclosures at the date of the financial statements, as well as revenue and expenses recorded during the reporting periods. We evaluate our estimates and judgments on an ongoing basis. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could therefore differ materially from these estimates under different assumptions or conditions.
While our significant accounting policies are described in more detail in Note 2 to our consolidated financial statements included elsewhere in this Annual Report on Form 10-K, we believe the following accounting policies to be critical to the judgments and estimates used in the preparation of our financial statements.
Revenue recognition
We derive revenue from the provision of precision oncology testing services provided to our ordering physicians and biopharmaceutical customers, as well as from biopharmaceutical research and development services provided to our biopharmaceutical customers. Precision oncology services include genomic profiling and the delivery of other genomic information derived from our platform. Development services include companion diagnostic development, information solutions and laboratory services. We currently receive payments from commercial third-party payors, certain hospitals and oncology centers and individual patients, as well as biopharmaceutical companies and research institutes.

Effective January 1, 2019, we began recognizing revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers, or ASC 606. Revenues are recognized when control of services is transferred to customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those services. ASC 606 provides for a five-step model that includes identifying the contract with a customer, identifying the performance obligations in the contract, determining the transaction price, allocating the transaction price to the performance obligations, and recognizing revenue when, or as, an entity satisfies a performance obligation.

Precision oncology testing

We recognize revenue from the sale of our precision oncology tests for clinical customers, including certain hospitals, cancer centers, other institutions and patients, at the time results of the test are reported to physicians. Most precision oncology tests requested by clinical customers are sold without a written agreement; however, we determine an implied contract exists with our clinical customers. We identify each sale of our liquid biopsy test to clinical customer as a single performance obligation. With the exception of certain limited contracted arrangements with insurance carriers and other institutions where the transaction price is fixed, a stated contract price does not exist and the transaction price for each implied contract with our clinical customers represents variable consideration. We estimate the variable consideration under the portfolio approach and consider the historical reimbursement data from third-party payers and patients, as well as known current or anticipated reimbursement trends not reflected in the historical data. We monitor the estimated amount to be collected in the portfolio at each reporting period based on actual cash collections in order to assess whether a revision to the estimate is required. Both the estimate and any subsequent revision contain uncertainty and require the use of judgment in the estimation of the variable consideration and application of the constraint for such variable consideration.

Revenue from sales of precision oncology tests to biopharmaceutical customers are based on a negotiated price per test or on the basis of an agreement to provide certain testing volume over a defined period. We identify our promise to


98

transfer a series of distinct liquid biopsy tests to biopharmaceutical customers as a single performance obligation. Precision oncology tests to biopharmaceutical customers are generally billed at a fixed price for each test performed. For agreements involving testing volume to be satisfied over a defined period, revenue is recognized over time based on the number of tests performed as the performance obligation is satisfied over time.

Results of our precision oncology services are delivered electronically, and as such there are no shipping or handling fees incurred by us or billed to customers.

Development services

We perform development services for our biopharmaceutical customers utilizing our precision oncology information platform. Development services typically represent a single performance obligation as we perform a significant integration service, such as analytical validation and regulatory submissions. The individual promises are not separately identifiable from other promises in the contracts and, therefore, are not distinct. However, under certain contracts, a biopharmaceutical customer may engage us for multiple distinct development services which are both capable of being distinct and separately identifiable from other promises in the contracts and, therefore, distinct performance obligations.

We collaborate with pharmaceutical companies in the development and clinical trials of new drugs. As part of these collaborations, we provide services related to regulatory filings with the FDA to support companion diagnostic device submissions for our liquid biopsy panels. Under these collaborations, we generate revenue from achievement of milestones, as well as provision of on-going support. These collaboration arrangements include no royalty obligations. For development services performed, we are compensated through a combination of an upfront fee and performance-based non-refundable regulatory and other developmental milestone payments. The transaction price of our development services contracts typically represents variable consideration. Application of the constraint for variable consideration to milestone payments is an area that requires significant judgment. We evaluate factors such as the scientific, clinical, regulatory, commercial, and other risks that must be managed to achieve the respective milestone and the level of effort and investment required to achieve the respective milestone. In making this assessment, we consider our historical experience with similar milestones, the degree of complexity and uncertainty associated with each milestone, and whether achievement of the milestone is dependent on parties other than us. The constraint for variable consideration is applied such that it is probable a significant reversal of revenue will not occur when the uncertainty associated with the contingency is resolved. Application of the constraint for variable consideration is updated at each reporting period as a revision to the estimated transaction price. We recognize development services revenue over the period in which biopharmaceutical research and development services are provided. Specifically, we recognize revenue using an input method to measure progress, utilizing costs incurred to-date relative to total expected costs as its measure of progress. For development of new products or services under these arrangements, costs incurred before technological feasibility is reached are included as research and development expenses in our consolidated statements of operations, while costs incurred thereafter are recorded as cost of development services.

Contracts with multiple performance obligations

Contracts with biopharmaceutical customers may include multiple distinct performance obligations, such as provision of precision oncology testing, biopharmaceutical research and development services, and clinical trial enrollment assistance, among others. We evaluate the terms and conditions included within our contracts with biopharmaceutical customers to ensure appropriate revenue recognition, including whether services are considered distinct performance obligations that should be accounted for separately versus together. We first identify material promises, in contrast to immaterial promises or administrative tasks, under the contract and then evaluates whether these promises are both capable of being distinct and distinct within the context of the contract. In assessing whether a promised service is capable of being distinct, we consider whether the customer could benefit from the service either on its own or together with other resources that are readily available to the customer, including factors such as the research, development, and commercialization capabilities of a third party and the availability of the associated expertise in the general marketplace. In assessing whether a promised service is distinct within the context of the contract, we consider whether we provide a significant integration of the services, whether the services significantly modify or customize one another, or whether the services are highly interdependent or interrelated.

For contracts with multiple performance obligations, the transaction price is allocated to the separate performance obligations on a relative standalone selling price basis. We determine standalone selling price by considering the historical selling price of these performance obligations in similar transactions as well as other factors, including, but not limited to, the price that customers in the market would be willing to pay, competitive pricing of other vendors, industry publications and current pricing practices, and expected costs of satisfying each performance obligation plus appropriate margin.

99


Variable interest entity
We review agreements we enter into with third party entities, pursuant to which we may have a variable interest in the entity, in order to determine if the entity is a variable interest entity, or VIE. If the entity is a VIE, we assess whether or not we are the primary beneficiary of that entity. In determining whether we are the primary beneficiary of an entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. If we determine we are the primary beneficiary of a VIE, we consolidate the statements of operations and financial condition of the VIE into our consolidated financial statements. Accounting for the consolidation is based on our determination if the VIE meets the definition of a business or and asset. Assets, liabilities and noncontrolling interests, excluding goodwill, of VIEs that are not determined to be businesses are recorded at fair value in our financial statements upon consolidation. Assets and liabilities that we have transferred to a VIE, after, or shortly before the date we became the primary beneficiary are recorded at the same amount at which the assets and liabilities would have been measured if they had not been transferred. Our determination about whether we should consolidate such VIEs is made continuously as changes to existing relationships or future transactions may result in a consolidation or deconsolidation event.

In May 2018, we and SoftBank formed and capitalized the Joint Venture for the sale, marketing and distribution of our tests in the JV Territory. We expect to rely on the Joint Venture to accelerate commercialization of our products in Asia, the Middle East and Africa, with an initial focus on Japan. As of March 31, 2018, the Joint Venture is deemed to be a VIE and we are identified as the primary beneficiary of the VIE. Consequently, we have consolidated the financial position, results of operations and cash flows of the Joint Venture in our financial statements and all intercompany balances have been eliminated in consolidation.

The joint venture agreement also includes a put-call arrangement with respect to the shares of the Joint Venture held by SoftBank and its affiliates. SoftBank will have a put right to cause us to purchase all shares of the Joint Venture held by SoftBank and its affiliates, and we will have a call right to purchase all such shares in the event of (i) certain material disagreement relating to the Joint Venture or its business that may seriously affect the ability of the Joint Venture to perform its obligations under the joint venture agreement or may otherwise seriously impair the ability of the Joint Venture to conduct its business in an effective matter, other than one relating to the Joint Venture’s business plan or to factual matters that may be capable of expert determination; (ii) the effectiveness of our initial public offering, a change in control, the seventh anniversary of the formation of the Joint Venture, or each subsequent anniversary of each of the foregoing events; or (iii) a material breach of the joint venture agreement by the other party that goes unremedied within 20 business days. Unless the shares of the Joint Venture are publicly traded and listed on a nationally recognized stock exchange, the purchase price per share of the Joint Venture in these situations will be determined by a third-party valuation firm on the assumption that the sale is on an arm’s-length basis on the date of the put or call notice. The third-party valuation firm may evaluate a range of factors and employ assumptions that are subjective in nature, which could result in the fair value of SoftBank’s interest in the Joint Venture being determined to be materially different from what has been recorded in our consolidated financial statements, including those included elsewhere in this Annual Report on Form 10-K.

In the event we exercise our call right, the fair value of the Joint Venture will be deemed to be no less than an amount that yields a 20% internal rate of return on each tranche of capital invested by SoftBank and its affiliates in the Joint Venture, taking into account all proceeds received by SoftBank and its affiliates arising from their shares through such date.

In the event SoftBank exercises its put right and the fair value of the Joint Venture is determined to be greater than 40% of our fair value, we will only be required to purchase the number of shares of the Joint Venture held by SoftBank and its affiliates having an aggregate value equal to the product of 40% of our fair value and the pro rata portion of the outstanding shares of the Joint Venture held by SoftBank and its affiliates.

We may pay the purchase price for the shares of the Joint Venture in cash, in shares of our common stock, or in a combination thereof. In the event we exercise the call right, SoftBank will choose the form of consideration. In the event SoftBank exercises the put right, we will choose the form of consideration. The noncontrolling interest held by SoftBank contains embedded put-call redemption features that are not solely within our control and has been classified outside of permanent equity in our consolidated balance sheets. The put-call feature embedded in the redeemable noncontrolling interest do not currently require bifurcation as it does not meet the definition of a derivative and is considered to be clearly and closely related to the redeemable noncontrolling interest. The noncontrolling interest is considered probable of becoming redeemable as SoftBank has the option to exercise its put right to sell its equity

100

ownership in the Joint Venture to us on or after the seventh anniversary of the formation of the Joint Venture, on each subsequent anniversary of the IPO and under certain other circumstances. We elected to recognize the change in redemption value immediately as they occur as if the put-call redemption feature were exercisable at the end of the reporting period.

Stock-based compensation
After the adoption of Accounting Standards Update 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting on January 1, 2019, we measure stock-based compensation expense for stock options granted to our employees, directors, and nonemployee consultants on the date of grant and recognize the corresponding compensation expense of those awards over the period that the related services are rendered, which is generally the vesting period of the respective award. Compensation expense for stock options with performance metrics is calculated based upon expected achievement of the metrics specified in the grant.

We estimate the fair value of stock options granted to our employees, directors, nonemployee consultants and purchase rights under our 2018 Employee Stock Purchase Plan on the grant date using the Black-Scholes option-pricing model. The Black-Scholes option-pricing model requires the use of assumptions regarding a number of variables that are complex, subjective and generally require significant judgment to determine. The assumptions used to calculate the fair value of our stock options were:

Expected term

Our expected term represents the period that our stock options are expected to be outstanding. After the adoption of Accounting Standards Update 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting on January 1, 2019, the expected term of stock options issued to employees and nonemployee consultants is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term), as we do not have sufficient historical data to use any other method to estimate expected term.

Expected volatility

Prior to the commencement of trading of our common stock on the Nasdaq Global Select Market on October 4, 2018 in connection with the IPO, there was no active trading market for our common stock. Due to limited historical data for the trading of our common stock, expected volatility is estimated based on the average volatility for comparable publicly traded peer group companies in the same industry plus our expected volatility for the available periods. The comparable companies are chosen based on their similar size, stage in the life cycle or area of specialty.

Risk-free interest rate

The risk-free interest rate is based on the U.S. treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of the stock option grants.

Expected dividend yield

We have never paid dividends on our common stock and have no plans to pay dividends on our common stock. Therefore, we use an expected dividend yield of zero.


101

Black-Scholes assumptions
The weighted-average assumptions used in our Black-Scholes option-pricing model were as follows for stock option granted to our employees, directors and nonemployees for the periods presented:
 
Year Ended December 31,
 
 
2019
 
2018
 
2017
 
 
 
 
 
 
 
 
Expected term (in years)
5.50 – 6.22
 
5.01 – 6.51
 
6.02 – 6.08
 
Expected volatility
63.2% – 68.7%
 
68.7% – 78.8%
 
74.1% – 75.1%
 
Risk-free interest rate
1.6% – 2.7%
 
2.5% – 3.0%
 
1.9% – 2.2%
 
Expected dividend yield
—%
 
—%
 
—%
 
We recognize stock-based compensation expense net of forfeitures as they occur in accordance with Accounting Standards Update 2016-09, Compensation - Stock Compensation (Topic 718).
We will continue to use judgment in evaluating the assumptions related to our stock-based compensation on a prospective basis. As we continue to accumulate additional data related to our common stock, we may have refinements to our estimates, which could materially impact our future stock-based compensation expense.

Recent accounting pronouncements
See Note 2, Summary of Significant Accounting Policies, to our consolidated financial statements included elsewhere in this Annual Report on Form 10-K for more information.
Item 7A. Quantitative and Qualitative Disclosures About Market Risk
We are exposed to market risk in the ordinary course of our business. Market risk represents the risk of loss that may impact our financial position due to adverse changes in financial market prices and rates.
Interest rate risk
We are exposed to market risk for changes in interest rates related primarily to our cash and cash equivalents, marketable securities and our indebtedness. As of December 31, 2019, we had cash and cash equivalents of $143.2 million held primarily in cash deposits and money market funds. Our marketable securities are held in U.S. government debt securities, U.S. government agency bonds and corporate bonds. As of December 31, 2019, we invested in short-term marketable securities of $379.6 million and long-term marketable securities of $268.8 million. Our primary exposure to market risk is interest income sensitivity, which is affected by changes in the general level of the interest rates in the United States. As of December 31, 2019, a hypothetical 100 basis point increase in interest rates would have resulted in an approximate $5.5 million decline of the fair value of our available-for-sale securities. This estimate is based on a sensitivity model that measures market value changes when changes in interest rates occur.
Foreign currency risk
The majority of our revenue is generated in the United States. Through December 31, 2019, we have generated an insignificant amount of revenues denominated in foreign currencies. As we expand our presence in the international market, our results of operations and cash flows are expected to increasingly be subject to fluctuations due to changes in foreign currency exchange rates and may be adversely affected in the future due to changes in foreign exchange rates. Our obligation related to a royalty denominated in Euros is subject to foreign currency risk. As of December 31, 2019, the effect of a hypothetical 10% change in foreign currency exchange rates would result in a foreign exchange gains or losses of $1.3 million, on total cumulative balance of obligations. To date, we have not entered into any hedging arrangements with respect to foreign currency risk. As our international operations grow, we will continue to reassess our approach to manage our risk relating to fluctuations in currency rates.

102

Item 8. Financial Statements and Supplementary Data
Guardant Health, Inc.
Index to Consolidated Financial Statements
As of December 31, 2019 and 2018, and
For the Years Ended December 31, 2019, 2018 and 2017
The supplementary financial information required by this Item 8 is included in Part II, Item 7 under the caption “Quarterly Results of Operations”, which is incorporated herein by reference.

103

Report of Independent Registered Public Accounting Firm
To the Stockholders and the Board of Directors of
Guardant Health, Inc.
Opinion on the Financial Statements
We have audited the accompanying consolidated balance sheets of Guardant Health, Inc. (the Company) as of December 31, 2019 and 2018, the related consolidated statements of operations, comprehensive loss, redeemable noncontrolling interest and stockholders’ equity and cash flows for each of the three years in the period ended December 31, 2019, and the related notes (collectively referred to as the “consolidated financial statements“). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2019 and 2018, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2019, in conformity with U.S. generally accepted accounting principles.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company’s internal control over financial reporting as of December 31, 2019, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated March 2, 2020 expressed an unqualified opinion thereon.
Adoption of ASU No. 2014-09
As discussed in Note 2 to the consolidated financial statements, the Company changed its method for recognizing revenue as a result of the adoption of Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (Topic 606), effective January 1, 2019.
Basis for Opinion
These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.
Critical Audit Matters

The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.

Precision Oncology Revenue (testing services provided to ordering physicians)
Description of the Matter

For the year ended December 31, 2019, revenue recognized from Precision Oncology was $180.5 million. As described in Note 2 to the consolidated financial statements, the Company recognizes revenue from the performance of precision oncology tests for clinical customers upon delivery of test results to the ordering physician. As most precision oncology tests requested by customers are sold based on a physician requisition form without further written terms and conditions, the Company determined an implied contract exists with its patients and estimates variable consideration to be received

104

for these services. Management estimates variable consideration based on historical payment data from third-party payers and patients adjusted for known and forecasted changes in payment patterns and subject to a constraint such that revenue recognized is not expected to be reversed.

Auditing the Company’s estimate of total consideration expected to be received for the precision oncology tests is complex and requires significant judgment to evaluate management’s estimate of payments to be received for the tests. This estimate is affected by assumptions on coverage of the tests for the patient and experience with collection from third-party payors.
How We Addressed the Matter in Our Audit
We obtained an understanding, evaluated the design, and tested the operating effectiveness of internal controls that address the risks of material misstatement relating to the measurement of precision oncology revenues based upon estimating variable consideration. This included testing controls relating to management’s review of the significant assumptions described above and inputs used in the determination of the estimated amount that would be collected for tests performed during the period. We also tested controls over the current and historical data used by management in determining this estimate of variable consideration, subject to a constraint, including the completeness and accuracy of the data.
Our audit procedures over the Company’s precision oncology revenue included, among others, assessing assumptions and inputs described above, testing the completeness and accuracy of the underlying data used by the Company in its analysis, including the constraint applied. We agreed the terms and conditions of the type of test (i.e. lung, non-lung, etc.) to be performed to the requisition forms submitted by the physician. We compared the significant assumptions and inputs used by management to the Company’s third-party payor collection trends and other relevant factors. This included testing inputs to the calculation by comparing historical information to source documents and evaluating the historical accuracy of management's estimates by comparing such estimates to actual results.

Valuation of Redeemable Non-Controlling Interest
Description of the Matter

As described in Note 3 to the consolidated financial statements, in May 2018, the Company entered into an agreement with an entity affiliated with SoftBank, a related party, to establish a Joint Venture to distribute the Company’s tests in certain markets outside the United States. The Company is consolidating the Joint Venture and as part of the accounting for the redeemable noncontrolling interest (NCI) held by Softbank, management is carrying the NCI at its fair value as the agreement has a put feature which contractually allows Softbank to return the NCI interest back to the Company. The fair value of the NCI was determined using two valuation models the income approach and the market approach. Determining the fair value of the NCI requires judgment and the use of significant estimates and assumptions, such as, discount rate and exit multiple rate. The discount rate is applied to calculate the present value the expected future cash flows of the Joint Venture. The selection of exit multiple rate establishes an exit event (i.e. sale or initial public offering) of the Joint Venture. These significant estimates and assumptions are forward looking and could be affected by future economic and market conditions. At December 31, 2019, the Company’s non-controlling interest was $49.6 million.

How We Addressed the Matter in Our Audit
We obtained an understanding, evaluated the design and tested the operating effectiveness of the Company’s controls over the fair value estimation of the NCI. We tested controls over the selection and application of the valuation models and the underlying significant estimates and assumptions noted above.
To test the estimated fair value of the NCI, our audit procedures included, among others, involvement of our valuation specialist to assist us in the evaluation of the Company’s valuation methodology and testing of the significant estimates and assumptions. For example, we compared the discount rate to industry trends and market conditions and the exit multiple rate to the comparable public companies. We also compared the revenue forecast to evidence of approval by the Joint Venture board of directors.

/s/ Ernst & Young LLP
We have served as the Company’s auditor since 2015.
Redwood City, California
March 2, 2020

105

Guardant Health, Inc.
Consolidated Balance Sheets
(in thousands, except share and per share data)
 
As of December 31,
 
2019
 
2018
ASSETS
 
 
 
Current assets:
 
 
 
Cash and cash equivalents
$
143,228

 
$
140,544

Short-term marketable securities
379,574

 
278,417

Accounts receivable
47,986

 
35,690

Inventory
15,181

 
9,136

Prepaid expenses and other current assets
11,389

 
5,204

Total current assets
597,358

 
468,991

Long-term marketable securities
268,783

 
77,563

Property and equipment, net
43,668

 
31,003

Right-of-use assets
29,140

 
—

Intangible assets, net
8,524

 
—

Goodwill
3,290

 
—

Capitalized license fees
6,890

 
7,800

Other assets
4,882

 
2,046

Total Assets(1)(2)
$
962,535

 
$
587,403

LIABILITIES, REDEEMABLE NONCONTROLLING INTEREST AND STOCKHOLDERS’ EQUITY
 
 
 
Current liabilities:
 
 
 
Accounts payable
$
16,197

 
$
10,642

Accrued compensation
18,557

 
12,986

Accrued expenses
25,703

 
7,178

Deferred revenue
12,277

 
16,138

Total current liabilities
72,734

 
46,944

Long-term operating lease liabilities
33,256

 
—

Deferred rent, net of current portion
—

 
7,844

Obligation related to royalty
6,880

 
7,338

Other long-term liabilities
1,672

 
325

Total Liabilities(1)(2)
114,542

 
62,451

Commitments and contingencies (Note 10)


 


Redeemable noncontrolling interest
49,600

 
41,800


106

Stockholders’ equity:
 
 
 
Preferred stock, par value of $0.00001 per share; 10,000,000 shares authorized, no shares issued and outstanding as of December 31, 2019 and 2018
—

 
—

Common stock, par value of $0.00001 per share; 350,000,000 and 350,000,000 shares authorized as of December 31, 2019 and 2018, respectively; 94,261,414 and 85,832,454 shares issued and outstanding as of December 31, 2019 and 2018, respectively
1

 
1

Additional paid-in capital
1,150,090

 
764,033

Accumulated other comprehensive gain (loss)
1,111

 
(83
)
Accumulated deficit
(352,809
)
 
(280,799
)
Total Stockholders’ Equity
798,393

 
483,152

Total Liabilities, Redeemable Noncontrolling Interest and Stockholders’ Equity
$
962,535

 
$
587,403

(1) As of December 31, 2019 and 2018, includes $45.1 million and $48.3 million of assets, respectively, that can be used only to settle obligations of the consolidated variable interest entity (“VIE”) and VIE’s subsidiaries, and $5.7 million and $1.2 million of liabilities, respectively, of the consolidated VIE  of liabilities of consolidated VIE and VIE’s subsidiaries for which their creditors do not have recourse to the general credit of the Company. See Note 3, Investment in Joint Venture.
(2) Fiscal 2018 does not reflect the impact of the adoption of the new revenue accounting and lease accounting standards in fiscal year 2019.
The accompanying notes are an integral part of these consolidated financial statements.

107

Guardant Health, Inc.
Consolidated Statements of Operations
(in thousands, except per share data)
 
 
Year Ended December 31,
 
 
2019
 
2018
 
2017
 
 
 
 
 
 
 
Revenue:
 
 
 
 
 
 
Precision oncology testing (1)
 
$
180,462

 
$
78,407

 
$
42,088

Development services (1)
 
33,913

 
12,232

 
7,754

Total revenue
 
214,375

 
90,639

 
49,842

Costs and operating expenses:
 
 
 
 
 
 
Cost of precision oncology testing
 
62,255

 
39,846

 
28,883

Cost of development services
 
8,465

 
3,364

 
2,735

Research and development expense
 
86,292

 
50,714

 
25,562

Sales and marketing expense
 
78,335

 
53,465

 
32,497

General and administrative expense
 
61,399

 
36,192

 
36,777

Total costs and operating expenses
 
296,746

 
183,581

 
126,454

Loss from operations
 
(82,371
)
 
(92,942
)
 
(76,612
)
Interest income
 
13,741

 
5,266

 
2,234

Interest expense
 
(1,181
)
 
(1,251
)
 
(2,702
)
Loss on debt extinguishment
 
—

 
—

 
(5,075
)
Other income (expense), net
 
88

 
4,702

 
(1,059
)
Loss before provision for income taxes
 
(69,723
)
 
(84,225
)
 
(83,214
)
Provision for (benefit from) income taxes
 
(1,872
)
 
38

 
7

Net loss
 
(67,851
)
 
(84,263
)
 
(83,221
)
Adjustment of redeemable noncontrolling interest
 
(7,800
)
 
(800
)
 
—

Net loss attributable to Guardant Health, Inc.
 
$
(75,651
)
 
$
(85,063
)
 
$
(83,221
)
Deemed dividend related to repurchase of Series A convertible preferred stock
 
—

 
—

 
(4,716
)
Deemed dividend related to change in conversion rate of Series D convertible preferred stock
 
—

 
—

 
(1,058
)
Net loss attributable to Guardant Health, Inc. common stockholders
 
$
(75,651
)
 
$
(85,063
)
 
$
(88,995
)
Net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted
 
$
(0.84
)
 
$
(2.80
)
 
$
(7.07
)
Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted
 
90,597

 
30,403

 
12,582

(1) Fiscal year 2018 and 2017 results do not reflect the impact of the adoption of the new revenue accounting standard in fiscal year 2019.
The accompanying notes are an integral part of these consolidated financial statements.

108

Guardant Health, Inc.
Consolidated Statements of Comprehensive Loss
(in thousands)
 
 
Year Ended December 31,
 
 
2019
 
2018
 
2017
 
 
 
 
 
 
 
Net loss
 
$
(67,851
)
 
$
(84,263
)
 
$
(83,221
)
Other comprehensive income (loss), net of tax impact:
 
 
 
 
 
 
Unrealized gain (loss) on available-for-sale securities
 
1,110
 
449

 
(446
)
Foreign currency translation adjustments
 
84

 
—

 
—

Other comprehensive income (loss)
 
1,194
 
449
 
(446)
Comprehensive loss
 
$
(66,657
)
 
$
(83,814
)
 
$
(83,667
)
Comprehensive loss attributable to redeemable noncontrolling interest
 
(7,800
)
 
(800
)
 
—

Comprehensive loss attributable to Guardant Health, Inc.
 
$
(74,457
)
 
$
(84,614
)
 
$
(83,667
)
The accompanying notes are an integral part of these consolidated financial statements.

109

Guardant Health, Inc.
Consolidated Statements of Redeemable Noncontrolling Interest and Stockholders’ Equity
(in thousands, except share data)
 
Redeemable Noncontrolling Interest

 
Convertible
Preferred Stock 
 
 
Common Stock 
 
 
Additional
Paid-in
Capital

 
Accumulated
Other
Comprehensive Gain (Loss)

 
 
Accumulated
Deficit

 
Total Stockholders’ Equity

 
 
Shares

 
Amount

 
Shares

 
Amount

 
Balance as of December 31, 2016
$
—

 
40,181,923

 
$
179,997

 
13,184,214

 
$
—

 
$
7,410

 
$
(86
)
 
$
(107,625
)
 
$
79,696

Cumulative effect adjustment for ASU 2016-09 adoption
—

 
—

 
—

 
—

 
—

 
174

 
—

 
(174
)
 
—

Issuance of Series D convertible preferred stock in exchange for a technology license agreement
—

 
141,774

 
1,060

 
—

 
—

 
—

 
—

 
—

 
1,060

Issuance of Series E convertible preferred stock, net of issuance cost of $883
—

 
38,970,592

 
319,536

 
—

 
—

 
—

 
—

 
—

 
319,536

Repurchase of Series A convertible preferred stock
—

 
(666,920
)
 
(619
)
 
—

 
—

 
—

 
—

 
(4,716
)
 
(5,335
)
Issuance of common stock upon exercise of stock options
—

 
—

 
—

 
342,946

 
—

 
753

 
—

 
—

 
753

Issuance of common stock upon exercise of warrants
—

 
—

 
—

 
89,030

 
—

 
12

 
—

 
—

 
12

Vesting of common stock exercised early
—

 
—

 
—

 
—

 
—

 
103

 
—

 
—

 
103

Repurchase of common stock
—

 
—

 
—

 
(1,719,308
)
 
—

 
(7,222
)
 
—

 
—

 
(7,222
)
Stock-based compensation
—

 
—

 
—

 
—

 
—

 
3,670

 
—

 
—

 
3,670

Other comprehensive loss, net of tax impact
—

 
—

 
—

 
—

 
—

 
—

 
(446
)
 
—

 
(446
)
Net loss
—

 
—

 
—

 

 
—

 
—

 
—

 
(83,221
)
 
(83,221
)
Balance as of December 31, 2017
—

 
78,627,369

 
499,974

 
11,896,882

 
—

 
4,900

 
(532
)
 
(195,736
)
 
308,606

Conversion of convertible preferred stock to common stock upon initial public offering
 
 
(78,627,369
)
 
(499,974
)
 
58,264,577

 
1

 
499,973

 
—

 
—

 
—

Issuance of common stock upon initial public offering, net of offering costs of $4,475 issuance of Series D convertible preferred stock in exchange for a technology license agreement
—

 
—

 
—

 
14,375,000

 
—

 
249,531

 
—

 
—

 
249,531

Issuance of common stock upon exercise of stock options
—

 
—

 
—

 
963,119

 
—

 
2,905

 
—

 
—

 
2,905

Issuance of common stock upon early exercise of stock options
—

 
—

 
—

 
44,268

 
—

 
—

 
—

 
—

 
—

Issuance of common stock upon exercise of warrants
—

 
—

 
—

 
320,289

 
—

 
45

 
—

 
—

 
45

Repurchase of common stock
—

 
—

 
—

 
(31,681
)
 
—

 
(172
)
 
—

 
—

 
(172
)
Stock-based compensation
—

 
—

 
—

 

 
—

 
6,851

 
—

 
—

 
6,851

Issuance of equity interests in redeemable noncontrolling interest
41,000

 
—

 
—

 
—

 
—

 
—

 
—

 
—

 
—

Adjustment of redeemable noncontrolling interest

800

 
—

 
—

 
—

 
—

 
—

 
—

 
(800
)
 
(800
)
Other comprehensive gain, net of tax impact
—

 
—

 
—

 

 
—

 
—

 
449

 
—

 
449

Net loss
—

 
—

 
—

 

 
—

 
—

 
—

 
(84,263
)
 
(84,263
)
Balance as of December 31, 2018
41,800

 
—

 
—

 
85,832,454

 
1

 
764,033

 
(83
)
 
(280,799
)
 
483,152

Cumulative effect adjustment for Topic 606 adoption
—

 
—

 
—

 
—

 
—

 
—

 
—

 
4,907

 
4,907

Cumulative effect adjustment for ASU 2018-07 adoption
—

 
—

 
—

 
—

 
—

 
1,266

 
—

 
(1,266
)
 
—

Issuance of common stock upon follow-on offering, net of offering costs of $723
—

 
 
 
 
 
5,175,000

 
 
 
349,709

 
—

 
—

 
349,709

Issuance of common stock upon exercise of stock options
—

 
—

 
—

 
2,999,419

 
—

 
11,638

 
—

 
—

 
11,638

Vesting of restricted stock units
—

 
—

 
—

 
22,208

 
—

 
—

 
—

 
—

 
—

Issuance of common stock exercised early
—

 
—

 
—

 
—

 
—

 
95

 
—

 
—

 
95

Common stock issued under employee stock purchase plan
—

 
—

 
—

 
232,333

 
—

 
6,395

 
—

 
—

 
6,395

Stock-based compensation
—

 
—

 
—

 
—

 
—

 
16,954

 
—

 
—

 
16,954

Adjustment of redeemable noncontrolling interest
7,800

 
—

 
—

 
—

 
—

 
—

 
—

 
(7,800
)
 
(7,800
)
Other comprehensive gain, net of tax impact
—

 
—

 
—

 
—

 
—

 
—

 
1,194

 
—

 
1,194

Net loss
—

 
—

 
—

 
—

 
—

 
—

 
—

 
(67,851
)
 
(67,851
)
Balance as of December 31, 2019
$
49,600

 
—

 
$
—

 
94,261,414

 
$
1

 
$
1,150,090

 
$
1,111

 
$
(352,809
)
 
$
798,393

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

110

The accompanying notes are an integral part of these consolidated financial statements.

111

Guardant Health, Inc.
Consolidated Statements of Cash Flows
(in thousands)
 
Year Ended December 31,
 
2019
 
2018
 
2017
 
 
 
 
 
 
OPERATING ACTIVITIES:
 
 
 
Net loss
$
(67,851
)
 
$
(84,263
)
 
$
(83,221
)
Adjustments to reconcile net loss to net cash used in operating activities:
 
 
 
 
 
Depreciation and amortization
11,411

 
7,136

 
5,206

Amortization of ROU
2,198

 
—

 
—

Unrealized translation (gains) losses on obligation related to royalty
(147
)
 
(357
)
 
980

Re-valuation of contingent consideration
300

 
—

 
—

Non-cash stock-based compensation
16,954

 
6,851

 
3,670

Non-cash interest expense
—

 
(13
)
 
685

Loss on debt extinguishment
—

 
—

 
5,075

Amortization of premium (discount) on marketable securities
(2,310
)
 
(412
)
 
359

Benefit from income tax differences
(1,597
)
 
—

 
—

Changes in operating assets and liabilities:
 
 
 
 
 
Accounts receivable
(7,389
)
 
(22,903
)
 
(9,292
)
Inventory
(6,045
)
 
(1,849
)
 
(4,518
)
Prepaid expenses and other current assets
(6,185
)
 
(3,663
)
 
30

Other assets
(2,852
)
 
(451
)
 
(883
)
Accounts payable
4,341

 
5,046

 
1,250

Accrued compensation
5,571

 
8,075

 
2,348

Accrued expenses and other current liabilities
9,213

 
286

 
4,657

Long-term operating lease liabilities net of ROU
1,039

 
—

 
—

Deferred rent
—

 
1,307

 
204

Deferred revenue
(3,861
)
 
13,025

 
1,215

Other liabilities
76

 
—

 
—

Net cash used in operating activities
(47,134
)
 
(72,185
)
 
(72,235
)
 
 
 
 
 
 
INVESTING ACTIVITIES:
 
 
 
 
 
Purchase of marketable securities
(614,290
)
 
(287,450
)
 
(236,835
)
Maturity of marketable securities
325,333

 
154,625

 
75,402

Business acquisition, net of cash acquired
(7,328
)
 
—

 
—

Purchase of property and equipment
(18,717
)
 
(20,203
)
 
(6,681
)
Purchase of intangible assets and capitalized license obligations
(2,500
)
 
—

 
—

Payment in connection with a license agreement
(68
)
 
—

 
(2,302
)
Net cash used in investing activities
(317,570
)
 
(153,028
)
 
(170,416
)
 
 
 
 
 
 
FINANCING ACTIVITIES:
 
 
 
 
 
Payment related to settlement of debt and buyout of royalty obligations
(311
)
 
—

 
(25,844
)
Payments made on capital lease obligations
(128
)
 
(443
)
 
(244
)
Proceeds from issuance of convertible preferred stock, net of issuance costs
—

 
—

 
319,536


112

Proceeds from issuance of common stock under employee stock purchase plan
6,395

 
—

 
—

Proceeds from issuance of common stock upon exercise of stock options
11,639

 
3,111

 
753

Proceeds from issuance of common stock upon the exercise of warrants
—

 
45

 
12

Repurchase of convertible preferred stock
—

 
—

 
(5,335
)
Repurchase of common stock
—

 
(172
)
 
(7,222
)
Proceeds from public offerings of common stock
350,432

 
254,006

 
—

Payment of offering costs related to public offerings of common stock
(723
)
 
(4,386
)
 
—

Net proceeds from issuance of equity interests in redeemable noncontrolling interest
—

 
41,000

 
—

Net cash provided by financing activities
367,304

 
293,161

 
281,656

Net effect of foreign exchange rate changes on cash, cash equivalents, and restricted cash
84

 
—

 
—

Net increase in cash, cash equivalents and restricted cash
2,684

 
67,948

 
39,005

Cash, cash equivalents and restricted cash - Beginning of period
140,544

 
72,596

 
33,591

Cash, cash equivalents and restricted cash - End of period
$
143,228

 
$
140,544

 
$
72,596

Supplemental Disclosures of Cash Flow Information:
 
 
 
 
 
Operating lease liabilities arising from obtaining right-of-use assets
$
16,714

 
$
—

 
$
—

Cash paid for interest
$
1,181

 
$
1,251

 
$
1,339

Cash paid for income taxes
$
298

 
$
102

 
$
26

Supplemental Disclosures of Noncash Investing and Financing Activities:
 
 
 
 
 
Capitalized license fees financed through future royalty payment
$
—

 
$
—

 
$
6,302

Issuance of Series D convertible preferred stock in exchange for a technology license agreement
$
—

 
$
—

 
$
1,060

Increase in purchases of property and equipment included in accounts payable and accrued expenses
$
3,296

 
$
897

 
$
591

Vesting of common stock exercised early
$
95

 
$
—

 
$
103

Property and equipment acquired under capital leases
$
—

 
$
—

 
$
346

Conversion of convertible preferred stock to common stock upon initial public offering
$
—

 
$
499,974

 
$
—

Initial fair value of contingent consideration at acquisition date
$
1,065

 
$
—

 
$
—

Deferred offering costs included in accounts payable and accrued expenses
$
—

 
$
89

 
$
—

The accompanying notes are an integral part of these consolidated financial statements.

113

 Guardant Health, Inc.
Notes to Consolidated Financial Statements

1. Description of Business
Guardant Health, Inc. (the “Company”) is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. The key to conquering cancer is unprecedented access to its molecular information throughout all stages of the disease, which it enables by a routine blood draw, or liquid biopsy. The Guardant Health Oncology Platform is designed to leverage the Company’s capabilities in technology, clinical development, regulatory, reimbursement and commercial adoption to improve patient clinical outcomes, lower healthcare costs and accelerate biopharmaceutical drug development. In pursuit of its goal to manage cancer across all stages of the disease, the Company has launched its Guardant360 and GuardantOMNI liquid biopsy-based tests for advanced stage cancer patients, and is developing tests from its LUNAR program which aims to address the needs of early stage cancer patients with neoadjuvant and adjuvant treatment selection, cancer survivors with surveillance, and asymptomatic individuals eligible for cancer screening and individuals at a higher risk for developing cancer with early detection.
The Company was incorporated in Delaware in December 2011 and is headquartered in Redwood City, California. In April 2018, the Company established Guardant Health AMEA, Inc. (the “Joint Venture”) in the United States with an entity affiliated with SoftBank. Under the terms of the joint venture agreement, the Company held a 50% ownership interest in the Joint Venture. The Joint Venture has subsidiaries in Singapore and Japan (see Note 3, Investment in Joint Venture) and the Company has a subsidiary in Switzerland which was incorporated in 2019.
Reverse Stock Split
In September 2018, the Company’s Board of Directors and its stockholders approved a 0.7378-for-one reverse stock split of the Company’s common stock. The reverse stock split became effective on September 19, 2018. The par value of the common stock was not adjusted as a result of the reverse stock split. Adjustments corresponding to the reverse stock split were made to the ratio at which the convertible preferred stock was convertible into common stock immediately prior to the closing of the Company’s initial public offering (the “IPO”). All share and per share amounts in the accompanying consolidated financial statements and notes thereto have been retroactively adjusted for all periods presented to give effect to this reverse stock split.
Approval of Amended and Restated Certificate of Incorporation
In September 2018, the Company’s Board of Directors and stockholders approved an amended and restated certificate of incorporation, which authorized 350,000,000 shares of common stock and 10,000,000 shares of preferred stock. The amended and restated certificate of incorporation became effective on October 9, 2018.
Initial Public Offering
On October 9, 2018, the Company completed the IPO, in which it issued and sold 14,375,000 shares of its common stock at a public offering price of $19.00 per share. The Company received net proceeds of $249.5 million after deducting underwriting discounts and commissions and offering expenses payable by the Company. All then-outstanding warrants to purchase the Company’s common stock were exercised prior to the completion of the IPO. In addition, in connection with the IPO, all shares of the Company’s then-outstanding convertible preferred stock were automatically converted into 58,264,577 shares of its common stock, and all then-outstanding warrants to purchase the Company’s convertible preferred stock were automatically converted into warrants to purchase 7,636 shares of the Company’s common stock.
Follow-on Offering

In May 2019, the Company completed an underwritten public offering, in which it issued and sold 5,175,000 shares of its common stock (including the exercise in full of the underwriters’ over-allotment option to purchase 675,000 additional shares) at a price of $71.00 per share. The Company received net proceeds of $349.7 million after deducting underwriting discounts and commissions and offering expenses payable by the Company.


114


2. Summary of Significant Accounting Policies
Basis of Presentation
The Company’s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying consolidated financial statements include the accounts of Guardant Health, Inc. and its consolidated Joint Venture. Other stockholders’ interests in the Joint Venture are shown in the consolidated financial statements as redeemable noncontrolling interest. All significant intercompany balances and transactions have been eliminated in consolidation.
The Company believes that its existing cash and cash equivalents and marketable securities as of December 31, 2019 will be sufficient to allow the Company to fund its current operating plan through at least a period of one year after the date the accompanying consolidated financial statements are issued. As the Company continues to incur losses, its transition to profitability is dependent upon a level of revenues adequate to support the Company’s cost structure. If the Company’s transition to profitability is not consistent with its current operating plan, the Company may have to seek additional capital.
Use of Estimates
The preparation of consolidated financial statements in conformity with GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the related disclosures at the date of the consolidated financial statements, as well as the reported amounts of revenues and expenses during the periods presented. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Estimates are used in several areas including, but not limited to, estimation of variable consideration, standalone selling price allocation included in contracts with multiple performance obligations, the fair value of assets acquired and liabilities assumed for business combinations, goodwill and identifiable intangible assets, stock-based compensation, contingencies, certain inputs into the provision for (benefit from) income taxes, including related reserves, valuation of redeemable noncontrolling interest, among others. These estimates generally involve complex issues and require judgments, involve the analysis of historical results and prediction of future trends, can require extended periods of time to resolve and are subject to change from period to period. Actual results may differ materially from management’s estimates.

JOBS Act Accounting Election
Effective December 31, 2019, we are no longer an “emerging growth company,” as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”). Prior to losing our status as an emerging growth company, the JOBS Act allowed us to delay adoption of new or revised accounting pronouncements applicable to public companies until such pronouncements were made applicable to private companies, and we had elected to use this extended transition period. We can no longer take advantage of this extended transition period.

Foreign Currency Translation
The functional currency of the subsidiaries of the consolidated Joint Venture is the local currency. The assets and liabilities of the subsidiaries are translated into U.S. dollars at exchange rates in effect at each balance sheet date, with the resulting translation adjustments recorded to a separate component of accumulated other comprehensive loss within stockholders’ equity. Income and expense accounts are translated at average exchange rates during the period. Foreign currency transaction gains and losses resulting from transactions denominated in a currency other than the functional currency are recognized in the consolidated statements of operations. For the year ended December 31, 2019 and 2018, foreign currency translation adjustment was immaterial. For the year ended December 31, 2017, the Company did not have foreign currency translation adjustment as the foreign subsidiaries were established in 2018.
Segment Information
The Company operates as one operating and reportable segment. The Company’s chief operating decision makers, the Chief Executive Officer, and the President and Chief Operating Officer, manage the Company’s operations on an aggregate basis for purposes of allocating resources.

115

Cash and Cash Equivalents and Restricted Cash
Cash equivalents consist of highly liquid investments with original maturities at the time of purchase of three months or less. Cash equivalents include bank demand deposits and money market accounts that invest primarily in U.S. government-backed securities and treasuries. Cash equivalents are carried at cost, which approximates their fair value.
In fiscal 2017, restricted cash consists of deposits related to the Company’s corporate credit card. The Company did not have any restricted cash as of December 31, 2019 and 2018.
Marketable Securities
Marketable securities consist primarily of high-grade corporate bonds, commercial papers and certificates of deposit with third parties. Marketable securities with original maturities at the time of purchase between three and twelve months from balance sheet dates are classified as short-term marketable securities and those with maturities over twelve months from balance sheet dates are classified as long-term marketable securities. The Company classifies all marketable securities as available-for-sale, which are recorded at fair value. Unrealized gains and losses are included in accumulated other comprehensive loss in stockholders’ equity. Any premium or discount arising at purchase is amortized or accreted to interest income or expense. Realized gains and losses and declines in value, if any, judged to be other than temporary on available‑for‑sale securities are reported in other income (expense), net. When securities are sold, any associated unrealized gain or loss initially recorded as a separate component of stockholders’ equity is reclassified out of stockholders’ equity on a specific‑identification basis and recorded in earnings for the period.
The Company periodically evaluates whether declines in fair values of its marketable securities below their book value are other-than-temporary. This evaluation consists of several qualitative and quantitative factors regarding the severity and duration of the unrealized loss as well as the Company’s ability and intent to hold the marketable security until a forecasted recovery occurs. Additionally, the Company assesses whether it has plans to sell the security or it is more likely than not that it will be required to sell any marketable securities before recovery of its amortized cost basis. Factors considered include quoted market prices, recent financial results and operating trends, implied values from any recent transactions or offers of investee securities, credit quality of debt instrument issuers, other publicly available information that may affect the value of the marketable security, duration and severity of the decline in value, and management’s strategy and intentions for holding the marketable security. To date, the Company has not recorded any impairment charges on its marketable securities related to other-than-temporary declines in market value.
Concentration of Risk
The Company is subject to credit risk from its portfolio of cash equivalents held at one commercial bank and investments in marketable securities. The Company limits its exposure to credit losses by investing in money market funds through a U.S. bank with high credit ratings. The Company’s cash may consist of deposits held with banks that may at times exceed federally insured limits, however, its exposure to credit risk in the event of default by the financial institution is limited to the extent of amounts recorded on the consolidated balance sheets. The Company performs evaluations of the relative credit standing of these financial institutions to limit the amount of credit exposure.
The Company also invests in investment‑grade debt instruments and has policy limits for the amount it can invest in any one type of security, except for securities issued or guaranteed by the U.S. government. The goals of the Company’s investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk; liquidity of investments sufficient to meet cash flow requirements; and a competitive after‑tax rate of return. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, investment type and issuer, as a result, the Company is not exposed to any significant concentrations of credit risk from these financial instruments.
The Company is also subject to credit risk from its accounts receivable. The majority of the Company’s accounts receivable arises from the provision of precision oncology services in the United States and are primarily with biopharmaceutical companies with high credit ratings. The Company has not experienced any material losses related to receivables from individual customers, or groups of customers. The Company does not require collateral. Accounts receivable are recorded at the invoiced amount and do not bear interest.
A significant customer is a biopharmaceutical customer or a clinical testing payer that represents 10% or more of the Company’s total revenue or accounts receivable balance. Revenue attributable to each significant customer, including its affiliated entities, as a percentage of the Company’s total revenue, for the respective period, and accounts receivable balance attributable to each significant customers, including its affiliated entities, as a percentage of the Company’s total accounts receivable balance, at the respective consolidated balance sheet date, are as follows:

116

 
Revenue
 
Accounts Receivable
 
Year Ended December 31,
 
As of December 31,
 
2019
 
2018
 
2017
 
2019
 
2018
 
 
 
 
 
 
 
 
 
 
Customer A
*

 
*

 
13
%
 
*

 
*

Customer B
26
%
 
18
%
 
13
%
 
40
%
 
65
%
Customer C
*

 
*

 
*

 
10
%
 
*

Customer D
14
%
 
*

 
*

 
*

 
*

*
less than 10%
Accounts Receivable
Accounts receivable represent valid claims against biopharmaceutical companies, research institutes and international distributors. The Company evaluates the collectability of its accounts receivable and provides for an allowance for potential credit losses based on management’s best estimate of the amount of probable credit losses. As of December 31, 2019 and December 31, 2018, the Company had no allowance for doubtful accounts.
Inventory
Inventories are stated at the lower of cost or net realizable value on a first-in, first-out basis. Inventory consisted entirely of supplies, which are consumed when providing liquid biopsy tests, and therefore the Company does not maintain any finished goods inventory.
In order to assess the ultimate realization of inventories, the Company is required to make judgments as to future demand requirements compared to current or committed inventory levels. The Company periodically reviews its inventories for excess or obsolescence and writes-down obsolete or otherwise unmarketable inventory to its estimated net realizable value. If the actual net realizable value is less than that estimated by the Company, or if it is determined that inventory utilization will further diminish based on estimates of demand, additional inventory write-downs may be required. Amounts written-down due to unmarketable inventory are recorded in cost of precision oncology testing.
Property and Equipment, Net
Property and equipment are recorded at cost. Depreciation is computed over estimated useful lives of the related assets using the straight-line method. Leasehold improvements are amortized using the straight-line method over the estimated useful lives of the assets or the remaining term of the lease, whichever is shorter. The Company periodically reviews the depreciable lives assigned to property and equipment placed in service and changes the estimates of useful lives, if necessary. Maintenance and repairs are expensed as incurred.
Estimated useful lives for property and equipment are as follows:
Property and Equipment
 
Estimated Useful Life
 
 
 
Machinery and equipment
 
3 – 5 years
Furniture and fixtures
 
7 years
Computer hardware and computer software
 
3 years
Leasehold improvements
 
Lesser of estimated useful life or remaining lease term

Business Combinations

The Company includes the results of operations of the businesses that are acquired as of the acquisition date. The Company allocates the purchase price of acquisitions to the assets acquired and liabilities assumed based on the estimated fair values. The excess of the purchase price over the fair values of the identifiable assets and liabilities is recorded as goodwill. Acquisition related costs are recognized separately from the business combination and are expensed as incurred.








117

Goodwill and Intangible Assets, net

Intangible assets related to in-process research and development costs (“IPR&D”) are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. If and when development is complete, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time. Prior to completion of the research and development efforts, the assets are considered indefinite-lived. During this period, the assets will not be amortized but will be tested for impairment on an annual basis and between annual tests if we become aware of any events occurring or changes in circumstances that would indicate a reduction in the fair value of the IPR&D projects below their respective carrying amounts.

Goodwill represents the excess of the purchase price over the fair value of net identifiable assets and liabilities. Goodwill and IPR&D are not amortized but are tested for impairment at least annually during the fourth fiscal quarter, or if circumstances indicate their value may no longer be recoverable. The Company continues to operate in one segment, which is considered to be the sole reporting unit and, therefore, goodwill was tested for impairment at the enterprise level. As of December 31, 2019, there has been no impairment of goodwill.

Intangible assets are carried at cost, net of accumulated amortization. The Company does not have intangible assets with indefinite useful lives other than goodwill and the acquired IPR&D. Amortization is recorded on a straight-line basis over the intangible asset's useful life, which is approximately 6-10 years.

Obligation Related to Royalty

Certain of the Company’s asset acquisitions involve the potential for future payment of consideration that is contingent upon the royalty payments due on future product net sales, subject to annual minimums. The fair value of such liabilities is determined at the acquisition date using unobservable inputs. These inputs include the estimated amount and timing of projected cash flows and the risk-adjusted discount rate used to present value the cash flows.
Impairment for Long-Lived Assets
The Company evaluates long-lived assets, including property and equipment, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the asset may not be fully recoverable. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying amount. Impairment, if any, is measured as the amount by which the carrying amount of a long-lived asset exceeds its fair value.
Leases

The Company determines if an arrangement contains a lease at inception. Operating lease right-of-use (“ROU”) assets and operating leases liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. ROU assets also include any initial direct costs incurred and any lease payments made at or before the lease commencement date, less lease incentives received. The Company uses its incremental borrowing rate based on the information available at the commencement date in determining the lease liabilities, as the Company's leases generally do not provide an implicit rate. Lease terms may include options to extend or terminate when the Company is reasonably certain the option will be exercised. Lease expense is recognized on a straight-line basis over the lease term. The Company also has lease arrangements with lease and non-lease components. The Company elected the practical expedient not to separate non-lease components from lease components for the Company’s facility leases. The Company also elected to apply the short-term lease measurement and recognition exemption in which ROU assets and lease liabilities are not recognized for leases with terms of 12 months or less.

Revenue Recognition under ASC 606
The Company derives revenue from the provision of precision oncology testing services provided to its ordering physicians and biopharmaceutical customers, as well as from biopharmaceutical research and development services provided to its biopharmaceutical customers. Precision oncology services include genomic profiling and the delivery of other genomic information derived from the Company’s platform. Development services include companion diagnostic development, information solutions and laboratory services. The Company currently receives payments from third-party commercial and governmental payers, certain hospitals and oncology centers and individual patients, as well as biopharmaceutical companies and research institutes.


118

Effective January 1, 2019, we adopted the new revenue recognition standard FASB ASC Topic 606, Revenue from Contracts with Customers, or ASC 606. Revenues are recognized when control of services is transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those services. ASC 606 provides for a five-step model that includes identifying the contract with a customer, identifying the performance obligations in the contract, determining the transaction price, allocating the transaction price to the performance obligations, and recognizing revenue when, or as, an entity satisfies a performance obligation.

Precision oncology testing

The Company recognizes revenue from the sale of its precision oncology tests for clinical customers, including certain hospitals, cancer centers, other institutions and patients, at the time results of the test are reported to physicians. Most precision oncology tests requested by clinical customers are sold without a written agreement; however, the Company determines an implied contract exists with its clinical customers. The Company identifies each sale of its liquid biopsy test to clinical customer as a single performance obligation. With the exception of certain limited contracted arrangements with insurance carriers and other institutions where the transaction price is fixed, a stated contract price does not exist and the transaction price for each implied contract with clinical customers represents variable consideration. The Company estimates the variable consideration under the portfolio approach and considers the historical reimbursement data from third-party commercial and governmental payers and patients, as well as known or anticipated reimbursement trends not reflected in the historical data. The Company monitors the estimated amount to be collected in the portfolio at each reporting period based on actual cash collections in order to assess whether a revision to the estimate is required. Both the estimate and any subsequent revision contain uncertainty and require the use of judgment in the estimation of the variable consideration and application of the constraint for such variable consideration. Revenue from sales of precision oncology tests to biopharmaceutical customers are based on a negotiated price per test or on the basis of an agreement to provide certain testing volume over a defined period. The Company identifies its promise to transfer a series of distinct liquid biopsy tests to biopharmaceutical customers as a single performance obligation. Precision oncology tests to biopharmaceutical customers are generally billed at a fixed price for each test performed. For agreements involving testing volume to be satisfied over a defined period, revenue is recognized over time based on the number of tests performed as the performance obligation is satisfied over time. Results of the Company’s precision oncology services are delivered electronically, and as such there are no shipping or handling fees incurred by the Company or billed to customers.

Development services

The Company performs development services for its biopharmaceutical customers utilizing its precision oncology information platform. Development services typically represent a single performance obligation as the Company performs a significant integration service, such as analytical validation and regulatory submissions. The individual promises are not separately identifiable from other promises in the contracts and, therefore, are not distinct. However, under certain contracts, a biopharmaceutical customer may engage the Company for multiple distinct development services which are both capable of being distinct and separately identifiable from other promises in the contracts and, therefore, distinct performance obligations. The Company collaborates with pharmaceutical companies in the development of new drugs. As part of these collaborations, the Company provides services related to regulatory filings with the FDA to support companion diagnostic device submissions for the Company’s liquid biopsy panels. Under these collaborations, the Company generates revenue from achievement of milestones, as well as provision of on-going support. For development services performed, the Company is compensated through a combination of an upfront fee and performance-based, non-refundable regulatory and other developmental milestone payments. The transaction price of the Company's development services contracts typically represents variable consideration. Application of the constraint for variable consideration to milestone payments is an area that requires significant judgment. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be managed to achieve the respective milestone and the level of effort and investment required to achieve the respective milestone. In making this assessment, the Company considers its historical experience with similar milestones, the degree of complexity and uncertainty associated with each milestone, and whether achievement of the milestone is dependent on parties other than the Company. The constraint for variable consideration is applied such that it is probable a significant reversal of revenue will not occur when the uncertainty associated with the contingency is resolved. Application of the constraint for variable consideration is updated at each reporting period as a revision to the estimated transaction price. The Company recognizes development services revenue over the period in which biopharmaceutical research and development services are provided. Specifically, the Company recognizes revenue using an input method to measure progress, utilizing costs incurred to-date relative to total expected costs as its measure of progress. For development of new products or services under these arrangements, costs incurred before technological feasibility is reached are included as research and development expenses in the Company’s consolidated statements of operations, while costs incurred thereafter are recorded as cost of development services.


119

Contracts with multiple performance obligations

Contracts with biopharmaceutical customers may include multiple distinct performance obligations, such as provision of precision oncology testing, biopharmaceutical research and development services, and clinical trial enrollment assistance, among others. The Company evaluates the terms and conditions included within its contracts with biopharmaceutical customers to ensure appropriate revenue recognition, including whether services are considered distinct performance obligations that should be accounted for separately versus together. The Company first identifies material promises, in contrast to immaterial promises or administrative tasks, under the contract, and then evaluates whether these promises are both capable of being distinct and distinct within the context of the contract. In assessing whether a promised service is capable of being distinct, the Company considers whether the customer could benefit from the service either on its own or together with other resources that are readily available to the customer, including factors such as the research, development, and commercialization capabilities of a third party as well as the availability of the associated expertise in the general marketplace. In assessing whether a promised service is distinct within the context of the contract, the Company considers whether it provides a significant integration of the services, whether the services significantly modify or customize one another, or whether the services are highly interdependent or interrelated. For contracts with multiple performance obligations, the transaction price is allocated to the separate performance obligations on a relative standalone selling price basis. The Company determines standalone selling price by considering the historical selling price of these performance obligations in similar transactions as well as other factors, including, but not limited to, the price that customers in the market would be willing to pay, competitive pricing of other vendors, industry publications and current pricing practices, and expected costs of satisfying each performance obligation plus appropriate margin.

Contract assets

Contract assets consists primarily of: i) precision oncology testing revenues to clinical customers that are recognized upon delivery of the test results prior to cash collection; and ii) development services revenues to biopharmaceutical customers that are recognized upon the achievement of performance-based milestones but prior to the establishment of billing rights. Contract assets are relieved when the Company receives payments from clinical customers, or when it invoices the biopharmaceutical customers when milestones are achieved, thereby reclassifying the balances from contract assets to accounts receivable. Contract assets are presented under accounts receivable and other assets on the Company’s consolidated balance sheets. As of December 31, 2019, the Company had contract assets of $6.2 million of which $1.0 million is recorded in other assets in the consolidated balance sheet. The Company had $4.9 million of contract assets as of January 1, 2019.

Deferred revenue

Deferred revenue, which is a contract liability, consists primarily of payments received in advance of revenue recognition from contracts with customers. For example, development services contracts with biopharmaceutical customers often contain upfront payments which results in the recording of deferred revenue to the extent cash is received prior to the Company’s performance of the related services. Contract liabilities are relieved as the Company performs its obligations under the contract and revenue is consequently recognized. As of December 31, 2019 and 2018, the deferred revenue balance was $12.3 million and $16.1 million, respectively, which included $4.8 million and $10.5 million, respectively, related to collaboration development efforts with pharmaceutical companies to be recognized as the Company performs research and development services in the future periods. Revenue recognized in the twelve months ended December 31, 2019 that was included in the deferred revenue balance as of January 1, 2019 was $15.2 million, which primarily represented revenue from provision of development services under the collaboration agreement with our biopharmaceutical companies. 

Transaction price allocated to the remaining performance obligations

Transaction price allocated to remaining performance obligations represents contracted revenue that has not yet been recognized, which includes deferred revenue and non-cancelable amounts that will be invoiced and recognized as revenues in future periods. The Company expects to recognize substantially all of the remaining transaction price in the next 12 months.










120

Revenue Recognition under ASC 605

The Company derives revenue from the provision of precision oncology testing services provided to its ordering physicians and biopharmaceutical customers, as well as from biopharmaceutical research and development services provided to its biopharmaceutical customers. Precision oncology services include genomic profiling and the delivery of other genomic information derived from the Company’s platform. Development services include the development of new platforms and information solutions, including companion diagnostic development and laboratory services. The Company currently receives payments from commercial third-party payers, certain hospitals and oncology centers and individual patients, as well as biopharmaceutical companies and research institutes.

The Company recognizes revenue when all of the following criteria are met: (i) persuasive evidence of an arrangement exists; (ii) delivery has occurred; (iii) the fee is fixed or determinable; and (iv) collectability is reasonably assured. Criterion (i) is satisfied when the Company has an arrangement or contract in place. Criterion (ii) is satisfied when the Company delivers a test report corresponding to each sample, without further commercial obligations. Determination of criteria (iii) and (iv) are based on management’s judgments regarding whether the fee is fixed or determinable, and whether the collectability of the fee is reasonably assured. The Company recognizes revenue from the sale of its precision oncology tests for clinical customers, including certain hospitals, cancer centers, other institutions and patients, at the time results of the test are reported to physicians, if criteria (i) through (iv) above are met. The Company recognizes revenue on a cash basis when it cannot conclude that criteria (iii) and (iv) have been met. Most of precision oncology tests requested by clinical customers are sold without a contracted engagement with a third-party payer; therefore, the Company experiences significant variability in collections and does not have sufficient history to establish a predictable pattern of payment. Because the price is not fixed or determinable and collectability is not reasonably assured, the Company recognizes revenue on a cash basis for sales of its liquid biopsy tests to clinical customers where collection depends on a third-party payer or the individual patient. The Company uses judgment in its assessment of whether the fee is fixed or determinable and whether collectability is reasonably assured in determining when to recognize revenue. Accordingly, the Company expects to recognize revenue on a cash basis for these clinical customers until it has sufficient history to reliably estimate payment patterns. The Company’s precision oncology information services are delivered electronically, and as such there are no shipping or handling fees incurred by the Company or billed to customers.

Revenue from sales of the Company’s tests to biopharmaceutical customers are based on a negotiated price per test or on the basis of an agreement to provide certain testing volume, data access or biopharmaceutical research and development services over a defined period. The Company recognizes revenue upon delivery of the test results, or over the period in which biopharmaceutical research and development services are provided, as appropriate.

Multiple-element arrangements.

The Company performs development services for its biopharmaceutical customers utilizing its precision oncology information platform. Contracts with biopharmaceutical customers are primarily analyzed as multiple-element arrangements given the nature of the service deliverables. For development services performed, the Company is compensated in various ways, including (i) through non-refundable regulatory and other developmental milestone payments; and (ii) through royalty and sales milestone payments. The Company performs development services as part of its normal activities. The Company records these payments as development services revenue in the consolidated statements of operations using a proportional performance model over the period which the unit of accounting is delivered or based on the level of effort expended to date over the total expected effort, whichever is considered the most appropriate measure of performance. For development of new products or services under these arrangements, costs incurred before technological feasibility is assured are included as research and development expenses in the Company’s consolidated statements of operations, while costs incurred thereafter are recorded as cost of development services. The Company collaborates with pharmaceutical companies in the development and clinical trials of new drugs. As part of these collaborations, the Company provides services related to regulatory filings with the FDA to support companion diagnostic device submissions for the Company’s liquid biopsy panels. Under these collaborations the Company generates revenue from achievement of milestones, as well as provision of on-going support. These collaboration arrangements include no royalty obligations.

For revenue arrangements with multiple deliverables, the Company evaluates each deliverable to determine whether it qualifies as a separate unit of accounting. This determination is based on whether the deliverable has stand-alone value to the customer and whether a general right of return exists. In assessing whether an item has standalone value, the Company considers factors such as the research, development and commercialization capabilities of a third party and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the other party in the arrangement can use the other deliverables for their intended purpose without the receipt of the remaining elements, whether the value of the deliverable is dependent on the undelivered items and whether there are other vendors that can provide the

121

undelivered elements. The consideration that is fixed or determinable is then allocated to each separate unit of accounting based on the relative selling price of each deliverable. The Company allocates the arrangement consideration following a hierarchy to determine the relative selling price to be used for allocating revenue to deliverables: (i) vendor-specific objective evidence of fair value (“VSOE”), (ii) third-party evidence of selling price (“TPE”), and (iii) best estimate of the selling price (“BESP”) if neither VSOE nor TPE is available. The Company typically uses BESP to estimate the selling price, since it generally does not have VSOE or TPE of selling price for its units of accounting under multiple-element arrangements. In developing the BESP for a unit of accounting, the Company considers applicable market conditions and estimated costs. The Company validates the BESP for units of accounting by evaluating whether changes in the key assumptions used to determine the BESP will have a significant effect on the allocation of arrangement consideration between multiple units of accounting. The consideration allocated to each unit of accounting is recognized as the related goods or services are delivered, limited to the consideration that is not contingent upon future deliverables. The Company uses judgment in identifying the deliverables in its arrangements, assessing whether each deliverable is a separate unit of accounting and in determining the best estimate of selling price for certain deliverables. The Company also uses judgment in determining the period over which the deliverables are recognized in certain of its arrangements. Any amounts received that do not meet the criteria for revenue recognition are recorded as deferred revenue until such criteria are met. The Company performed laboratory installation and maintenance services for one of its customers as part of a multiple-element arrangement entered into in 2017. The Company recognized certain revenue from its construction service deliverables in a multiple-element collaboration arrangement based on the completed-contract method. This method was used as the Company determined that it did not have the basis for estimating performance under the contract. Other construction service deliverables under that contract were recognized under the percentage-of-completion method due to the Company’s ability to make reasonably dependable estimates of the extent of progress toward contract completion. All construction services under this arrangement were completed in March 2018.

Milestones

The Company recognizes payments that are contingent upon achievement of a substantive milestone in their entirety in the period in which the milestone is achieved. Milestones are defined as events that can only be achieved based on the Company’s performance and there is substantive uncertainty about whether the event will be achieved at the inception of the arrangement. Events that are contingent only on the passage of time or only on counterparty performance are not considered substantive milestones. Further, the amounts received must relate solely to prior performance, be reasonable relative to all of the deliverables and payment terms within the agreement and commensurate with the Company’s performance to achieve the milestone after commencement of the agreement. Any contingent payment that becomes payable upon achievement of events that are not considered substantive milestones are allocated to the units of accounting previously identified at the inception of an arrangement when the contingent payment is received and revenue is recognized based on the revenue recognition criteria for each unit of accounting. Revenue from commercial milestone payments are recorded as revenue upon achievement of the milestone, assuming all other revenue recognition criteria are met.

Costs of Precision Oncology Testing

Cost of precision oncology testing generally consists of cost of materials, direct labor including bonus, benefit and stock-based compensation, equipment and infrastructure expenses associated with processing liquid biopsy test samples (including sample accessioning, library preparation, sequencing, quality control analyses and shipping charges to transport blood samples), freight, curation of test results for physicians and license fees due to third parties. Infrastructure expenses include depreciation of laboratory equipment, rent costs, amortization of leasehold improvements and information technology costs. Costs associated with performing the Company’s tests are recorded as the tests are performed regardless of whether revenue was recognized with respect to that test. Royalties for licensed technology calculated as a percentage of revenues generated using the associated technology are recorded as expense at the time the related revenues are recognized. One-time royalty payments related to signing of license agreements or other milestones, such as issuance of new patents, are amortized to expense over the expected useful life of the applicable patent rights.
Cost of Development Services
Cost of development service includes costs incurred for the performance of development services requested by the Company’s customers. For development of new products, costs incurred before technological feasibility has been achieved are reported as research and development expenses, while costs incurred thereafter are reported as cost of development services.
Research and Development Expenses
Research and development expenses are comprised of costs incurred to develop technology and include salaries and benefits, reagents and supplies used in research and development laboratory work, infrastructure expenses, including allocated facility occupancy and information technology costs, contract services and other outside costs. Research and development expenses

122

also include costs related to activities performed under contracts with biopharmaceutical companies. Research and development costs are expensed as incurred. Payments made prior to the receipt of goods or services to be used in research and development are deferred and recognized as expense in the period in which the related goods are received or services are rendered. Costs to develop the Company’s technology capabilities are recorded as research and development unless they meet the criteria to be capitalized as internal-use software costs.
Advertising
The Company expenses advertising costs as incurred. The Company incurred advertising costs of $1.3 million, $0.2 million and $0.3 million for the years ended December 31, 2019, 2018 and 2017, respectively.
Deferred Offering Costs
Deferred offering costs consist of fees and expenses incurred in connection with the anticipated sale of the Company’s common stock in the IPO, including the legal, accounting, printing and other IPO-related costs. In October 2018, upon completion of the IPO, the Company reclassified deferred offering costs of $4.5 million into additional paid-in capital as a reduction of the net proceeds received from the IPO. There were no deferred offering costs as of December 31, 2019.
Stock‑Based Compensation
Stock‑based compensation related to stock options granted to the Company’s employees, directors and nonemployees is measured at the grant date based on the fair value of the award. The fair value is recognized as expense over the requisite service period, which is generally the vesting period of the respective awards. Compensation expense for stock options with performance metrics is calculated based upon expected achievement of the metrics specified in the grant.

In 2018, the Company accounted for stock options issued to nonemployees consultants based on the estimated fair value at the grant date and re-measured at each reporting period. Starting January 1, 2019, upon adoption of Accounting Standards Update (“ASU”) 2018-07, Compensation - Stock Compensation (Topic 718), Improvements to Nonemployee Share-Based Payment Accounting, the fair value of stock options issued to nonemployee consultants is determined as of the grant date, and compensation expense is being recognized over the period that the related services are rendered.

The Company uses the Black‑Scholes option‑pricing model to estimate the fair value of its stock options and purchase rights under its 2018 Employee Stock Purchase Plan. The Black-Scholes option-pricing model requires assumptions to be made related to expected term of an award, expected volatility, risk-free rate and expected dividend yield. Starting January 1, 2017, forfeitures are accounted for as they occur.

The Company accounts for restricted stock units issued to employees based on the grant date fair value which is determined based on the closing market price of the common stock on the date of grant. The expense is recognized in the Company’s consolidated statement of operations on a straight-line basis over the requisite vesting period.

Income Taxes

Income taxes are recorded using an asset and liability approach. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. Tax benefits are recognized when it is more likely than not that a tax position will be sustained during an audit. Deferred tax assets are reduced by a valuation allowance if current evidence indicates that it is considered more likely than not that these benefits will not be realized.
The Company’s tax positions are subject to income tax audits. The Company recognizes the tax benefit of an uncertain tax position only if it is more likely than not that the position is sustainable upon examination by the taxing authority, based on the technical merits. The tax benefit recognized is measured as the largest amount of benefit which is more likely than not to be realized upon settlement with the taxing authority. The Company recognizes interest accrued and penalties related to unrecognized tax benefits in its tax provision. The Company evaluates uncertain tax positions on a regular basis. The evaluations are based on a number of factors, including changes in facts and circumstances, changes in tax law, correspondence with tax authorities during the course of the audit, and effective settlement of audit issues. The provision for income taxes includes the effects of any accruals that the Company believes are appropriate, as well as the related net interest and penalties.

123

Net Loss Per Share Attributable to Common Stockholders
The Company calculates basic net loss per share attributable to common stockholders by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period. The diluted net loss per share attributable to common stockholders is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, convertible preferred stock, common stock warrants, stock options, restricted stock units, shares issuable pursuant to the employee stock purchase plan, shares subject to repurchase from early exercised options and contingently issuable shares are considered common stock equivalents but have been excluded from the calculation of diluted net loss per share attributable to common stockholders as their effect is anti-dilutive.

Prior to the closing of the Company’s IPO in October 2018 and the conversion of its convertible preferred stock into common stock, the Company calculated its basic and diluted net loss per share attributable to common stockholders of the Company in conformity with the two-class method required for companies with participating securities. The Company considered its convertible preferred stock to be participating securities. In the event a dividend had been declared or paid on the Company’s common stock, holders of convertible preferred stock were entitled to a share of such dividend in proportion to the holders of common stock on an as-if converted basis. Under the two-class method, net loss attributable to common stockholders is determined by allocating undistributed earnings between common and preferred stockholders. The net loss attributable to common stockholders was not allocated to the convertible preferred stock under the two-class method as the convertible preferred stock did not have a contractual obligation to share in the Company’s losses.

Accounting Pronouncements Adopted

Revenues

The Company adopted ASU 2014-09, Revenue from Contracts with Customers (Topic 606) and all related amendments (collectively, “ASC 606”) on January 1, 2019 utilizing the modified retrospective method. The cumulative effect of applying the standard to all contracts that were not completed as of the date of initial application was recognized to beginning accumulated deficit as of January 1, 2019. The Company identified certain differences in accounting for revenue recognition as a result of the adoption of ASC 606 which have impacted its financial position and results of operations. For precision oncology testing revenue with certain clinical customers, the Company historically deferred revenue recognition until cash receipt when the price pursuant to the underlying customer arrangement became fixed and determinable and collectability became reasonably assured. Under the new standard, this is considered variable consideration and revenue is recognized at the estimated transaction price upon delivery. This results in earlier revenue recognition under the new standard as compared to previous revenue recognition. For development services revenue with certain biopharmaceutical customers, the Company historically limited revenue recognition based on the right to invoice the customer. Under the new standard, for these arrangements, the Company constrains revenue such that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. For arrangements with regulatory and other developmental milestone payments, this results in a change to the timing and pattern of revenue recognition under the new standard as compared to previous revenue recognition. Comparative information from prior periods has not been restated and continues to be reported under the accounting standards in effect for those periods. The cumulative effect of changes made to the consolidated balance sheet as of January 1, 2019 related to the adoption of ASC 606 were as follows:
 
As of December 31, 2018
Adjustments due to ASC 606
As of January 1, 2019
 
(in thousands)
Assets:
 
 
 
Accounts receivable
$
35,690

$
4,907

$
40,597

Equity:
 
 
 
Accumulated deficit
$
(280,799
)
$
4,907

$
(275,892
)

In accordance with ASC 606 requirements under the modified retrospective method of adoption, the impact of the adoption of ASC 606 on the Company’s consolidated statement of operations and consolidated balance sheet was as follows:


124

 
For the year ended December 31, 2019
 
As Reported Under ASC 606
Effect of Change
Balances Without Adoption of ASC 606
 
(in thousands)
Revenue:
 
 
 
Precision oncology testing
$
180,462

$
(347
)
$
180,115

Development services
$
33,913

$
—

$
33,913



 
As of December 31, 2019
 
As Reported Under ASC 606
Effect of Change
Balances Without Adoption of ASC 606
 
(in thousands)
Assets:
 
 
 
Accounts receivable
$
47,986

$
(347
)
$
47,639

Equity:
 
 
 
Accumulated deficit
$
(352,809
)
$
(347
)
$
(353,156
)


ASC 606 did not have an aggregate impact on the Company’s net cash used in operating activities but resulted in offsetting changes in certain assets presented within net cash used in operating activities in the Company’s consolidated statement of cash flows, as reflected in the above table. The the Company’s revenue is generated primarily from the sale of precision oncology testing and development services. Precision oncology testing revenue is generated from sales of the Company’s current products to clinical and biopharmaceutical customers. Total precision oncology testing revenues from sales to clinical customers for the years ended December 31, 2019, 2018 and 2017 were $94.2 million, $43.7 million and $24.5 million, respectively. Total precision oncology testing revenues from sales to biopharmaceutical customers for the years ended December 31, 2019, 2018 and 2017 were $79.5 million, $34.7 million, and $17.6 million, respectively. Development services revenue represent services, other than precision oncology testing, that we provide to biopharmaceutical companies and large medical institutions.

Leases

The Company adopted ASC 842, Leases, and its related amendments which requires the recognition of right-of-use (“ROU”) assets and lease liabilities for operating leases on the consolidated balance sheet on January 1, 2019 using a modified retrospective transition approach by applying the new standard to all leases existing at the date of initial application and not restating comparative periods. The Company elected the package of practical expedients permitted under the transition guidance within the new standard, which among other things, allowed us to carry forward the historical lease classification of those leases in place as of January 1, 2019. The Company also elected the practical expedient to not separate lease and non-lease components for its facility leases, and to not recognize ROU assets and operating lease liabilities for short-term leases.

Under ASC 842, the Company determines if an arrangement contains a lease and the classification of that lease, if applicable, at inception or upon modification of a contract. The Company has elected to not recognize a lease liability or ROU asset for short-term leases (leases with a term of twelve months or less and does not include an option to purchase the underlying asset that the Company is reasonably certain to exercise). The Company has elected to not allocate the contract consideration for operating lease contracts with lease and non-lease components, and account for the lease and non-lease components as a single lease component. ROU assets represent the Company's right to use an underlying asset for the lease term. Lease liabilities represent the Company's obligation to make lease payments under the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. In determining the present value of lease payments, the Company uses the incremental borrowing rate based on the information available at lease commencement date. The operating lease ROU asset also includes any lease prepayments, net of lease incentives. Certain of the Company's leases include options to extend or terminate the lease. An option to extend the lease

125

is considered in connection with determining the ROU asset and lease liability when it is reasonably certain we will exercise that option. An option to terminate is considered unless it is reasonably certain that the Company will not exercise the option.

The primary impact of adopting Topic 842 was the recognition of ROU assets and lease liabilities for operating leases of $14.5 million and $22.4 million respectively, on January 1, 2019, which included reclassifying prepaid rent and deferred rent as a component of the ROU asset. Topic 842 did not have a material impact on the Company's consolidated statements of operations and cash flows.

The short-term liabilities from the Company's operating leases are included in accrued expenses in the consolidated balance sheet. The Company's accounting for finance leases (formerly referred to as capital leases prior to the adoption of Topic 842) remains substantially unchanged. Finance leases are not material to the consolidated financial statements.

Lease expense for lease payments for the operating leases is recognized on a straight-line basis over the term of the lease.

Stock Compensation

In June 2018, the FASB issued ASU 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, which expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees, with certain exceptions. The Company early adopted this new guidance effective January 1, 2019. In accordance with the transition guidance, the Company assessed its outstanding nonemployee awards for which a measurement date had not been established. These outstanding awards were re-measured to fair value as of the January 1, 2019 adoption date. For nonemployee awards that contain performance condition, the measurement is based on the outcome that is probable as opposed to the lowest aggregate fair value within a range of possible outcomes. The adoption of ASU 2018-07 provided administrative relief by fixing the measurement date of nonemployee awards and eliminating the requirement of quarterly re-measurement. The Company adopted this standard on a modified retrospective basis and recorded a cumulative-effect adjustment of $1.3 million as an increase to accumulated deficit and an equal increase to additional paid-in capital as of January 1, 2019.

Income Taxes
On December 22, 2017, the U.S. federal government enacted the Tax Cuts and Jobs Act (the “Tax Act”), which contains, among other things, significant changes to corporate taxation, including reduction of the corporate tax rate from a top marginal rate of 35% to a flat rate of 21% for tax years beginning after December 31, 2017, limitation of the deduction for net operating losses to 80% of current year taxable income and elimination of net operating loss carrybacks, implementing a territorial tax system, and requiring a mandatory one-time tax on U.S. owned undistributed foreign earnings and profits known as the transition tax. In December 2017, SEC staff issued Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act (“SAB 118”) to address the accounting implications of the enacted U.S. federal tax reform. SAB 118 allows companies to record provisional amounts during a measurement period not to extend beyond one year of the enactment date to address ongoing guidance and tax interpretations that are expected over the next 12 months. The Company has adopted SAB 118 and no measurement period adjustments were recognized due to the full valuation allowance on the Company’s deferred tax assets.
Accounting Pronouncements Not Yet Adopted
Financial Instruments
In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments, which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables and available for sale debt securities. The guidance is effective for the Company beginning January 1, 2020 with early adoption permitted. The Company is currently evaluating the impact of the new guidance on its consolidated financial statements.
Goodwill
In January 2017, the FASB issued ASU 2017-04, Intangibles—Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment which eliminates Step 2 from the goodwill impairment test and instead requires entities to perform its annual or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. The guidance is effective for the Company beginning January 1, 2020 with early adoption permitted. The Company is currently evaluating the impact of the new guidance on its consolidated financial statements.
Fair Value Measurements

126

In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement, which eliminates, adds and modifies certain disclosure requirements for fair value measurements in ASC 820, Fair Value Measurement, as part of its disclosure framework project. The guidance is effective for the Company beginning January 1, 2020 with early adoption permitted. The amendments in ASU 2018-13 on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments in ASU 2018-13 should be applied retrospectively to all periods presented upon their effective date. Early adoption is permitted upon issuance of ASU 2018-13. The Company is currently evaluating the impact of the new guidance on its consolidated financial statements.

Cloud Computing

In August 2018, the FASB issued ASU 2018-15—Intangibles-Goodwill and Other-Internal—Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract, which requires a customer in a cloud computing arrangement that is a service contract to follow the internal-use software guidance in ASC Topic 350, Intangibles—Goodwill and Other, to determine which implementation costs to capitalize as assets or expense as incurred. The guidance is effective for the Company beginning January 1, 2020 with early adoption permitted. The Company is currently evaluating the impact of the new guidance on its consolidated financial statements.

Collaborative Arrangements
In November 2018, the FASB amended ASC 808 and ASC 606 to clarify that certain transactions between participants in a collaborative arrangement should be accounted for under ASC 606 when the counterparty is a customer. The guidance is effective for us beginning January 1, 2020 and early adoption is permitted. The Company is currently evaluating the impact of the new guidance on its consolidated financial statements.
Income Taxes
In December 2019, the FASB issued ASU 2019-12, Income Taxes - Topic 740, which simplifies the accounting for income taxes.  Amendments include removal of certain exceptions to the general principles of ASC 740, Income Taxes, related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period, and the recognition of deferred tax liabilities for outside basis differences. ASU 2019-12 also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill.  The guidance is effective for the Company beginning January 1, 2021, and early adoption is permitted.  The Company is currently evaluating the impact of the new guidance on its consolidated financial statements.

3. Investment in Joint Venture
Variable Interest Entity (“VIE”)
In connection with SoftBank’s purchase of its Series E convertible preferred stock, the Company entered into a joint venture agreement with an entity affiliated with SoftBank, a related party. In May 2018, the Company and SoftBank formed and capitalized Guardant Health AMEA, Inc. (the “Joint Venture”) for the sale, marketing and distribution of the Company’s tests in all areas worldwide, outside of North America, Central America, South America, the United Kingdom, all other member states of the European Union as of May 2017, Iceland, Norway, Switzerland and Turkey. The Company expects to rely on the Joint Venture to accelerate commercialization of its products in Asia, the Middle East and Africa, with an initial focus on Japan.
Under the terms of the joint venture agreement, the Company paid $9.0 million for 40,000 shares of common stock, or 50% ownership interest, of the Joint Venture, and the affiliate of SoftBank contributed $41.0 million for 40,000 shares of common stock, or the other 50% ownership interest, of the Joint Venture. Neither party has the obligation to provide additional financial support to the Joint Venture. Each party holds two seats on the board of the Joint Venture and has to cast through its representatives on the board at least one vote for any board resolution of the Joint Venture to pass. The representatives of the Company on the Joint Venture’s board of directors have the right to appoint and remove a chief executive officer and a legal representative for the Joint Venture, in each case, subject to the approval of the full Joint Venture board of directors. The Joint Venture’s board of directors has the right to appoint and remove all other members of the Joint Venture’s senior management reporting to its chief executive officer and to approve the compensation of all foregoing individuals, including the compensation of the chief executive officer and legal representative.
At the inception of the arrangement and at the end of each reporting period, the Company assesses whether the Joint Venture is a variable interest entity (“VIE”), and if so, who is the primary beneficiary of the VIE. As of December 31, 2019, the Company and SoftBank had equal ownership interests and equal voting rights in the Joint Venture, and the Joint Venture’s board consisted of an equal number of directors representing the interest of the Company and SoftBank, respectively. As of December 31, 2019, the Joint Venture’s board had the right to vote on all critical matters that most significantly impact the Joint Venture’s economic performance, except that the Company had the unilateral right to make pricing decisions. As of December 31, 2019, the Company had responsibility for the Joint Venture’s daily operations, while SoftBank served as a financing partner. The Company also entered into various ancillary agreements with the Joint Venture necessary to operate its business. The Joint Venture is deemed to be a VIE, and considering the power and benefits criterion, the Company and SoftBank, collectively as a related party group, has the characteristics of the primary beneficiary of the Joint Venture, as the related party group has the power to direct the activities of the

127

VIE that most significantly impact the VIE’s economic performance and has the obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE. Because the Company is most closely associated with the Joint Venture within the related party group, it has been identified as the VIE’s primary beneficiary. As the primary beneficiary, the Company has consolidated the financial position, results of operations and cash flows of the Joint Venture in its financial statements and all intercompany balances have been eliminated in consolidation. The Company concluded the Joint Venture did not meet the definition of a business upon consolidation as it lacked the processes required to generate outputs. Upon consolidation no liabilities were assumed and other than cash, and any identifiable assets were related to intellectual property rights that the Company transferred to the Joint Venture shortly before it became its primary beneficiary and therefore such transfer was treated as a common control transaction. Upon initial consolidation, the non-controlling interest of the affiliate of SoftBank was recorded at its estimated fair value of $41.0 million, which is equal to the original investment made by the affiliate of SoftBank.
As of December 31, 2019, the Joint Venture had total assets of approximately $45.1 million, which was primarily comprised of cash and security deposits. Although the Company consolidates the Joint Venture, the legal structure of the Joint Venture limits the recourse that its creditors will have over the Company’s general credit or assets.  Similarly, the assets held in the Joint Venture can be used only to settle obligations of the Joint Venture. As of December 31, 2019, the Company has not provided financial or other support to the Joint Venture that was not previously contracted or required.
Put-call arrangements
The joint venture agreement includes a put-call arrangement with respect to the shares of the Joint Venture held by SoftBank and its affiliates. Under certain specified circumstances and on terms specified in the joint venture agreement, including timely written notice, SoftBank has the right to cause the Company to purchase all shares of the Joint Venture held by SoftBank and its affiliates (the “put right”), and the Company has a right to purchase all such shares (the “call right”).
If the Company’s business model were to change such that the sale, marketing and distribution of its tests in the territory covered by the joint venture agreement was no longer economical, SoftBank would have the right to cause the Company to purchase, or the Company would have the right to purchase, all of the shares of the Joint Venture held by SoftBank and its affiliates. In this instance, the Company would be required to repurchase the shares at an aggregate purchase price of $41.0 million, the original purchase price paid by SoftBank to the Joint Venture for the shares.
Additionally, each of the Company and SoftBank may exercise its respective put-call rights for the Company to purchase all shares of the Joint Venture held by SoftBank in the event of (i) certain material disagreements relating to the Joint Venture or its business that may seriously affect the ability of the Joint Venture to perform its obligations under the joint venture agreement or may otherwise seriously impair the ability of the Joint Venture to conduct its business in an effective matter, other than one relating to the Joint Venture’s business plan or to factual matters that may be capable of expert determination; (ii) the effectiveness of the Company’s initial public offering, a change in control of the Company, the seventh anniversary of the formation of the Joint Venture, or each subsequent anniversary of each of the foregoing events; or (iii) a material breach of the joint venture agreement by the other party that goes unremedied within 20 business days. Unless the shares of the Joint Venture are publicly traded and listed on a nationally recognized stock exchange, the purchase price per share of the Joint Venture in these situations will be determined by a third-party valuation firm on the assumption that the sale is on an arm’s-length basis on the date of the put or call notice. The third-party valuation firm may evaluate a range of factors and employ assumptions that are subjective in nature, which could result in the fair value of SoftBank’s interests in the Joint Venture being determined to be materially different from what has been recorded in the Company’s consolidated financial statements including those included elsewhere in this Annual Report on Form 10-K. As a result of the IPO, the put-call rights for the Company to purchase all shares of the Joint Venture held by SoftBank are exercisable on each subsequent anniversary of the IPO by the Company or SoftBank.
In the event the Company exercises its call right, the fair value of the Joint Venture will be deemed to be no less than an amount that yields a 20% internal rate of return on each tranche of capital invested by SoftBank and its affiliates in the Joint Venture, taking into account all proceeds received by SoftBank and its affiliates arising from their shares through such date.
In the event SoftBank exercises its put right and the fair value of the Joint Venture is determined to be greater than 40% of the fair value of the Company, the Company will only be required to purchase the number of shares of the Joint Venture held by SoftBank and its affiliates having an aggregate value equal to the product of 40% of the Company’s fair value and the pro rata portion of the outstanding shares of the Joint Venture held by SoftBank and its affiliates.
The Company may pay the purchase price for the shares of the Joint Venture in cash, in shares of its capital stock (which may be a non-voting security with senior preferences to all other classes of its equity or, if its common stock is publicly

128

traded on a national exchange, its common stock), or in a combination thereof. In the event the Company exercises the call right, SoftBank will choose the form of consideration. In the event SoftBank exercises the put right, the Company will choose the form of consideration.
The noncontrolling interest held by SoftBank contains embedded put-call redemption features that are not solely within the Company’s control and has been classified outside of permanent equity in the consolidated balance sheets. The put-call feature embedded in the redeemable noncontrolling interest do not currently require bifurcation as it does not meet the definition of a derivative and is considered to be clearly and closely related to the redeemable noncontrolling interest. The noncontrolling interest is considered probable of becoming redeemable as SoftBank has the option to exercise its put right to sell its equity ownership in the Joint Venture to the Company on or after the seventh anniversary of the formation of the Joint Venture, on each subsequent anniversary of the IPO and under certain other circumstances. The Company elected to recognize the change in redemption value immediately as they occur as if the put-call redemption feature were exercisable at the end of the reporting period. The carrying value of the redeemable noncontrolling interest is first adjusted for the earnings or losses attributable to the redeemable noncontrolling interest based on the percentage of the economic or ownership interest retained in the consolidated VIE by the noncontrolling parties, and then adjusted to equal to its redemption amount, or the fair value of the noncontrolling interest held by SoftBank, as if the redemption were to occur at the end of the reporting date.
As of December 31, 2019, the fair value of the redeemable noncontrolling interest held by SoftBank was determined using the combination of the income approach and the market approach. Determining the fair value of the redeemable noncontrolling interest requires judgment and the use of significant estimates and assumptions. Such estimates and assumptions include future revenue growth rates, gross profit margins, EBITDA margins, future capital expenditures, weighted average costs of capital and future market conditions, among others. The fair value measurement of the redeemable noncontrolling interest is classified within Level 3 of the fair value hierarchy. The change in the value of the redeemable noncontrolling interest consists of net loss of $3.9 million and increase in fair value adjustment of $11.7 million for the year ended December 31, 2019.
4. Consolidated Balance Sheet Components
Property and Equipment, Net
Property and equipment, net consist of the following:
 
As of December 31,
 
2019
 
2018
 
 
 
 
 
(in thousands)
Machinery and equipment
$
29,119

 
$
23,440

Computer hardware
6,296

 
4,949

Leasehold improvements
21,031

 
13,965

Furniture and fixtures
1,962

 
1,522

Computer software
829

 
643

Construction in progress
6,354

 
3,118

Property and equipment, gross
65,591

 
47,637

Less: accumulated depreciation and amortization
(21,923
)
 
(16,634
)
Property and equipment, net
$
43,668

 
$
31,003


Depreciation and amortization expense related to property and equipment was $9.3 million, $6.1 million and $4.2 million for the years ended December 31, 2019, 2018 and 2017, respectively.

129

Accrued Expenses
Accrued expenses consist of the following:
 
As of December 31,
 
2019
 
2018
 
 
 
 
 
(in thousands)
Accrued royalty obligations
$
1,564

 
$
707

Accrued legal expenses
1,046

 
814

Accrued tax liabilities
3,050

 
1,470

Accrued professional services
3,464

 
1,791

Accrued clinical trials and studies
2,029

 
236

Purchases of property and equipment included in accrued expenses
2,424

 
343

Operating lease liabilities
7,140

 
—

Other
4,986

 
1,817

Total accrued expenses
$
25,703

 
$
7,178



5. Fair Value Measurements, Cash Equivalents and Marketable Securities
Financial instruments consist of cash equivalents, marketable securities, prepaid expenses and other current assets, accounts payable and accrued expenses. Cash equivalents and marketable securities are stated at fair value. Prepaid expenses and other current assets, accounts payable and accrued expenses are stated at their carrying value, which approximates fair value due to the short time to the expected receipt or payment date.
Fair value is defined as the exchange price that would be received from sale of an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The identification of market participant assumptions provides a basis for determining what inputs are to be used for pricing each asset or liability. A financial instrument’s classification within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement.
A fair value hierarchy has been established which gives precedence to fair value measurements calculated using observable inputs over those using unobservable inputs. This hierarchy prioritized the inputs into three broad levels as follows:
Level 1 - Quoted prices in active markets for identical assets or liabilities.
Level 2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

130

The Company’s financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used in such measurements were as follows:
 
December 31, 2019
 
Fair Value
 
Level 1
 
Level 2
 
Level 3
 
 
 
 
 
 
 
 
 
(in thousands)
Financial Assets:
 
 
 
 
 
 
 
Money market funds
$
10,734

 
$
10,734

 
$
—

 
$
—

Total cash equivalents
$
10,734

 
$
10,734

 
$
—

 
$
—

 
 
 
 
 
 
 
 
Corporate bonds
$
16,690

 
—

 
$
16,690

 
—

U.S. government debt securities
362,884

 
—

 
362,884

 
—

Total short-term marketable securities
$
379,574

 
$
—

 
$
379,574

 
$
—

 
 
 
 
 
 
 
 
U.S. government debt securities
$
268,783

 
—

 
$
268,783

 
—

Total long-term marketable securities
268,783

 
—

 
268,783

 
—

Total
$
659,091

 
$
10,734

 
$
648,357

 
$
—

 
 
 
 
 
 
 
 
Financial Liabilities:
 
 
 
 
 
 
 
Contingent consideration
$
1,365

 
—

 
—

 
$
1,365

 
$
1,365

 
$
—

 
$
—

 
$
1,365

 
December 31, 2018
 
Fair Value
 
Level 1
 
Level 2
 
Level 3
 
 
 
 
 
 
 
 
 
(in thousands)
Financial Assets:
 
 
 
 
 
 
 
Money market funds
$
25,796

 
$
25,796

 
$
—

 
$
—

Total cash equivalents
$
25,796

 
$
25,796

 
$
—

 
$
—

 
 
 
 
 
 
 
 
Corporate bonds
$
38,397

 
$
—

 
$
38,397

 
$
—

U.S. government debt securities
235,016

 
—

 
235,016

 
—

U.S. government agency bonds
5,004

 
 
 
5,004

 
 
Total short-term marketable securities
$
278,417

 
$
—

 
$
278,417

 
$
—

 
 
 
 
 
 
 
 
Corporate bonds
$
3,805

 
$
—

 
$
3,805

 
$
—

U.S. government debt securities
73,758

 
—

 
73,758

 
—

Total long-term marketable securities
$
77,563

 
$
—

 
$
77,563

 
$
—

Total
$
381,776

 
$
25,796

 
$
355,980

 
$
—


The Company measures the fair value of money market funds based on quoted prices in active markets for identical securities. Corporate bonds, U.S. government debt securities and U.S. government agency bonds are valued taking into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads; benchmark securities; prepayment/default projections based on historical data; and other observable inputs.
The Company's contingent consideration was valued using the discounted cash flow method. Significant unobservable inputs used in the fair value measurement of the Company’s contingent consideration liability include the estimated amount and timing of projected cash flows, and the risk-adjusted discount rate used to present value the cash flows. The change in discount rate has an inverse relationship to the overall valuation of the contingent consideration.

131

The use of different inputs in the valuation of the contingent consideration liability could result in materially different fair value estimates.
There were no transfers between Level 1, Level 2 and Level 3 during the periods presented.
Cash Equivalents and Marketable Securities
The following tables summarizes the Company’s cash equivalents and marketable securities’ amortized costs, gross unrealized gains, gross unrealized losses and estimated fair values by significant investment category:
 
December 31, 2019
 
Amortized Cost
 
Gross Unrealized Gain
 
Gross Unrealized Loss
 
Estimated Fair Value
 
 
 
 
 
 
 
 
 
(in thousands)
Money market fund
$
10,734

 
$
—

 
$
—

 
$
10,734

Corporate bond
16,679

 
11

 
—

 
16,690

U.S. government debt securities
630,283

 
1,422

 
(39
)
 
631,666

Total
$
657,696

 
$
1,433

 
$
(39
)
 
$
659,090

 
December 31, 2018
 
Amortized Cost
 
Gross Unrealized Gain
 
Gross Unrealized Loss
 
Estimated Fair Value
 
 
 
 
 
 
 
 
 
(in thousands)
Money market fund
$
25,796

 
$
—

 
$
—

 
$
25,796

Corporate bond
42,273

 
—

 
(71
)
 
42,202

U.S. government debt securities
308,775

 
235

 
(236
)
 
308,774

U.S. government agency bonds................
5,014

 
—

 
(10
)
 
5,004

Total
$
381,858

 
$
235

 
$
(317
)
 
$
381,776


There have been no material realized gains or losses on marketable securities for the periods presented. None of the Company’s investments in marketable securities has been in an unrealized loss position for more than one year. The Company determined that it did have the ability and intent to hold all marketable securities that have been in a continuous loss position until maturity or recovery, thus there has been no recognition of any other-than-temporary impairment in the year ended December 31, 2019 and 2018. The maturities of the Company’s long-term marketable securities range from 1.04 to 1.75 years from December 31, 2019.
6. Acquisition of Bellwether Bio
In April 2019, the Company purchased of all of the outstanding shares of Bellwether Bio, Inc. (“Bellwether Bio”), a privately-held company developing a method for early blood-based cancer detection. The Company accounted for the acquisition as a business combination. The total purchase consideration was $8.7 million, which consisted of i)     $7.6 million in cash paid upon closing; and ii) future contingent consideration liability with a fair value of $1.1 million on the acquisition date. The contingent consideration is subject to the achievement of certain commercialization milestones with a maximum payout amount of $10.0 million. The Company will also pay additional earn-out consideration of up to $10.0 million subject to the achievement of certain commercialization milestones and the continued provision of services to the Company by certain former employees and consultants of Bellwether Bio. The contingent consideration and earn-out consideration may be paid, at the Company’s election, in cash or in the Company’s common stock. As of December 31, 2019, the Company did not believe the earn-out consideration is probable to be achieved, and therefore, did not record any compensation expense.
The excess purchase consideration over the fair value of assets acquired and liabilities assumed was recorded as goodwill. Goodwill is attributable to future revenue opportunities that we expect to achieve from leveraging Bellwether Bio’s existing license and IPR&D, as well as the assembled workforce. The valuation of the intangible assets acquired was determined using currently available information and reasonable assumptions. The following table summarizes the allocation of the total consideration to the estimated fair values of assets acquired and liabilities assumed:

132

 
 
Amount
 
 
(in thousands)
Cash
 
$
521

Identified intangible assets
 
6,700

Goodwill
 
3,289

Net liabilities assumed
 
(1,802
)
Total
 
$
8,708


The following table presents details of the identified intangible assets acquired from the Bellwether Bio acquisition:
 
 
Fair Value
 
Estimated Useful Life
 
 
(in thousands)
 
 
Acquired license
 
$
5,100

 
10 years
IPR&D
 
1,600

 
*
Total
 
$
6,700

 
 
*
IPR&D assets are not subject to amortization.
In connection with the acquisition of Bellwether Bio, the Company also entered into non-compete agreements with certain key individuals based on their experience and importance to the operation of Bellwether Bio. The Company accounted for the covenants not to compete as purchases of intangible assets separate from the business combination as these non-compete agreements were initiated by the Company to protect its interests. The fair value of acquired covenants not to compete was estimated to be $2.5 million, which is recorded within intangible assets on the consolidated balance sheet and will be amortized over an estimated useful life of 6 years using the straight-line method.
The following table presents other intangible assets - net:
 
 
 
 
As of December 31, 2019
 
 
 
 
(in thousands)
 
 
Weighted Average Useful Life
 
Gross
 
Accumulated Depreciation
 
Net
Acquired license
 
9.5
 
$
5,100

 
$
373

 
$
4,727

Non-compete agreements
 
5.5
 
2,500

 
303

 
2,197

 
 
 
 
$
7,600

 
676

 
$
6,924

 
 
 
 
 
 
 
 
 
IPR&D
 
 
 
$
1,600

 
—

 
$
1,600

Goodwill
 
 
 
3,290

 
—

 
3,290

Total intangible assets
 
 
 
$
12,490

 
$
676

 
$
11,814


There were no intangible assets as of December 31, 2018.
The following table summarizes estimated future amortization expense of finite-lived intangible assets—net:
Years
Amount
 
(in thousands)
2020
$
928

2021
928

2022
928

2023
928

2024 and thereafter
3,212

Total
$
6,924


Acquisition-related contingent consideration is measured at fair value on a quarterly basis based on additional information as it becomes available and change in estimated contingent consideration to be paid will be included in

133

operating expenses in the consolidated statements of operations. The fair value of acquisition-related contingent consideration is estimated using a multiple-outcome discounted cash flow valuation technique. Contingent consideration is classified within Level 3 of the fair value hierarchy, as it is based on a probability that includes significant unobservable inputs. The significant unobservable inputs include a probability-weighted estimate of achievement of certain commercialization milestones, continued services from certain former employees and consultants, resulting contingent payments, and discount rate to present value the expected payments. A significant change in any of these input factors in isolation could have a material impact to fair value measurement.
Since initial valuation on the date of acquisition, contingent consideration liability increased by $0.3 million due to change in estimate relating to inputs used to determine the fair value of contingent consideration. As of December 31, 2019, contingent consideration liability of $1.4 million was recorded within other long-term liabilities on the consolidated balance sheet.
For the period ended December 31, 2019, the Company incurred acquisition-related transaction costs of $0.4 million which are included in general and administrative expenses in the consolidated statements of operations.
7. Patent License Agreement
In January 2017, the Company entered into a license agreement with a biotechnology company for an exclusive, non-transferable right to use proprietary technology related to high-throughput screening and identification of mutations in targeted gene sequences. The payment terms of the license agreement included (i) a one-time upfront payment of €1.0 million; (ii) issuance of 141,774 shares of the Company’s Series D convertible preferred stock; (iii) a milestone payment of €1.0 million associated with the achievement of a specified milestone event; and (iv) future royalty payments at the minimum of €13.4 million in the aggregate based on annual net sales in which the licensed technology are used. The Company made a one-time upfront payment of $1.1 million in January 2017 and a milestone payment of $1.2 million in August 2017 upon achievement of the specified milestone event. The Series D convertible preferred stock issued under the license agreement had a fair value of $1.1 million on the date of issuance. The transaction was treated as an acquisition of an asset and the Company capitalized the upfront payment, milestone payments and fair value of Series D convertible preferred stock in addition to license fees of $6.3 million related to the future minimum royalty payments discounted to the present value. The Company recorded the obligation at the estimated present value of the future payments using a discount rate of 15%, the Company’s estimate of its effective borrowing rate for similar obligations.
As of December 31, 2019 and 2018, unamortized capitalized license fees plus one-time upfront and milestone payments totaled $6.9 million and $7.8 million, respectively, which will be amortized over the remaining useful life of 7.0 and 8.0 years, respectively. Amortization of capitalized license fees plus one-time upfront and milestone payments totaled $1.0 million and $0.9 million for the years ended December 31, 2019 and 2018, respectively.
8. Senior Term Loan and Royalty Purchase Agreement
In 2015, the Company entered into a credit agreement with a financial institution for a senior term loan (the “Credit Agreement”). The Credit Agreement provided for up to $40.0 million in borrowing capacity. The Company borrowed $20.0 million on the effective date of the Credit Agreement. The Credit Agreement provided for an interest rate equal to the greater of (i) three-month LIBOR or (ii) 1% per annum plus 8.75% on the outstanding balance of the term loan not exceeding $20.0 million.
Concurrent with the Credit Agreement, the Company also entered into a Royalty Purchase Agreement (the “Royalty Agreement”) with the same financial institution, which obligated the Company to make quarterly royalty payments of (i) 1.5% applied to total Company fiscal year revenues of up to $50 million and (ii) 2.45% applied to fiscal year revenues in excess of $50 million. The Royalty Agreement included a buyout option, by which the Company had the right, exercisable in its sole discretion, to buy out the obligation to make future royalty payments. The price of this buyout option was calculated based on a table with axes of principal balance outstanding and time, less the cumulative sum of royalty payments at the time the buy-out option is exercised.
In June 2017, the Company exercised its prepayment right under the Credit Agreement and repaid the outstanding principal balance of $19.8 million and accrued interest of $0.7 million. The prepayment option also required the Company to pay a prepayment penalty of $1.5 million. Concurrent with the prepayment of the senior term loan, the Company also excised its royalty buyout option for $4.5 million. The transaction was accounted for as a debt extinguishment. The net carrying amount of the debt and royalty liabilities immediately before the extinguishment was $20.7 million. As a result, the difference between the reacquisition price and the net carrying amount of $5.1 million was recorded as loss on debt extinguishment in the accompanying consolidated statements of operations. As of December 31, 2019 and 2018, the Company had no outstanding balance under the senior term loan and its related royalty obligations.

134

9. Leases
The Company has entered into various operating lease agreements for office space, with remaining terms ranging from 1 year to 8 years some of which include one or more options to renew. As leases approach maturity, the Company considers various factors such as market conditions and the terms of any renewal options that may exist to determine whether we will renew the lease, as such, we do not include renewal options in our lease terms for calculating our lease liability, as the renewal options allow us to maintain operational flexibility and we are not reasonably certain we will exercise these renewal options at the time of the lease commencement.
Operating lease expense for the year ended December 31, 2019 was $4.4 million which includes both lease and non-lease components (primarily common area maintenance charges and property taxes).
Rent expense for the facility leases was $4.6 million and $1.8 million for the years ended December 31, 2018 and 2017, respectively.
As of December 31, 2019, the weighted-average remaining lease term and weighted-average discount rate for operating leases is 6.4 years and 7.77% respectively.
The following table summarizes our future principal contractual obligations for operating lease commitments as of
December 31, 2019:
Year Ending December 31,
 
 
(in thousands)
2020
$
7,582

2021
7,534

2022
7,684

2023
8,276

2024 and thereafter
20,816

Total operating lease payments
$
51,892

Less: Imputed Interest
(11,496
)
Total operating lease liabilities
$
40,396


As of December 31, 2019, the Company has additional future minimum lease payments relating to a facility agreement had not yet commenced amounting to $13.7 million (imputed interest of $3.4 million) net of sublease income of $0.1 million.
Finance leases are not material to the Company's consolidated financial statements.
ASC 840 Disclosures
The Company elected modified retrospective transition approach and is required to present previously disclosed information under the prior accounting standards for leases. Total minimum lease payments as of December 31, 2018 are as follows:
Year Ending December 31,
 
 
(in thousands)
2019
$
4,099

2020
5,273

2021
5,358

2022
5,557

2023
6,105

2024 and thereafter
15,786

Total
$
42,178




135

10. Commitments and Contingencies
License Agreements
The Company has patent license agreements with four different parties. Under these agreements, the Company has made one-time upfront and milestone payments, which it has capitalized and is amortizing to expense ratably over the useful life of the underlying patent right(s). Under some of these agreements, the Company is obligated to pay low single-digit percentage running royalties on net sales where the licensed patent right(s) are used in the product or service sold, subject to minimum annual royalties or fees in certain agreements.
Royalty expenses were included in cost of precision oncology testing on the accompanying consolidated statements of operations. The Company recognized royalty expenses of $4.4 million, $1.4 million and $1.1 million, or 2%, 2% and 2% of precision oncology testing revenue in each period, for the years ended December 31, 2019, 2018 and 2017, respectively. As of December 31, 2019, future minimum royalty payments are due as follows regardless of sales amounts:
Year Ending December 31,
 
 
(in thousands)
2020
$
1,402

2021
1,402

2022
1,682

2023
1,682

2024 and thereafter
5,607

Total future minimum royalty payments
11,775

Less: amount representing interest
(4,895
)
Present value of future minimum royalty payments
$
6,880


Indemnification Agreements
The Company has entered into indemnification agreements with certain directors and officers that require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. To date, no such matters have arisen and the Company does not believe that the outcome of any claims under indemnification arrangements will have a material adverse effect on its financial positions, results of operations or cash flows. Accordingly, the Company has not recorded a liability related to such indemnifications as of December 31, 2019.
Security Incidents
In connection with a former employee’s complaints alleging non-compliance with applicable provisions of the Health Insurance Portability and Accountability Act of 1996, the Company received requests for information from the Office for Civil Rights, or OCR, of the U.S. Department of Health and Human Services in August 2019. After the Company responded to these requests, the Company was informed by the OCR that it has closed this matter without further action.
Legal Proceedings
The Company is subject to claims and assessments from time to time in the ordinary course of business. The Company will accrue a liability for such matters when it is probable that a liability has been incurred and the amount can be reasonably estimated. When only a range of possible loss can be established, the most probable amount in the range is accrued. If no amount within this range is a better estimate than any other amount within the range, the minimum amount in the range is accrued. The accrual for a litigation loss contingency might include, for example, estimates of potential damages, outside legal fees and other directly related costs expected to be incurred.
Patent Disputes
In May 2016, Foundation Medicine, Inc. (“Foundation Medicine”) filed a lawsuit for patent infringement against the Company in the United States District Court for the Eastern District of Texas, alleging that the Company infringed Foundation Medicine’s patent relating to its tissue biopsy assay technology and seeking compensatory damages and attorneys’ fees. The Company filed three petitions for inter partes review (“IPR”) with the Patent Trial and Appeal Board (“PTAB”) at the U.S. Patent and Trademark Office, challenging the patentability of Foundation Medicine’s patent. In July 2018, the Company reached an agreement with Foundation Medicine to settle the lawsuit and resolve the IPRs. As part of the settlement agreement, which was accepted by the PTAB and the United States District Court,

136

the Company made a one-time payment of $3.0 million to Foundation Medicine. The Company recorded $3.0 million as litigation settlement expense, a component of general and administrative expenses, at December 31, 2017.
In November 2017, the Company filed separate lawsuits against Foundation Medicine and Personal Genome Diagnostics, Inc. (“Personal Genome Diagnostics”) in the United States District Court for the District of Delaware, alleging that each of the two companies has infringed a patent relating to the Company’s digital sequencing technology. The Company subsequently amended its original complaints in each case to assert infringement of three additional patents relating to its digital sequencing technology. In each lawsuit, the Company is seeking compensatory damages, injunctive relief and attorneys’ fees. Personal Genome Diagnostics and Foundation Medicine have each asserted counterclaims of patent invalidity and non-infringement. In March 2018, Personal Genome Diagnostics filed two petitions for post-grant review with the PTAB, challenging the patentability of two of the patents asserted by the Company. Prior to reaching a decision on the merits, the two post-grant review petitions were dismissed with prejudice in July 2018. Subsequently, Foundation Medicine filed six petitions for inter partes review with the PTAB, challenging the patentability of all four of the patents asserted by the Company, which actions are currently pending at the PTAB. The Company plans to vigorously defend its patent rights during such PTAB actions. At this time, the Company cannot reasonably ascertain the likelihood that any of the challenged patents will be found to be invalid or unenforceable.
License Dispute
In November 2018, the Company filed a request for arbitration to the International Chamber of Commerce claiming that one of its licensors, KeyGene N.V. (“Licensor”), has breached its patent license agreement with the Company. In January 2019, Licensor responded with its answer and counterclaims and alleged that the Company has breached the patent license agreement. The Company subsequently followed up with supplemental claims, for which Licensor responded with its supplemental answer. The Company is seeking damages, declaratory relief and alternative forms of relief including recession and reformation to address Licensor’s alleged breaches of the patent license agreement. Licensor is seeking damages, recovery of costs and fees and declaratory relief in addition to the dismissal of the Company’s claims. The arbitration is in preliminary stages, and no date has been set for rendering a final decision. At this time, the Company cannot reasonably ascertain the likelihood that any of its claims or Licensor’s counterclaims will be heard by the arbitration panel or succeed on the merits.
Other Disputes
In the first quarter of 2018, the Company settled a commercial dispute. In connection with the settlement, the Company received a payment of $4.25 million, which was reported as other income in the consolidated statements of operations for the year ended December 31, 2018.
11. Common Stock
The Company’s common stockholders are entitled to dividends if and when declared by the Company’s Board of Directors (the “Board of Directors”). As of December 31, 2019 and 2018, no dividends on the Company’s common stock had been declared by the Board of Directors.
The Company’s common stock has been reserved for the following potential future issuances:
 
As of December 31,
 
2019
 
2018
Shares underlying outstanding stock options
4,494,889

 
7,588,405
Shares available for future stock option grants
2,726,225

 
3,556,507
Shares available for issuance under the 2018 Employee Stock Purchase Plan
689,917

 
922,250
Total
7,911,031

 
12,067,162

Reverse Stock Split

In September 2018, the Board of Directors and its stockholders approved a 0.7378-for-one reverse stock split of the Company’s common stock. The reverse stock split became effective on September 19, 2018. The par value of the common stock was not adjusted as a result of the reverse stock split. Adjustments corresponding to the reverse stock split were made to the ratio at which the convertible preferred stock was convertible into common stock immediately prior to the closing of the IPO.




137

Initial Public Offering

On October 9, 2018, the Company completed the IPO, in which it issued and sold 14,375,000 shares of its common stock at a price of $19.00 per share. The Company received net proceeds of $249.5 million after deducting underwriting discounts and commissions and offering expenses payable by the Company. All then-outstanding warrants to purchase the Company’s common stock were exercised prior to the completion of the IPO. In addition, in connection with the IPO, all shares of the Company’s then-outstanding convertible preferred stock were automatically converted into 58,264,577 shares of its common stock, and all then-outstanding warrants to purchase the Company’s convertible preferred stock were automatically converted into warrants to purchase 7,636 shares of the Company’s common stock.

Follow-on Offering

In May 2019, the Company completed an underwritten public offering, in which it issued and sold 5,175,000 shares of its common stock at a price of $71.00 per share. The Company received net proceeds of $349.7 million after deducting underwriting discounts and commissions and offering expenses payable by the Company.

12. Warrants
In connection with a bank loan agreement with a financial institution in September 2013, the Company issued warrants to purchase 5,386 shares of Series A convertible preferred stock at an exercise price of $0.93 per share. In October 2014, the Company issued additional warrants to the same financial institution to purchase 4,965 shares of Series B convertible preferred stock at an exercise price of $3.16 per share. These preferred stock warrants were converted to warrants to purchase common stock upon the consummation of the IPO and were net exercised into 6,548 shares of common stock in October 2018. No warrants remained outstanding as of December 31, 2019 and 2018.
In 2012, the Company issued to certain investors warrants to purchase 495,775 shares of common stock. The exercise price of the warrants is $0.14 per share and the warrants have a contractual term through September 2023. For the year ended December 31, 2018 and 2017, 313,741 and 89,030 shares, respectively, were issued upon the exercise of these warrants. As of December 31, 2017, warrants to purchase 313,741 shares of common stock were outstanding, and these warrants were fully exercised prior to the consummation of the IPO in October 2018.

13. Convertible Preferred Stock
The Company previously issued convertible preferred stock in one or more series, each with such designations, rights, qualifications, limitations, and restrictions as set forth in the Company’s certificate of incorporation, as in effect prior to the IPO. Immediately prior to the completion of the IPO, as described in Note 1, Description of Business, all shares of convertible preferred stock then outstanding were automatically converted to 58,264,577 shares of common stock at the respective conversion ratios in October 2018.
In May 2017, the Company entered into the Series E convertible preferred stock purchase agreement with SoftBank and certain of the Company’s existing stockholders. Pursuant to the purchase agreement, the Company issued and sold an aggregate of 38,174,246 shares of Series E convertible preferred stock at a purchase price of $8.3936 per share, for an aggregate purchase price of $320.4 million. The purchase agreement also provided that the Company would issue additional shares of Series E convertible preferred stock to the Series E investors in such an amount as to cause SoftBank’s equity ownership in the Company to equal 35% of the Company’s outstanding fully-diluted capital stock measured 70 days after the initial closing. This gross-up was intended to enable the Company to engage in various repurchases of its equity from existing stockholders and still maintain SoftBank’s equity ownership at 35%. As a result, in July 2017, the Company repurchased an aggregate of 1,588,065 shares of common stock from certain of its directors and executive officers for a purchase price of $10.23887 per share, which represented a price equal to 90% of the original price per shares for the Series E convertible preferred stock, as adjusted to reflect the 0.7378-for-one reverse stock split of the Company’s common stock effected on September 19, 2018. The Company also engaged in a tender offer pursuant to which it repurchased 131,243 shares of common stock from certain employees at the same per share price paid for the Series E convertible preferred stock as adjusted to reflect the 0.7378-for-one reverse stock split of the Company’s common stock effected on September 19, 2018, and 666,920 shares of Series A convertible preferred stock from existing stockholders at a purchase price of $8.00 per share of Series A convertible preferred stock. Following these repurchases, in October 2017, the Company issued an additional 796,346 shares of Series E convertible preferred stock to the Series E investors for a purchase price of $0.00001 per share pursuant to the terms of the gross up provision. The conversion price of Series E convertible preferred stock was adjusted as a result of the dilutive issuance of Series E convertible preferred stock under the gross up provision.

138

In May 2017, in accordance with its certificate of incorporation then in effect, the Company adjusted the conversion price of Series D convertible preferred stock from $10.1338 per share to $9.8329 per share. The Company accounted for the transaction as a modification. A deemed dividend of $1.1 million, calculated as the additional 253,361 shares of common stock to be received upon the conversion of the Series D convertible preferred stock after the conversion ratio adjustment, multiplied by the then current fair value of the Company’s common stock, was reported as an increase to net loss attributable to common stockholders for the year ended December 31, 2018.
Repurchase of Series A Convertible Preferred Stock
During the year ended December 31, 2017, the Company repurchased 666,920 shares of outstanding Series A convertible preferred stock at a price of $8.00 per share for a total consideration of $5.3 million. The difference between the repurchase amount and the carrying value of these shares of $4.7 million was recorded as a deemed dividend in accumulated deficit on the accompanying consolidated statements of stockholders’ equity.

14. Stock-Based Compensation
2012 Stock Plan and 2018 Incentive Award Plan
In June 2012 and September 2018, the Company’s Board of Directors adopted and its stockholders approved the Company’s 2012 Stock Plan (as amended and restated, the “2012 Plan”) and the Company’s 2018 Incentive Award Plan (the “2018 Plan”), respectively, under which the Company may grant cash and equity incentive awards such as stock options, restricted shares, stock units and stock appreciation rights to its employees and non-employees. Stock options granted may be either incentive stock options or nonstatutory stock options. Shares issued under the 2018 Plan may be authorized but unissued shares, or shares purchased in the open market or treasury shares. Upon effectiveness of the 2018 Plan in connection with the IPO in October 2018, the 2012 Plan was terminated and 508,847 shares reserved under the 2012 Plan were forfeited. Any outstanding awards granted under the 2012 Plan remain outstanding, subject to the terms of the 2012 Plan and applicable award agreement, and further cancellation of awards granted under the 2012 Plan are not available for grant in the future. No further grants will be made under the 2012 Plan.

139

Stock Option Activity
A summary of the Company’s stock option activity under the 2012 Plan and the 2018 Plan and related information is as follows:
 
 
 
Options Outstanding
 
Shares
Available for Grant 
 
Shares Subject to Options Outstanding
 
Weighted-Average Exercise Price 
 
Weighted-Average Remaining Contractual Life (Years)
 
Aggregate Intrinsic Value
 
 
 
 
 
 
 
 
 
 
 
 
 
(in thousands)
Balance as of December 31, 2017
1,698,790

 
7,391,052

 
$
3.63

 
8.6
 
$
3,325

Shares authorized
3,658,602

 
—

 
 
 
 
 
 
Shares forfeited
(508,847
)
 
—

 
 
 
 
 
 
Granted
(2,088,639
)
 
2,088,639

 
7.19

 
 
 
 
Exercised
—

 
(1,007,387
)
 
3.09

 
 
 
 
Canceled
795,371

 
(883,899
)
 
4.57

 
 
 
 
Repurchase of early exercised shares
1,230

 
—

 
 
 
 
 
 
Balance as of December 31, 2018
3,556,507

 
7,588,405

 
$
4.58

 
8.3
 
250,495

Shares authorized
—

 
—

 
 
 
 
 
 
Shares forfeited
—

 
—

 
 
 
 
 
 
Granted
(324,579
)
 
324,579

 
88.18

 
 
 
 
Exercised
—

 
(2,999,419
)
 
3.87

 
 
 
 
Canceled
12,636

 
(418,676
)
 
6.64

 
 
 
 
Repurchase of early exercised shares
—

 
—

 
 
 
 
 
 
Balance as of December 31, 2019
3,244,564

 
4,494,889

 
$
10.90

 
7.7
 
$
306,392

Vested and Exercisable as of December 31, 2019
 
 
1,908,216

 
$
5.27

 
7.2
 
$
139,337


Aggregate intrinsic value represents the difference between the estimated fair value of the underlying common stock and the exercise price of outstanding, in-the-money options. The total intrinsic value of the options exercised was $218.2 million, $8.4 million and $0.6 million for the years ended December 31, 2019, 2018 and 2017, respectively.
The weighted-average grant date fair value of options granted was $52.37, $5.17 and $2.90 per share for the years ended December 31, 2019, 2018 and 2017, respectively.
Future stock-based compensation for unvested options as of December 31, 2019 was $26.0 million, which is expected to be recognized over a weighted-average period of 2.7 years.
In December 2019, the Company modified one of the performance based awards issued to a nonemployee which resulted in reversal of expense of $1.0 million due to options not vested.
Restricted Stock Units

A summary of the Company’s restricted stock unit activity under the 2012 Plan and the 2018 Plan and related information is as follows:


140

 
 
 
 
 
Restricted Stock Units Outstanding
 
Weighted-Average Grant Date Fair Value
Balance as of December 31, 2018
—

 
$
—

Granted
567,425

 
78.61

Vested
(22,208
)
 
47.78

Canceled
(49,086
)
 
57.51

Balance as of December 31, 2019
496,131

 
$
82.08

 
 
 
 


Future stock-based compensation for unvested restricted stock units as of December 31, 2019 was $36.5 million, which is expected to be recognized over a weighted-average period of 3.5 years.

Stock‑Based Compensation Expense
The following table presents the effect of employee and non‑employee related stock‑based compensation expense:
 
Year Ended December 31,
 
2019
 
2018
 
2017
 
 
 
 
 
 
 
(in thousands)
Cost of precision oncology testing
$
863

 
$
512

 
$
162

Research and development expense
5,907

 
1,684

 
507

Sales and marketing expense
4,716

 
1,727

 
80

General and administrative expense
5,468

 
2,928

 
2,921

Total stock-based compensation expense
$
16,954

 
$
6,851

 
$
3,670


Valuation of Stock Options
Starting January 1, 2019, the Company adopted ASU 2018-07 which aligns the accounting treatment of nonemployee awards with employee awards, and the fair value of stock options issued to employees and nonemployee consultants are both determined as of the grant date. 

The grant date fair value of employee and nonemployee stock options was estimated using a Black-Scholes option-pricing model with the following weighted-average assumptions:
 
 
Year Ended December 31,
 
 
2019
 
2018
 
2017
 
 
 
 
 
 
 
Expected term (in years)
 
5.50 – 6.22
 
5.01 – 6.51
 
6.02 – 6.08
Expected volatility
 
63.2% – 68.7%
 
68.7% – 78.8%
 
74.1% – 75.1%
Risk-free interest rate
 
1.6% – 2.7%
 
2.5% – 3.0%
 
1.9% – 2.2%
Expected dividend yield
 
—%
 
—%
 
—%

The determination of the fair value of stock options on the date of grant using a Black-Scholes option-pricing model is affected by the estimated fair value of the Company’s common stock, as well as assumptions regarding a number of variables that are complex, subjective and generally require significant judgment to determine. The valuation assumptions were determined as follows:
Fair Value of Common Stock
Prior to the IPO, the grant date fair value of the Company’s common stock was determined by the Company’s Board of Directors with the assistance of management and an independent third-party valuation specialist. The grant date fair value of the Company’s common stock was determined using valuation methodologies which utilizes certain assumptions including probability weighting of events, volatility, time to liquidation, a risk-free interest rate and an assumption for a discount for lack of marketability (Level 3 inputs). In determining the fair value of the Company’s

141

common stock, the methodologies used to estimate the enterprise value of the Company were performed using methodologies, approaches, and assumptions consistent with the American Institute of Certified Public Accountants Accounting and Valuation Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation. Subsequent to the IPO, the fair value of the Company’s common stock is determined by the closing price, on the date of grant, of its common stock, which is traded on the Nasdaq Global Select Market.
Expected Term
The expected term represents the period that the options granted are expected to be outstanding and is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term) as the Company has concluded that its stock option exercise history does not provide a reasonable basis upon which to estimate expected term.
Expected Volatility
Prior to the commencement of trading of the Company’s common stock on the Nasdaq Global Select Market on October 4, 2018 in connection with the IPO, there was no active trading market for the Company’s common stock. Due to limited historical data for the trading of the Company’s common stock, expected volatility is estimated based on the average volatility for comparable publicly traded peer group companies in the same industry plus the Company's expected volatility for the available periods. The comparable companies are chosen based on their similar size, stage in the life cycle or area of specialty.

Risk-Free Interest Rate

The risk-free interest rate is based on the U.S. Treasury rate, with maturities similar to the expected term of the stock options.
Expected Dividend Yield
The Company does not anticipate paying any dividends in the foreseeable future and, therefore, uses an expected dividend yield of zero.
2018 Employee Stock Purchase Plan
In September 2018, the Company’s Board of Directors adopted and its stockholders approved the 2018 Employee Stock Purchase Plan (the “ESPP”). A total of 922,250 shares of common stock are initially reserved for issuance under the ESPP. The number of shares may be increased in accordance with the terms of the ESPP.
Subject to any plan limitations, the ESPP allows eligible employees to contribute, normally through payroll deductions, up to 10% of their earnings for the purchase of the Company’s common stock at a discounted price per share. The price at which common stock is purchased under the ESPP is equal to 85% of the fair market value of the Company’s common stock on the first or last day of the offering period, whichever is lower. The initial offering period ran from October 2, 2018 to January 31, 2019, the second offering period ran from February 1, 2019 to July 31, 2019, and the third offering period began on August 1, 2019 and ran to November 14, 2019. On a going forward basis, the ESPP will provide for separate six-month offering periods beginning on May 15 and November 15 of each year.
During the year ended December 31, 2019, 232,333 shares were purchased under the ESPP. No shares were purchased under the ESPP during the year ended December 31, 2018. The total compensation expense related to the ESPP for year ended December 31, 2019 and December 31, 2018 was $2.3 million and $0.3 million, respectively.
The fair value of the stock purchase right granted under the ESPP was estimated on the first day of each offering period using the Black-Scholes option pricing model. The following assumptions were used to calculate the stock-based compensation for each stock purchase right granted under the ESPP:
 
 
Year Ended December 31,
 
 
 
2019
 
2018
 
 
 
 
 
 
 
Expected term (in years)
 
0.29 – 0.5
 
0.33
 
Expected volatility
 
58.8% – 60.3%
 
43.6%
 
Risk-free interest rate
 
1.6% – 2.5%
 
2.4%
 
Expected dividend yield
 
—%
 
—%
 


142


Future stock-based compensation under the ESPP as of December 31, 2019 was $0.8 million, which is expected to be recognized over a weighted-average period of 0.4 years.
Liabilities for Early Exercise of Employee Options
The Company allowed certain stock option holders to exercise unvested options to purchase shares of the Company’s common stock. Shares received from such early exercises are subject to repurchase in the event of the optionee’s employment termination, at the original issuance price, until the options are fully vested. As of December 31, 2019 and 2018, 23,981 shares and 44,268 shares of common stock were subject to repurchase at weighted-average price of $4.66 per share. As of December 31, 2019 and December 31, 2018, the cash proceeds received for unvested shares of common stock of $0.1 million and $0.2 million was recorded within other long-term liabilities on the consolidated balance sheet, respectively. The shares issued pursuant to unvested options have been included in shares issued and outstanding on the consolidated balance sheet and consolidated statement of redeemable noncontrolling interest and stockholders’ equity as such shares are considered legally outstanding.

15. Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders
The following table sets forth the computation of the basic and diluted net loss per share attributable to Guardant Health, Inc. common stockholders:
 
Year Ended December 31,
 
2019
 
2018
 
2017
 
 
 
 
 
 
 
(in thousands, except per share data)
Net loss
$
(67,851
)
 
$
(84,263
)
 
$
(83,221
)
Adjustment of redeemable noncontrolling interest
(7,800
)
 
(800
)
 
—

Net loss attributable to Guardant Health, Inc.
(75,651
)
 
(85,063
)
 
(83,221
)
Deemed dividend related to repurchase of Series A convertible preferred stock
—

 
—

 
(4,716
)
Deemed dividend related to change in conversion rate of Series D convertible preferred stock
—

 
—

 
(1,058
)
Net loss attributable to Guardant Health, Inc. common stockholders, basic and diluted
$
(75,651
)
 
$
(85,063
)
 
$
(88,995
)
Net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted
$
(0.84
)
 
$
(2.80
)
 
$
(7.07
)
Weighted-average shares used in computing net loss per share attributable to Guardant Health, Inc. common stockholders, basic and diluted
90,597

 
30,403

 
12,582



143


Since the Company was in a loss position for all periods presented, basic net loss per share attributable to Guardant Health, Inc. common stockholders is the same as diluted net loss per share attributable to Guardant Health, Inc. common stockholders, as the inclusion of all potential shares of common stock outstanding would have been anti-dilutive. The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share attributable to Guardant Health, Inc. common stockholders for the periods presented as they had an anti-dilutive effect:
 
Year Ended December 31,
 
2019
 
2018
 
2017
 
 
 
 
 
 
 
(in thousands)
Convertible preferred stock (on an as if converted basis)
—

 
43,898

 
44,818

Stock options issued and outstanding
5,976

 
7,527

 
5,179

ESPP obligation
52

 
22

 
—

Preferred stock warrants (on an as if converted basis)
—

 
6

 
8

Common stock warrants
—

 
208

 
382

Restricted stock units
252

 
—

 
—

Common stock subject to repurchase
31

 
46

 
28

Total
6,311

 
51,707

 
50,415



144

16. Income Taxes
The components of loss before provision for income taxes were as follows (in thousands):
 
Year Ended December 31,
 
2019
 
2018
 
2017
 
 
 
 
 
 
 
(in thousands)
United States
$
(69,930
)
 
$
(84,313
)
 
$
(83,214
)
Foreign
207

 
88

 
—

Total
$
(69,723
)
 
$
(84,225
)
 
$
(83,214
)

The components of the provision for income taxes are as follows:
 
Year Ended December 31,
 
2019
 
2018
 
2017
 
 
 
 
 
 
 
(in thousands)
Current:
 
 
 
 
 
State
$
3

 
$
4

 
$
—

Foreign
266

 
34

 
7

Total current tax expense
$
269

 
$
38

 
$
7

Deferred:
 
 
 
 
 
Federal
$
(1,652
)
 
$
—

 
$
—

State
(311
)
 
—

 
—

Foreign
(178
)
 
—

 
—

Total deferred tax expense
$
(2,141
)
 
$
—

 
$
—

Total provision for income taxes
$
(1,872
)
 
$
38

 
$
7


Deferred income taxes reflect the tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company’s deferred tax assets are as follows:

145

 
Year Ended December 31,
 
2019
 
2018
 
 
 
 
 
(in thousands)
Deferred tax assets:
 
 
 
Net operating losses carryforwards
$
90,534

 
$
36,783

Intangible assets
14,165

 
17,107

Accruals and reserves
4,936

 
5,127

Research and development credits
11,031

 
5,753

Stock-based compensation
3,143

 
1,289

Lease liabilities
10,195

 
—

Other
160

 
210

Total deferred tax asset
$
134,164

 
$
66,269

Deferred tax liabilities:
 
 
 
Property and equipment
$
(119
)
 
$
(73
)
Section 481 (a) adjustment
(914
)
 
—

Right-of-use asset
(7,363
)
 
—

Unrealized gain/loss on investments
(346
)
 
—

Less: valuation allowance
(125,245
)
 
(66,196
)
Net deferred tax assets
$
177

 
$
—


The following table presents a reconciliation of the income tax expense computed at the statutory federal rate and the Company’s income tax expense for the periods presented:
 
Year Ended December 31,
 
2019
 
2018
 
2017
 
 
 
 
 
 
 
(in thousands)
Tax at the statutory federal rate
$
(14,642
)
 
$
(17,690
)
 
$
(28,293
)
Other nondeductible items
887

 
329

 
371

Stock-based compensation
(33,042
)
 
497

 
3,819

Research and development credits
(5,266
)
 
(1,726
)
 
(714
)
Change in valuation allowance
59,049

 
22,516

 
5,415

State taxes, net of federal benefits
(8,253
)
 
(4,231
)
 
(1,868
)
Change in tax rate due to Tax Act
—

 
—

 
21,346

Other
(605
)
 
343

 
(69
)
Total provision for (benefit from) income taxes
$
(1,872
)
 
$
38

 
$
7


The Company’s actual tax expense differed from the statutory federal income tax expense using a tax rate of 21% for the year ended December 31, 2019 primarily due to state and foreign income taxes, nondeductible expenses, research and development tax credits, the acquisition of Bellwether Bio, and the change in valuation allowance. The Company’s actual tax expense differed from the statutory federal income tax expense using a tax rate of 21% and 34% for the years ended December 31, 2018, and 2017, respectively, primarily due to state income taxes, nondeductible expenses, research and development tax credits, and the change in valuation allowance. The benefit from income taxes for the year ended December 31, 2019 included a release of a valuation allowance of $1.6 million associated with nondeductible intangible assets recorded as a result of the acquisition of Bellwether Bio. In connection with the acquisition of Bellwether Bio, a deferred tax liability was established for the book-tax basis differences related to the non-goodwill intangible assets. The net deferred tax liability from this acquisition creates an additional source of income to offset the Company’s deferred tax assets. The benefit from income taxes for the year ended December 31, 2019 also included a benefit of $0.4 million associated with the utilization of tax losses from continuing operations against other comprehensive income gains in accordance with intra-period tax allocation under ASC Topic 740.


146

As of December 31, 2019 and 2018, the Company had a net operating loss carryforwards of $365.3 million and $152.3 million for federal purposes, respectively, and $223.2 million and $73.2 million for state and local purposes, respectively, which may be subject to limitations as described below. If not utilized, these carryforwards will begin to expire in 2031 for federal, and 2020 for state and local purposes. Under the newly enacted federal income tax law, federal net operating losses incurred in 2018 and in future years may be carried forward indefinitely, but the deductibility of such federal net operating losses is limited. It is uncertain if and to what extent various states will conform to the newly enacted federal income tax law.
As of December 31, 2019 and 2018, the Company had research and development tax credit carryforwards for federal tax purposes of $6.8 million and $3.5 million, and state research and development tax credit carryforwards of $5.3 million and $2.9 million, respectively. The federal research and development tax credit carryforwards will expire at various dates beginning in the year 2032. The Company’s state research and development tax credit carryforwards do not expire.
Utilization of the net operating loss (“NOL”) carryforwards and credits may be subject to a substantial annual limitation due to the ownership change limitations provided by the Internal Revenue Code of 1986, as amended, and similar state provisions. The annual limitation may result in the expiration of NOL carryforwards and credits before utilization. Current laws impose substantial restrictions on the utilization of NOL carryforwards and credits in the event of an “ownership change” within a three-year period as defined by the Internal Revenue Code Section 382 (“Section 382”). If there should be an ownership change, the Company’s ability to utilize its NOL carryforwards and credits could be limited. The Company has not performed a Section 382 analysis.
Realization of the future tax benefits is dependent on the Company’s ability to generate sufficient taxable income within the carryforward period. Due to the Company’s history of U.S. operating losses, the Company believes that the recognition of the deferred tax assets arising from the above-mentioned future tax benefits is currently not more likely than not to be realized and, accordingly, have provided a full valuation allowance against net U.S. deferred tax assets. The net change in total valuation allowance was an increase of $59.0 million and an increase of $22.5 million for the years ended December 31, 2019 and 2018, respectively.
The SEC staff issued SAB 118 on December 23, 2017 regarding application of the Tax Act. It provides a “measurement period,” lasting through December 22, 2018, to allow registrants time to obtain, prepare and analyze information to complete the accounting required under ASC 740, Income Taxes. The Company completed its analysis during the measurement period and there were no measurement period adjustments recognized during 2019.
The Company has not recorded a provision for deferred U.S. tax expense that could result from the remittance of foreign undistributed earnings since the Company intends to reinvest the earnings in its foreign subsidiaries indefinitely.
The Company has made an accounting policy election to treat Global Intangible Low-Taxed Income ("GILTI") taxes as a current period expense rather than including these amounts in the measurement of deferred taxes.
Uncertain Tax Positions
The Company records unrecognized tax benefits, where appropriate, for all uncertain income tax positions. The Company recorded unrecognized tax benefits for uncertain tax positions of $6.5 million and $3.4 million as of December 31, 2019 and 2018, respectively, none of which would impact the Company’s effective tax rate if recognized, because the benefit would be offset by an increase in the valuation allowance.
A reconciliation of the beginning and ending balance of total unrecognized tax benefits is as follows:
 
Year Ended December 31,
 
2019
 
2018
 
2017
 
 
 
 
 
 
 
(in thousands)
Unrecognized tax benefits - Beginning of period
$
3,427

 
$
1,712

 
$
884

Increases related to current year’s tax positions
3,116

 
1,635

 
828

Increases related to prior years’ tax positions
—

 
80

 
—

Unrecognized tax benefits - End of period
$
6,543

 
$
3,427

 
$
1,712


The Company’s policy is to recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. During the years ended December 31, 2019 and 2018, the Company recognized no interest and penalties associated with unrecognized tax benefits. There are no tax positions for which it is reasonably possible that

147

the total amounts of unrecognized tax benefits will significantly increase or decrease within twelve months of the reporting date.
Due to the net operating loss carryforwards, all years remain open for income tax examination by tax authorities in the United States, various states and foreign tax jurisdictions in which the Company files tax returns.
17. Employee Benefit Plan
The Company sponsors a 401(k) plan, and pursuant to its terms, eligible employees can elect to contribute to the 401(k) plan, subject to certain limitations, up to the lesser of the statutory maximum or 100% of eligible compensation on a pre-tax basis. For the year ended December 31, 2019, the Company contributed $0.3 million to match employee contributions as permitted by the plan. For the years ended December 31, 2018 and 2017, the Company did not elect to match employee contributions as permitted by the plan. The Company pays the administrative costs for the plan.
18. Segment and Geographic Information
The following table sets forth the Company’s revenue by geographic areas based on the customers’ locations:
 
Year Ended December 31,
 
2019
 
2018
 
2017
 
 
 
 
 
 
 
(in thousands)
United States (2)
$
194,312

 
$
77,916

 
$
43,715

International(1) (2)
20,063

 
12,723

 
6,127

Total revenue
$
214,375

 
$
90,639

 
$
49,842


(1)
No single country outside of the United States accounted for more than 10% of total revenue during each of the years ended December 31, 2019, 2018 and 2017.
(2) Fiscal years 2018 and 2017 results do not reflect the impact of the adoption of the new revenue accounting standard in fiscal year 2019.
As of December 31, 2019 and 2018, 97% and 100%, respectively, of the Company’s long-lived assets are located in the United States.
19. Related Party Transactions
As discussed in Note 3, Investment in Joint Venture, and Note 13, Convertible Preferred Stock, in connection with Softbank’s purchase of its Series E convertible preferred stock in 2017, the Company entered into a joint venture agreement with an entity affiliated with SoftBank. In May 2018, the Company and SoftBank formed and capitalized the Joint Venture to accelerate commercialization of its products in Asia, the Middle East and Africa, with an initial focus on Japan. The Company has consolidated the financial position, results of operations and cash flows of the Joint Venture in its financial statements and all intercompany balances have been eliminated in consolidation.
As discussed in Note 11, Common Stock, in July and August 2017, the Company repurchased an aggregate of 1,640,901 shares of outstanding common stock from certain executive officers for $16.9 million. The difference between the repurchase amount and the fair value of repurchased shares of $10.0 million were recorded as cash-based compensation expense in the accompanying consolidated statements of operations.
For each of the years ended December 31, 2019 and 2017, the Company recognized revenue of $0.5 million from an entity affiliated with a member of the Company’s Board of Directors, who serves on the board of both the aforementioned entity and the Company. This individual was appointed to the Company’s board in January 2017. There was no revenue recognized by the Company from that entity for the year ended December 31, 2018.

148

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
None.

Item 9A. Controls and Procedures
Evaluation of disclosure controls and procedures
Our management, with the participation of our chief executive officer, or CEO, and chief financial officer, or CFO, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or Exchange Act), as of the end of the period covered by this Annual Report on Form 10-K. Based on that evaluation, our CEO and CFO have concluded that as of December 31, 2019, our disclosure controls and procedures are designed at a reasonable assurance level and are effective to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC, and that such required information is accumulated and communicated to our management, including our CEO and CFO, as appropriate, to allow timely decisions regarding required disclosures.
Management report on internal control over financial reporting
Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in the Exchange Act Rules 13a-15(f). Under the supervision and with the participation of our management, including our CEO and CFO, we conducted an assessment of the effectiveness of our internal control over financial reporting based on the framework in Internal Control Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on the results of our assessment under the framework in the Internal Control—Integrated Framework (2013), our management concluded that our internal control over financial reporting was effective as of December 31, 2019.The effectiveness of our internal control over financial reporting as of December 31, 2019, has been audited by an independent registered public accounting firm, as stated in their report included in Part II, Item 8, “Financial Statements” of this Annual Report on Form 10-K.

Changes in internal control
There was no change in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the period covered by this Annual Report on Form 10-K that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
Inherent Limitations Over Internal Controls

Our internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. GAAP.

Our internal control over financial reporting includes those policies and procedures that:

(i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets;

(ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with U.S. GAAP, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and

(iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of our assets that could have a material effect on the financial statements.

Management, including our CEO and CFO, do not expect that our internal controls will prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of internal controls can provide absolute assurance that

149

all control issues and instances of fraud, if any, have been detected. Also, any evaluation of the effectiveness of controls in future periods are subject to the risk that those internal controls may become inadequate because of changes in business conditions, or that the degree of compliance with the policies or procedures may deteriorate.
Report of Independent Registered Public Accounting Firm
To the Stockholders and the Board of Directors of Guardant Health, Inc.
Opinion on Internal Control Over Financial Reporting
We have audited Guardant Health, Inc.’s internal control over financial reporting as of December 31, 2019, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Guardant Health, Inc. (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2019, based on the COSO criteria.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2019 and 2018 and consolidated statements of operations, comprehensive loss, redeemable noncontrolling interest and stockholders’ equity and cash flows for each of the three years in the period ended December 31, 2019, and the related notes and our report dated March 2, 2020 expressed an unqualified opinion thereon.
Basis for Opinion
The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management's Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.
Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.
Definition and Limitations of Internal Control Over Financial Reporting
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

/s/ Ernst & Young LLP
Redwood City, California
March 2, 2020


Item 9B. Other Information.
We filed a Current Report on Form 8-K with the SEC on December 5, 2019 (the “Original 8-K Report”), which reported, among other things, that on December 2, 2019, Richard Lanman, M.D., notified us of his decision to retire as our Chief Medical Officer, effective as of December 31, 2019. This Item 9B disclosure intends to provide information called for under Item 5.02(e) of Form 8-K that had not been determined at the time of filing of the Original 8-K Report.

150


Following Dr. Lanman’s retirement, we and Dr. Lanman, on February 28, 2020, entered into a part-time employment agreement for Dr. Lanman to continue with us as an advisor to facilitate a successful transition (the “Advisor Agreement”). Pursuant to the Advisor Agreement, Dr. Lanman will receive an hourly wage and will be entitled to a one-time bonus of $100,000 for his services provided to us in 2019 and the continued vesting of his equity awards previously granted by us during his part-time employment with us. The general terms and conditions of such equity awards are described in our definitive proxy statement filed on April 29, 2019 with the SEC.
This summary of the Advisor Agreement does not purport to be complete and is subject to and qualified in its entirety by reference to the full text of the Advisor Agreement. The full text of the Advisor Agreement is included as Exhibit 10.21 to this Annual Report on Form 10-K and is incorporated herein by reference.


151

PART III

Item 10. Directors, Executive Officers and Corporate Governance
The information required by this Item 10 of Form 10-K will be included in our 2020 Proxy Statement to be filed with the SEC in connection with the solicitation of proxies for our 2020 Annual Meeting of Stockholders and is incorporated herein by reference. The 2020 Proxy Statement will be filed with the SEC within 120 days after the end of the fiscal year to which this Annual Report on Form 10-K relates.

Item 11. Executive Compensation
The information required by this Item 11 of Form 10-K will be included in our 2020 Proxy Statement and is incorporated herein by reference.

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
The information required by this Item 12 of Form 10-K will be included in our 2020 Proxy Statement and is incorporated herein by reference.

Item 13. Certain Relationships and Related Transactions, and Director Independence
The information required by this Item 13 of Form 10-K will be included in our 2020 Proxy Statement and is incorporated herein by reference.

Item 14. Principal Accounting Fees and Services
The information required by this Item 14 of Form 10-K will be included in our 2020 Proxy Statement and is incorporated herein by reference.
PART IV
Item 15. Exhibits, Financial Statement Schedules
(a)    Documents filed as part of this report
(1)    All financial statements
See Index to Consolidated Financial Statements in Part II, Item 8 of this Annual Report on Form 10-K.
(2)    Financial Statement Schedules
All financial statement schedules have been omitted since the required information was not applicable or was not present in amounts sufficient to require submission of the schedules, or because the information required is included in the consolidated financial statements or the accompanying notes.
(3)    Exhibits required by Item 601 of Regulation S-K
The exhibits listed in the following Index to Exhibits are filed, furnished or incorporated by reference as part of this Annual Report on Form 10-K.

152


INDEX TO EXHIBITS
 
 
 
 
Incorporated by Reference

 
 
Exhibit Number
 
Exhibit Description
 
Form
 
File No.
 
Exhibit
 
Filing Date
 
Filed/Furnished Herewith
3.1
 
 
8-K
 
001-38683
 
3.1
 
10/9/2018
 
 
3.2
 
 
8-K
 
001-38683
 
3.2
 
10/9/2018
 
 
4.1
 
 
 
 
 
 
 
 
 
 
*
10.1
 
 
S-1
 
333-227206
 
10.1
 
9/6/2018
 
 
10.2#
 
 
S-1
 
333-227206
 
10.3
 
9/6/2018
 
 
10.2(a)#
 
 
S-1
 
333-227206
 
10.4
 
9/6/2018
 
 
10.3#
 
 
S-8
 
333-227762
 
99.2(a)
 
10/10/2018
 
 
10.3(a)#
 
 
S-1/A
 
333-227206
 
10.9(a)
 
9/21/2018
 
 
10.3(b)#
 
 
S-1/A
 
333-227206
 
10.9(b)
 
9/21/2018
 
 
10.3(c)#
 
 
S-1/A
 
333-227206
 
10.9(c)
 
9/21/2018
 
 
10.4#
 
 
S-8
 
333-227762
 
99.3
 
10/10/2018
 
 
10.4(a)#
 
 
10-K
 
001-38683
 
10.4(a)
 
3/29/2019
 

10.5#
 
 
S-1/A
 
333-227206
 
10.13
 
9/21/2018
 
 
10.5(a)#
 
 
10-K
 
001-38683
 
10.5(a)
 
3/29/2019
 
 
10.6#
 
 
10-Q
 
001-38683
 
10.3
 
5/10/2019
 
 
10.7#
 
 
10-Q
 

001-38683
 
10.9
 
11/19/2018
 
 
10.8#
 
 
10-Q
 
001-38683
 
10.10
 
11/19/2018
 
 
10.9
 
 
S-1/A
 
333-227206
 
10.8
 
9/18/2018
 
 
10.10
 
 
S-1
 
333-227206
 
10.2
 
9/6/2018
 
 
10.11
 
 
S-1
 
333-227206
 
10.2(a)
 
9/6/2018
 
 
10.12§
 
 
S-1
 
333-227206
 
10.5
 
9/6/2018
 
 
10.13§
 
 
S-1
 
333-227206
 
10.7
 
9/6/2018
 
 
10.14§
 
 
S-1
 
333-227206
 
10.7(a)
 
9/6/2018
 
 
10.15§
 
 
S-1
 
333-227206
 
10.7(b)
 
9/6/2018
 
 


153


10.16§
 
 
S-1
 
333-227206
 
10.7(c)
 
9/6/2018
 
 
10.17§
 
 
S-1
 
333-227206
 
10.7(d)
 
9/6/2018
 
 
10.18#
 
 

10-K
 
001-38683
 
10.19
 
3/29/2019
 
 
10.19#
 
 
10-Q
 
001-38683
 
10.6
 
5/10/2019
 
 
10.20#+
 
 
10-Q
 
001-38683
 
10.5
 
5/10/2019
 
 
10.21#+
 
 
 
 
 
 
 
 
 
 
*

21.1
 
 
 
 
 
 
 
 
 
 
*
23.1
 
 
 
 
 
 
 
 
 
 
*
24.1
 
 
 
 
 
 
 
 
 
 
*
31.1
 
 
 
 
 
 
 
 
 
 
*
31.2
 
 
 
 
 
 
 
 
 
 
*
32.1
 
 
 
 
 
 
 
 
 
 
**
32.2
 
 
 
 
 
 
 
 
 
 
**
101.INS
 
Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
 
 
 
 
 
 
 
 
 
*
101.SCH
 
Inline XBRL Taxonomy Extension Schema Document
 
 
 
 
 
 
 
 
 
*
101.CAL
 
Inline XBRL Taxonomy Extension Calculation Linkbase Document
 
 
 
 
 
 
 
 
 
*
101.DEF
 
Inline XBRL Taxonomy Extension Definition Linkbase Document
 
 
 
 
 
 
 
 
 
*
101.LAB
 
Inline XBRL Taxonomy Extension Label Linkbase Document
 
 
 
 
 
 
 
 
 
*
101.PRE
 
Inline XBRL Taxonomy Extension Presentation Linkbase Document
 
 
 
 
 
 
 
 
 
*
104
 
Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101)
 
 
 
 
 
 
 
 
 
*
___________________________
*
Filed herewith.
**
Furnished herewith.
#
Indicates management contract or compensatory plan.


154


§
Portions of this exhibit (indicated by asterisks) have been omitted pursuant to, a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended, or Item 601(a)(5) of Regulation S-K.
+ Schedules and attachments to this exhibit have been omitted pursuant to Item 601(a)(5) of Regulation S-K.

Item 16. Form 10-K Summary
None.


155

SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
GUARDANT HEALTH, INC.
 
 
 
 
Dated:
March 2, 2020
By:
/s/ Helmy Eltoukhy
 
 
Name:
Helmy Eltoukhy
 
 
Title:
Chief Executive Officer
Power of Attorney
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Helmy Eltoukhy, his or her attorneys-in-fact, each with the power of substitution, for him or her in any and all capacities, to sign any amendments to this Annual Report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that each of said attorneys-in-fact, or his substitute or substitutes, may do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated:
Signature
 
Title
 
Date
/s/ Helmy Eltoukhy
 
Chief Executive Officer and Director
(Principal Executive Officer)
 
March 2, 2020
Helmy Eltoukhy
 
 
 
 
 
 
 
 
 
/s/ Derek Bertocci
 
Chief Financial Officer
(Principal Accounting Officer and Principal Financial Officer)
 
March 2, 2020
Derek Bertocci
 
 
 
 
 
 
 
 
 
/s/ AmirAli Talasaz
 
President, Chief Operating Officer and Chairman of the Board of Directors
 
March 2, 2020
AmirAli Talasaz
 
 
 
 
 
 
 
 
 
/s/ Ian Clark
 
Director
 
March 2, 2020
Ian Clark
 
 
 
 
 
 
 
 
 
/s/ Bahija Jallal
 
Director
 
March 2, 2020
Bahija Jallal
 
 
 
 
 
 
 
 
 
/s/ Samir Kaul
 
Director
 
March 2, 2020
Samir Kaul
 
 
 
 
 
 
 
 
 
/s/ Stanley Meresman
 
Director
 
March 2, 2020
Stanley Meresman
 
 
 
 
 
 
 
 
 
/s/ Dipchand Nishar
 
Director
 
March 2, 2020
Dipchand Nishar
 
 
 
 

156
 EX-4.1 2 descriptionofregistran.htm EXHIBIT 4.1 Exhibit

Exhibit 4.1

Description of the Registrant’s Securities Registered
Pursuant to Section 12 of the Securities Exchange Act of 1934

Except as otherwise indicated herein or as the context otherwise requires, references in this exhibit to “we,” “us,” “our” and “our company” refer to Guardant Health, Inc. The following description of our common stock and certain provisions of our amended and restated certificate of incorporation and amended and restated bylaws are summaries and are qualified in their entirety by reference to the full text of our amended and restated certificate of incorporation and amended and restated bylaws. We urge you to read those documents, each of which are incorporated by reference as exhibits to our filings with the Securities and Exchange Commission, for additional information.

General

Our common stock is registered under Section 12 of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Our amended and restated certificate of incorporation authorizes 350,000,000 shares of common stock, all with a par value of $0.00001 per share. Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders and do not have cumulative voting rights. The election of directors by holders of our common stock is determined by a plurality of the votes cast by the stockholders entitled to vote on the election, subject to any preferential voting rights of any series of preferred stock that we may designate and issue in the future. Holders of our common stock are entitled to receive proportionately any dividends as may be declared by our board of directors, subject to any preferential dividend rights of any series of preferred stock that we may designate and issue in the future.

In the event of our liquidation or dissolution, the holders of our common stock are entitled to receive proportionately our net assets available for distribution to stockholders after the payment of all debts and other liabilities and subject to the prior rights of any outstanding preferred stock. Holders of our common stock have no preemptive, subscription, redemption or conversion rights. Outstanding shares of our common stock are, when issued and paid for, validly issued, fully paid and nonassessable. The rights, preferences and privileges of holders of our common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of preferred stock that we may designate and issue in the future.

Anti-takeover Provisions

Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws

Because our stockholders do not have cumulative voting rights, our stockholders holding a majority of the voting power of our shares of common stock outstanding will be able to elect all of our directors. Our amended and restated certificate of incorporation and amended and restated bylaws provide that all stockholder actions must be effected at a duly called meeting of stockholders and not by consent in writing. A special meeting of stockholders may be called only by a majority of our board of directors, the chair of our board of directors or our chief executive officer.

Our amended and restated certificate of incorporation further provides that the affirmative vote of holders of at least sixty-six and two-thirds percent (66-2/3%) of the voting power of all of the then outstanding shares of voting stock, voting as a single class, is required to amend certain provisions of our amended and restated certificate of incorporation, including provisions relating to the size of the board, removal of directors, special meetings, actions by written consent and cumulative voting. The affirmative vote of holders of at least sixty-six and two-thirds percent (66-2/3%) of the voting power of all of the then outstanding shares of voting stock, voting as a single class, is required to amend or repeal our amended and restated bylaws, although our amended and restated bylaws may be amended by a simple majority vote of our board of directors.

Our amended and restated certificate of incorporation further provides that our board of directors is divided into three classes, Class I, Class II and Class III, with each class serving staggered terms.

Finally, our amended and restated certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum, to the fullest extent permitted by law, the Court of Chancery of the State of Delaware is the sole and exclusive forum for: (i) any derivative action or proceeding brought on behalf of us; (ii) any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other employees or agents to us or our stockholders; (iii) any action asserting a claim against us arising pursuant to any provision of the Delaware General Corporation Law or our amended and restated certificate of incorporation or amended and restated bylaws; or (iv) any action asserting a claim against us governed by the internal affairs doctrine; provided that, the exclusive forum provision will not apply to suits brought to enforce any liability or duty created by the Exchange Act, or any other claim for which the federal courts have exclusive jurisdiction; and provided further that, if and only if the Court of Chancery of the State of Delaware dismisses any such action for lack of subject matter jurisdiction, such action may be brought in another state or federal court sitting in the State of Delaware. Our amended and restated certificate of incorporation also provides that the federal district courts of the United States of America will be the exclusive forum for the resolution of any complaint asserting a cause of action against us or any of our directors, officers, employees or agents and arising under the Securities Act of 1933, as amended, or the Securities Act. However, a Delaware court recently held that such an exclusive forum provision relating to federal courts was unenforceable under Delaware law, and unless and until the Delaware court decision is reversed on appeal or otherwise abrogated, we do not intend to enforce such a provision in the event of a complaint asserting a cause of action arising under the Securities Act against us or any of our directors, officers, employees or agents.

The foregoing provisions may make it more difficult for our existing stockholders to replace our board of directors as well as for another party to obtain control of our company by replacing our board of directors. Since our board of directors has the power to retain and discharge our officers, these provisions may also make it more difficult for existing stockholders or another party to effect a change in management. In addition, the authorization of undesignated preferred stock makes it possible for our board of directors to issue preferred stock with voting or other rights or preferences that could impede the success of any attempt to change the control of our company.

These provisions are intended to enhance the likelihood of continued stability in the composition of our board of directors and its policies and to discourage certain types of transactions that may involve an actual or threatened acquisition of our company. These provisions are also designed to reduce our vulnerability to an unsolicited acquisition proposal and to discourage certain tactics that may be used in proxy rights. However, these provisions may have the effect of discouraging others from making tender offers for our shares and may have the effect of deterring hostile takeovers or delaying changes in control of our company or our management. As a consequence, these provisions also may inhibit fluctuations in the market price of our stock that could result from actual or rumored takeover attempts.

Section 203 of the Delaware General Corporation Law

We are subject to Section 203 of the Delaware General Corporation Law, which prohibits a Delaware corporation from engaging in any business combination with any interested stockholder for a period of three years after the date that such stockholder became an interested stockholder, with the following exceptions:
 
 
•
before such date, the board of directors of the corporation approved either the business combination or the transaction that resulted in the stockholder becoming an interested stockholder;
In general, Section 203 defines business combination to include the following:
 
 
•
upon closing of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least eight-five percent (85%) of the voting stock of the corporation outstanding at the time the transaction began, excluding for purposes of determining the voting stock outstanding (but not the outstanding voting stock owned by the interested stockholder) those shares owned by (i) persons who are directors and also officers and (ii) employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or
 
 
•
on or after such date, the business combination is approved by the board of directors and authorized at an annual or special meeting of the stockholders, and not by written consent, by the affirmative vote of at least sixty-six and two-thirds percent (66 2/3%) of the outstanding voting stock that is not owned by the interested stockholder.
 
 
•
any merger or consolidation involving the corporation and the interested stockholder;
In general, Section 203 defines an “interested stockholder” as an entity or person who, together with the person’s affiliates and associates, beneficially owns, or within three years prior to the time of determination of interested stockholder status did own, fifteen percent (15%) or more of the outstanding voting stock of the corporation.
 
 
•
any sale, transfer, pledge or other disposition of ten percent (10%) or more of the assets of the corporation involving the interested stockholder;
 
 
•
subject to certain exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder;
 
 
•
any transaction involving the corporation that has the effect of increasing the proportionate share of the stock or any class or series of the corporation beneficially owned by the interested stockholder; or
 
 
•
the receipt by the interested stockholder of the benefit of any loss, advances, guarantees, pledges or other financial benefits by or through the corporation.






 EX-10.21 3 a10-kexhibit1021lanman.htm EXHIBIT 10.21 Exhibit
gh.jpgEx 10.21

GUARDANT HEALTH 505 Penobscot Drive, Redwood City, CA 94063 USA / 855.698.8887 client services / www.guardanthealth.com



December 31, 2019
CONFIDENTIAL

Dr. Richard Lanman
556 Van Buren St.
Los Altos, CA 94022
Re:
Employment as Advisor
Dear Rick:
This letter will provide details regarding your employment as a part-time Advisor for Guardant Health, Inc. (the “Company”). This letter constitutes the entire agreement between you and the Company with respect to the subject matter hereof and supersedes and replaces any and all prior agreements or representations relating to such subject matter including, but not limited to, your July 29, 2014 offer of employment with the Company which will become null and void upon your agreement to this letter.
The details of your employment as an Advisor are as follows:
Start Date as Advisor: You will begin serving as an Advisor, effective January 3, 2020. Although it is anticipated that your position as Advisor will last until December 31, 2020 (the “End Date”), you will remain an at-will employee during the entire term of your employment, as described below.
Compensation: The majority of your compensation for your services as an Advisor will be related to your continued vesting of your outstanding equity awards (see Stock Options/RSUs below). Nevertheless, the Company will pay you an hourly rate of $22.00 per hour for compliance reasons. Your position is classified as non-exempt, meaning you are eligible for overtime pay. You will be paid overtime as required by state and federal law. As required by California law, I’ve provided detailed information about the terms of your wages in the enclosed Notice to Employee (Labor Code section 2810.5). Please also sign and return one copy of the notice with this signed letter.
Sick Leave/Paid Time Off: As a part-time employee regularly scheduled to work fewer than 30 hours per week, you are not eligible to accrue vacation or to receive paid holidays. As a part-time employee you will accrue sick time at one hour for every 30 hours worked. You may only use accrued sick leave beginning on the 90th day of employment.

Stock Options/RSUs: The parties acknowledge that your seamless transition from Global Chief Medical Officer to part-time Advisor does not constitute a break in service for purposes of your outstanding stock options and restricted stock unit awards (together, the “Equity Awards”). In addition, the vesting schedule of your Equity Awards will continue in accordance with the same vesting schedule applicable while you were employed as Global Chief Medical Officer, and you will continue to vest in such awards so long as you continue to provide services as an Advisor to the Company.
Bonus: Despite your transition from Global Chief Medical Officer, the Company will pay you a one-time bonus of $100,000 to recognize your efforts during 2019. You will not be eligible for any other incentive compensation for past services or services under this Agreement.

1



Benefits: In your role as Advisor, you are not eligible for any Company benefits (including any severance benefits that you may have had available to you when you were previously an executive of the Company), except as otherwise described in this letter and as otherwise required by state, federal, or local law. As a result of your transition from Company executive to Advisor, the Company will reimburse your COBRA premiums during the term of your continued employment as an Advisor.
Expense Reimbursement: You must obtain prior approval from AmirAli Talasaz for any business-related travel, with any arrangements relating to transportation, lodging and meals to be mutually agreed between the parties in advance.
At-Will Employment: Consistent with state law, your employment with the Company will be “at-will.” This means that your employment with the Company will not last for any specific period of time, and either you or the Company can terminate your employment with 60 days’ notice and for any reason or for no reason. This letter will reflect the final, total and complete agreement between you and the Company regarding how your employment may be terminated. The “at-will” nature of your employment may only be changed if the CEO of the Company signs a written contract which explicitly changes at-will status.
Offer Acceptance: In order to accept this agreement, you must sign this letter and the other document enclosed for your signature, and I must receive them back before close of business on February 28, 2020. This letter, once accepted, constitutes the entire agreement between you and Guardant Health, Inc. with respect to the subject matter hereof and supersedes and replaces any and all prior agreements or representations relating to such subject matter including, but not limited to, your July 29, 2014 offer of employment. If you have any questions about this letter, then before signing please contact me.
Sincerely,
/s/ Amelia Merrill____
Amelia Merrill
VP, People
Guardant Health, Inc.


I, Dr. Richard Lanman, have read this letter and understand and agree to its terms.
 
Signature: /s/ Richard Lanman____
Date: February 28, 2020 Dr. Richard Lanman




 EX-21.1 4 exhibit211.htm EXHIBIT 21.1 Exhibit
Exhibit 21.1

Subsidiaries of Guardant Health, Inc.
Name
Jurisdiction of Incorporation
 
 
Guardant Health AMEA, Inc.
Delaware
 
 
Guardant Health Pte. Ltd.
Singapore
 
 
Guardant Health Japan Corp.
Japan
 
 
Guardant Holdings (Switzerland) GmbH
                                                                        Switzerland
 
 
Bellwether Bio, Inc.
Washington

EX-23.1 5 exhibit231.htm EXHIBIT 23.1 Exhibit



Exhibit 23.1


Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the Registration Statement (Form S-8 No. 333-227762) of Guardant Health, Inc. of our reports dated March 2, 2020, with respect to the consolidated financial statements of Guardant Health, Inc. and the effectiveness of internal control over financial reporting of Guardant Health Inc., included in this Annual Report (Form 10-K) for the year ended December 31, 2019.

/s/ Ernst & Young LLP

Redwood City, California
March 2, 2020



 EX-31.1 6 exhibit311.htm EXHIBIT 31.1 Exhibit
Exhibit 31.1
CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Helmy Eltoukhy, certify that:
1.
I have reviewed this Annual Report on Form 10-K of Guardant Health, Inc.;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date:
March 2, 2020
/s/ Helmy Eltoukhy
 
Helmy Eltoukhy
 
Chief Executive Officer
 
(Principal Executive Officer)

 EX-31.2 7 exhibit312.htm EXHIBIT 31.2 Exhibit
Exhibit 31.2
CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Derek Bertocci, certify that:
1.
I have reviewed this Annual Report on Form 10-K of Guardant Health, Inc.;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date:
March 2, 2020
/s/ Derek Bertocci
 
Derek Bertocci
 
Chief Financial Officer
 
(Principal Financial Officer)

 EX-32.1 8 exhibit321.htm EXHIBIT 32.1 Exhibit
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of Guardant Health, Inc. (the “Company”) on Form 10-K for the period ended December 31, 2019 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
1.
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
2.
The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
Date:
March 2, 2020
/s/ Helmy Eltoukhy
 
Helmy Eltoukhy
 
Chief Executive Officer
 
(Principal Executive Officer)
The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. § 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.


 EX-32.2 9 exhibit322.htm EXHIBIT 32.2 Exhibit
Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of Guardant Health, Inc. (the “Company”) on Form 10-K for the period ended December 31, 2019 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
1.
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
2.
The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
Date:
March 2, 2020
/s/ Derek Bertocci
 
Derek Bertocci
 
Chief Financial Officer
 
(Principal Financial Officer)
The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. § 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

 EX-101.SCH 10 gh-20191231.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2106100 - Disclosure - Acquisition of Bellwether Bio link:presentationLink link:calculationLink link:definitionLink 2406403 - Disclosure - Acquisition of Bellwether Bio - Assets Acquired and Liabilities Assumed (Details) link:presentationLink link:calculationLink link:definitionLink 2406406 - Disclosure - Acquisition of Bellwether Bio - Future Amortization Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2406404 - Disclosure - Acquisition of Bellwether Bio - Intangible Assets Acquired (Details) link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Acquisition of Bellwether Bio - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2406405 - Disclosure - Acquisition of Bellwether Bio - Other Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2406405 - Disclosure - Acquisition of Bellwether Bio - Other Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - Acquisition of Bellwether Bio (Tables) link:presentationLink link:calculationLink link:definitionLink 2110100 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2410402 - Disclosure - Commitments and Contingencies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2410403 - Disclosure - Commitments and Contingencies - Schedule of Future Royalty Payments (Details) link:presentationLink link:calculationLink link:definitionLink 2410403 - Disclosure - Commitments and Contingencies - Schedule of Future Royalty Payments (Details) link:presentationLink link:calculationLink link:definitionLink 2310301 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 2111100 - Disclosure - Common Stock link:presentationLink link:calculationLink link:definitionLink 2411402 - Disclosure - Common Stock (Details) link:presentationLink link:calculationLink link:definitionLink 2104100 - Disclosure - Consolidated Balance Sheet Components link:presentationLink link:calculationLink link:definitionLink 2404403 - Disclosure - Consolidated Balance Sheet Components - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2404404 - Disclosure - Consolidated Balance Sheet Components - Schedule of Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 2404402 - Disclosure - Consolidated Balance Sheet Components - Schedule of Property, Plant and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 2304301 - Disclosure - Consolidated Balance Sheet Components (Tables) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1001001 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1005000 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - Consolidated Statements of Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - Consolidated Statements of Redeemable Noncontrolling Interest and Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 1004001 - Statement - Consolidated Statements of Redeemable Noncontrolling Interest and Stockholders' Equity (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 2113100 - Disclosure - Convertible Preferred Stock link:presentationLink link:calculationLink link:definitionLink 2413402 - Disclosure - Convertible Preferred Stock (Details) link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - Description of Business link:presentationLink link:calculationLink link:definitionLink 2401401 - Disclosure - Description of Business (Details) link:presentationLink link:calculationLink link:definitionLink 2117100 - Disclosure - Employee Benefit Plan link:presentationLink link:calculationLink link:definitionLink 2417401 - Disclosure - Employee Benefit Plan (Details) link:presentationLink link:calculationLink link:definitionLink 2105100 - Disclosure - Fair Value Measurements. Cash Equivalents and Marketable Securities link:presentationLink link:calculationLink link:definitionLink 2405403 - Disclosure - Fair Value Measurements. Cash Equivalents and Marketable Securities - Cash Equivalents and Marketable Securities (Details) link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - Fair Value Measurements. Cash Equivalents and Marketable Securities - Fair Value Assets and Liabilities Measured on Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 2405404 - Disclosure - Fair Value Measurements. Cash Equivalents and Marketable Securities - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - Fair Value Measurements. Cash Equivalents and Marketable Securities (Tables) link:presentationLink link:calculationLink link:definitionLink 2116100 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2416405 - Disclosure - Income Taxes - Effective Tax Rate Reconciliation (Details) link:presentationLink link:calculationLink link:definitionLink 2416406 - Disclosure - Income Taxes - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2416407 - Disclosure - Income Taxes - Reconciliation of the Balance of Total Gross Unrecognized Tax Benefits (Details) link:presentationLink link:calculationLink link:definitionLink 2416404 - Disclosure - Income Taxes - Schedule of the Components of Deferred Tax Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2416403 - Disclosure - Income Taxes - Schedule of Components of the Provision for Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2416402 - Disclosure - Income Taxes - Schedule of Loss Before Components of the Provision for Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2316301 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 2103100 - Disclosure - Investment in Joint Venture link:presentationLink link:calculationLink link:definitionLink 2403401 - Disclosure - Investment in Joint Venture (Details) link:presentationLink link:calculationLink link:definitionLink 2109100 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 2409402 - Disclosure - Leases - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2409404 - Disclosure - Leases - Schedule of Future Minimal Lease Payments (Details) link:presentationLink link:calculationLink link:definitionLink 2409403 - Disclosure - Leases - Schedule of Operating Liability Maturities (Details) link:presentationLink link:calculationLink link:definitionLink 2409403 - Disclosure - Leases - Schedule of Operating Liability Maturities (Details) link:presentationLink link:calculationLink link:definitionLink 2309301 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 2115100 - Disclosure - Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders link:presentationLink link:calculationLink link:definitionLink 2415403 - Disclosure - Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders - Schedule of Antidilutive Securities (Details) link:presentationLink link:calculationLink link:definitionLink 2415402 - Disclosure - Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders - Schedule of Net Loss Per Share Attributable to Common Stockholders (Details) link:presentationLink link:calculationLink link:definitionLink 2315301 - Disclosure - Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders (Tables) link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - Patent License Agreement link:presentationLink link:calculationLink link:definitionLink 2407401 - Disclosure - Patent License Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 2119100 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 2419401 - Disclosure - Related Party Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 2118100 - Disclosure - Segment and Geographic Information link:presentationLink link:calculationLink link:definitionLink 2418402 - Disclosure - Segment and Geographic Information (Details) link:presentationLink link:calculationLink link:definitionLink 2318301 - Disclosure - Segment and Geographic Information (Tables) link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - Senior Term Loan and Royalty Purchase Agreement link:presentationLink link:calculationLink link:definitionLink 2408401 - Disclosure - Senior Term Loan and Royalty Purchase Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 2114100 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 2414402 - Disclosure - Stock-Based Compensation - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2414404 - Disclosure - Stock-Based Compensation - Restricted Stock Unit Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2414405 - Disclosure - Stock-Based Compensation - Stock Based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2414403 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2314301 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 2414407 - Disclosure - Stock-Based Compensation - Valuation of Employee Stock Purchase Plan (Details) link:presentationLink link:calculationLink link:definitionLink 2414406 - Disclosure - Stock-Based Compensation - Valuation of Stock Options (Details) link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2402407 - Disclosure - Summary of Significant Accounting Policies - Adoption of ASC 606 (Details) link:presentationLink link:calculationLink link:definitionLink 2402403 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2202201 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2402406 - Disclosure - Summary of Significant Accounting Policies - Remaining Performance Obligation (Details) link:presentationLink link:calculationLink link:definitionLink 2402404 - Disclosure - Summary of Significant Accounting Policies - Schedule of Concentration Risk (Details) link:presentationLink link:calculationLink link:definitionLink 2302302 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 2402405 - Disclosure - Summary of Significant Accounting Policies - Useful Life of Property and Equipment, Net (Details) link:presentationLink link:calculationLink link:definitionLink 2311301 - Disclosure - (Tables) link:presentationLink link:calculationLink link:definitionLink 2112100 - Disclosure - Warrants link:presentationLink link:calculationLink link:definitionLink 2412401 - Disclosure - Warrants (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 11 gh-20191231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 12 gh-20191231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 13 gh-20191231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Schedule of Stock Option Activity Share-based Compensation, Stock Options, Activity [Table Text Block] Schedule of Restricted Stock Unit Activity Schedule of Nonvested Restricted Stock Units Activity [Table Text Block] Schedule of Stock Based Compensation Expense Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block] Schedule of Stock Options Valuation Assumptions Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of Employee Stock Purchase Plan Valuation Assumptions Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block] Equity [Abstract] Common Stock Stockholders' Equity Note Disclosure [Text Block] Statement of Cash Flows [Abstract] Statement [Table] Statement [Table] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Convertible Preferred Stock Convertible Preferred Stock [Member] Common Stock Common Stock [Member] Statement [Line Items] Statement [Line Items] OPERATING ACTIVITIES: Net Cash Provided by (Used in) Operating Activities [Abstract] Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Depreciation and amortization Depreciation, Depletion and Amortization Amortization of ROU Amortization Of Right-Of-Use Assets Amortization Of Right-Of-Use Assets Unrealized translation (gains) losses on obligation related to royalty Unrealized Translations Gain (Loss) On Obligation Related To Royalty Unrealized Translations Gain (Loss) On Obligation Related To Royalty Re-valuation of contingent consideration Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Non-cash stock-based compensation Share-based Compensation Non-cash interest expense Noncash Interest Expense Paid Noncash Interest Expense Paid Loss on debt extinguishment Gain (Loss) on Extinguishment of Debt Amortization of premium (discount) on marketable securities Accretion (Amortization) of Discounts and Premiums, Investments Benefit from income tax differences Income Tax Credits and Adjustments Changes in operating assets and liabilities: Increase (Decrease) in Other Operating Assets and Liabilities, Net [Abstract] Accounts receivable Increase (Decrease) in Accounts Receivable Inventory Increase (Decrease) in Inventories Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Other assets Increase (Decrease) in Other Operating Assets Accounts payable Increase (Decrease) in Accounts Payable Accrued compensation Increase (Decrease) in Employee Related Liabilities Accrued expenses and other current liabilities Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Long-term operating lease liabilities net of ROU Long-Term Operating Lease Liabilities Net Of Right Of Use Assets Long-Term Operating Lease Liabilities Net Of Right Of Use Assets Deferred rent Increase (Decrease) in Deferred Charges Deferred revenue Increase (Decrease) in Deferred Revenue Other liabilities Increase (Decrease) in Other Operating Liabilities Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities INVESTING ACTIVITIES: Net Cash Provided by (Used in) Investing Activities [Abstract] Purchase of marketable securities Payments to Acquire Marketable Securities Maturity of marketable securities Proceeds from Sale and Maturity of Marketable Securities Business acquisition, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Purchase of property and equipment Payments to Acquire Property, Plant, and Equipment Purchase of intangible assets and capitalized license obligations Payments to Acquire Intangible Assets Payment in connection with a license agreement Payments In Connection With License Agreements Payments In Connection With License Agreements Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities FINANCING ACTIVITIES: Net Cash Provided by (Used in) Financing Activities [Abstract] Payment related to settlement of debt and buyout of royalty obligations Payment Related to Settlement of Debt and Buyout of Royalty Obligations Payment Related to Settlement of Debt and Buyout of Royalty Obligations Payments made on capital lease obligations Repayments of Long-term Capital Lease Obligations Proceeds from issuance of convertible preferred stock, net of issuance costs Proceeds from Issuance of Convertible Preferred Stock Proceeds from issuance of common stock under employee stock purchase plan Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Excluding Stock Options Proceeds from issuance of common stock upon exercise of stock options Proceeds from Stock Options Exercised Proceeds from issuance of common stock upon the exercise of warrants Proceeds from Warrant Exercises Repurchase of convertible preferred stock Payments for Repurchase of Convertible Preferred Stock Repurchase of common stock Payments for Repurchase of Common Stock Proceeds from public offerings of common stock Proceeds from Issuance of Common Stock Payment of offering costs related to public offerings of common stock Payments of Stock Issuance Costs Net proceeds from issuance of equity interests in redeemable noncontrolling interest Proceeds from Noncontrolling Interests Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Net effect of foreign exchange rate changes on cash, cash equivalents, and restricted cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Net increase in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, cash equivalents and restricted cash - Beginning of period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash, cash equivalents and restricted cash - End of period Supplemental Disclosures of Cash Flow Information: Supplemental Cash Flow Information [Abstract] Operating lease liabilities arising from obtaining right-of-use assets Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activities Cash paid for income taxes Income Taxes Paid, Net Supplemental Disclosures of Noncash Investing and Financing Activities: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Capitalized license fees financed through future royalty payment Capitalized License Fees Financed Through Future Royalty Payment Capitalized License Fees Financed Through Future Royalty Payment Issuance of Series D convertible preferred stock in exchange for a technology license agreement Value Of Convertible Preferred Stock Issued In Exchange For License Agreement Value Of Convertible Preferred Stock Issued In Exchange For License Agreement Increase in purchases of property and equipment included in accounts payable and accrued expenses Increase (Decrease) In Capital Expenditures Incurred But Not Yet Paid Increase (Decrease) In Capital Expenditures Incurred But Not Yet Paid Vesting of common stock exercised early Stock Issued During Period, Value, Stock Options Exercised Early Stock Issued During Period, Value, Stock Options Exercised Early Property and equipment acquired under capital leases Capital Lease Obligations Incurred Conversion of convertible preferred stock to common stock upon initial public offering Conversion of Stock Upon Initial Public Offering Conversion of Stock Upon Initial Public Offering Initial fair value of contingent consideration at acquisition date Business Combination, Contingent Consideration, Liability Deferred offering costs included in accounts payable and accrued expenses Offering Costs Incurred but Not yet Paid Offering Costs Incurred but Not yet Paid Fair Value Disclosures [Abstract] Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-sale [Table] Financial Instrument [Axis] Financial Instrument [Axis] Financial Instruments [Domain] Financial Instruments [Domain] Money market funds Money Market Funds [Member] Corporate bonds Corporate Debt Securities [Member] U.S. government debt securities US Treasury Securities [Member] U.S. government agency bonds US Government Agencies Debt Securities [Member] Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-sale [Line Items] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Amortized cost, debt securities, available-for-sale Debt Securities, Available-for-sale, Amortized Cost Amortized cost, cash and cash equivalents and debt securities available-for-sale Debt Securities, Available-for-sale, and Cash and Cash Equivalents Amortized Cost Debt Securities, Available-for-sale, and Cash and Cash Equivalents Amortized Cost Gross Unrealized Gain Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax Gross Unrealized Loss Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax Estimated Fair Value, Cash and Cash Equivalents Cash and Cash Equivalents, Fair Value Disclosure Estimated Fair Value, Debt Securities Debt Securities, Available-for-sale Estimated Fair Value, Cash, Cash Equivalents and Debt Securities Cash, Cash Equivalents and Debt Securities, Fair Value Cash, Cash Equivalents and Debt Securities, Fair Value Statement of Comprehensive Income [Abstract] Other comprehensive income (loss), net of tax impact: Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Unrealized gain (loss) on available-for-sale securities Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax Foreign currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax Other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax Comprehensive loss Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Comprehensive loss attributable to redeemable noncontrolling interest Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest Comprehensive loss attributable to Guardant Health, Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Award Type [Axis] Award Type [Axis] Equity Award [Domain] Equity Award [Domain] Restricted stock units Restricted Stock Units (RSUs) [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Restricted Stock Units Outstanding Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Restricted stock units outstanding, beginning balance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Restricted stock units outstanding, granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Restricted stock units outstanding, vested (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Restricted stock units outstanding, canceled (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Restricted stock units outstanding, ending balance (in shares) Weighted-Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Weighted-average grant date fair value, beginning balance (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Weighted-average grant date fair value, granted (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted-average grant date fair value, vested (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Weighted-average grant date fair value, canceled (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Weighted-average grant date fair value, ending balance (in usd per share) Warrants and Rights Note Disclosure [Abstract] Class of Warrant or Right [Table] Class of Warrant or Right [Table] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] Series A Convertible Preferred Stock Series A Convertible Preferred Stock [Member] Series A Convertible Preferred Stock [Member] Series B Convertible Preferred Stock Series B Convertible Preferred Stock [Member] Series B Convertible Preferred Stock [Member] Class of Warrant or Right [Line Items] Class of Warrant or Right [Line Items] Number of securities called by warrants Class of Warrant or Right, Number of Securities Called by Warrants or Rights Exercise price of warrants (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Stock issued from exercise of warrants (in shares) Stock Issued During Period, Shares, Exercise of Warrants Stock Issued During Period, Shares, Exercise of Warrants Warrants, outstanding Class of Warrant or Right, Outstanding Shares issued during period, exercise of warrants prior to IPO Stock Issued During Period, Shares, Exercise of Warrants Prior to IPO Stock Issued During Period, Shares, Exercise of Warrants Prior to IPO Income Tax Disclosure [Abstract] Current: Current Income Tax Expense (Benefit), Continuing Operations [Abstract] State Current State and Local Tax Expense (Benefit) Foreign Current Foreign Tax Expense (Benefit) Total current tax expense Current Income Tax Expense (Benefit) Deferred: Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract] Federal Deferred Federal Income Tax Expense (Benefit) State Deferred State and Local Income Tax Expense (Benefit) Foreign Deferred Foreign Income Tax Expense (Benefit) Total deferred tax expense Deferred Income Tax Expense (Benefit) Total provision for income taxes Income Tax Expense (Benefit) Schedule of components of loss before provision for income taxes Schedule Of Components Before Income Tax Expense Benefit [Table Text Block] Schedule Of Components Before Income Tax Expense Benefit [Table Text Block] Schedule of components of the provision for income taxes Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Schedule of the components of deferred tax assets and liabilities Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Effective tax rate reconciliation Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Reconciliation of the balance of total gross unrecognized tax benefits Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block] Accounting Policies [Abstract] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] Remaining performance obligation, percentage Revenue, Remaining Performance Obligation, Percentage Remaining performance obligation, expected recognition period Revenue, Remaining Performance Obligation, Optional Exemption, Remaining Duration Revenue, Initial Application Period Cumulative Effect Transition [Table] Revenue, Initial Application Period Cumulative Effect Transition [Table] Customer [Axis] Customer [Axis] Customer [Domain] Customer [Domain] Clinical Customers Clinical Customers [Member] Clinical Customers [Member] Biopharmaceutical Customers Biopharmaceutical Customers [Member] Biopharmaceutical Customers [Member] Adjustments for New Accounting Pronouncements [Axis] Adjustments for New Accounting Pronouncements [Axis] Type of Adoption [Domain] Type of Adoption [Domain] Topic 606 adoption Accounting Standards Update 2014-09 [Member] Initial Application Period Cumulative Effect Transition [Axis] Initial Application Period Cumulative Effect Transition [Axis] Initial Application Period Cumulative Effect Transition [Domain] Initial Application Period Cumulative Effect Transition [Domain] Effect of Change Difference between Revenue Guidance in Effect before and after Topic 606 [Member] Balances Without Adoption of ASC 606 Calculated under Revenue Guidance in Effect before Topic 606 [Member] Revenue, Initial Application Period Cumulative Effect Transition [Line Items] Revenue, Initial Application Period Cumulative Effect Transition [Line Items] Accounts receivable Accounts Receivable, Net, Current Accumulated deficit Retained Earnings (Accumulated Deficit) Precision oncology testing Revenue from Precision Oncology Testing Revenue from Precision Oncology Testing Development services Revenue from Development Services Revenue from Development Services Warrants Earnings Per Share [Abstract] Schedule of Earnings Per Share, Basic and Diluted Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Domain] Property, Plant and Equipment, Type [Domain] Machinery and equipment Machinery and Equipment [Member] Furniture and fixtures Furniture and Fixtures [Member] Computer hardware and computer software Computer Equipment and Software [Member] Computer Equipment and Software [Member] Range [Axis] Range [Axis] Range [Domain] Range [Domain] Minimum Minimum [Member] Maximum Maximum [Member] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Useful life (in years) Property, Plant and Equipment, Useful Life Balance Sheet Related Disclosures [Abstract] Computer hardware Computer Equipment [Member] Leasehold improvements Leasehold Improvements [Member] Computer software Software and Software Development Costs [Member] Construction in progress Construction in Progress [Member] Property and equipment, gross Property, Plant and Equipment, Gross Less: accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Property and equipment, net Property, Plant and Equipment, Net Business Combinations [Abstract] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Business Acquisition [Axis] Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Bellweather Bio, Inc. Bellweather Bio, Inc. [Member] Bellweather Bio, Inc. [Member] Business Acquisition [Line Items] Business Acquisition [Line Items] 2020 Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months 2021 Finite-Lived Intangible Assets, Amortization Expense, Year Two 2022 Finite-Lived Intangible Assets, Amortization Expense, Year Three 2023 Finite-Lived Intangible Assets, Amortization Expense, Year Four 2024 and thereafter Finite-Lived Intangible Assets, Amortization Expense, after Year Five Total Finite-Lived Intangible Assets, Net Statement of Financial Position [Abstract] ASSETS Assets [Abstract] Current assets: Assets, Current [Abstract] Cash and cash equivalents Short-term marketable securities Marketable Securities, Current Inventory Inventory, Net Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Total current assets Assets, Current Long-term marketable securities Marketable Securities, Noncurrent Property and equipment, net Right-of-use assets Operating Lease, Right-of-Use Asset Intangible assets, net Intangible Assets, Net (Excluding Goodwill) Goodwill Goodwill Capitalized license fees Other assets Other Assets, Noncurrent Total Assets Assets LIABILITIES, REDEEMABLE NONCONTROLLING INTEREST AND STOCKHOLDERS’ EQUITY Liabilities and Equity [Abstract] Current liabilities: Liabilities, Current [Abstract] Accounts payable Accounts Payable, Current Accrued compensation Deferred Compensation Liability, Current Accrued expenses Accrued Liabilities, Current Deferred revenue Deferred Revenue, Current Total current liabilities Liabilities, Current Long-term operating lease liabilities Operating Lease, Liability, Noncurrent Deferred rent, net of current portion Deferred Rent Credit, Noncurrent Obligation related to royalty Accrued Royalties, Noncurrent Accrued Royalties, Noncurrent Other long-term liabilities Other Liabilities, Noncurrent Total Liabilities Liabilities Commitments and contingencies (Note 10) Commitments and Contingencies Redeemable noncontrolling interest Redeemable Noncontrolling Interest, Equity, Carrying Amount Stockholders’ equity: Stockholders' Equity Attributable to Parent [Abstract] Preferred stock, par value of $0.00001 per share; 10,000,000 shares authorized, no shares issued and outstanding as of December 31, 2019 and 2018 Preferred Stock, Value, Outstanding Common stock, par value of $0.00001 per share; 350,000,000 and 350,000,000 shares authorized as of December 31, 2019 and 2018, respectively; 94,261,414 and 85,832,454 shares issued and outstanding as of December 31, 2019 and 2018, respectively Common Stock, Value, Outstanding Additional paid-in capital Additional Paid in Capital Accumulated other comprehensive gain (loss) Accumulated Other Comprehensive Income (Loss), Net of Tax Total Stockholders’ Equity Stockholders' Equity Attributable to Parent Total Liabilities, Redeemable Noncontrolling Interest and Stockholders’ Equity Liabilities and Equity Leases [Abstract] Leases Lessee, Operating Leases [Text Block] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Covenants Not To Compete Covenants Not To Compete [Member] Covenants Not To Compete [Member] Measurement Frequency [Axis] Measurement Frequency [Axis] Fair Value, Measurement Frequency [Domain] Fair Value, Measurement Frequency [Domain] Fair value, measurements, recurring Fair Value, Measurements, Recurring [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Level 2 Fair Value, Inputs, Level 2 [Member] Contingent Consideration by Type [Axis] Contingent Consideration by Type [Axis] Contingent Consideration Type [Domain] Contingent Consideration Type [Domain] Commercialization Milestones Commercialization Milestones [Member] Commercialization Milestones [Member] Earn-Out Consideration Earn-Out Consideration [Member] Earn-Out Consideration [Member] Total purchase consideration Business Combination, Consideration Transferred Cash paid upon closing Payments to Acquire Businesses, Gross Contingent liability from business acquisition Maximum contingent liability Business Combination, Contingent Consideration, Maximum Amount Payable Business Combination, Contingent Consideration, Maximum Amount Payable Identified intangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Weighted Average Useful Life Acquired Finite-lived Intangible Assets, Weighted Average Useful Life Acquisition related costs Business Combination, Acquisition Related Costs Schedule of Recognized Identified Assets Acquired and Liabilities Assumed Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Schedule of Intangible Assets Acquired Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block] Schedule of Intangible Assets and Goodwill Schedule of Intangible Assets and Goodwill [Table Text Block] Schedule of Future Amortization Expense Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Segment Reporting [Abstract] Segment and Geographic Information Segment Reporting Disclosure [Text Block] Convertible Preferred Stock Preferred Stock [Text Block] Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Unrecognized tax benefits - Beginning of period Unrecognized Tax Benefits Increases related to current year’s tax positions Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Increases related to prior years’ tax positions Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions Unrecognized tax benefits - End of period Accrued royalty obligations Accrued Royalties, Current Accrued legal expenses Estimated Litigation Liability, Legal Fees, Current Estimated Litigation Liability, Legal Fees, Current Accrued tax liabilities Accrued Income Taxes, Current Accrued professional services Accrued Professional Fees, Current Accrued clinical trials and studies Accrued Clinical Trials and Studies Accrued Clinical Trials and Studies Purchases of property and equipment included in accrued expenses Accrued Expenses, Property and Equipment, Current Accrued Expenses, Property and Equipment, Current Operating lease liabilities Operating Lease, Liability, Current Other Other Accrued Liabilities, Current Total accrued expenses Plan Name [Axis] Plan Name [Axis] Plan Name [Domain] Plan Name [Domain] 2018 Employee Stock Purchase Plan 2018 Employee Stock Purchase Plan [Member] 2018 Employee Stock Purchase Plan [Member] Stock option Employee Stock Option [Member] Employee Stock Employee Stock [Member] Shares canceled (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options Available for Grant, Forfeitures in Period, Gross Share-based Compensation Arrangement by Share-based Payment Award, Options Available for Grant, Forfeitures in Period, Gross Exercises in period, intrinsic value Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value Weighted average grant date fair value, grants in period (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Stock based compensation not recognized Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options Stock based compensation not recognized, period for recognition (years) Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Reversal of stock based compensation expense Reversal Of Stock Based Compensation Expense Reversal Of Stock Based Compensation Expense Stock based compensation not recognized, restricted stock Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options Expected dividend yield (percent) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Employee stock purchase plan, maximum employee subscription rate Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate Employee stock purchase plan, purchase price of common stock (percent of stock value) Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent Common stock issued under employee stock purchase plan (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Share-based compensation expense Allocated Share-based Compensation Expense Stock subject to repurchase (in shares) Common Stock Subject to Repurchase or Cancellation Common Stock Subject to Repurchase or Cancellation Stock subject to repurchase, per share Weighted Average Number of Shares, Common Stock Subject to Repurchase or Cancellation, Per Share Weighted Average Number of Shares, Common Stock Subject to Repurchase or Cancellation, Per Share Cash proceeds received for unvested shares Deferred Compensation Share-based Arrangements, Liability, Classified, Noncurrent Debt Disclosure [Abstract] Senior Term Loan and Royalty Purchase Agreement Debt Disclosure [Text Block] Statement of Stockholders' Equity [Abstract] Redeemable Noncontrolling Interest Redeemable Noncontrolling Interest [Member] Redeemable Noncontrolling Interest [Member] Convertible Preferred Stock Preferred Stock [Member] Additional Paid-in Capital Additional Paid-in Capital [Member] Accumulated Other Comprehensive Gain (Loss) AOCI Attributable to Parent [Member] Accumulated Deficit Retained Earnings [Member] ASU 2016-09 adoption Accounting Standards Update 2016-09 [Member] ASU 2018-07 adoption Accounting Standards Update 2018-07 [Member] Accounting Standards Update 2018-07 [Member] Series D Convertible Preferred Stock Series D Convertible Preferred Stock [Member] Series D Convertible Preferred Stock [Member] Series E Convertible Preferred Stock Series E Convertible Preferred Stock [Member] Series E Convertible Preferred Stock [Member] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Beginning balance Beginning balance (in shares) Shares, Outstanding Cumulative effect of new accounting principle Cumulative Effect of New Accounting Principle in Period of Adoption Conversion of convertible preferred stock to common stock upon initial public offering (in shares) Stock Issued During Period, Shares, Conversion of Convertible Preferred Stock to Common Stock Upon Initial Public Offering Stock Issued During Period, Shares, Conversion of Convertible Preferred Stock to Common Stock Upon Initial Public Offering Conversion of convertible preferred stock to common stock upon initial public offering Stock Issued During Period, Value, Conversion of Convertible Preferred Stock to Common Stock Upon Initial Public Offering Stock Issued During Period, Value, Conversion of Convertible Preferred Stock to Common Stock Upon Initial Public Offering Issuance of common stock upon follow-on offering, net of offering costs (in shares) Stock Issued During Period, Shares, New Issues Issuance of common stock upon follow-on offering, net of offering costs of $723 Stock Issued During Period, Value, New Issues Issuance of convertible preferred stock, net of issuance costs (in shares) Stock Issued During Period, Shares, Conversion of Convertible Securities Issuance of convertible preferred stock, net of issuance costs Stock Issued During Period, Value, Conversion of Convertible Securities Repurchase of common and convertible preferred stock (in shares) Stock Repurchased During Period, Shares Repurchase of common and convertible preferred stock Stock Repurchased During Period, Value Issuance of common stock upon exercise of stock options (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Issuance of common stock upon exercise of stock options Stock Issued During Period, Value, Stock Options Exercised Vesting of restricted stock units (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Gross Issuance of common stock upon early exercise of stock options (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Early Exercises in Period Share-based Compensation Arrangement by Share-based Payment Award, Options, Early Exercises in Period Issuance of common stock upon early exercise of stock options Common stock issued under employee stock purchase plan (in shares) Common stock issued under employee stock purchase plan Stock Issued During Period, Value, Employee Stock Purchase Plan Issuance of common stock upon exercise of warrants (in shares) Issuance of common stock upon exercise of warrants Stock Issued During Period, Value, Exercise of Warrants Stock Issued During Period, Value, Exercise of Warrants Vesting of common stock exercised early Adjustments to Additional Paid in Capital, Share-based Compensation For Early Exercised Stock Options Adjustments to Additional Paid in Capital, Share-based Compensation For Early Exercised Stock Options Stock-based compensation Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Adjustment of redeemable noncontrolling interest Net Income (Loss) Attributable to Redeemable Noncontrolling Interest Other comprehensive (loss) gain, net of tax impact Net loss Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest Ending balance (in shares) Ending balance Increase (Decrease) in Temporary Equity [Roll Forward] Increase (Decrease) in Temporary Equity [Roll Forward] Beginning balance Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests Issuance of equity interests in redeemable noncontrolling interest Temporary Equity, Stock Issued During Period, Value, New Issues Ending balance Net Loss Per Share Attributable to Guardant Health, Inc. Common Stockholders Earnings Per Share [Text Block] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value Measurements, Recurring and Nonrecurring [Table] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] U.S. government debt securities US Government Debt Securities [Member] Level 1 Fair Value, Inputs, Level 1 [Member] Level 3 Fair Value, Inputs, Level 3 [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Cash equivalents Debt securities, short-term Debt Securities, Current Debt securities, long-term Debt Securities, Noncurrent Total assets Assets, Fair Value Disclosure Total liabilities Financial Liabilities Fair Value Disclosure Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Balance Sheet Location [Axis] Balance Sheet Location [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Assets Assets [Member] Concentration Risk Type [Axis] Concentration Risk Type [Axis] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Geographic Concentration Risk Geographic Concentration Risk [Member] Geographical [Axis] Geographical [Axis] Geographical [Domain] Geographical [Domain] United States UNITED STATES International Non-US [Member] Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Total revenue Revenues Concentration risk, percentage Concentration Risk, Percentage Income Statement [Abstract] Revenue: Revenues [Abstract] Costs and operating expenses: Costs and Expenses [Abstract] Cost of precision oncology testing Costs of Precision Oncology Testing Costs of Precision Oncology Testing Cost of development services Cost of Development Services Cost of Development Services Research and development expense Research and Development Expense Sales and marketing expense Selling and Marketing Expense General and administrative expense General and Administrative Expense Total costs and operating expenses Costs and Expenses Loss from operations Operating Income (Loss) Interest income Investment Income, Interest Interest expense Interest Expense Loss on debt extinguishment Other income (expense), net Other Nonoperating Income (Expense) Loss before provision for income taxes Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Provision for (benefit from) income taxes Net loss Net loss attributable to Guardant Health, Inc. Net Income (Loss) Attributable to Parent Deemed dividend related to repurchase of convertible preferred stock Preferred Stock Dividends, Income Statement Impact Net loss attributable to Guardant Health, Inc. common stockholders Net Income (Loss) Available to Common Stockholders, Basic Net loss per share attributable to common stockholders, basic and diluted (in usd per share) Earnings Per Share, Basic and Diluted Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted (in shares) Weighted Average Number of Shares Outstanding, Basic and Diluted Related Party Transactions [Abstract] Related Party Transactions Related Party Transactions Disclosure [Text Block] Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Acquired license License [Member] Non-compete agreements Noncompete Agreements [Member] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets, Gross Finite-Lived Intangible Assets, Gross Accumulated Depreciation Finite-Lived Intangible Assets, Accumulated Amortization IPR&D Indefinite-lived Intangible Assets (Excluding Goodwill) Total intangible assets Intangible Assets, Gross (Including Goodwill) Intangible Assets, Gross (Including Goodwill) Total intangible assets Intangible Assets, Net (Including Goodwill) Operating lease expense Operating Lease, Expense Rent expense under Topic 840 Operating Leases, Rent Expense, Net Weighted average remaining lease term Operating Lease, Weighted Average Remaining Lease Term Weighted average discount rate Operating Lease, Weighted Average Discount Rate, Percent Lease not yet commenced, liability Lessee, Operating Lease, Lease Not Yet Commenced, Lease Liability Lessee, Operating Lease, Lease Not Yet Commenced, Lease Liability Lease not yet commenced, imputed interest Lessee, Operating Lease, Lease Not Yet Commenced, Undiscounted Excess Amount Lessee, Operating Lease, Lease Not Yet Commenced, Undiscounted Excess Amount Lease not yet commenced, sublease income Lessee, Operating Lease, Lease Not Yet Commenced, Sublease Income Lessee, Operating Lease, Lease Not Yet Commenced, Sublease Income Fair Value Measurements, Recurring and Nonrecurring Fair Value, Assets Measured on Recurring Basis [Table Text Block] Debt Securities, Available-for-sale Debt Securities [Table Text Block] Debt Securities [Table Text Block] Equity Method Investments and Joint Ventures [Abstract] Investment in Joint Venture Equity Method Investments and Joint Ventures Disclosure [Text Block] Retirement Benefits [Abstract] Defined contribution plan, maximum annual employee contributions per employee, percent Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent Defined contribution plan, employer contributions Defined Contribution Plan, Cost Deferred tax assets: Components of Deferred Tax Assets [Abstract] Net operating losses carryforwards Deferred Tax Assets, Operating Loss Carryforwards Intangible assets Deferred Tax Assets, Goodwill and Intangible Assets Accruals and reserves Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals Research and development credits Deferred Tax Assets, Tax Credit Carryforwards Stock-based compensation Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost Lease liabilities Deferred Tax Assets, Lease Liabilities Deferred Tax Assets, Lease Liabilities Other Deferred Tax Assets, Other Total deferred tax asset Deferred Tax Assets, Gross Deferred tax liabilities: Components of Deferred Tax Liabilities [Abstract] Property and equipment Deferred Tax Liabilities, Property, Plant and Equipment Section 481 (a) adjustment Deferred Tax Liabilities, Section 481 (a) Adjustment Deferred Tax Liabilities, Section 481 (a) Adjustment Right-of-use asset Deferred Tax Liabilities, Right-Of-Use Assets Deferred Tax Liabilities, Right-Of-Use Assets Unrealized gain/loss on investments Deferred Tax Liabilities, Unrealized Gains on Trading Securities Less: valuation allowance Deferred Tax Assets, Valuation Allowance Net deferred tax assets Deferred Tax Assets, Net of Valuation Allowance Consolidated Balance Sheet Components Additional Financial Information Disclosure [Text Block] Acquisition of Bellwether Bio Business Combination Disclosure [Text Block] Preferred stock, par value (in usd per share) Preferred Stock, Par or Stated Value Per Share Preferred stock, shares authorized Preferred Stock, Shares Authorized Preferred stock, shares outstanding Preferred Stock, Shares Outstanding Preferred stock, shares issued Preferred Stock, Shares Issued Common stock, par value (in usd per share) Common Stock, Par or Stated Value Per Share Common stock, shares authorized Common Stock, Shares Authorized Common stock, shares outstanding Common Stock, Shares, Outstanding Common stock, shares issued Common Stock, Shares, Issued Variable interest entity, assets Variable Interest Entity, Consolidated, Carrying Amount, Assets Variable interest entity, liabilities Variable Interest Entity, Consolidated, Carrying Amount, Liabilities Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table] Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table] Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] Adjustment of redeemable noncontrolling interest Net loss attributable to Guardant Health, Inc. Net loss attributable to Guardant Health, Inc. common stockholders Schedules of Concentration of Risk, by Risk Factor Schedules of Concentration of Risk, by Risk Factor [Table Text Block] Property, Plant and Equipment Property, Plant and Equipment [Table Text Block] Schedule of Impact of Adoption of ASC 606 Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block] Expected term (years) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Volatility, minimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum Volatility, maximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum Risk free interest rate, minimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum Risk free interest rate, maximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table] Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table] Other Assets Other Assets [Member] Type of Arrangement and Non-arrangement Transactions [Axis] Type of Arrangement and Non-arrangement Transactions [Axis] Arrangements and Non-arrangement Transactions [Domain] Arrangements and Non-arrangement Transactions [Domain] Collaborative Arrangement Collaborative Arrangement [Member] Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Restricted cash Restricted Cash Allowance for doubtful accounts Allowance for Doubtful Accounts Receivable Contract asset Contract with Customer, Asset, Net Advertising expense Advertising Expense Payment of offering costs related to initial public offering Intangible assets, useful life Finite-Lived Intangible Asset, Useful Life Deferred revenue Contract with Customer, Liability Deferred revenue, revenue recognized Contract with Customer, Liability, Revenue Recognized Deferred offering costs Deferred Offering Costs Operating lease, liability Operating Lease, Liability Schedule of Accrued Liabilities Schedule of Accrued Liabilities [Table Text Block] 2020 Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months 2021 Lessee, Operating Lease, Liability, Payments, Due Year Two 2022 Lessee, Operating Lease, Liability, Payments, Due Year Three 2023 Lessee, Operating Lease, Liability, Payments, Due Year Four 2024 and thereafter Lessee, Operating Lease, Liability, Payments, Due after Year Five Less: Imputed Interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Total operating lease payments Lessee, Operating Lease, Liability, Payments, Due Total operating lease liabilities Schedule of Future Minimum Royalty Payments Contractual Obligation, Fiscal Year Maturity Schedule [Table Text Block] Maturity period (years) Marketable Securities, Maturity Period Marketable Securities, Maturity Period Income Taxes Income Tax Disclosure [Text Block] Cover page. Document Type Document Type Document Annual Report Document Annual Report Document Period End Date Document Period End Date Document Transition Report Document Transition Report Entity File Number Entity File Number Entity Registrant Name Entity Registrant Name Amendment Flag Amendment Flag Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Title of 12(b) Security Title of 12(b) Security Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Voluntary Filers Entity Current Reporting Status Entity Current Reporting Status Entity Interactive Data Current Entity Interactive Data Current Entity Filer Category Entity Filer Category Entity Small Business Entity Small Business Entity Emerging Growth Company Entity Emerging Growth Company Entity Shell Company Entity Shell Company Entity Public Float Entity Public Float Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Documents Incorporated by Reference Documents Incorporated by Reference [Text Block] Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Litigation Case [Axis] Litigation Case [Axis] Litigation Case [Domain] Litigation Case [Domain] Foundation Medicine, Inc. vs. Guardant Health, Inc.. Foundation Medicine, Inc. vs. Guardant Health, Inc. [Member] Foundation Medicine, Inc. vs. Guardant Health, Inc. [Member] Personal Genome Diagnostics, Inc. vs. Guardant Health, Inc. Personal Genome Diagnostics, Inc. vs. Guardant Health, Inc. [Member] Personal Genome Diagnostics, Inc. vs. Guardant Health, Inc. [Member] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] General and administrative expense General and Administrative Expense [Member] Other Income Other Income [Member] Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Number of parties with patent license agreement Number of Parties With Patent License Agreement Number of Parties With Patent License Agreement Royalty expense Royalty Expense Percentage of precision oncology testing revenue Royalty Expense, Percentage of Precision Oncology Testing Revenue Royalty Expense, Percentage of Precision Oncology Testing Revenue Number of petitions filed Number of Petitions Filed Number of Petitions Filed Payments for legal settlements Payments for Legal Settlements Litigation settlement, expense Litigation Settlement, Expense Number of companies that infringed on a patent Number of Companies that Infringed on a Patent Number of Companies that Infringed on a Patent Number of asserted patents Number of Asserted Patents Number of Asserted Patents Amount awarded from other party Litigation Settlement, Amount Awarded from Other Party Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Use of Estimates Use of Estimates, Policy [Policy Text Block] JOBS Act Accounting Election JOBS Act Accounting Election [Policy Text Block] JOBS Act Accounting Election [Policy Text Block] Foreign Currency Translations Foreign Currency Transactions and Translations Policy [Policy Text Block] Segment Information Segment Reporting, Policy [Policy Text Block] Cash and Cash Equivalents and Restricted Cash Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Marketable Securities Marketable Securities, Policy [Policy Text Block] Concentration of Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Accounts Receivable Receivables, Policy [Policy Text Block] Inventory Inventory, Policy [Policy Text Block] Property and Equipment, Net Property, Plant and Equipment, Policy [Policy Text Block] Business Combinations Business Combinations Policy [Policy Text Block] Goodwill and Intangible Assets, net Goodwill and Intangible Assets, Policy [Policy Text Block] Obligation Related to Royalty Obligation Related to Royalty [Policy Text Block] Obligation Related to Royalty [Policy Text Block] Impairment for Long-Lived Assets Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Leases Lessee, Leases [Policy Text Block] Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Costs of Precision Oncology Testing Costs of Precision Oncology Testing [Policy Text Block] Costs of Precision Oncology Testing [Policy Text Block] Cost of Development Services Cost of Development Services [Policy Text Block] Cost of Development Services [Policy Text Block] Research and Development Expenses Research and Development Expense, Policy [Policy Text Block] Advertising Advertising Costs, Policy [Policy Text Block] Deferred Offering Costs Deferred Charges, Policy [Policy Text Block] Stock-Based Compensation Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] Income Taxes Income Tax, Policy [Policy Text Block] Net Loss Per Share Attributable to Common Shareholders Earnings Per Share, Policy [Policy Text Block] Recent Accounting Pronouncements Not Yet Adopted New Accounting Pronouncements, Policy [Policy Text Block] Finite-Lived Intangible Assets, Net [Abstract] Measurement Input Type [Axis] Measurement Input Type [Axis] Measurement Input Type [Domain] Measurement Input Type [Domain] Discount Rate Measurement Input, Discount Rate [Member] Patent Licensing Agreement Licensing Agreements [Member] One-time upfront payment for finite-lived intangible asset Stock issued during period for purchase of asset, shares Stock Issued During Period, Shares, Purchase of Assets Milestone payment License Agreement Milestone, Payment Upon Achievement License Agreement Milestone, Payment Upon Achievement Future royalty payments Payments for Future Royalties Payments for Future Royalties Fair value of stock issued for purchase of license agreement Stock Issued During Period, Value, Purchase of Assets Debt security, measurement input Debt Instrument, Measurement Input Intangible assets, useful life Amortization of intangible assets Amortization of Intangible Assets Line of Credit Facility [Table] Line of Credit Facility [Table] Royalty Agreement, by Payment Tier [Axis] Royalty Agreement, by Payment Tier [Axis] Royalty Agreement, by Payment Tier [Axis] Royalty Agreement, by Payment Tier [Domain] Royalty Agreement, by Payment Tier [Domain] [Domain] for Royalty Agreement, by Payment Tier [Axis] Tier One Tier One [Member] Tier One [Member] Tier Two Tier Two [Member] Tier Two [Member] Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Credit Agreement Credit Agreement [Member] Credit Agreement [Member] Royalty Agreement Royalty Agreement [Member] Royalty Agreement [Member] Credit Facility [Axis] Credit Facility [Axis] Credit Facility [Domain] Credit Facility [Domain] Senior Term Loan Senior Loans [Member] Line of Credit Facility [Line Items] Line of Credit Facility [Line Items] Maximum borrowing capacity (up to) Line of Credit Facility, Maximum Borrowing Capacity Proceeds from borrowing Proceeds from Lines of Credit Debt instrument, stated interest rate Debt Instrument, Variable Rate Basis, Base Rate Debt Instrument, Variable Rate Basis, Base Rate Basis spread (percent) Debt Instrument, Basis Spread on Variable Rate Remaining borrowing capacity Line of Credit Facility, Remaining Borrowing Capacity Royalty agreement payment tier threshold Royalty Agreement Payment Tier Threshold Royalty Agreement Payment Tier Threshold Quarterly royalty payments, percentage of revenue Royalty Payments, Percentage of Revenue Royalty Payments, Percentage of Revenue Repayments of debt Repayments of Debt Payment of accrued interest Payment of Accrued Interest, Debt Payment of Accrued Interest, Debt Prepayment penalty Payment for Debt Extinguishment or Debt Prepayment Cost Extinguishment of debt Extinguishment of Debt, Amount Long-term debt Debt Instrument, Repurchase Amount Loss on debt extinguishment Outstanding balance Long-term Debt Precision oncology testing Precision Oncology Testing [Member] Precision Oncology Testing [Member] Research and development expense Research and Development Expense [Member] Sales and marketing expense Selling and Marketing Expense [Member] Total stock-based compensation expense Depreciation and amortization expense Depreciation Cash Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Net liabilities assumed Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities Total Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net United States Income (Loss) from Continuing Operations before Equity Method Investments, Federal, Income Taxes, Noncontrolling Interest Income (Loss) from Continuing Operations before Equity Method Investments, Federal, Income Taxes, Noncontrolling Interest Foreign Income (Loss) from Continuing Operations before Equity Method Investments, Foreign, Income Taxes, Noncontrolling Interest Income (Loss) from Continuing Operations before Equity Method Investments, Foreign, Income Taxes, Noncontrolling Interest Stock-Based Compensation Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Organization, Consolidation and Presentation of Financial Statements [Abstract] Description of Business Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Schedule of Stock by Class Schedule of Stock by Class [Table Text Block] Schedule of Segment Reporting Information, by Segment Schedule of Segment Reporting Information, by Segment [Table Text Block] 2019 Operating Leases, Future Minimum Payments Due, Next Twelve Months 2020 Operating Leases, Future Minimum Payments, Due in Two Years 2021 Operating Leases, Future Minimum Payments, Due in Three Years 2022 Operating Leases, Future Minimum Payments, Due in Four Years 2023 Operating Leases, Future Minimum Payments, Due in Five Years 2024 and thereafter Operating Leases, Future Minimum Payments, Due Thereafter Total Operating Leases, Future Minimum Payments Due Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Title of Individual [Axis] Title of Individual [Axis] Relationship to Entity [Domain] Relationship to Entity [Domain] Executive Officer Executive Officer [Member] Related Party [Axis] Related Party [Axis] Related Party [Domain] Related Party [Domain] Affiliated Entity Affiliated Entity [Member] Related Party Transaction [Line Items] Related Party Transaction [Line Items] Stock repurchased during period (in shares) Stock repurchased during period, value Share-based compensation expense Common Stock, Compensation Expense Common Stock, Compensation Expense Revenue from related parties Revenue from Related Parties Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Counterparty Name [Axis] Counterparty Name [Axis] Counterparty Name [Domain] Counterparty Name [Domain] SoftBank SoftBank [Member] SoftBank [Member] Class of Stock [Line Items] Class of Stock [Line Items] Shares purchased in joint venture (in shares) Sale of Stock, Number of Shares Issued in Transaction Sale of stock, price (usd per share) Sale of Stock, Price Per Share Aggregate purchase price Sale of Stock, Consideration Received Per Transaction Threshold percentage of new shares issued Threshold Percentage of New Shares Issued Threshold Percentage of New Shares Issued Threshold period after initial closing to issue new shares Threshold Period After Initial Closing to Issue New Shares Threshold Period After Initial Closing to Issue New Shares Treasury stock acquired, average cost per share Treasury Stock Acquired, Average Cost Per Share Percentage of the original price per share of Series E convertible preferred stock Percentage of the Original Price per Share of the Convertible Preferred Stock Percentage of the Original Price per Share of the Convertible Preferred Stock Stock split, conversion ratio Stockholders' Equity Note, Stock Split, Conversion Ratio Share price of stock issued (in usd per share) Shares Issued, Price Per Share Preferred stock, convertible, conversion price Convertible Preferred Stock, Conversion Price Convertible Preferred Stock, Conversion Price Deemed dividend related to repurchase of convertible preferred stock Incremental common shares attributable to dilutive effect of conversion of preferred stock Preferred Stock Dividends, Shares Repurchase of shares Expected volatility rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Risk free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Concentration Risk [Table] Concentration Risk [Table] Customer A Customer A [Member] Customer A [Member] Customer B Customer B [Member] Customer B Customer C Customer C [Member] Customer C Customer D Customer D [Member] Customer D [Member] Credit Concentration Risk Customer Concentration Risk [Member] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Revenue Sales Revenue, Net [Member] Accounts Receivable Accounts Receivable [Member] Concentration Risk [Line Items] Concentration Risk [Line Items] Schedule of Operating Lease Liability Maturities Lessee, Operating Lease, Liability, Maturity [Table Text Block] Schedule of Future Minimum Rental Payments for Operating Leases Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table] Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table] Acquired Finite-Lived Intangible Assets [Line Items] Acquired Finite-Lived Intangible Assets [Line Items] Acquired license Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles IPR&D Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets Identified intangible assets Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Convertible Preferred Stock Antidilutive Securities [Axis] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Stock options issued and outstanding ESPP obligation Employee Stock Purchase Plan Obligation [Member] Employee Stock Purchase Plan Obligation [Member] Warrant Warrant [Member] Common stock subject to repurchase Treasury Stock, Common [Member] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive securities excluded from computation of earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Sale of Stock [Axis] Sale of Stock [Axis] Sale of Stock [Domain] Sale of Stock [Domain] IPO IPO [Member] Shares available for future stock option grants Shares Available For Future Stock Option Grants [Member] Shares Available For Future Stock Option Grants [Member] 2018 Employee Stock Purchase Plan Common stock, shares reserved for future issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance Issuance of common stock upon follow-on offering, shares Proceeds from initial public offering and follow on offering Proceeds from Issuance Initial Public Offering Issuance of common stock upon follow-on offering, net of offering costs Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Income Taxes [Table] Income Taxes [Table] Income Taxes [Table] Income Tax Authority [Axis] Income Tax Authority [Axis] Income Tax Authority [Domain] Income Tax Authority [Domain] Federal Domestic Tax Authority [Member] State State and Local Jurisdiction [Member] Income Taxes [Line Items] Income Taxes [Line Items] [Line Items] for Income Taxes [Table] Release from valuation allowance Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Benefit from intraperiod tax allocation Income Tax Expense (Benefit), Intraperiod Tax Allocation Net operating loss carryforwards Operating Loss Carryforwards Tax credit carryforwards, research Deferred Tax Assets, Tax Credit Carryforwards, Research Change in valuation allowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount Unrecognized tax benefits Fair Value Measurements. Cash Equivalents and Marketable Securities Fair Value Disclosures [Text Block] 2020 Contractual Obligation, Due in Next Fiscal Year 2021 Contractual Obligation, Due in Second Year 2022 Contractual Obligation, Due in Third Year 2023 Contractual Obligation, Due in Fourth Year 2024 and thereafter Contractual Obligation, Due In Fifth Year And After Fifth Year Contractual Obligation, Due In Fifth Year And After Fifth Year Total future minimum royalty payments Contractual Obligation Less: amount representing interest Contractual Obligation, Future Minimum Payments, Interest Amount Included in Payments Contractual Obligation, Future Minimum Payments, Interest Amount Included in Payments Present value of future minimum royalty payments Contractual Obligation, Future Minimum Payments, Present Value of Net Minimum Payments Contractual Obligation, Future Minimum Payments, Present Value of Net Minimum Payments Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Warrants, Preferred Stock Warrants, Preferred Stock [Member] Warrants, Preferred Stock [Member] Investment, Name [Axis] Investment, Name [Axis] Investment, Name [Domain] Investment, Name [Domain] Guardant Health AMEA, Inc Guardant Health AMEA, Inc [Member] Guardant Health AMEA, Inc [Member] Underwriters Over-Allotment Option Over-Allotment Option [Member] Subsidiary, Sale of Stock [Line Items] Subsidiary, Sale of Stock [Line Items] Equity method investment, ownership percentage Equity Method Investment, Ownership Percentage Common stock, shares authorized (in shares) Convertible preferred stock, shares authorized (in shares) Sale of stock, number of shares issued in transaction (in shares) Tax at the statutory federal rate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount Other nondeductible items Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount Stock-based compensation Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Compensation Cost, Amount Research and development credits Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount State taxes, net of federal benefits Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount Change in tax rate due to Tax Act Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount Other Effective Income Tax Rate Reconciliation, Other Adjustments, Amount Shares Available for Grant Share-based Compensation Arrangement by Share-based Payment Award, Shares Available for Grant [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Shares Available for Grant [Roll Forward] Beginning number of shares, available for grant Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Shares authorized (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized Shares forfeited (in shares) Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options Available for Grant, Grants in Period, Gross Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Exercised (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options Available for Grant, Exercised in Period, Gross Share-based Compensation Arrangement by Share-based Payment Award, Options Available for Grant, Exercised in Period, Gross Canceled (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options Available for Grant, Cancellations in Period, Gross Share-based Compensation Arrangement by Share-based Payment Award, Options Available for Grant, Cancellations in Period, Gross Repurchase of early exercised shares Share-based Compensation Arrangement by Share-based Payment Award, Shares Available For Grant, Repurchase of Early Exercised Shares Share-based Compensation Arrangement by Share-based Payment Award, Shares Available For Grant, Repurchase of Early Exercised Shares Ending number of shares, available for grant Shares Subject to Options Outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Beginning number of shares, outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Exercised (in shares) Canceled (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Ending number of shares, outstanding Weighted-Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Beginning balance of options outstanding (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Granted (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Exercised (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Canceled (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Ending balance of options outstanding (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Options outstanding, Weighted average remaining contractual term (in years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Options outstanding, Aggregate intrinsic value Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Options vested and exercisable, Number of options (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number Options vested and exercisable, Weighted average exercise price per share (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Options vested and exercisable, Weighted average remaining contractual term (in years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Options vested and exercisable, Aggregate intrinsic value (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Patent License Agreement Intangible Assets Disclosure [Text Block] Schedule of Equity Method Investments [Table] Schedule of Equity Method Investments [Table] Legal Entity [Axis] Legal Entity [Axis] Entity [Domain] Entity [Domain] Schedule of Equity Method Investments [Line Items] Schedule of Equity Method Investments [Line Items] Payments to acquire interest in joint venture Payments to Acquire Interest in Joint Venture Equity method investment, shares purchased Equity Method Investment, Shares Purchased Equity Method Investment, Shares Purchased Redeemable noncontrolling interest, redemption value Redeemable Noncontrolling Interest, Equity, Redemption Value Redeemable noncontrolling interest, fair value Redeemable Noncontrolling Interest, Equity, Fair Value Threshold period for unremedied material breach of the joint venture agreement by the other party Variable Interest Entity, Threshold Period For Unremedied Material Breach of the Joint Venture Agreement By The Other Party Variable Interest Entity, Threshold Period For Unremedied Material Breach of the Joint Venture Agreement By The Other Party Threshold percentage of fair value that is no less than internal rate of return Variable Interest Entity, Threshold Percentage of Fair Value that is No Less Than Internal Rate of Return Variable Interest Entity, Threshold Percentage of Fair Value that is No Less Than Internal Rate of Return Threshold percentage of fair value (greater than) Variable Interest Entity, Threshold Percentage of Fair Value Variable Interest Entity, Threshold Percentage of Fair Value Percentage of the product Variable Interest Entity, Percentage of the Product Variable Interest Entity, Percentage of the Product Noncontrolling interest in net loss joint venture Noncontrolling Interest in Net Income (Loss) Joint Venture Partners, Redeemable Redeemable noncontrolling interest, fair value adjustment Redeemable Noncontrolling Interest, Fair Value Adjustment Redeemable Noncontrolling Interest, Fair Value Adjustment Issuance costs Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Employee Benefit Plan Compensation and Employee Benefit Plans [Text Block] EX-101.PRE 14 gh-20191231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 15 gh.jpg begin 644 gh.jpg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graphic3.jpg begin 644 graphic3.jpg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end GRAPHIC 17 guardantgraphic201910k.jpg begin 644 guardantgraphic201910k.jpg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end GRAPHIC 18 marketopportunity.jpg begin 644 marketopportunity.jpg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end GRAPHIC 21 stockchart.jpg begin 644 stockchart.jpg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œT-_$J7.C)J$)^Q MRB,W;RNEU&7C_>1L['@%1V&=X/I79US-A>:;::C9I>6%UI-U' +&VCG4F(*2 M/E1URA)*J.2"<#BNFH *\]O-9N-(UK5+31$COFO+EB8I+"1V:3:-Z!@0KJHY M.<8SCFO0JY>O7FM2@"OJ!@&FW1NY&CMQ"_FNI(*K@Y((Y''I7G%O;^')[2UMQ_;)N$D M@$M[-]H\N)S("GFH\FT%L#MCY@>.*]&U*":YTV>"W$)>1"FVX4E&!X((!!Y& M17-%8+*W%OKFB7%K")(I'N+61KF*0Q ;-Y'SX&U?O+CCD]: .NHJ*VN8;RVC MN+61989%#(Z'(85+0!R'B^_32-:L-1BGC6ZB@E4I-;/*BQ%DW.2G*I7F"\-Y&59@@P IY4@#) M^4GJ30!NT444 >>W8\/?V]J(G36M1N);EMD-L]PN"!^\"%7"LJD<],%L<\5U MOAB&WM_"VG1V4YN+=8%\N4C!9<9&1V-90M[S2[B2>\T47&YI'^UZ9*Q9#( & M/E.<@G:/NEN><=:V-!N-,DTN.VT9_P!Q: 0^6RLKQX'1E8!@?KS0!I54U8VZ MZ+>F^E>&V%O(9I$)#(FT[B".00,U;JIJMM+>:3<6T"P.TR%"EP&*,IX8':0> M1D9[9[]* . L8/#TC:?"BZQ]JANK;S;N;[1Y:3"16"2(\A"L^ .A WJ1VKTJ MN3>6&TC6/7M'N;2-+B.Y>YMW:YADDC50K,P^?C8GWE'W1DUU,,T=S;QSP.LD M4JAT=3D,I&01^% #ZX[Q9J*:-X@M=1@FC^U):NKI-:O*B1EA\VY.4);"CKG. M*[&N?UK3[N;4#>YH W]%CM8M T M^/3G:2S2UC6!V/+1A1M)_#%7:S]$N=.GTJ*/1WS;6H%NJ%64Q[0 %(;!! QP M:T* ,?Q3]D&ALU[+<1;9HFA>V3?*)0XV;5PQU/% '54444 :"\C9)#@!>,\%0 !\I('YT ;=%%% $4W^MM_P#K MH?\ T%JEJ*;_ %MO_P!=#_Z"U2T %%%% !1110 4444 %16G_'G#_P!,5Z+5(Z-IYO[>]%I&MQ M;;A$Z#;MW##<#@\>M7: "L7Q1ID^J6%NL%O#>+!APO:LOV2WF4FX;<]JZJL33_"EAI6M1ZA8-.A6WD@9);B2 M;=N9&R"['&-G;KGVK;H *YZ7P]J5SJEY-+XBU&"VD<-;Q6SQC8,O3CGVP 7/#-G]@\.6E ML;F.Z,88>=&VX/\ ,3G-:M4-$TM=%T:WT^.0RK " [#DY)/J?6K] $%]%-/I M]Q#;2^3-)$RQRC^!B" WX'FN2O/"]SI^AVZ:?>K;!G@%Y#<73O$S!U)9&?E6 M)&.P;/3.*["XA6YMI8)"P25"C%&VD C'!'0URX^'^GC3H8FN+IKJ)HV-PUU, MPNIK+P6XT&>&&3SE$QEB\S$9X) W+TX., M],XYX-73K'7X/$(EU34H[VS^RLH\J#R563>I&5WMDX!Y[?C6]10 5'<><;67 M[-M$VP^66Z;L<9]LU)10!Q=$^T07$B>; ^1N:-UP,=0 M5R>.A['M*** "LGQ!:ZC>6]I#IEQ-;!KD?:)8"H=8]K8,#C 6NEHHH *XKQ18^) +O M[/J%_<6MPZ^1'9I"#!\PX8%"Q'7Y@WU&*[6B@"*VB>"W2.6>2Y=1@RRA0S>Y MV@#\@*EHHH JZHMRVD7BZ?D79@<08('S[3MZ\=<=:YD6WB*[D?49/MUG-!+; M);VC3Q[)$RHE+JC,#G+\DY QBNPHH **** .;\6#7(XVFT19YE>SF@\N!U5 MHY&*E),,1GH1ZC.1GFI/"\-[%)>M/%?PV3LGV:/4;CS9@0"').YB 3C )]>F M:Z"B@ HHHH Y>TTS7TDO;NVU.2.5KR8K:WH\V%X]YV8YW)QZ''M71VK3O:1- M>1)%.5'F)&^Y5;N <#(_"I:* "JFJI=R:->IIK!+QK>06[$])-IVG\\5;HH MX"UMO$"ZC:LT.MK&;B'[/Y]VKB*(,#/YVUL,2-VW.>V,5W]%% !7)^,8=4EG M06BZH]LUM(L8TR81LMP2-I689)7 MWL24!<;NI ;.">?RK:HHH *X>Z\-SBXOQ/X7T_5Y;BXDEBOIK@*X5F)522I9 M=H('RGH!WKN*YS_A"=.EOKRXO);R:+2WC@#D8W;5"Y MQVZ5;H S]_2LE/#TUIX@TNYEU^ M\NQ%))B"^DC^8F-A\@5%R1G)]LUK:YI0UK2)K(SR6Y?!66)F4J0'CJVNQ MW-U-*+6*V*1"&Y>)X9=V=XV\'C YZ8Z')I/#EG>VE_JW]I7<%U*TT>'B/S;1 M&H!=?X6( )'3N.#4FK>&;76=4@N[N:X"11-&T,=Q)&KY.0WR,N".?7(/T(DT M3P_;:#->FS>0Q74BR!))&D*84+]YB2>F: -:BBB@"*;_ %MO_P!=#_Z"U2U% M-_K;?_KH?_06J6@ HHHH **** "BBB@ J*T_X\X?^N:_RJ6HK3_CSA_ZYK_* M@"6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M ***KWU_;:;9O=7TRPPQCECW/8 #DD] !R3P* +%%9<7B/3)1_K9HF\Y(=D] MM+$^YSA/E90<$@\XQP>>*NQ7MO/>7%I%)NGMMIE3:1MW#*\]#P.U $]%%% ! M1110 4454OM4M--:(7DA1I=_EA8V M#RQ:"]+*C,!"3@/P._8=3@\<&G:AX@TW3+CR+N=_-V&1UBA>4QI_>?8#L7W; M X/H: -*BD!#*"I!!&01WI: "BBB@ HHILDBQ1/)(<(BEF..@% #J*S;/Q#I M>H6]E-9W0DCOY&CMR$8;V4,6!!'RD!&ZXZ5%;>*=)N[@PPSR[OWFUGM941_+ M.'VLRA6(P> 3T- &O145K=0WMG#=6K[X9XUDC;!&Y6&0<'GH:EH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (IO];;_ /70_P#H M+5+44W^MM_\ KH?_ $%JEH **** "BBB@ HHHH *BM/^/.'_ *YK_*I:BM/^ M/.'_ *YK_*@"6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"LK7-)N]52%;/5)]/,9)8Q _/G'7!'3^M:M%1.$:D>66Q=._D__P 776T5S?4J'9_>_P#,ZOKU?NONC_D< ME_PB&K_]#7>_D_\ \74MWH6IVVD6?E73ZM_^*KGQVR3OJEO]H#( MR*(IR?F@&3]P9RIZ#YNF>=UX]2TKQ%J5U;:9)J,-^D3(T4L:>4Z+MVOO8?+T M.5SU/'KT5%=QB(,[1N !QR ZDLY9 L\?WDYSQR/I5JBDT MFK,3U5CC_P#A#=8_Z&Z^_)__ (Y1_P (;K'_ $-U]^3_ /QRNPHKG^JTNWXO M_,S]E#^FSC_^$-UC_H;K[\G_ /CE7=/\.ZCI\=X;G6KG4O.MVC2*7( 8]^6/ MT_&NCHJHX>G%W7YL:IQ3NCA=*\,:GIFK>''B@46D<:RWR>8O^CSK:M$2!GD- ME0<9Y7/>H=-\.ZG#<6^-.NX)8I;PS3SW:R0O')YA58X_,;:Q)C.0J]#G.>?0 M**W-#/T"UFLO#>F6MTFR:"TBCD7(.UE0 C(XZBM"BB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH BF_UMO_ -=#_P"@M4M13?ZV MW_ZZ'_T%JEH **** "BBB@ HHHH *@CBGCB5%ECPH &8S_\ %5/10!%MN/\ MGK%_WZ/_ ,51MN/^>L7_ 'Z/_P 54M% $6VX_P">L7_?H_\ Q5&VX_YZQ?\ M?H__ !52T4 1;;C_ )ZQ?]^C_P#%4;;C_GK%_P!^C_\ %5+10!%MN/\ GK%_ MWZ/_ ,51MN/^>L7_ 'Z/_P 54M% $6VX_P">L7_?H_\ Q5&VX_YZQ?\ ?H__ M !52T4 1;;C_ )ZQ?]^C_P#%4;;C_GK%_P!^C_\ %5+10!%MN/\ GK%_WZ/_ M ,51MN/^>L7_ 'Z/_P 54M% $6VX_P">L7_?H_\ Q5&VX_YZQ?\ ?H__ !52 MT4 1;;C_ )ZQ?]^C_P#%4;;C_GK%_P!^C_\ %5+10!%MN/\ GK%_WZ/_ ,51 MMN/^>L7_ 'Z/_P 54M% $6VX_P">L7_?H_\ Q5&VX_YZQ?\ ?H__ !52T4 1 M;;C_ )ZQ?]^C_P#%4;;C_GK%_P!^C_\ %5+10!%MN/\ GK%_WZ/_ ,51MN/^ M>L7_ 'Z/_P 54M% $6VX_P">L7_?H_\ Q5&VX_YZQ?\ ?H__ !52T4 1;;C_ M )ZQ?]^C_P#%4;;C_GK%_P!^C_\ %5+10!%MN/\ GK%_WZ/_ ,51MN/^>L7_ M 'Z/_P 54M% $6VX_P">L7_?H_\ Q5&VX_YZQ?\ ?H__ !52T4 1;;C_ )ZQ M?]^C_P#%4;;C_GK%_P!^C_\ %5+10!%MN/\ GK%_WZ/_ ,51MN/^>L7_ 'Z/ M_P 54M% $6VX_P">L7_?H_\ Q5&VX_YZQ?\ ?H__ !52T4 1;;C_ )ZQ?]^C M_P#%4;;C_GK%_P!^C_\ %5+10!%MN/\ GK%_WZ/_ ,51MN/^>L7_ 'Z/_P 5 M4M% $6VX_P">L7_?H_\ Q5&VX_YZQ?\ ?H__ !52T4 1;;C_ )ZQ?]^C_P#% M4;;C_GK%_P!^C_\ %5+10!%MN/\ GK%_WZ/_ ,51MN/^>L7_ 'Z/_P 54M% M$6VX_P">L7_?H_\ Q5&VX_YZQ?\ ?H__ !52T4 1;;C_ )ZQ?]^C_P#%4;;C M_GK%_P!^C_\ %5+10!%MN/\ GK%_WZ/_ ,51MN/^>L7_ 'Z/_P 54M% $6VX M_P">L7_?H_\ Q5&VX_YZQ?\ ?H__ !52T4 1;;C_ )ZQ?]^C_P#%4;;C_GK% M_P!^C_\ %5+10!%MN/\ GK%_WZ/_ ,51MN/^>L7_ 'Z/_P 54M% $6VX_P"> ML7_?H_\ Q5&VX_YZQ?\ ?H__ !52T4 0^5*TB-)(A"'.%0C/!'K[U-110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % 6%%% !1110 4444 %%%% !1110!__V0$! end XML 22 R65.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Common Stock (Details)
$ / shares in Units, $ in Thousands
 1 Months Ended 12 Months Ended
Oct. 09, 2018
USD ($)
$ / shares
shares
Sep. 19, 2018
May 31, 2019
USD ($)
$ / shares
shares
Sep. 30, 2018
Dec. 31, 2019
USD ($)
shares
Dec. 31, 2018
shares
Class of Stock [Line Items]            
Common stock, shares reserved for future issuance (in shares)         7,911,031 12,067,162
Stock split, conversion ratio   0.7378   0.7378    
Issuance of common stock upon follow-on offering, shares     5,175,000      
Proceeds from initial public offering and follow on offering | $ $ 249,500          
Share price of stock issued (in usd per share) | $ / shares     $ 71.00      
Issuance of common stock upon follow-on offering, net of offering costs | $     $ 349,700   $ 349,709  
Stock options issued and outstanding            
Class of Stock [Line Items]            
Common stock, shares reserved for future issuance (in shares)         4,494,889 7,588,405
Shares available for future stock option grants            
Class of Stock [Line Items]            
Common stock, shares reserved for future issuance (in shares)         2,726,225 3,556,507
2018 Employee Stock Purchase Plan            
Class of Stock [Line Items]            
Common stock, shares reserved for future issuance (in shares)         689,917 922,250
Convertible Preferred Stock            
Class of Stock [Line Items]            
Issuance of convertible preferred stock, net of issuance costs (in shares) 58,264,577          
Common Stock            
Class of Stock [Line Items]            
Issuance of common stock upon follow-on offering, shares     5,175,000   5,175,000  
Issuance of convertible preferred stock, net of issuance costs (in shares) 7,636          
Additional Paid-in Capital            
Class of Stock [Line Items]            
Issuance of common stock upon follow-on offering, net of offering costs | $     $ 349,700   $ 349,709  
IPO            
Class of Stock [Line Items]            
Issuance of common stock upon follow-on offering, shares 14,375,000          
Sale of stock, price (usd per share) | $ / shares $ 19.00          
Proceeds from initial public offering and follow on offering | $ $ 249,500          

XML 23 R61.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Leases - Schedule of Operating Liability Maturities (Details) - USD ($)
$ in Thousands
Dec. 31, 2019
Jan. 01, 2019
Leases [Abstract]    
2020 $ 7,582  
2021 7,534  
2022 7,684  
2023 8,276  
2024 and thereafter 20,816  
Less: Imputed Interest (11,496)  
Total operating lease payments 51,892  
Total operating lease liabilities $ 40,396 $ 22,400
XML 24 R69.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Stock-Based Compensation - Stock Option Activity (Details) - USD ($)
$ / shares in Units, $ in Thousands
 1 Months Ended 12 Months Ended
Oct. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Shares Available for Grant        
Beginning number of shares, available for grant   3,556,507 1,698,790  
Shares authorized (in shares)   0 3,658,602  
Shares forfeited (in shares) (508,847) 0 (508,847)  
Granted (in shares)   (324,579) (2,088,639)  
Exercised (in shares)   0 0  
Canceled (in shares)   12,636 795,371  
Repurchase of early exercised shares   0 1,230  
Ending number of shares, available for grant   3,244,564 3,556,507 1,698,790
Shares Subject to Options Outstanding        
Beginning number of shares, outstanding   7,588,405 7,391,052  
Granted (in shares)   324,579 2,088,639  
Exercised (in shares)   (2,999,419) (1,007,387)  
Canceled (in shares)   (418,676) (883,899)  
Ending number of shares, outstanding   4,494,889 7,588,405 7,391,052
Weighted-Average Exercise Price        
Beginning balance of options outstanding (in dollars per share)   $ 4.58 $ 3.63  
Granted (in dollars per share)   88.18 7.19  
Exercised (in dollars per share)   3.87 3.09  
Canceled (in dollars per share)   6.64 4.57  
Ending balance of options outstanding (in dollars per share)   $ 10.90 $ 4.58 $ 3.63
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]        
Options outstanding, Weighted average remaining contractual term (in years)   7 years 8 months 12 days 8 years 3 months 18 days 8 years 7 months 6 days
Options outstanding, Aggregate intrinsic value   $ 306,392 $ 250,495 $ 3,325
Options vested and exercisable, Number of options (in shares)   1,908,216    
Options vested and exercisable, Weighted average exercise price per share (in dollars per share)   $ 5.27    
Options vested and exercisable, Weighted average remaining contractual term (in years)   7 years 2 months 12 days    
Options vested and exercisable, Aggregate intrinsic value (in dollars per share)   $ 139,337    
XML 25 R42.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Summary of Significant Accounting Policies - Schedule of Concentration Risk (Details) - Credit Concentration Risk
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Customer A | Revenue      
Concentration Risk [Line Items]      
Concentration risk, percentage     13.00%
Customer B | Revenue      
Concentration Risk [Line Items]      
Concentration risk, percentage 26.00% 18.00% 13.00%
Customer B | Accounts Receivable      
Concentration Risk [Line Items]      
Concentration risk, percentage 40.00% 65.00%  
Customer C | Accounts Receivable      
Concentration Risk [Line Items]      
Concentration risk, percentage 10.00%    
Customer D | Revenue      
Concentration Risk [Line Items]      
Concentration risk, percentage 14.00%    
XML 26 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 27 R46.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Investment in Joint Venture (Details) - USD ($)
$ in Millions
 1 Months Ended 12 Months Ended
May 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Apr. 30, 2018
Schedule of Equity Method Investments [Line Items]        
Variable interest entity, assets   $ 45.1 $ 48.3  
Noncontrolling interest in net loss joint venture   3.9    
Redeemable noncontrolling interest, fair value adjustment   11.7    
Guardant Health AMEA, Inc        
Schedule of Equity Method Investments [Line Items]        
Payments to acquire interest in joint venture $ 9.0      
Equity method investment, shares purchased 40,000      
Equity method investment, ownership percentage 50.00%     50.00%
Redeemable noncontrolling interest, fair value   $ 41.0    
Threshold period for unremedied material breach of the joint venture agreement by the other party   20 days    
Threshold percentage of fair value that is no less than internal rate of return   20.00%    
Percentage of the product   40.00%    
SoftBank | Guardant Health AMEA, Inc        
Schedule of Equity Method Investments [Line Items]        
Payments to acquire interest in joint venture $ 41.0      
Equity method investment, shares purchased 40,000      
Equity method investment, ownership percentage 50.00%      
Redeemable noncontrolling interest, redemption value $ 41.0      
Threshold percentage of fair value (greater than)   40.00%    
ZIP 28 0001628280-20-002613-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-20-002613-xbrl.zip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�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�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�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ΐ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end GRAPHIC 19 slide1a01.jpg begin 644 slide1a01.jpg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�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end GRAPHIC 20 slide1a03.jpg begin 644 slide1a03.jpg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